WO2011041694A2 - Compounds as lysophosphatidic acid receptor antagonists - Google Patents

Compounds as lysophosphatidic acid receptor antagonists Download PDF

Info

Publication number
WO2011041694A2
WO2011041694A2 PCT/US2010/051150 US2010051150W WO2011041694A2 WO 2011041694 A2 WO2011041694 A2 WO 2011041694A2 US 2010051150 W US2010051150 W US 2010051150W WO 2011041694 A2 WO2011041694 A2 WO 2011041694A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
compound
isoxazol
biphenyl
cyclopropanecarboxylic acid
Prior art date
Application number
PCT/US2010/051150
Other languages
French (fr)
Other versions
WO2011041694A3 (en
Inventor
Thomas Jon Seiders
Lucy Zhao
Jeannie M. Arruda
Bowei Wang
Brian Andrew Stearns
Yen Pham Truong
Jill Melissa Scott
John Howard Hutchinson
Ryan Clark
Heather Renee Coate
Nicholas Simon Stock
Deborah Volkots
Original Assignee
Amira Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals, Inc. filed Critical Amira Pharmaceuticals, Inc.
Priority to US13/498,491 priority Critical patent/US9090573B2/en
Priority to JP2012532357A priority patent/JP2013506694A/en
Priority to CN2010800546595A priority patent/CN102639515A/en
Priority to IN2735DEN2012 priority patent/IN2012DN02735A/en
Priority to EP10821345.5A priority patent/EP2483252B1/en
Publication of WO2011041694A2 publication Critical patent/WO2011041694A2/en
Publication of WO2011041694A3 publication Critical patent/WO2011041694A3/en
Priority to US14/755,383 priority patent/US9624182B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders or conditions associated with one or more of the lysophosphatidic acid (LPA) receptors.
  • LPA lysophosphatidic acid
  • Lysophospho lipids are membrane-derived bioactive lipid mediators. Lysophospho lipids affect fundamental cellular functions that include proliferation, differentiation, survival, migration, adhesion, invasion, and morphogensis. These functions influence many biological processes that include, but are not limited to, neurogensis, angiogenesis, wound healing, fibrosis, immunity, and carcinogenesis.
  • Lysophosphatidic acid is a lysophospholipid that has been shown to act through sets of specific G protein-coupled receptors (GPCRs) in an autocrine and paracrine fashion. LPA binding to its cognate GPCRs (LPAi, LPA 2 , LPA 3 , LPA 4 , LPA 5 , LPA 6 ) activates intracellular signaling pathways to produce a variety of biological responses. Antagonists of the LPA receptors find use in the treatment of diseases, disorders or conditions in which LPA plays a role.
  • LPA lysophosphatidic acid
  • compounds of Formula (I) that inhibit the physiological activity of lysophosphatidic acid (LPA), and therefore, are useful as agents for the treatment or prevention of diseases in which inhibition of the physiological activity of LPA is useful, such as diseases in which an LPA receptor participates, is involved in the etiology or pathology of the disease, or is otherwise associated with at least one symptom of the disease.
  • diseases in which an LPA receptor participates is involved in the etiology or pathology of the disease, or is otherwise associated with at least one symptom of the disease.
  • such compounds are useful as agents for the treatment or prevention of side effects, complications, or adverse events associated with the use of a different therapeutic agent or therapeutic action (e.g., radiation, surgery, etc) used in treating a disease or condition.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is useful for the treatment of fibrosis of organs (liver, kidney, lung, heart and the like), liver diseases (acute hepatatis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, non- alcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like), cell proliferative disease (cancer (solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL) and the like) and invasive metastasis of cancer cell, and the like), inflammatory disease (psoriasis, nephropathy, pneumonia and the like), gastrointestinal tract disease (irritable bowel syndrome
  • compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) are antagonists of at least one of the LPA receptors selected from LPAi, LPA 2 , LPA 3 , LPA 4; LPA 5 and LPA 6 .
  • compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) are antagonists of LPAi.
  • compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) are antagonists of LPAi and/or LPA 3 .
  • compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) are antagonists of LPAi and/or LPA 2 .
  • compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) are selective antagonists for one of the LPA receptors relative to the other LPA receptors.
  • such a selective antagonist is selective for the LPAi receptor.
  • such a selective antagonist is selective for the LPA 2 receptor.
  • such a selective antagonist is selective for the LPA3 receptor.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of diseases, disorders, or conditions in which activation of at least one LPA receptor by LPA contributes to the symptomology or progression of the disease, disorder or condition.
  • diseases, disorders, or conditions may arise from one or more of a genetic, iatrogenic,
  • the methods, compounds, pharmaceutical compositions, and medicaments described herein comprise antagonists of LPA receptors. In one aspect, the methods, compounds, pharmaceutical compositions, and medicaments described herein comprise antagonists of LPAi. [009] In one aspect, provided herein is a compound of Formula (I), or a pharmaceutically acceptable solvate, a pharmaceutically acce table salt, a prodrug, or a metabolite thereof:
  • R 5 is H, Ci-C 4 alkyl, or Ci-C 4 fluoroalkyl; or , and R 3 is H, Ci-C 4 alkyl, or Ci-C 4 fluoroalkyl;
  • n 0, 1 or 2;
  • L 1 is absent, Ci-C 4 alkylene, Ci-C 4 fluoroalkylene, C 3 -C 6 cycloalkylene, -C 3 -C 6 cycloalkylene- Ci-C 4 alkylene-, or -[C(R la )(R lb )] q -; q is 1, 2 or 3;
  • R la and R lb are each independently selected from H, Ci-C 4 alkyl and substituted or unsubstituted benzyl;
  • R D is H or C C 6 alkyl;
  • R E is C
  • L 3 is a substituted or unsubstituted Ci-C 6 alkylene, substituted or unsubstituted Ci-
  • each R 13 is independently selected from F, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, hydroxyl, Ci-C 4 alkoxy, Ci-C 4 fluoroalkoxy and a substituted or unsubstituted phenyl; or
  • L 3 is - ⁇ 1 -!. 5 -;
  • L 4 is absent or a substituted or unsubstituted Ci-C 4 alkylene, where if L 4 is substituted then L 4 is substituted with 1, 2, or 3 R 14 ; each R 14 is independently selected from F, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, hydroxyl, Ci-C 4 alkoxy and Ci-C 4 fluoroalkoxy;
  • R 8 is H, Ci-C 4 alkyl, or Ci-C 4 fmoroalkyl
  • L 5 is absent or a substituted or unsubstituted Ci-C 4 alkylene, where if L 5 is substituted then L 5 is substituted with 1, 2, or 3 R 15 ; each R 15 is independently selected from F, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, hydroxyl, Ci-C 4 alkoxy and Ci-C 4 fluoroalkoxy;
  • R 6 is Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, substituted or unsubstituted C 3 -Ci 0 cycloalkyl, a
  • R 6 substituted or unsubstituted C3-Cioheterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted monocyclic heteroaryl, or a substituted or unsubstituted bicyclic heteroaryl, wherein if R 6 is substituted then R 6 is substituted with 1 , 2 or 3 R c ;
  • each R 9 is independently selected from H, Ci-Ci 2 alkyl, Ci-C 6 heteroalkyl, Ci-C 6 fluoroalkyl, a substituted or unsubstituted C 3 -C 6 cycloalkyl, a substituted or unsubstituted C 2 -
  • Ceheterocycloalkyl a substituted or unsubstituted phenyl, a substituted or unsubstituted monocyclic heteroaryl, -Ci-C 4 alkylene-(substituted or unsubstituted C3-C 6 cycloalkyl), - Ci-C 4 alkylene-(substituted or unsubstituted C 2 -C 6 heterocycloalkyl), -Ci-C 4 alkylene- (substituted or unsubstituted phenyl), or -Ci-C 4 alkylene-(substituted or unsubstituted heteroaryl); or
  • R 10 is selected from Ci-C 6 alkyl, Ci-C 6 heteroalkyl, Ci-C 6 fluoroalkyl, a substituted or
  • substituents are selected from among from a subset of the listed alternatives.
  • R 1 is -C0 2 R D .
  • R 1 is -CO 2 H.
  • R E is Ci-C 6 alkyl.
  • R E is -CH 3 or - CH 2 CH 3 .
  • R D is H, -CH 3 or -CH 2 CH 3 .
  • R D is H.
  • the compound has the structure of Formula (II):
  • R D is H or Ci-C 6 alkyl
  • R E is Ci-C 6 alkyl or a substituted or unsubstituted phenyl
  • L 1 is absent, Ci-C 4 alkylene, Ci-C 4 fluoroalkylene, C 3 -C 6 cycloalkylene, -C 3 -C 6 cycloalkylene-
  • R la and R lb are each independently selected from H, Ci-C 4 alkyl and benzyl; each R A is independently selected from halogen, -CN, -OH, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, C
  • each R B is independently selected from halogen, -CN, -OH, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, Ci-
  • R 5 is H or Ci-C 4 alkyl
  • n 0 or 1.
  • the compound has the structure of Formula (III):
  • IT is H or Ci-C 6 alkyl
  • R E is Ci-C 6 alkyl or a substituted or unsubstituted phenyl
  • L 1 is absent, Ci-C 4 alkylene, C 3 -C 6 cycloalkylene, -C 3 -C 6 cycloalkylene-Ci-C 4 alkylene-, -Cr
  • R la and R lb are each independently selected from H, Ci-C 4 alkyl and benzyl; each R A is independently selected from halogen, -CN, -OH, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, C C 4 fluoroalkoxy, Ci-C 4 alkoxy, and Ci-C 4 heteroalkyl;
  • each R is independently selected from halogen, -CN, -OH, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, Ci- C 4 fluoroalkoxy, Ci-C 4 alkoxy, and Ci-C 4 heteroalkyl;
  • R 3 is H or Ci-C 4 alkyl
  • n 0 or 1.
  • L 1 is absent, -CH 2 -, -CH(CH 3 )-, -C(CH 3 ) 2 -, -CH(CH 2 CH 3 )-, -
  • L 1 is absent, -CH 2 -, -CH(CH 3 )-, - C(CH 3 ) 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, cyclopropyl- 1 , 1 -diyl, cyclopropyl- 1 ,2-diyl, cyclobutyl- 1 , 1 -diyl, cyclopentyl- 1,1 -diyl, cyclohexyl- 1 , 1 -diyl, -C(CH 2 CH 2 )CH 2 - or -CH 2 C(CH 2 CH 2 )-;
  • R 6 is C 3 - C 6 cycloalkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic heteroaryl
  • Ci-C 4 alkyl Ci-C 4 fluoroalkyl, Ci-C 4 fluoroalkoxy, Ci-C 4 alkoxy, and Ci-C 4 heteroalkyl.
  • L 1 is -CH 2 -, cyclopropyl- 1 , 1 -diyl, or -C(CH 2 CH 2 )CH 2 -;
  • L 3 is a substituted or unsubstituted C 3 -C 6 alkylene, substituted or unsubstituted C 3 -C 6 fluoroalkylene, or substituted or unsubstituted C 3 -C 6 heteroalkylene, where if L 3 is substituted then L 3 is substituted with 1, 2 or 3 R 13 ; each R 13 is independently selected from F, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, hydroxyl, Ci- C 4 alkoxy, Ci-C 4 fluoroalkoxy and phenyl.
  • L 3 is a substituted or unsubstituted C 3 -C 4 alkylene, substituted or unsubstituted C 3 -C 4 fluoroalkylene, -(substituted or unsubstituted C 3 -C 4 alkylene)-0-, -(substituted or unsubstituted Ci-C 3 alkylene)-0-(substituted or unsubstituted Ci-C 3 alkylene)-, -0-(substituted or unsubstituted C 3 -C 4 alkylene)-, -(substituted or unsubstituted C 3 -C 4 alkylene)-S-, -(substituted or unsubstituted Ci-C 3 alkylene)-S-(substituted or unsubstituted Ci-C 3 alkylene)-, -S-(substituted or unsubstituted C 3 alkylene)-S-
  • L 3 is a substituted or unsubstituted C 3 -C 4 alkylene, substituted or unsubstituted C 3 -C 4 fluoroalkylene, -(substituted or unsubstituted Ci-C 3 alkylene)-0-(substituted or unsubstituted Ci-C 3 alkylene)-, -(substituted or unsubstituted Ci-C 3 alkylene)-S-(substituted or unsubstituted Ci-C 3 alkylene)-, -NH-(substituted or unsubstituted C 3 -C 4 alkylene)-; where if L 3 is substituted then L 3 is substituted with 1 or 2 R 13 .
  • L 1 is -CH 2 -, cyclopropyl- 1 , 1 -diyl, or -C(CH 2 CH 2 )CH 2 -;
  • L 3 is - ⁇ -X ⁇ L 5 -;
  • L 4 is a substituted or unsubstituted Ci-C 4 alkylene, where if L 4 is substituted then L 4 is substituted with 1 or 2 R 14 ; each R 14 is independently selected from F, -CH 3 , -CH 2 CH 3 , -CF 3 , hydroxyl, -OCH 3 , -OCH 2 CH 3 , and -OCF 3 ;
  • each R 15 is independently selected from F, -CH 3 , -CH 2 CH 3 , -CF 3 , hydroxyl, -OCH 3 , -OCH 2 CH 3 , and -OCF 3 .
  • L 5 is a substituted or unsubstituted Ci-C 4 alkylene, where if L 5 is substituted then L 5 is substituted with 1 or 2 R 15 ; each R 15 is independently selected from F, -CH 3 , - CH 2 CH 3 , -CF 3 , hydroxyl, -OCH 3 , -OCH 2 CH 3 , and -OCF 3 .
  • X 1 is -0-, -S-, or -NR 7 -.
  • L 1 is -CH 2 -, cyclopropyl- 1 , 1 -diyl, or -C(CH 2 CH 2 )CH 2 -;
  • L 3 is -L 4 -X x -L 5 -;
  • L 4 is absent;
  • X 1 is -NR 7 -;
  • R 7 is H or C C 4 alkyl;
  • L 5 is absent or a substituted or unsubstituted Ci-C 4 alkylene, where if L 5 is substituted then L 5 is substituted with 1 or 2 R 15 ; each R 15 is independently selected from F, -CH 3 , -CH 2 CH 3 , -CF 3 , hydroxyl, -OCH 3 , - OCH 2 CH 3 , and -OCF 3 .
  • the compound has a structure of Formula (VI), or a pharmaceutically acceptable salt thereof:
  • R D is H or C C 6 alkyl
  • R E is Ci-C 6 alkyl, C 3 -C 6 cycloalkyl, or substituted or unsubstituted phenyl;
  • L 3 is a substituted or unsubstituted C 3 -C 6 alkylene, a substituted or unsubstituted C 3 -
  • each R 13 is independently selected from F, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, and -OH;
  • each of R A , R B , and R c are independently selected from H, halogen, -CN, -N0 2 , -OH, -OR 9 , -
  • Ci-C 4 alkyl Ci-C 4 fluoroalkyl
  • Ci-C 4 fluoroalkoxy Ci-C 4 alkoxy
  • Ci-C 4 alkoxy Ci-C 4 alkoxy
  • R 5 is H or C C 4 alkyl
  • each R 9 is independently selected from H, Ci-C 6 alkyl, Ci-C 6 fiuoroalkyl, a substituted or unsubstituted phenyl, or -CH 2 -(substituted or unsubstituted phenyl); or
  • n 0 or 1
  • p 0, 1 , or 2.
  • the compound has a structure of Formula (VII), or a pharmaceutically acceptable salt thereof:
  • R D is H or Ci-C 6 alkyl
  • R E is Ci-C 6 alkyl, C 3 -C 6 cycloalkyl, or substituted or unsubstituted phenyl;
  • L 3 is a substituted or unsubstituted C 3 -C 6 alkylene, a substituted or unsubstituted C 3 -
  • each R 13 is independently selected from F, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, and -OH;
  • each of R A , R B , and R c are independently selected from H, halogen, -CN, -N0 2 , -OH, -OR 9 , -
  • R 3 is H or Ci-C 4 alkyl
  • each R 9 is independently selected from H, Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, a substituted or unsubstituted phenyl, or -CH 2 -(substituted or unsubstituted phenyl); or
  • n 0 or 1
  • p 0, 1 , or 2.
  • R D is H or C C 4 alkyl;
  • R E is d- C 4 alkyl;
  • L 3 is a substituted or unsubstituted butylene, a substituted or unsubstituted fluorobutylene, or a substituted or unsubstituted difluorobutylene; where if L 3 is substituted then L 3 is substituted with 1 or 2 R 13 .
  • L 3 is a substituted or unsubstituted C 3 -C 6 heteroalkylene; where if L 3 is substituted then L 3 is substituted with 1 or 2 R 13 .
  • L 3 is -(substituted or unsubstituted C 3 -C 4 alkylene)-0-, -(substituted or unsubstituted Ci-C 3 alkylene)-0-(substituted or unsubstituted Ci-C 3 alkylene)-, -0-(substituted or unsubstituted C 3 -C 4 alkylene)-, -(substituted or unsubstituted C 3 -C 4 alkylene)-S-, -(substituted or unsubstituted Ci-C 3 alkylene)-S-(substituted or unsubstituted Ci-C 3 alkylene)-, -S-((substituted or unsubstituted Ci-
  • L 3 is -NH-(substituted or unsubstituted C 3 -C 4 alkylene); where if L 3 is substituted then L 3 is substituted with R 13 . In some embodiments, L 3 is -NH-(substituted or unsubstituted propylene); where if L 3 is substituted then L 3 is substituted with R 13 .
  • L 3 is -(substituted or unsubstituted Ci-C 3 alkylene)-0-(substituted or unsubstituted Ci-C 3 alkylene)-, or -(substituted or unsubstituted Ci-C 3 alkylene)-S-(substituted or unsubstituted Ci-C 3 alkylene)-; where if L 3 is substituted then L 3 is substituted with R 13 .
  • L 3 is -(substituted or unsubstituted ethylene)-0-(substituted or unsubstituted methylene)-, or -(substituted or unsubstituted ethylene)-S-(substituted or unsubstituted methylene)-; where if L 3 is substituted then L 3 is substituted with R 13 .
  • R 6 is
  • the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is an antagonist of a LP A receptor. In some embodiments, the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is an antagonist of LPAi. In some embodiments, the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is an antagonist of LPA 2 . In some embodiments, the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is an antagonist of LPA 3 .
  • composition comprising a
  • the pharmaceutical composition also contains at least one pharmaceutically acceptable inactive ingredient.
  • composition comprising a
  • the pharmaceutical composition is formulated for intravenous injection, subcutaneous injection, oral administration, inhalation, nasal administration, topical administration, ophthalmic administration or otic administration.
  • the pharmaceutical composition is a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop or an ear drop.
  • the pharmaceutical composition further comprises one or more additional therapeutically active agents selected from: corticosteroids, immunosuppresants, analgesics, anti-cancer agent, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, monoacylglycerol kinase inhibitors, phospholipase Ai inhibitors, phospholipase A 2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, decongestants, antihistamines, mucolytics,
  • additional therapeutically active agents selected from: corticosteroids, immunosuppresants, analgesics, anti-cancer agent, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, monoacylglycerol kinase inhibitors, phospholipa
  • a method comprising administering a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) to a human with a LPA-dependent or LPA-mediated disease or condition.
  • the human is already being administered one or more additional therapeutically active agents other than a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • the method further comprises administering one or more additional therapeutically active agents other than a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • the one or more additional therapeutically active agents other than a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are selected from: corticosteroids, immunosuppresants, analgesics, anti-cancer agent, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, monoacylglycerol kinase inhibitors, phospholipase Ai inhibitors, phospholipase A 2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, decongestants, antihistamines, mucolytics, anticholinergics, antitussives, expectorants, and ⁇ -2 agonists.
  • corticosteroids corticosteroids
  • immunosuppresants analgesics
  • anti-cancer agent anti-inflammatories
  • compositions described herein are administerable to a subject in a variety of ways by multiple administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical or transdermal administration routes.
  • the pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered orally.
  • a compounds of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered topically.
  • the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, shampoos, scrubs, rubs, smears, medicated sticks, medicated bandages, balms, creams or ointments.
  • Such pharmaceutical compounds can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered topically to the skin.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered by inhalation.
  • a compound of Formula (I) is administered by inhalation that directly targets the pulmonary system.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated for intranasal adminstration.
  • Such formulations include nasal sprays, nasal mists, and the like.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated as eye drops.
  • the LPA is selected from LPA l5 LPA 2 , LPA 3 , LPA 4 , LPA 5 and LPA 6 .
  • the LPA receptor is LPAi.
  • the disease or condition is any of the diseases or conditions specified herein.
  • any of the aforementioned aspects are further embodiments in which: (a) the effective amount of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is systemically administered to the mammal; and/or (b) the effective amount of the compound is administered orally to the mammal; and/or (c) the effective amount of the compound is intravenously administered to the mammal; and/or (d) the effective amount of the compound is administered by inhalation; and/or (e) the effective amount of the compound is administered by nasal administration; or and/or (f) the effective amount of the compound is administered by injection to the mammal; and/or (g) the effective amount of the compound is administered topically to the mammal; and/or (h) the effective amount of the compound is administered by ophthalmic administration; and/or (i) the effective amount of the compound is administered rectally to the mammal; and/or (j) the effective amount is adminstered non-systemically or locally to
  • administrations of the effective amount of the compound including further embodiments in which (i) the compound is administered once; (ii) the compound is administered to the mammal multiple times over the span of one day; (iii) continually; or (iv) continuously.
  • any of the aforementioned aspects are further embodiments comprising multiple administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered continuously or intermittently: as in a a single dose; (ii) the time between multiple administrations is every 6 hours; (iii) the compound is administered to the mammal every 8 hours; (iv) the compound is administered to the mammal every 12 hours; (v) the compound is administered to the mammal every 24 hours.
  • the method comprises a drug holiday, wherein the administration of the compound is temporarily suspended or the dose of the compound being administered is temporarily reduced; at the end of the drug holiday, dosing of the compound is resumed.
  • the length of the drug holiday varies from 2 days to 1 year.
  • Also provided is a method of inhibiting the physiological activity of LP A in a mammal comprising administering a therapuetically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
  • a medicament for treating a LPA-dependent or LPA-mediated disease or condition in a mammal comprising a therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • a method for treating or preventing a LPA-dependent or LPA-mediated disease or condition in a mammal comprising administering a therapuetically effective amount of a compound of Formula (I), (II), (III), (LV), (V), (VI), or (VII).
  • LPA-dependent or LPA-mediated diseases or conditions include, but are not limited to, fibrosis of organs or tissues, scarring, liver diseases, dermatological conditions, cancer, cardiovascular disease, respiratory diseases or conditions, inflammatory disease, gastrointestinal tract disease, renal disease, urinary tract-associated disease, inflammatory disease of lower urinary tract, dysuria, frequent urination, pancreas disease, arterial obstruction, cerebral infarction, cerebral hemorrhage, pain, peripheral neuropathy, and fibromyalgia.
  • the LPA-dependent or LPA-mediated disease or condition is a respiratory disease or condition.
  • the respiratory disease or condition is asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary arterial hypertension or acute respiratory distress syndrome.
  • COPD chronic obstructive pulmonary disease
  • pulmonary fibrosis pulmonary arterial hypertension or acute respiratory distress syndrome.
  • the LPA-dependent or LPA-mediated disease or condition is selected from idiopathic pulmonary fibrosis; other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, langerhans cell granulomatosis, lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease); radiation induced fibrosis; chronic obstructive pulmonary disease (COPD); scleroderma; bleomycin induced pulmonary fibrosis; chronic asthma; silicosis; asbestos induced pulmonary fibrosis; acute respiratory distress syndrome (ARDS); kidney fibrosis;
  • COPD chronic obstructive pulmonary disease
  • tubulointerstitium fibrosis tubulointerstitium fibrosis; glomerular nephritis; focal segmental glomerular sclerosis; IgA nephropathy; hypertension; Alport; gut fibrosis; liver fibrosis; cirrhosis; alcohol induced liver fibrosis; toxic/drug induced liver fibrosis; hemochromatosis; nonalcoholic steatohepatitis (NASH); biliary duct injury; primary biliary cirrhosis; infection induced liver fibrosis; viral induced liver fibrosis; and autoimmune hepatitis; corneal scarring; hypertrophic scarring; Duputren disease, keloids, cutaneous fibrosis; cutaneous scleroderma; spinal cord injury/fibrosis; myelofibrosis;
  • NASH nonalcoholic steatohepatitis
  • vascular restenosis atherosclerosis; arteriosclerosis; Wegener's granulomatosis; Peyronie's disease, chronic lymphocytic leukemia, tumor metastasis, transplant organ rejection, endometreosis, neonatal respiratory distress syndrome and neuropathic pain.
  • the LPA-dependent or LPA-mediated disease or condition is described herein.
  • a method for the treatment or prevention of organ fibrosis in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) or a pharmaceutically acceptable salt thereof to a mammal in need thereof.
  • the organ fibrosis comprises lung fibrosis, renal fibrosis, or hepatic fibrosis.
  • a method of improving lung function in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
  • the mammal has been diagnosed as having lung fibrosis.
  • compounds disclosed herein are used to treat idiopathic pulmonary fibrosis (usual interstitial pneumonia) in a mammal.
  • compounds disclosed herein are used to treat diffuse parenchymal interstitial lung diseases in mammal: iatrogenic drug induced, occupational/environmental (Farmer lung), granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease (scleroderma and others), alveolar proteinosis, langerhans cell granulonmatosis,
  • lymphangioleiomyomatosis Hermansky-Pudlak Syndrome
  • Tuberous sclerosis neurofibromatosis
  • metabolic storage disorders familial interstitial lung disease.
  • compounds disclosed herein are used to treat post-transplant fibrosis associated with chronic rejection in a mammal: Bronchiolitis obliterans for lung transplant.
  • compounds disclosed herein are used to treat cutaneous fibrosis in a mammal: cutaneous scleroderma, Dupuytren disease, keloids.
  • compounds disclosed herein are used to treat hepatic fibrosis with or without cirrhosis in a mammal: toxic/drug induced (hemochromatosis), alcoholic liver disease, viral hepatitis (hepatitis B virus, hepatitis C virus, HCV), nonalcoholic liver disease (NASH), metabolic and autoimmune.
  • toxic/drug induced hemochromatosis
  • alcoholic liver disease alcoholic liver disease
  • viral hepatitis hepatitis B virus, hepatitis C virus, HCV
  • NASH nonalcoholic liver disease
  • compounds disclosed herein are used to treat renal fibrosis in a mammal: tubulointerstitium fibrosis, glomerular sclerosis.
  • any of the aforementioned aspects involving the treatment of LPA dependent diseases or conditions are further embodiments comprising administering at least one additional agent in addition to the administartion of a compound having the structure of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • each agent is administered in any order, including simultaneously.
  • the mammal is a human.
  • compounds provided herein are administered to a human.
  • compounds provided herein are orally administered.
  • compounds provided herein are used as antagonists of at least one
  • LPA receptor In some embodiments, compounds provided herein are used for inhibiting the activity of at least one LPA receptor or for the treatment of a disease or condition that would benefit from inhibition of the activity of at least one LPA receptor.
  • the LPA receptor is LPAi.
  • compounds provided herein are used for the formulation of a medicament for the inhibition of LPAi activity.
  • Articles of manufacture which include packaging material, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII), within the packaging material, and a label that indicates that the compound or composition, or pharmaceutically acceptable salt, tautomers, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, is used for inhibiting the activity of at least one LPA receptor, or for the treatment, prevention or amelioration of one or more symptoms of a disease or condition that would benefit from inhibition of the activity of at least one LPA receptor, are provided.
  • Lysophospho lipids are membrane-derived bioactive lipid mediators. Lysophospho lipids include, but are not limited to, lysophosphatidic acid (l-acyl-2-hydroxy-s «-glycero-3 -phosphate; LPA), sphingosine 1 -phosphate (SIP), lysophosphatidylcholine (LPC), and
  • SPC sphingosylphosphorylcholine
  • morphogensis These functions influence many biological processes that include neurogensis, angiogenesis, wound healing, immunity, and carcinogenesis.
  • LPA acts through sets of specific G protein-coupled receptors (GPCRs) in an autocrine and paracrine fashion. LPA binding to its cognate GPCRs (LPAi, LPA 2 , LPA 3 , LPA 4 , LPA 5 , LPA 6 ) activates intracellular signaling pathways to produce a variety of biological responses.
  • GPCRs G protein-coupled receptors
  • Lysophospholipids such as LPA
  • LPA are quantitatively minor lipid species compared to their major phospholipid counterparts (e.g., phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin).
  • LPA has a role as a biological effector molecule, and has a diverse range of physiological actions such as, but not limited to, effects on blood pressure, platelet activation, and smooth muscle contraction, and a variety of cellular effects, which include cell growth, cell rounding, neurite retraction, and actin stress fiber formation and cell migration.
  • the effects of LPA are predominantly receptor mediated.
  • LPAi LPA 2 , LPA 3 , LPA 4 , LPA 5 , LPA 6
  • LPA LPA receptors
  • Activation of the LPA receptors (LPAi, LPA 2 , LPA 3 , LPA 4 , LPA 5 , LPA 6 ) with LPA mediates a range of downstream signaling cascades.
  • LPAi mitogen-activated protein kinase
  • AC adenylyl cyclase
  • LPA LPA receptor activation
  • cAMP cyclic adenosine monophosphate
  • Cdc42 cell division cycle 42/GTP -binding protein
  • c- RAF proto-oncogene serine/threonine-protein kinase Raf
  • c-src proto-oncogene tyrosine-protein kinase Src
  • ERK focal adhesion kinase
  • FK focal adhesion kinase
  • GEF guanine nucleotide exchange factor
  • GEF glycogen synthase kinase 3b
  • JNK c-jun amino-terminal kinase
  • MEK myosin light chain II (MLC II), nuclear factor kB (NF-kB), N-methyl-D-aspartate (NMD A) receptor activation, phosphatidylinositol 3-kinase (PI3K), protein kinase A (PKA), protein kinase C (PKC), ras-related C3 botulinum toxin substrate 1 (RACl).
  • PI3K phosphatidylinositol 3-kinase
  • PKA protein kinase A
  • PKC protein kinase C
  • RACl ras-related C3 botulinum toxin substrate 1
  • the actual pathway and realized end point are dependent on a range of variables that include receptor usage, cell type, expression level of a receptor or signaling protein, and LPA concentration. Nearly all mammalian cells, tissues and organs co-express several LPA-receptor subtypes, which indicates that LPA receptors signal in a cooperative manner. LPAi, LPA 2 , and LP A3 share high amino acid sequence similarity.
  • LPA is produced from activated platelets, activated adipocytes, neuronal cells, and other cell types. Serum LPA is produced by multiple enzymatic pathways that involve monoacylglycerol kinase, phospholipase Ai, secretory phospholipase A 2 , and lysophospholipase D (lysoPLD), including autotaxin. Several enzymes are involved in LPA degradation: lysophospholipase, lipid phosphate phosphatase, and LPA acyl transferase such as endophilin. LPA concentrations in human serum are estimated to be 1-5 ⁇ .
  • Serum LPA is bound to albumin, low-density lipoproteins, or other proteins, which possibly protect LPA from rapid degradation.
  • LPA molecular species with different acyl chain lengths and saturation are naturally occurring, including 1-palmitoyl (16:0), 1- palmitoleoyl (16: 1), 1-stearoyl (18:0), 1-oleoyl (18: 1), 1-linoleoyl (18:2), and 1 -arachidonyl (20:4) LPA.
  • Quantitatively minor alkyl LPA has biological activities similar to acyl LPA, and different LPA species activate LPA receptor subtypes with varied efficacies.
  • LPAi (previously called VZG-l/EDG-2/mrecl .3) couples with three types of G proteins, Gi/ 0 , G q , and G 12 /13. Through activation of these G proteins, LPA induces a range of cellular responses through LPAi including but not limited to: cell proliferation, serum-response element (SRE) activation, mitogen-activated protein kinase (MAPK) activation, adenylyl cyclase (AC) inhibition, phospholipase C (PLC) activation, Ca 2+ mobilization, Akt activation, and Rho activation.
  • SRE serum-response element
  • MAPK mitogen-activated protein kinase
  • AC adenylyl cyclase
  • PLC phospholipase C
  • LPAi Wide expression of LPAi is observed in adult mice, with clear presence in testis, brain, heart, lung, small intestine, stomach, spleen, thymus, and skeletal muscle.
  • human tissues also express LPAi; it is present in brain, heart, lung, placenta, colon, small intestine, prostate, testis, ovary, pancreas, spleen, kidney, skeletal muscle, and thymus.
  • LPA 2 (EDG-4) also couples with three types of G proteins, Gi/ 0 , G q , and G 12 /13, to mediate LPA-induced cellular signaling.
  • Expression of LPA 2 is observed in the testis, kidney, lung, thymus, spleen, and stomach of adult mice and in the human testis, pancreas, prostate, thymus, spleen, and peripheral blood leukocytes.
  • Expression of LPA 2 is upregulated in various cancer cell lines, and several human LPA 2 transcriptional variants with mutations in the 3 '-untranslated region have been observed.
  • LPA 2 in mice has not shown any obvious phenotypic abnormalities, but has demonstrated a significant loss of normal LPA signaling (e.g., PLC activation, Ca 2+ mobilization, and stress fiber formation) in primary cultures of mouse embryonic fibroblasts (MEFs).
  • LPA signaling e.g., PLC activation, Ca 2+ mobilization, and stress fiber formation
  • MEFs mouse embryonic fibroblasts
  • LPAi contributes to normal LPA-mediated signaling responses in at least some cell types (Choi et al, Biochemica et Biophysica Acta 2008, 1781 , p531-539).
  • LPA 3 (EDG-7) is distinct from LPAi and LPA 2 in its ability to couple with Gy Q and G q but not G 12 /13 and is much less responsive to LPA species with saturated acyl chains. LPA 3 can mediate pleiotropic LPA-induced signaling that includes PLC activation, Ca 2+ mobilization, AC
  • LPA 3 is observed in adult mouse testis, kidney, lung, small intestine, heart, thymus, and brain. In humans, it is found in the heart, pancreas, prostate, testis, lung, ovary, and brain (frontal cortex, hippocampus, and amygdala).
  • LPA 4 (p2y 9 /GPR23) is of divergent sequence compared to LPAi, LPA 2 , and LPA 3 with closer similarity to the platelet-activating factor (PAF) receptor.
  • LPA 4 mediates LPA induced Ca 2+ mobilization and cAMP accumulation, and functional coupling to the G protein Gs for AC activation, as well as coupling to other G proteins.
  • the LPA gene is expressed in the ovary, pancreas, thymus, kidney and skeletal muscle.
  • LPA 5 (GPR92) is a member of the purinocluster of GPCRs and is structurally most closely related to LPA 4 .
  • LPA 5 is expressed in human heart, placenta, spleen, brain, lung and gut.
  • LPA 5 also shows very high expression in the CD8+ lymphocyte compartment of the gastrointestinal tract.
  • LPA 6 (p2y5) is a member of the purinocluster of GPCRs and is structurally most closely related to LPA 4 .
  • LPA 6 is an LPA receptor coupled to the G12/13-Rho signaling pathways and is expressed in the inner root sheaths of human hair follicles.
  • LPA is one such mediator that is released from activated platelets; this induces platelet aggregation along with mitogenic/migration effects on the surrounding cells, such as endothelial cells, smooth muscle cells, fibroblasts, and keratinocytes.
  • Topical application of LPA to cutaneous wounds in mice promotes repair processes (wound closure and increased neoepithelial thickness) by increasing cell proliferation/ migration without affecting secondary inflammation.
  • ECM dermal extracellular matrix
  • LPA regulates many important functions of fibroblasts in wound healing, including proliferation, migration, differentiation and contraction. Fibroblast proliferation is required in wound healing in order to fill an open wound. In contrast, fibrosis is characterized by intense proliferation and accumulation of myofibroblasts that actively synthesize ECM and proinflammatory cytokines. LPA can either increase or suppress the proliferation of cell types important in wound healing, such as epithelial and endothelial cells (EC), macrophages, keratinocytes, and fibroblasts.
  • EC epithelial and endothelial cells
  • a role for LPAi in LPA-induced proliferation was provided by the observation that LPA-stimulated proliferation of fibroblasts isolated from LPAi receptor null mice was attenuated (Mills et al, Nat Rev. Cancer 2003; 3: 582-591). LPA induces cytoskeletal changes that are integral to fibroblast adhesion, migration, differentiation and contraction.
  • Tissue injury initiates a complex series of host wound-healing responses; if successful, these responses restore normal tissue structure and function. If not, these responses can lead to tissue fibrosis and loss of function.
  • fibrosis For the majority of organs and tissues the development of fibrosis involves a multitude of events and factors. Molecules involved in the development of fibrosis include proteins or peptides (profibrotic cytokines, chemokines, metalloproteinases etc.) and phospholipids. Phospholipids involved in the development of fibrosis include platelet activating factor (PAF), phosphatidyl choline, sphingosine- 1 phosphate (SIP) and lysophosphatidic acid (LPA).
  • PAF platelet activating factor
  • SIP sphingosine- 1 phosphate
  • LPA lysophosphatidic acid
  • CTGF connective tissue growth factor
  • LPA is associated with the progression of liver fibrosis.
  • LPA induces stellate cell and hepatocyte proliferation. These activated cells are the main cell type responsible for the accumulation of ECM in the liver.
  • LPA plasma levels rise during CCl 4 -induced liver fibrosis in rodents, or in hepatitis C virus-induced liver fibrosis in human (N. Watanabe, et ah, Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity, Life Sci. 81 (2007) 1009-1015; N.Watanabe, et al., J. Clin. Gastroenterol. 41 (2007) 616-623).
  • LPA is associated with heart disease and mycocardial remodeling. Serum LPA levels are increased after myocardial infarction in patients and LPA stimulates rat cardiac fibroblast proliferation and collagen production (Chen et al. FEBS Lett. 2006 Aug 21;580(19):4737-45).
  • Fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF) are associated with high morbidity and mortality.
  • LPA is an important mediator of fibroblast recruitment in pulmonary fibrosis.
  • LPA and LPAi play key pathogenic roles in pulmonary fibrosis.
  • Fibroblast chemoattractant activity plays an important role in the lungs in patients with pulmonary fibrosis.
  • Profibrotic effects of LPAi -receptor stimulation is explained by LPAi -receptor-mediated vascular leakage and increased fibroblast recruitment, both profibrotic events.
  • the LPA-LPAi pathway has a role in mediating fibroblast migration and vascular leakage in IPF. The end result is the aberrant healing process that
  • the LPAi receptor is the LPA receptor most highly expressed on fibroblasts obtained from patients with IPF. Furthermore, BAL obtained from IPF patients induced chemotaxis of human foetal lung fibroblasts that was blocked by the dual LPAi- LP A3 receptor antagonist Ki 16425. In an experimental bleomycin-induced lung injury mouse model, it was shown that LPA levels were high in bronchoalveolar lavage samples compared with unexposed controls. LPAx knockout mice are protected from fibrosis after bleomycin challenge with reduced fibroblast accumulation and vascular leakage. In human subjects with IPF, high LPA levels were observed in bronchoalveolar lavage samples compared with healthy controls.
  • the LPA-LPAx pathway is crucial in fibroblast recruitment and vascular leakage in pulmonary fibrosis .
  • LPA induces avP6-mediated TGF- ⁇ activation on human lung epithelial cells (Xu et al. Am. J. Pathology, vol. 174, no. 2, 1264- 1279, 2009).
  • the LPA-induced avP6-mediated TGF- ⁇ activation is mediated by the LPA2 receptor. Expression of the LPA2 receptor is increased in epithelial cells and mesenchymal cells in areas of lung fibrosis from IPF patients compared to normal human lung tissue.
  • the LPA-LPA2 pathway contributes to the activation of the TGF- ⁇ pathway in pulmonary fibrosis.
  • compounds that inhibit LPA2 show efficacy in the treatment of lung fibrosis.
  • compounds that inhibit both LPAI and LPA2 show improved efficacy in the treatment of lung fibrosis compared to compounds which inhibit only LPAI or LPA2.
  • LPA and LPAi are involved in the etiology of kidney fibrosis.
  • LPA has effetcs on both proliferation and contraction of glomerular mesangial cells and thus has been implicated in proliferative glomerulonephritis (C.N. Inoue, et ah, Clin. Sci. (Colch.) 96, 431- 436, 1999).
  • UUO unilateral ureteral obstruction
  • LPA can participate in intraperitonial accumulation of monocyte/macrophages and that LPA can induce expression of the profibrotic cytokine CTGF in primary cultures of human fibroblasts (J.S. Ko ,et al., J. Clin. Invest. 102 (1998) 716-727).
  • tubulointerstitial fibrosis TGF
  • TGF tubulointerstitial fibrosis
  • LPA is implicated in liver disease and fibrosis. Plasma LPA levels and serum autotoxin (enzyme responsible for LPA production) are elevated in hepatitis patients and animal models of liver injury in correlation with increased fibrosis. LPA also regulates liver cell function. LPAi and LPA 2 receptors are expressed by mouse hepatic stellate cells and LPA stimulates migration of hepatic myofibroblasts.
  • LPA is in involved in wound healing in the eye.
  • LPAi and LPA 3 receptors are detectable in the normal rabbit corneal epithelial cells, keratocytes and endothelial cells and LPAi and LP A3 expression are increased in corneal epithelial cells following injury.
  • LPA and its homologues are present in the aqueous humor and the lacrimal gland fluid of the rabbit eye and these levels are increased in a rabbit corneal injury model.
  • LPA induces actin stress fiber formation in rabbit corneal endothelial and epithelial cells and promotes contraction corneal fibroblasts. LPA also stimulates proliferation of human retinal pigmented epithelial cells
  • LPA is implicated in myocardial infarction and cardiac fibrosis. Serum LPA levels are increased in patients following mycocardial infarction (MI) and LPA stimulates proliferation and collagen production (fibrosis) by rat cardiac fibroblasts. Both LPAI and LP A3 receptors are highly expressed in human heart tissue.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to treat or prevent fibrosis in a mammal.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to treat fibrosis of an organ or tissue in a mammal.
  • a method for preventing a fibrosis condition in a mammal comprising administering to the mammal at risk of developing one or more fibrosis conditions a therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • the mammal has been exposed to one or more environmental conditions that are known to increase the risk of fibrosis of an organ or tissue. In one aspect, the mammal has been exposed to one or more environmental conditions that are known to increase the risk of lung, liver or kidney fibrosis. In one aspect, the mammal has a genetic predisposition of developing fibrosis of an organ or tissue. In one aspect, a compound of Formula (I),
  • injury includes surgery.
  • fibrosis refers to conditions that are associated with the abnormal accumulation of cells and/or fibronectin and/or collagen and/or increased fibroblast recruitment and include but are not limited to fibrosis of individual organs or tissues such as the heart, kidney, liver, joints, lung, pleural tissue, peritoneal tissue, skin, cornea, retina, musculoskeletal and digestive tract.
  • Exemplary diseases, disorders, or conditions that involve fibrosis include, but are not limited to: Lung diseases associated with fibrosis, e.g., idiopathic pulmonary fibrosis, pulmonary fibrosis secondary to systemic inflammatory disease such as rheumatoid arthritis, scleroderma, lupus, cryptogenic fibrosing alveolitis, radiation induced fibrosis, chronic obstructive pulmonary disease (COPD), scleroderma, chronic asthma, silicosis, asbestos induced pulmonary or pleural fibrosis, acute lung injury and acute respiratory distress (including bacterial pneumonia induced, trauma induced, viral pneumonia induced, ventilator induced, non-pulmonary sepsis induced, and aspiration induced); Chronic nephropathies associated with injury/fibrosis (kidney fibrosis), e.g.,
  • glomerulonephritis secondary to systemic inflammatory diseases such as lupus and scleroderma, diabetes,, glomerular nephritis, focal segmental glomerular sclerosis, IgA nephropathy, hypertension, allograft and Alport; Gut fibrosis, e.g., scleroderma, and radiation induced gut fibrosis; Liver fibrosis, e.g., cirrhosis, alcohol induced liver fibrosis, nonalcoholic steatohepatitis (NASH), biliary duct injury, primary biliary cirrhosis, infection or viral induced liver fibrosis (e.g., chronic HCV infection), and autoimmune hepatitis; Head and neck fibrosis, e.g., radiation induced; Corneal scarring, e.g., LASIK (laser-assisted in situ keratomileusis), corneal transplant, and trabeculectomy
  • Atherosclerosis arteriosclerosis, Wegener's granulomatosis, mixed connective tissue disease, and Peyronie's disease.
  • a mammal suffering from one of the following non-limiting exemplary diseases, disorders, or conditions will benefit from therapy with a compound of Formula (I), (II),
  • Atherosclerosis atherosclerosis, thrombosis, heart disease, vasculitis, formation of scar tissue, restenosis, phlobitis, COPD (chronic obstructive pulmonary disease), pulmonary hypertension, pulmonary fibrosis, pulmonary inflammation, bowel adhesions, bladder fibrosis and cystitis, fibrosis of the nasal passages, sinusitis, inflammation mediated by neutrophils, and fibrosis mediated by fibroblasts.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is adminstered to a mammal with fibrosis of an organ or tissue or with a predisposition of developing fibrosis of an organ or tissue with one or more other agents that are used to treat fibrosis.
  • the one or more agents include corticosteroids.
  • the one or more agents include
  • the one or more agents include B-cell antagonists. In one aspect, the one or more agents include uteroglobin.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to treat a dermatological disorders in a mammal.
  • dermatological disorder refers to a skin disorder.
  • Such dermatological disorders include, but are not limited to, proliferative or inflammatory disorders of the skin such as, atopic dermatitis, bullous disorders, collagenoses, psoriasis, psoriatic lesions, scleroderma, dermatitis, contact dermatitis, eczema, urticaria, rosacea, wound healing, scarring, hypertrophic scarring, keloids, Kawasaki Disease, rosacea, Sjogren-Larsso Syndrome, urticaria.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to treat systemic sclerosis.
  • LPAi Since LPA is released following tissue injury, LPAi plays an important role in the initiation of neuropathic pain. LPAi, unlike LPA 2 or LP A3, is expressed in both dorsal root ganglion (DRG) and dorsal root neurons. Using the antisense oligodeoxynucleotide (AS-ODN) for LPAi and LPAi- null mice, it was found that LPA-induced mechanical allodynia and hyperalgesia is mediated in an LPAi -dependent manner. LPAi and downstream Rho-ROCK activation play a role in the initiation of neuropathic pain signaling.
  • AS-ODN antisense oligodeoxynucleotide
  • LPA signaling appears to induce important neuropathic pain markers such as protein kinase Cy (PKCy) and a voltage-gated calcium channel ⁇ 2 ⁇ 1 subunit (Caa281) in an LPAi and Rho-dependent manner (M. Inoue, et ah, Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling, Nat. Med. 10 (2004) 712-718).
  • PKCy protein kinase Cy
  • Caa281 subunit Caa281 subunit
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of pain in a mammal.
  • the pain is acute pain or chronic pain.
  • the pain is neuropathic pain.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of fibromylagia.
  • fibromyalgia stems from the formation of fibrous scar tissue in contractile (voluntary) muscles. Fibrosis binds the tissue and inhibits blood flow, resulting in pain.
  • Lysophospho lipid receptor signaling plays a role in the etiology of cancer.
  • Lysophosphatidic acid (LPA) and its G protein-coupled receptors (GPCRs) LPA l5 LPA 2 , and/or LPA 3 play a role in the development of several types of cancers.
  • the initiation, progression and metastasis of cancer involve several concurrent and sequential processes including cell proliferation and growth, survival and anti-apoptosis, migration of cells, penetration of foreign cells into defined cellular layers and/or organs, and promotion of angiogenesis.
  • Autotaxin is a prometastatic enzyme initially isolated from the conditioned medium of human melanoma cells that stimulates a myriad of biological activities, including angiogenesis and the promotion of cell growth, migration, survival, and differentiation through the production of LPA (Mol Cancer Ther 2008;7(10):3352-62).
  • LPA contributes to tumorigenesis by increasing motility and invasiveness of cells. LPA has been implicated in the initiation or progression of ovarian cancer. LPA is present at significant concentrations (2-80 ⁇ ) in the ascitic fluid of ovarian cancer patients. Ovarian cancer cells constitutively produce increased amounts of LPA as compared to normal ovarian surface epithelial cells, the precursor of ovarian epithelial cancer. Elevated LPA levels are also detected in plasma from patients with early-stage ovarian cancers compared with controls. LPA receptors (LPA2 and LPA3) are also overexpressed in ovarian cancer cells as compared to normal ovarian surface epithelial cells.
  • LPA stimulates Cox-2 expression through transcriptional activation and post- transcriptional enhancement of Cox-2 mRNA in ovarian cancer cells.
  • Prostaglandins produced by Cox-2 have been implicated in a number of human cancers and pharmacological inhibition of Cox-2 activity reduces colon cancer development and decreases the size and number of adenomas in patients with familial adenomatous polyposis.
  • LPA has also been implicated in the initiation or progression of prostate cancer, breast cancer, melanoma, head and neck cancer, bowel cancer (colorectal cancer), thyroid cancer and other cancers (Gardell et al, Trends in Molecular Medicine, vol. 12, no. 2, p 65-75, 2006; Ishii et al, Annu. Rev.
  • LPA receptors mediate both migration of and invasion by pancreatic cancer cell lines: an antagonist of LPA ⁇ and LPA 3 (Ki 16425) and LPAx -specific siRNA effectively blocked in vitro migration in response to LPA and peritoneal fluid (ascites) from pancreatic cancer patients; in addition, Ki 16425 blocked the LPA-induced and ascites-induced invasion activity of a highly peritoneal metastatic pancreatic cancer cell line (Yamada et al, J. Biol. Chem., 279, 6595-6605, 2004).
  • Colorectal carcinoma cell lines show significant expression of LPAi mRNA and respond to LPA by cell migration and production of angiogenic factors. Overexpression of LPA receptors has a role in the pathogenesis of thyroid cancer.
  • LP A3 was originally cloned from prostate cancer cells, concordant with the ability of LPA to induce autocrine proliferation of prostate cancer cells.
  • LPA has stimulatory roles in cancer progression in many types of cancer.
  • LPA is produced from and induces proliferation of prostate cancer cell lines.
  • LPA induces human colon carcinoma DLD 1 cell proliferation, migration, adhesion, and secretion of angiogenic factors through LPAi signalling.
  • LPA enhances cell proliferation and secretion of angiogenic factors.
  • LPA2 and LPA3 receptor activation results in proliferation of the cells.
  • the genetic or pharmacological manipulation of LPA metabolism, specific blockade of receptor signaling, and/or inhibition of downstream signal transduction pathways, represent approaches for cancer therapies.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of cancer.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of malignant and benign proliferative disease.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to prevent or reduce proliferation of tumor cells, invasion and metastasis of carcinomas, pleural mesothelioma (Yamada, Cancer Sci., 2008, 99(8), 1603-1610) or peritoneal mesothelioma, cancer pain, bone metastases (Boucharaba et al, J. Clin. Invest., 2004, 114(12), 1714-1725; Boucharaba et al, Proc. Natl. acad. Sci., 2006, 103(25) 9643-9648).
  • a method of treating cancer in a mammal comprising administering to the mammal a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and a second therapeutic agent, wherein the second therapeutic agent is an anti-cancer agent.
  • cancer refers to an abnormal growth of cells which tend to proliferate in an uncontrolled way and, in some cases, to metastasize (spread).
  • types of cancer include, but is not limited to, solid tumors (such as those of the bladder, bowel, brain, breast, endometrium, heart, kidney, lung, lymphatic tissue (lymphoma), ovary, pancreas or other endocrine organ (thyroid), prostate, skin (melanoma or basal cell cancer) or hematological tumors (such as the leukemias) at any stage of the disease with or without metastases.
  • cancers include, acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer,
  • craniopharyngioma cutaneous T-Cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, Acute lymphoblastic leukemia, acute myeloid leukemia, chronic
  • LPA concentrations are consistently higher in ascites samples than in matched plasma samples.
  • LPA is a contributor to the pathogenesis of respiratory diseases.
  • the respiratory disease is asthma.
  • Proinflammatory effects of LPA include degranulation of mast cells, contraction of smooth-muscle cells and release of cytokines from dendritic cells.
  • Airway smooth muscle cells, epithelial cells and lung fibroblasts all show responses to LPA.
  • LPA induces the secretion of IL-8 from human bronchial epithelial cells.
  • IL-8 is found in increased concentrations in BAL fluids from patients with asthma, chronic obstructive lung disease, pulmonary sarcoidosis and acute respiratory distress syndrome and 11-8 has been shown to exacerbate airway inflammation and airway remodeling of asthmatics.
  • LPA1, LPA2 and LP A3 receptors have all been shown to contribute to the LPA-induced IL-8 production.
  • Studies cloning multiple GPCRs that are activated by LPA allowed the demonstration of the presence of mRNA for the LPAi, LPA 2 and LPA 3 in the lung (J.J.A. Contos, et al, Mol. Pharmacol. 58, 1188-1196, 2000).
  • the release of normal repair mediators, including LPA is exaggerated or the actions of the repair mediators are inappropriately prolonged leading to inappropriate airway remodeling.
  • Major structural features of the remodeled airway observed in asthma include a thickened lamina reticularis (the basement membrane-like structure just beneath the airway epithelial cells), increased numbers and activation of myofibroblasts, thickening of the smooth muscle layer, increased numbers of mucus glands and mucus secretions, and alterations in the connective tissue and capillary bed throughout the airway wall.
  • LPA contributes to these structural changes in the airway.
  • LPA is involved in acute airway
  • LPA contributes to the long- term structural remodeling and the acute hyperresponsiveness of the asthmatic airway. In one aspect, LPA contributes to the hyper-responsiveness that is a primary feature of acute exacerbations of asthma.
  • EGF receptor upregulation is induced by LPA and is also seen in asthmatic airways (M. Amishima, et ah, Am. J. Respir. Crit. Care Med. 157, 1907- 1912, 1998).
  • Chronic inflammation is a contributor to asthma, and several of the transcription factors that are activated by LPA are known to be involved in inflammation (Ediger et al, Eur Respir J 21 :759-769, 2003).
  • the fibroblast proliferation and contraction and extracellular matrix secretion stimulated by LPA contributes to the fibroproliferative features of other airway diseases, such as the peribronchiolar fibrosis present in chronic bronchitis, emphysema, and interstitial lung disease.
  • Emphysema is also associated with a mild fibrosis of the alveolar wall, a feature which is believed to represent an attempt to repair alveolar damage.
  • LPA plays a role in the fibrotic interstitial lung diseases and obliterative bronchiolitis, where both collagen and myofibroblasts are increased.
  • LPA is involved in several of the various syndromes that constitute chronic obstructive pulmonary disease.
  • LPA in vivo induces airway hyper-responsiveness, itch-scratch responses, infiltration and activation of eosinophils and neutrophils, vascular remodeling, and nociceptive flexor responses.
  • LPA also induces histamine release from mouse and rat mast cells.
  • histamine induces various responses, such as contraction of smooth muscle, plasma exudation, and mucus production. Plasma exudation is important in the airway, because the leakage and subsequent airway-wall edema contribute to the development of airway hyperresponsiveness.
  • Plasma exudation progresses to conjunctival swelling in ocular allergic disorder and nasal blockage in allergic rhinitis (Hashimoto et ah, J Pharmacol Sci 100, 82 - 87, 2006).
  • plasma exudation induced by LPA is mediated by histamine release from mast cells via one or more LPA receptors.
  • the LPA receptor(s) include LPAi and/or LPA 3 .
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of various allergic disorders in a mammal.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of respiratory diseases, disorders or conditions in a mammal.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of asthma in a mammal.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of chronic asthma in a mammal.
  • Respiratory disease refers to diseases affecting the organs that are involved in breathing, such as the nose, throat, larynx, eustachian tubes, trachea, bronchi, lungs, related muscles (e.g., diaphram and intercostals), and nerves.
  • Respiratory diseases include, but are not limited to, asthma, adult respiratory distress syndrome and allergic (extrinsic) asthma, non- allergic (intrinsic) asthma, acute severe asthma, chronic asthma, clinical asthma, nocturnal asthma, allergen-induced asthma, aspirin-sensitive asthma, exercise-induced asthma, isocapnic
  • asthma refers to any disorder of the lungs characterized by variations in pulmonary gas flow associated with airway constriction of whatever cause (intrinsic, extrinsic, or both; allergic or non-allergic).
  • the term asthma may be used with one or more adjectives to indicate cause.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the treatment or prevention of chronic obstructive pulmonary disease in a mammal comprising administering to the mammal at least once an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • chronic obstructive pulmonary disease includes, but is not limited to, chronic bronchitis or emphysema, pulmonary hypertension, interstitial lung fibrosis and/or airway inflammation, and cystic fibrosis.
  • the nervous system is a major locus for LPAi expression; there it is spatially and temporally regulated throughout brain development.
  • Oligodendrocytes the myelinating cells in the central nervous system (CNS)
  • CNS central nervous system
  • Schwann cells the myelinating cells of the peripheral nervous system
  • LPAi which is involved in regulating Schwann cell survival and morphology.
  • LPA peripheral nervous system cell lines to LPA produces a rapid retraction of their processes resulting in cell rounding, which was, in part, mediated by polymerization of the actin cytoskeleton.
  • LPA causes neuronal degeneration under pathological conditions when the blood-brain barrier is damaged and serum components leak into the brain (Moolenaar, Curr. Opin. Cell Biol. 7:203-10, 1995).
  • Immortalized CNS neuroblast cell lines from the cerebral cortex also display retraction responses to LPA exposure through Rho activation and actomyosin interactions.
  • LPA is associated with post-ischemic neural damage (J. Neurochem. 61 , 340, 1993; J. Neurochem., 70:66, 1998).
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) for use in the treatment or prevention of a nervous system disorder in a mammal.
  • the term "nervous system disorder,” as used herein, refers to conditions that alter the structure or function of the brain, spinal cord or peripheral nervous system, including but not limited to Alzheimer's Disease, cerebral edema, cerebral ischemia, stroke, multiple sclerosis, neuropathies, Parkinson's Disease, those found after blunt or surgical trauma (including post-surgical cognitive dysfunction and spinal cord or brain stem injury), as well as the neurological aspects of disorders such as degenerative disk disease and sciatica.
  • CNS disorders include, but are not limited to, multiple sclerosis, Parkinson's disease, Alzheimer's disease, stroke, cerebral ischemia, retinal ischemia, post-surgical cognitive dysfunction, migraine, peripheral neuropathy/neuropathic pain, spinal cord injury, cerebral edema and head injury.
  • Cardiovascular phenotypes observed after targeted deletion of lysophospho lipid receptors reveal important roles for lysophospho lipid signaling in the development and maturation of blood vessels, formation of atherosclerotic plaques and maintenance of heart rate (Ishii, I. et al. Annu. Rev. Biochem. 73, 321-354, 2004).
  • Angiogenesis the formation of new capillary networks from preexisting vasculature, is normally invoked in wound healing, tissue growth and myocardial angiogenesis after ischemic injury.
  • Peptide growth factors e.g. vascular endothelial growth factor (VEGF)
  • lysophospholipids control coordinated proliferation, migration, adhesion,
  • VECs vascular endothelial cells
  • VSMCs vascular smooth- muscle cells
  • dysregulation of the processes mediating angiogenesis leads to atherosclerosis, hypertension, tumor growth, rheumatoid arthritis and diabetic retinopathy (Osborne, N. and Stainier, D.Y. Annu. Rev. Physiol. 65, 23-43, 2003).
  • Downstream signaling pathways evoked by lysophospholipid receptors include Rac- dependent lamellipodia formation (e.g. LPAi) and Rho-dependent stress-fiber formation (e.g. LPAi), which is important in cell migration and adhesion.
  • Dysfunction of the vascular endothelium can shift the balance from vasodilatation to vasoconstriction and lead to hypertension and vascular remodeling, which are risk factors for atherosclerosis (Maguire, J.J. et al., Trends Pharmacol. Sci. 26, 448-454, 2005).
  • LPA contributes to both the early phase (barrier dysfunction and monocyte adhesion of the endothelium) and the late phase (platelet activation and intra-arterial thrombus formation) of atherosclerosis, in addition to its overall progression.
  • LPAi and LPA 3 cognate GPCRs expressed on platelets (Siess, W. Biochim. Biophys. Acta 1582, 204-215, 2002; Rother, E. et al. Circulation 108, 741-747, 2003). This triggers platelet shape change and aggregation, leading to intra-arterial thrombus formation and, potentially, myocardial infarction and stroke.
  • LPA can also be a mitogen and motogen to VSMCs and an activator of endothelial cells and macrophages.
  • mammals with cardiovascular disease benefit from LPA receptor antagonists that prevent thrombus and neointima plaque formation.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to treat or prevent cardiovascular disease in mammal.
  • cardiovascular disease refers to diseases affecting the heart or blood vessels or both, including but not limited to: arrhythmia (atrial or ventricular or both);
  • Atherosclerosis and its sequelae angina; cardiac rhythm disturbances; myocardial ischemia;
  • myocardial infarction cardiac or vascular aneurysm; vasculitis, stroke; peripheral obstructive arteriopathy of a limb, an organ, or a tissue; reperfusion injury following ischemia of the brain, heart or other organ or tissue; endotoxic, surgical, or traumatic shock; hypertension, valvular heart disease, heart failure, abnormal blood pressure; shock; vasoconstriction (including that associated with migraines); vascular abnormality, inflammation, insufficiency limited to a single organ or tissue.
  • kits for preventing or treating vasoconstriction, atherosclerosis and its sequelae myocardial ischemia, myocardial infarction, aortic aneurysm, vasculitis and stroke comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) or pharmaceutical composition or medicament thereof.
  • kits for reducing cardiac reperfusion injury following myocardial ischemia and/or endotoxic shock comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • kits for reducing the constriction of blood vessels in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • kits for lowering or preventing an increase in blood pressure of a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • LPA has been shown to regulate immunological responses by modulating activities/functions of immune cells such as T-/B-lymphocytes and macrophages.
  • T cells In activated T cells, LPA activates IL- 2 production/cell proliferation through LPAx (Gardell et al, TRENDS in Molecular Medicine Vol.12 No.2 February 2006).
  • LPAi and LPA 3 Expression of LPA-induced inflammatory response genes is mediated by LPAi and LPA 3 (Biochem Biophys Res Commun. 363(4): 1001-8, 2007).
  • LPA modulates the chemotaxis of inflammatory cells ⁇ Biochem Biophys Res Commun., 1993, 15; 193(2), 497).
  • LPA lymphoid protein
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to treat or prevent inflammation in a mammal.
  • antagonists of LPAi and/or LP A3 find use in the treatment or prevention of inflammatory/immune disorders in a mammal.
  • the antagonist of LPA i is a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • inflammatory/immune disorders include psoriasis, rheumatoid arthritis, vasculitis, inflammatory bowel disease, dermatitis, osteoarthritis, asthma, inflammatory muscle disease, allergic rhinitis, vaginitis, interstitial cystitis, scleroderma, eczema, allogeneic or xenogeneic transplantation (organ, bone marrow, stem cells and other cells and tissues) graft rejection, graft- versus-host disease, lupus erythematosus, inflammatory disease, type I diabetes, pulmonary fibrosis, dermatomyositis, Sjogren's syndrome, thyroiditis (e.g., Hashimoto's and autoimmune thyroiditis), myasthenia gravis, autoimmune hemolytic anemia, multiple sclerosis, cystic fibrosis, chronic relapsing hepatitis, primary biliary cirrhosis, allergic conjun
  • the subject already has a LPA-dependent or LPA-mediated disease or condition at the time of administration, or is at risk of developing a LPA- dependent or LPA-mediated disease or condition.
  • the activity of LPAi in a mammal is directly or indirectly modulated by the administration of (at least once) a therapeutically effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • modulation includes, but is not limited to, reducing and/or inhibiting the activity of LPAi.
  • the activity of LPA in a mammal is directly or indirectly modulated, including reducing and/or inhibiting, by the
  • Such modulation includes, but is not limited to, reducing and/or inhibiting the amount and/or activity of a LPA receptor.
  • the LPA receptor is LPAi.
  • LPA has a contracting action on bladder smooth muscle cell isolated from bladder, and promotes growth of prostate-derived epithelial cell ⁇ The Journal of Urology , 1999, vol. 162, pp. 1779-1784; The Journal of Urology , 2000, vol. 163, pp. 1027-1032).
  • LPA contracts the urinary tract and prostate in vitro and increases intraurethral pressure in vivo (WO 02/062389).
  • eosinophil and/or basophil and/or dendritic cell and/or neutrophil and/or monocyte and/or T-cell recruitment comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III),
  • cystitis including, e.g., interstitial cystitis, comprising administering at least once to the mammal a therapeutically effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • methods described herein include the diagnosis or determination of whether or not a patient is suffering from a LPA-dependent or LPA-mediated disease or condition by administering to the subject a therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and determining whether or not the patient responds to the treatment.
  • LPA-dependent or LPA-mediated conditions or diseases including, but not limited to, lung fibrosis, kindney fibrosis, liver fibrosis, scarring, asthma, rhinitis, chronic obstructive pulmonary disease, pulmonary hypertension, interstitial lung fibrosis, arthritis, allergy, psoriasis, inflammatory bowel disease, adult respiratory distress syndrome, myocardial infarction, aneurysm, stroke, cancer, pain, proliferative disorders and inflammatory conditions.
  • LPA-dependent conditions or diseases include those wherein an absolute or relative excess of LP A is present and/or observed.
  • the LPA-dependent or LPA-mediated diseases or conditions include, but are not limited to, organ fibrosis, asthma, allergic disorders, chronic obstructive pulmonary disease, pulmonary hypertension, lung or pleural fibrosis, peritoneal fibrosis, arthritis, allergy, cancer, cardiovascular disease, ult respiratory distress syndrome, myocardial infarction, aneurysm, stroke, and cancer.
  • compounds of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are used to improve the corneal sensitivity decrease caused by corneal operations such as laser-assisted in situ keratomileusis (LASIK) or cataract operation, corneal sensitivity decrease caused by corneal degeneration, and dry eye symptom caused thereby.
  • corneal operations such as laser-assisted in situ keratomileusis (LASIK) or cataract operation
  • corneal sensitivity decrease caused by corneal degeneration corneal degeneration
  • dry eye symptom caused thereby.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the treatment or prevention of ocular inflammation and allergic conjunctivitis, vernal keratoconjunctivitis, and papillary conjunctivitis in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • LPA and LPA receptors are involved in the pathogenesis of osteoarthritis (Kotani et al, Hum. Mol. Genet., 2008, 17, 1790-1797).
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the treatment or prevention of osteoarthritis in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • LPA receptors contribute to the pathogenesis of rheumatoid arthritis (Zhao et al, Mol. Pharmacol., 2008, 73(2), 587-600).
  • LPA receptors e.g. LPA l 5 LPA 3
  • LPA l 5 LPA 3 contribute to the pathogenesis of rheumatoid arthritis (Zhao et al, Mol. Pharmacol., 2008, 73(2), 587-600).
  • presented herein is the use of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the treatment or prevention of rheumatoid arthritis in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • LPA receptors contribute to adipogenesis.
  • LPAi LPA receptors
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the promotion of adipose tissue formation in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (LV), (V), (VI), or (VII).
  • R 3 is , and Pv 5 is H, Ci-C 4 alkyl, or Ci-C 4 fluoroalkyl; or
  • Pv 5 is , and Pv 3 is H, Ci-C 4 alkyl, or Ci-C 4 fluoroalkyl;
  • R la and R lb are each independently selected from H, Ci-C 4 alkyl and substituted or unsubstituted benzyl;
  • R D is H or Ci-C 6 alkyl
  • R E is C C 6 alkyl or a substituted or unsubstituted phenyl
  • L 3 is a substituted or unsubstituted Ci-C 6 alkylene, substituted or unsubstituted C
  • each R 13 is independently selected from F, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, hydroxyl, Ci-C 4 alkoxy and Ci-C 4 fluoroalkoxy; or L 3 is - ⁇ 1 -!. 5 -;
  • L 4 is absent or a substituted or unsubstituted Ci-C 4 alkylene, where if L 4 is substituted then L 4 is substituted with 1 to 3 R 14 ; each R 14 is independently selected from F, Ci-
  • Ci-C 4 fluoroalkyl hydroxyl
  • Ci-C 4 alkoxy Ci-C 4 fluoroalkoxy and a substituted or unsubstituted phenyl
  • Ci-C 4 fluoroalkyl or Ci-C 4 heteroalkyl
  • R 8 is H, Ci-C 4 alkyl, or Ci-C 4 fluoroalkyl
  • L 5 is absent or a substituted or unsubstituted Ci-C 4 alkylene, where if L 5 is substituted then L 5 is substituted with 1 to 3 R 15 ; each R 15 is independently selected from F, Ci-
  • Ci-C 4 fluoroalkyl hydroxyl, Ci-C 4 alkoxy and Ci-C 4 fluoroalkoxy;
  • R 6 is Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, substituted or unsubstituted C 3 -Ci 0 cycloalkyl, a
  • substituted or unsubstituted C 3 -Cioheterocycloalkyl a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted monocyclic heteroaryl, or a substituted or unsubstituted bicyclic heteroaryl, wherein if R 6 is substituted then R 6 is substituted with 1 to 3 R c ;
  • each R 9 is independently selected from H, Ci-C 6 alkyl, Ci-C 6 heteroalkyl, Ci-C 6 fluoroalkyl, a substituted or unsubstituted C3-C 6 cycloalkyl, a substituted or unsubstituted C 2 - Ceheterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted monocyclic heteroaryl, -Ci-C 4 alkylene-(substituted or unsubstituted C 3 -C 6 cycloalkyl), - Ci-C 4 alkylene-(substituted or unsubstituted C 2 -C 6 heterocycloalkyl), -Ci-C 4 alkylene- (substituted or unsubstituted phenyl), or -Ci-C 4 alkylene-(substituted or unsubstituted heteroaryl); or
  • R 10 is selected from Ci-C 6 alkyl, Ci-C 6 heteroalkyl, Ci-C 6 fluoroalkyl, a substituted or
  • R is -C0 2 R D .
  • R 5 is H, -CH 3 , or -CH 2 CH 3 . In some embodiments, R 5 is -CH 3 , or -CH 2 CH 3 . In some embodiments, R 5 is -CH 3 . In some embodiments, R 5 is H. In some embodiments, R 5 is -H, -CH 3 or -CH 2 CH 3 ; R 1 is -C0 2 R D ; R D is H or Ci-C 6 alkyl.
  • the compound of Formula (I) has the structure of Formula (II):
  • the compound of Formula (II) has the following structure:
  • R 5 is R 3 is H, Ci-C 4 alkyl, or Ci-C 4
  • R 5 is . In some embodiments, R is
  • R 3 is H, -CH 3 , or -CH 2 CH 3 . In some embodiments, R 3 is or -CH 2 CH 3 . In some embodiments, R 3 is -CH 3 . In some embodiments, R 3 is H. In some embodiments, R 3 is -H, -CH 3 or -CH 2 CH 3 ; R 1 is -C0 2 R D ; R D is H or C C 6 alkyl.
  • the compound of Formula (I) has the structure of Formula (III)
  • the compound of Formula III has the following structure:
  • each R is independently selected from halogen, -CN, -OH, - C 4 alkyl, Ci-C 4 fluoroalkyl, Ci-C 4 fluoroalkoxy, Ci-C 4 alkoxy, and Ci-C 4 heteroalkyl.
  • each R A is independently selected from halogen, -CN, -OH, -CH 3 , -CH 2 CH 3 , -CF 3 , - OCF 3 , -OCH 3 and -OCH 2 CH 3 .
  • each R A is independently halogen, -CN, -OH, -CH 3 , -CH 2 CH 3 , -CF 3 , -OCF 3 , -OCH 3 or -OCH 2 CH 3 . In some embodiments, each R A is independently halogen, -OH, or -CH 3 .
  • each R B is independently selected from halogen, -CN, -OH, Ci- C 4 alkyl, Ci-C 4 fluoroalkyl, Ci-C 4 fluoroalkoxy, Ci-C 4 alkoxy, and Ci-C 4 heteroalkyl.
  • each R B is independently selected from halogen, -CN, -OH, -CH 3 , -CH 2 CH 3 , -CF 3 , - OCF 3 , -OCH 3 and -OCH 2 CH 3 .
  • each R B is independently halogen, -CN, -OH, - CH 3 , -CH 2 CH 3 , -CF 3 , -OCF 3 , -OCH 3 or -OCH 2 CH 3 . In some embodiments, each R B is independently halogen, -OH, or -CH 3 .
  • L 1 is absent, Ci-C 4 alkylene, C 3 -C 6 cycloalkylene, -C 3 -
  • L 1 is Ci-C 4 alkylene, C 3 -C 6 cycloalkylene, -C 3 - C 6 cycloalkylene-Ci-C 4 alkylene-, -Ci-C 4 alkylene-C 3 -C 6 cycloalkylene- or -C(R la )(R lb )-.
  • R 6 is substituted with 1, 2 or 3 R c . In some embodiments, R 6 is substituted with 1 or 2 R c . In some embodiments, R 6 is substituted with R c . In some embodiments, R 6 is unsubstituted. In some embodiments, if R 6 is substituted then R 6 is substituted with 1, 2 or 3 R c . In some embodiments, if R 6 is substituted then R 6 is substituted with 1 or 2 R c . In some
  • R 6 if R 6 is substituted then R 6 is substituted with R c . In some embodiments, R 6 is unsubstituted.
  • each R c is halogen, -CN, -OH, -CH 3 , -CH 2 CH 3 , -CF 3 , -OCF 3 , -OCH 3 , -OCH 2 CH 3 , - CH 2 OCH 3 , -CH 2 OCH 2 CH 3 , or -CH 2 N( CH 3 ) 2 .
  • each R c is independently selected from halogen, -OH, -CN, -CH 3 , -CH 2 CH 3 , -CF 3 , -OCF 3 , -OCH 3 and -OCH 2 CH 3 .
  • R 6 is Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, substituted or unsubstituted C 3 - Ciocycloalkyl, a substituted or unsubstituted C 3 -Cioheterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted monocyclic heteroaryl, or a substituted or unsubstituted bicyclic heteroaryl.
  • R 6 is substituted or unsubstituted C 3 -Ciocycloalkyl, a substituted or unsubstituted phenyl, or a substituted or
  • R 6 is a substituted or unsubstituted phenyl or a substituted or unsubstituted monocyclic heteroaryl. In some embodiments, R 6 is a substituted or unsubstituted phenyl.
  • R 6 is C 3 -C 6 cycloalkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic heteroaryl, wherein if R 6 is substituted then R 6 is substituted with 1 to 3 R c ; each R c is independently selected from H, halogen, -CN, -N0 2 , -OH, Ci-C 4 alkyl, C C 4 fluoroalkyl, Ci-C 4 fluoroalkoxy, Ci-C 4 alkoxy, and Ci-C 4 heteroalkyl.
  • R 6 is a substituted or unsubstituted phenyl, wherein if R 6 is substituted then R 6 is substituted with 1 to 3 R c .
  • L 1 is absent, -CH 2 -, -CH(CH 3 )-, -C(CH 3 ) 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, cyclopropyl- 1,1 -diyl, cyclopropyl- 1 ,2-diyl, cyclobutyl- 1,1 -diyl, cyclopentyl- 1 , 1 -diyl, cyclohexyl- 1 , 1 - diyl, or -C(CH 2 CH 2 )CH 2 -.
  • L 1 is -CH(CH 3 )-, -C(CH 3 ) 2 -, cyclopropyl- 1,1 -diyl, cyclopropyl- 1 ,2- diyl, cyclobutyl- 1,1 -diyl, cyclopentyl- 1 , 1 -diyl, cyclohexyl- 1,1 -diyl, or -C(CH 2 CH 2 )CH 2 -.
  • L 1 is cyclopropyl- 1,1 -diyl, cyclopropyl- 1 ,2-diyl, or -C(CH 2 CH 2 )CH 2 -. In some embodiments, L 1 is cyclopropyl- 1,1 -diyl.
  • each R 9 is independently selected from H, Ci-C 6 alkyl, C 3 - C 6 cycloalkyl, a substituted or unsubstituted phenyl, and -CH 2 -(substituted or unsubstituted phenyl); or two R 9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted heterocycle;
  • R 10 is selected from Ci-C 6 alkyl, C 3 -
  • L 3 is substituted with 1, 2 or 3 R 13 . In some embodiments, L 3 is substituted with 1 or 2 R 13 . In some embodiments, L 3 is substituted with R 13 . In some embodiments, L 3 is unsubstituted. In some embodiments, if L 3 is substituted then L 3 is substituted with 1, 2 or 3 R 13 . In some embodiments, if L 3 is substituted then L 3 is substituted with 1 or 2 R 13 . In some
  • each R 13 is independently selected from F, Ci-C 4 alkyl, Ci- C 4 fluoroalkyl, hydroxyl, Ci-C 4 alkoxy, Ci-C 4 fluoroalkoxy and a substituted or unsubstituted phenyl. In some embodiments, each R 13 is independently selected from F, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, hydroxyl, Ci-C 4 alkoxy, and Ci-C 4 iluoroalkoxy.
  • each R 13 is independently selected from F, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, and -OH. In some embodiments, each R 13 is independently selected from F, Ci-C 4 alkyl, and -OH. In some embodiments, each R 13 is
  • each R 13 is independently selected from F, -CH 3 , -CH 2 CH 3 , -CF 3 , and -OH. In some embodiments, each R 13 is independently selected from F, -CH 3 , and -OH. In some embodiments, each R 13 is independently selected from - CH 3 , and -OH. In some embodiments, R 13 is F, -CH 3 , -CH 2 CH 3 , -CF 3 , or -OH. In some embodiments,
  • R 13 is F, -CH 3 , -CH 2 CH 3 , or -OH. In some embodiments, R 13 is -CH 3 or -OH. In some embodiments, R 13 is Ci-C 4 alkyl, or -OH.
  • L 3 is a substituted or unsubstituted C 3 -C6alkylene, substituted or unsubstituted C 3 -C6fluoroalkylene, or substituted or unsubstituted C 3 -C6heteroalkylene, where if L 3 is substituted then L 3 is substituted with 1 to 3 R 13 ; each R 13 is independently selected from F, Ci-
  • Ci-C 4 fluoroalkyl hydroxyl
  • Ci-C 4 alkoxy Ci-C 4 fluoroalkoxy
  • L 3 is a substituted or unsubstituted C 3 -C6alkylene, where if L 3 is substituted then L 3 is substituted with 1 to 3 R 13 ; each R 13 is independently selected from F, Ci-
  • Ci-C 4 fluoroalkyl hydroxyl
  • Ci-C 4 alkoxy Ci-C 4 fluoroalkoxy
  • L 3 is a substituted or unsubstituted C 3 -C 6 fluoroalkylene, where if L 3 is substituted then L 3 is substituted with 1 to 3 R 13 ; each R 13 is independently selected from F, Ci-
  • Ci-C 4 fluoroalkyl hydroxyl
  • Ci-C 4 alkoxy Ci-C 4 fluoroalkoxy
  • L 3 is a substituted or unsubstituted C 3 -C 6 heteroalkylene, where if L 3 is substituted then L 3 is substituted with 1 to 3 R 13 ; each R 13 is independently selected from F, Ci- C 4 alkyl, Ci-C 4 fluoroalkyl, hydroxyl, Ci-C 4 alkoxy and Ci-C 4 fluoroalkoxy.
  • L 3 is a substituted or unsubstituted Ci-C 6 alkylene, substituted or unsubstituted Ci-C6fluoroalkylene, substituted or unsubstituted -Ci-C6alkylene-0-, substituted or unsubstituted -Ci-C 3 alkylene-0-Ci-C 3 alkylene-, substituted or unsubstituted -0-Ci-C6alkylene-, substituted or unsubstituted -Ci-C 6 alkylene-S-, substituted or unsubstituted -Ci-C 3 alkylene-S-Cr C 3 alkylene-, substituted or unsubstituted -S-Ci-C6alkylene-, substituted or unsubstituted -Ci- C6alkylene-SO-, substituted or unsubstituted -Ci-C 3 alkylene-SO-Ci-C 3 alkylene-SO-, substituted or
  • each R 13 is independently selected from F, -CH 3 , -CF 3 , hydroxyl, -OCH 3 , and -OCF 3 .
  • L 3 is a substituted or unsubstituted Ci-C 4 alkylene, substituted or unsubstituted Ci-C 4 fluoroalkylene, substituted or unsubstituted -Ci-C 4 alkylene-0-, substituted or unsubstituted -Ci-C 3 alkylene-0-Ci-C 3 alkylene-, substituted or unsubstituted -0-Ci-C 4 alkylene-, substituted or unsubstituted -Ci-C 4 alkylene-S-, substituted or unsubstituted -Ci-C 3 alkylene-S-Ci- C 3 alkylene-, substituted or unsubstituted -S-Ci-C 4 alkylene-, substituted or unsubstituted -C
  • L 3 is a substituted or unsubstituted C 3 -C 4 alkylene, substituted or unsubstituted C 3 -C 4 fluoroalkylene, substituted or unsubstituted -C2-C 4 alkylene-0-, substituted or unsubstituted -Ci-C 3 alkylene-0-Ci-C 3 alkylene-, substituted or unsubstituted -0-C2-C 4 alkylene-, substituted or unsubstituted -C2-C 4 alkylene-S-, substituted or unsubstituted -Ci-C 3 alkylene-S-Ci- C 3 alkylene-, substituted or unsubstituted -S-C2-C 4 alkylene-, substituted or unsubstituted -C 2 - C 4 alkylene-NH-, substituted or unsubstituted -Ci-C 3 alkylene-NH-Ci-C 3
  • L 3 is a substituted or unsubstituted C 4 alkylene or substituted or unsubstituted C 4 fluoroalkylene; where if L 3 is substituted then L 3 is substituted with 1 or 2 R 13 ; each R 13 is independently selected from F, -CH 3 , -CF 3 ,and hydroxyl.
  • L 3 is a substituted or unsubstituted -Ci-C 4 alkylene-0-, substituted or unsubstituted -Ci-C 3 alkylene-0-Ci-C 3 alkylene-, substituted or unsubstituted -0-Ci-C 4 alkylene-, substituted or unsubstituted -Ci-C 4 alkylene-S-, substituted or unsubstituted -Ci-C 3 alkylene-S-Cr C 3 alkylene-, substituted or unsubstituted -S-Ci-C 4 alkylene-, substituted or unsubstituted -Ci- C 4 alkylene-NH-, substituted or unsubstituted -Ci-C 3 alkylene-NH-Ci-C 3 alkylene-, substituted or unsubstituted -NH-Ci-C 4 alkylene-; where if L 3 is substituted then L 3
  • L 3 is a substituted or unsubstituted -C2-C 4 alkylene-0-, substituted or unsubstituted -Ci-C 3 alkylene-0-Ci-C 3 alkylene-, substituted or unsubstituted -0-C 2 -C 4 alkylene-, substituted or unsubstituted -C2-C 4 alkylene-S-, substituted or unsubstituted -Ci-C 3 alkylene-S-Ci- C 3 alkylene-, substituted or unsubstituted -S-C2-C 4 alkylene-, substituted or unsubstituted -C 2 - C 4 alkylene-NH-, substituted or unsubstituted -Ci-C 3 alkylene-NH-Ci-C 3 alkylene-, substituted or unsubstituted -NH-C2-C 4 alkylene-; where if L 3 is substituted then L 3 is substituted then L 3 is substituted
  • L 3 is a substituted or unsubstituted -Ci-C 4 alkylene-0-, substituted or unsubstituted -Ci-C 3 alkylene-0-Ci-C 3 alkylene-, or substituted or unsubstituted -0-Ci-C 4 alkylene-; where if L is substituted then L is substituted with 1 or 2 R ; each R is independently selected from F, -CH 3 , -CF 3 , and hydroxyl.
  • L 3 is a substituted or unsubstituted -C2-C 4 alkylene-0-, substituted or unsubstituted -Ci-C 3 alkylene-0-Ci-C 3 alkylene-, or substituted or unsubstituted -0-C2-C 4 alkylene-; where if L is substituted then L is substituted with 1 or 2 R ; each R is independently selected from F, -CH 3 , -CF 3 , and hydroxyl.
  • L 3 is a substituted or unsubstituted -Ci-C 4 alkylene-S-, substituted or unsubstituted -Ci-C 3 alkylene-S-Ci-C 3 alkylene-, or substituted or unsubstituted -S-Ci-C 4 alkylene-; where if L is substituted then L is substituted with 1 or 2 R ; each R is independently selected from F, -CH 3 , -CF 3 , and hydroxyl.
  • L 3 is a substituted or unsubstituted -C2-C 4 alkylene-S-, substituted or unsubstituted -Ci-C 3 alkylene-S-Ci-C 3 alkylene-, or substituted or unsubstituted -S-C2-C 4 alkylene-; where if L is substituted then L is substituted with 1 or 2 R ; each R is independently selected from F, -CH 3 , -CF 3 , and hydroxyl.
  • L 3 is a substituted or unsubstituted -Ci-C 4 alkylene-NH-, substituted or unsubstituted -Ci-C 3 alkylene-NH-Ci-C 3 alkylene-, substituted or unsubstituted -NH-Cr
  • L 3 is a substituted or unsubstituted -C 2 -C 4 alkylene-NH-, substituted or unsubstituted -Ci-C 3 alkylene-NH-Ci- C 3 alkylene-, substituted or unsubstituted -NH-C2-C 4 alkylene-; where if L 3 is substituted then L 3 is substituted with 1 or 2 R 13 ; each R 13 is independently selected from F, -CH 3 , -CF 3 , and hydroxyl.
  • L 3 is a substituted or unsubstituted C 3 -C 4 alkylene, a substituted or unsubstituted C 3 -C 4 fluoroalkylene, or a substituted or unsubstituted C 3 -C 6 heteroalkylene.
  • L 3 is a substituted or unsubstituted propylene, a substituted or unsubstituted propenylene, a substituted or unsubstituted butylene, a substituted or unsubstituted butenylene, a substituted or unsubstituted pentylene, a substituted or unsubstituted pentenylene.
  • L 3 is a substituted or unsubstituted butylene, a substituted or unsubstituted butenylene, a substituted or unsubstituted fluorobutylene, a substituted or unsubstituted
  • L 3 is a substituted or unsubstituted butylene, a substituted or unsubstituted fluorobutylene, or a substituted or unsubstituted difluorobutylene. [0213] In some embodiments, L 3 is a substituted or unsubstituted C3-C6heteroalkylene. In some embodiments, L 3 is a substituted or unsubstituted C3-C 4 heteroalkylene.
  • L 3 is -(substituted or unsubstituted C 3 -C 4 alkylene)-0-, -(substituted or unsubstituted Ci-C3alkylene)-0-(substituted or unsubstituted Ci-C3alkylene)-, -0-(substituted or unsubstituted C3-C 4 alkylene)-, -(substituted or unsubstituted C3-C 4 alkylene)-S-, -(substituted or unsubstituted Ci-C 3 alkylene)-S-(substituted or unsubstituted Ci-C 3 alkylene)-, -S-(substituted or unsubstituted C3-C 4 alkylene)-, -(substituted or unsubstituted C3-C 4 alkylene)-NH-, -(substituted or unsubstituted
  • L 3 is -NH-(substituted or unsubstituted C3-C 4 alkylene).
  • L 3 is -(substituted or unsubstituted Ci-C3alkylene)-0-(substituted or unsubstituted Ci-C 3 alkylene)-, or -(substituted or unsubstituted Ci-C 3 alkylene)-S-(substituted or unsubstituted Ci-C3alkylene)-.
  • L 3 is -(substituted or unsubstituted ethylene)- 0-(substituted or unsubstituted methylene)-, or -(substituted or unsubstituted ethylene)-S-(substituted or unsubstituted methylene)- .
  • L 3 is - ⁇ ⁇ 1 -!, 5 -.
  • L 4 is absent or a substituted or unsubstituted Ci-C 4 alkylene, where if L 4 is substituted then L 4 is substituted with 1 or 2 R 14 ; each R 14 is independently selected from F, - CH 3 , -CF 3 , hydroxyl, -OCH 3 , and -OCF 3 ;
  • R 8 is H, or Ci-C 4 alkyl
  • L 5 is absent or a substituted or unsubstituted Ci- C 4 alkylene, where if L 5 is substituted then L 5 is substituted with 1 or 2 R 15 ; each R 15 is independently selected from F, -CH 3 , -CF 3 , hydroxyl, -OCH 3 , and -OCF 3 .
  • L 4 is absent;
  • L 5 is a substituted or unsubstituted Ci-C 4 alkylene, where if L 5 is substituted then L 5 is substituted with 1 or 2 R 15 ; each R 15 is independently selected from F, - CH 3 , -CF 3 , hydroxyl, -OCH 3 , and -OCF 3 .
  • L 4 is absent;
  • L 5 is a substituted or unsubstituted C 2 -C 4 alkylene, where if L 5 is substituted then L 5 is substituted with 1 or 2 R 15 ; each R 15 is independently selected from F, - CH 3 , -CF 3 , or hydroxyl.
  • L 4 is a substituted or unsubstituted Ci-C 4 alkylene, where if L 4 is substituted then L 4 is substituted with 1 or 2 R 14 ; each R 14 is independently selected from F, -CH 3 , - CF 3 , hydroxyl, -OCH 3 , and -OCF 3 ; L 5 is absent.
  • L 4 is a substituted or unsubstituted C2-C 4 alkylene, where if L 4 is substituted then L 4 is substituted with 1 or 2 R 14 ; each R 14 is independently selected from F, -CH 3 , - CF 3 , or hydroxyl; L 5 is absent.
  • L 4 is a substituted or unsubstituted C2-C 4 alkylene, where if L 4 is substituted then L 4 is substituted with 1 or 2 R 14 ; each R 14 is independently selected from F, -CH 3 , -
  • L 5 is a substituted or unsubstituted C 2 -C 4 alkylene, where if L 5 is substituted then L 5 is substituted with 1 or 2 R 15 ; each R 15 is independently selected from F, -CH 3 , -CF 3 , or hydroxyl.
  • X 1 is -0-, -S-, or -NR 7 -.
  • n is 0 or 1.
  • n 0.
  • the compound of Formula (I) has the structure of Formula (IV), or a pharmaceutically acceptable solvate, or a pharmaceutically acceptable salt, or a prodrug, or a metabolite thereof:
  • L 1 is absent, Ci-C 4 alkylene, C 3 -C 6 cycloalkylene, -C 3 -C 6 cycloalkylene-Ci-C 4 alkylene-, or -
  • R la and R lb are each independently selected from H, Ci-C 4 alkyl and substituted or unsubstituted benzyl;
  • each R is independently selected from H, F, Ci-C 4 alkyl, C C 4 fluoroalkyl, hydroxyl, Ci-C 4 alkoxy and Ci-C 4 fluoroalkoxy;
  • R 8 is H, Ci-C 4 alkyl, or Ci-C 4 fluoroalkyl; L 5 absent or a substituted or unsubstituted Ci-C 4 alkylene, where if L 5 is substituted then L 5 is substituted with 1 to 3 R 15 ; each R 15 is independently selected from F, Ci-C 4 alkyl, d- C 4 fluoroalkyl, hydroxyl, Ci-C 4 alkoxy and Ci-C 4 fluoroalkoxy;
  • n 0, 1, or 2
  • p 0, 1, or 2
  • each of R A , R B , and R c are independently selected from H, halogen, -CN, -N0 2 , -OH, -OR 9 , - N(R 9 ) 2 , Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, Ci-C 4 fluoroalkoxy, Ci-C 4 alkoxy, and C C 4 heteroalkyl;
  • each R 9 is independently selected from H, Ci-C 6 alkyl, Ci-C 6 fiuoroalkyl, a substituted or unsubstituted phenyl, or -CH 2 -(substituted or unsubstituted phenyl); or
  • R 10 is selected from Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, C 3 -C 6 cycloalkyl, and a substituted or unsubstituted phenyl.
  • the compound of Formula (I) has a structure of Formula (V), or a pharmaceutically acceptable solvate, or a pharmaceutically acceptable salt, or a prodrug, or a metabolite thereof:
  • L 1 is absent, Ci-C 4 alkylene, C3-C 6 cycloalkylene, -C3-C 6 cycloalkylene-Ci-C 4 alkylene-, or - C(R la )(R lb )-;
  • R la and R lb are each independently selected from H, Ci-C 4 alkyl and substituted or unsubstituted benzyl;
  • each R 14 is independently selected from H, F, Ci-C 4 alkyl, C
  • R 8 is H, Ci-C 4 alkyl, or Ci-C 4 fluoroalkyl;
  • each R 15 is independently selected from F, Ci-C 4 alkyl, C
  • n 0, 1, or 2
  • p 0, 1, or 2
  • each of R A , R B , and R c are independently selected from H, halogen, -CN, -N0 2 , -OH, -OR 9 , -
  • Ci-C 4 alkyl Ci-C 4 fluoroalkyl
  • Ci-C 4 fluoroalkoxy Ci-C 4 alkoxy
  • Ci-C 4 alkoxy Ci-C 4 alkoxy
  • each R 9 is independently selected from H, Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, a substituted or unsubstituted phenyl, or -CH 2 -(substituted or unsubstituted phenyl); or
  • R 10 is selected from Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, C3-C 6 cycloalkyl, and a substituted or
  • L 1 is Ci-C 4 alkylene, C3-C6cycloalkylene, -C 3 -C6cycloalkylene-Ci- C 4 alkylene-, or -C(R la )(R lb )-.
  • L 1 is -CH 2 -, -CH(CH 3 )-, -CH(substituted or unsubstituted benzyl)-, - C(CH 3 ) 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, cyclopropyl- 1 , 1 -diyl, cyclopropyl- 1 ,2-diyl, cyclobutyl- 1 , 1 -diyl, cyclopentyl-l,l-diyl, cyclohexyl- 1 , 1 -diyl, or -C(CH 2 CH 2 )CH 2 -.
  • L 1 is -CH(CH 3 )-, -CH(substituted or unsubstituted benzyl)-, - C(CH 3 ) 2 -, cyclopropyl- 1,1 -diyl, cyclopropyl- 1 ,2-diyl, or -C(CH 2 CH 2 )CH 2 -.
  • L 1 is cyclopropyl- 1,1 -diyl, cyclopropyl- 1 ,2-diyl, or -C(CH 2 CH 2 )CH 2 -.
  • L 1 is C 3 -C 6 cycloalkylene, or -C 3 -C 6 cycloalkylene-Ci-C 4 alkylene.
  • L 1 is C 3 -C6cycloalkylene.
  • L 1 is cyclopropyl- 1,1 -diyl, cyclopropyl- 1 ,2-diyl, cyclobutyl- 1,1 -diyl, cyclopentyl- 1 , 1 -diyl, cyclohexyl- 1 , 1 -diyl.
  • L 4 is absent or a substituted or unsubstituted Ci-C 4 alkylene, where if L 4 is substituted then L 4 is substituted with 1 or 2 R 14 ; each R 14 is independently selected from F, - CH 3 , -CF 3 , hydroxyl, -OCH 3 , and -OCF 3 ;
  • R 8 is H, or Ci-C 4 alkyl
  • L 5 is absent or a substituted or unsubstituted Ci-C 4 alkylene, where if L 5 is substituted then L 5 is substituted with 1 or 2 R 15 ; each R 15 is independently selected from F, -CH 3 , -CF 3 , hydroxyl, -OCH 3 , and -OCF 3 .
  • L 4 is absent.
  • L 5 is a substituted or unsubstituted Ci-C 4 alkylene, where if L 5 is substituted then L 5 is substituted with 1 or 2 R 15 ; each R 15 is independently selected from F, -CH 3 , - CF 3 , hydroxyl, -OCH 3 , and -OCF 3 .
  • L 4 is a substituted or unsubstituted Ci-C 4 alkylene, where if L 4 is substituted then L 4 is substituted with 1 or 2 R 14 ; each R 14 is independently selected from F, -CH 3 , -
  • L 5 is absent.
  • L 4 is a substituted or unsubstituted Ci-C 4 alkylene, where if L 4 is substituted then L 4 is substituted with 1 or 2 R 14 ; each R 14 is independently selected from F, -CH 3 , - CF 3 , or hydroxyl.
  • L 5 is a substituted or unsubstituted Ci-C 4 alkylene, where if L 5 is substituted then L 5 is substituted with 1 or 2 R 15 ; each R 15 is independently selected from F, - CH 3 , -CF 3 , or hydroxyl.
  • X 1 is -0-, -S-, or -NR 7 -. In some embodiments, X 1 is -O- or -S-. In some embodiments, X 1 is -NR 7 -.
  • each of R A , R B , and R c are independently selected from H, halogen, -
  • n is 0 or 1; n is 0 or 1. In some embodiments, m is 0. In some embodiments, n is 0.
  • p is 0 or 1. In some embodiments, p is 1 or 2. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
  • each R c is independently selected from H, halogen, -CN, -OH, -CH 3 , - CF 3 , -OCF 3 , and -OCH 3 .
  • the compound of Formula (I) has a structure of Formula (VI), or a pharmaceutically acceptable salt thereof:
  • R D is H or Ci-C 6 alkyl
  • R E is Ci-C 6 alkyl, C 3 -C 6 cycloalkyl, or substituted or unsubstituted phenyl;
  • L 3 is a substituted or unsubstituted C3-C 6 alkylene, a substituted or unsubstituted C 3 -
  • each R 13 is independently selected from F, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, and -OH;
  • each of R A , R B , and R c are independently selected from H, halogen, -CN, -N0 2 , -OH, -OR 9 , -
  • R 5 is H or Ci-C 4 alkyl
  • each R 9 is independently selected from H, Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, a substituted or unsubstituted phenyl, or -CH 2 -(substituted or unsubstituted phenyl); or
  • n 0 or 1 ;
  • n 0 or 1 ;
  • p 0, 1 , or 2.
  • the compound of Formula (I) has a structure of Formula (VII), or a pharmaceutically acceptable salt thereof:
  • R D is H or Ci-C 6 alkyl
  • R E is Ci-C 6 alkyl, C 3 -C 6 cycloalkyl, or substituted or unsubstituted phenyl;
  • L 3 is a substituted or unsubstituted C 3 -C 6 alkylene, a substituted or unsubstituted C 3 -
  • each R 13 is independently selected from F, Ci-C 4 alkyl, Ci-C 4 fluoroalkyl, and -OH;
  • each of R A , R B , and R c are independently selected from H, halogen, -CN, -N0 2 , -OH, -OR 9 , -
  • Ci-C 4 alkyl Ci-C 4 fluoroalkyl
  • Ci-C 4 fluoroalkoxy Ci-C 4 alkoxy
  • Ci-C 4 alkoxy Ci-C 4 alkoxy
  • R 3 is H or C C 4 alkyl
  • each R 9 is independently selected from H, Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, a substituted or unsubstituted phenyl, or -CH 2 -(substituted or unsubstituted phenyl); or
  • n 0 or 1 ;
  • n 0 or 1 ;
  • p 0, 1 , or 2.
  • the compound of Formula (I) has one of the following structures:
  • R 6 is as described in Table 1 and/or 2.
  • L 1 is as described in Table 1 and/or 2.
  • L 3 is as described in Table 1 and/or 2.
  • R E is as described in Table 2.
  • the starting material used for the synthesis of the compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) are either synthesized or obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, Fluka, Acros Organics, Alfa Aesar, and the like.
  • the compounds described herein, and other related compounds having different substituents are synthesized using techniques and materials described herein or otherwise known, including those found in March, ADVANCED ORGANIC CHEMISTRY 4 th Ed., (Wiley 1992); Carey and Sundberg, ADVANCED ORGANIC CHEMISTRY 4 th Ed., Vols.
  • the synthesis of compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) described herein begins with the reaction of an alkyl acetoacetate with methylamine to provide a compound of structure l-II.
  • Compounds of structure l-II are reacted with a substituted or unsubstituted 4-halo-benzoyl chloride (structure l-III) to provide compounds of structure 1-IV.
  • ureas of structure 2-V are prepared as outlined in Scheme 2.
  • a Curtius rearrangement of carboxylic acids of structure 2-1 in the presence of tert-butanol provides carbamate compounds of structure 2-II. Removal of the tert-butyl group with acid provides amines of structure 2-III Amines of structure 2-III are reacted with isocyantes of structure 2-IV to provide ureas of structure 2-V. Ureas of structure 2-V are used in the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein.
  • amides of structure 3-III are prepared as outlined in Scheme 3.
  • Amines of structure 2-III are reacted with acid chlorides of structure 3-II to provide amides of structure 3-III.
  • Amides of structure 3-III are used in the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein.
  • amines of structure 2-III are reacted with, but not limited to, a carboxylic acid (R 6 -L 5 -C0 2 H) and coupling reagent such as EDC EDC, DCC, BOP, HATU or the like, or a carboxylic acid activated ester or an acid chloride (i.e. compound of structure 3-II), in the presence of a suitable base and a suitable solvent to afford compounds of structure 3-III.
  • a carboxylic acid R 6 -L 5 -C0 2 H
  • coupling reagent such as EDC EDC, DCC, BOP, HATU or the like
  • a carboxylic acid activated ester or an acid chloride i.e. compound of structure 3-II
  • amines of structure 3-III are prepared as outlined in Scheme 3.
  • Amines of structure 2-III are reacted with aldehydes of structure 4-II under reductive amination conditions to provide amines of structure 4-III.
  • Compounds of structure 4-IV are used in the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein.
  • amines, amides, carbamates, and ureas are prepared as shown below.
  • Oxidation of the alcohol of 1-X provides aldehydes of structure 5-1.
  • Reductive amination of the aldehydes with amines e.g. R 6 -L 5 -NH 2
  • Alkylation, acetylation, and the like, of the secondary amines provides compounds of structure 5-IV.
  • reductive amination of aldehydes 5-1 with amines R 7 -NH2 provides amines of structure 5-V.
  • R 7 is a protecting group that is optionally removed.
  • Reaction of amines of structure 5-V with acid chlorides, isocyantes, or chloro formates provides compounds of structure 5-VI, where Y is, absent, O, or NH.
  • Compounds of structure 5-IV and 5-VI are used in the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein.
  • olefination of the aldehydes of structure 4-1 provides isoxazoles are olefinated to provide compounds of structure 8-1, where L 3 comprises an alkenylene.
  • ethers and thioethers are prepared as shown in Scheme 6.
  • alcohols of structure 1-X are brominated, chlorinated, or activated with an activating agent (e.g. tosyl chloride, mesyl chloride and the like) and then reacted with alcohols or thiol compounds to provide compounds of structure 6-III.
  • an activating agent e.g. tosyl chloride, mesyl chloride and the like
  • Compounds of structure 6-1 and 6-III are used in the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein.
  • alcohols of structure 1-X are used to prepare esters, carbamates, carbonates and the like as shown in scheme 7.
  • a Suzuki reaction between compounds of structure 8-1 and compounds of structure 8-II is used to provide compounds of structure 8-III.
  • Other metal mediated coupling reactions contemplated for the preparation of compounds of structure 8-III include, but are not limited to Suzuki reactions, Stille cross couplings, Negishi couplings, Kumada couplings, Ullmann reactions, Hiyama Coupling, and variants thereof (Metal-Catalyzed Cross-Coupling Reactions, Armin de Meijere (Editor), Francois Diederich (Editor), John Wiley & Sons; 2nd edition, 2004; Ozdemir, et al, Tetrahedron, 2005, 61, 9791-9798; Ackermann, et al, Org.
  • the coupling partners in the metal mediated reaction condition includes those outlined in Scheme 9.
  • halides of structure 8-1 are reacted with a borylating agent using transition metal mediated reaction conditions to form boronate compounds of structure 9-1.
  • Boronate compounds of structure 9-1 are reacted with compounds of structure 9-III under palladium mediated coupling conditions to form biphenyl aldehydes of structure 9-IV.
  • compounds of structure 10-1 are used to prepare a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • compounds of structure 10-1 are prepared using the methodology described herein or known in the art.
  • the isoxazole in any of the schemes described herein are prepared as outlined in Scheme 12.
  • the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) described herein begins with the reaction of an alkyl acetoacetate with methylamine to provide a compound of structure 12-11. Reaction of 12-11 provides compounds 12-IV which are then treated with hydroxylamine to provide isoxazoles of structure 12-V. Isoxazoles of structure 12-V are then elaborated into a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein. [0284] Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) possess one or more stereocenters and each stereocenter exists independently in either the R or S configuration.
  • the compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof.
  • the compounds and methods provided herein include all cis, trans, syn, anti,
  • E
  • Z
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds/salts, separating the diastereomers and recovering the optically pure enantiomers.
  • resolution of enantiomers is carried out using covalent diastereomeric derivatives of the compounds described herein.
  • diastereomers are seprated by separation/resolution techniques based upon differences in solubility.
  • separation of steroisomers is performed by chromatography or by the forming diastereomeric salts and separation by recrystallization, or chromatography, or any combination thereof.
  • stereoisomers are obtained by stereoselective synthesis.
  • compositions described herein include the use of amorphous forms as well as crystalline forms (also known as polymorphs).
  • compounds described herein are in the form of pharmaceutically acceptable salts.
  • active metabolites of these compounds having the same type of activity are included in the scope of the present disclosure.
  • the compounds described herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
  • the solvated forms of the compounds presented herein are also considered to be disclosed herein.
  • prodrugs refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. In some embodiments, the design of a prodrug increases the effective water solubility.
  • prodrug is a compound described herein, which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial.
  • prodrug a compound described herein, which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial.
  • prodrug might be a short peptide
  • a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of the compound.
  • a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound.
  • prodrugs are designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug.
  • Prodrug forms of the herein described compounds, wherein the prodrug is metabolized in vivo to produce a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as set forth herein are included within the scope of the claims.
  • some of the herein-described compounds may be a prodrug for another derivative or active compound.
  • sites on the aromatic ring portion of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are susceptible to various metabolic reactions Therefore incorporation of appropriate substituents on the aromatic ring structures will reduce, minimize or eliminate this metabolic pathway.
  • the appropriate substituent to decrease or eliminate the susceptibility of the aromatic ring to metabolic reactions is, by way of example only, a halogen, or an alkyl group.
  • the compounds described herein are labeled isotopically (e.g. with a radioisotope) or by another other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
  • Compounds described herein include isotopically-labeled compounds, which are identical to those recited in the various formulae and structures presented herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into the present compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, such as, for example, 3 ⁇ 4, 3 H, 13 C, 14 C, 15 N, 18 0, 17 0, 35 S, 18 F, 36 C1.
  • isotopically-labeled compounds described herein for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays.
  • substitution with isotopes such as deuterium affords certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements.
  • the compounds described herein are metabolized upon administration to an organism in need to produce a metabolite that is then used to produce a desired effect, including a desired therapeutic effect.
  • “Pharmaceutically acceptable,” as used herein, refers a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively nontoxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • pharmaceutically acceptable salt refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound.
  • pharmaceutically acceptable salts are obtained by reacting a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with acids.
  • Pharmaceutically acceptable salts are also obtained by reacting a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with a base to form a salt.
  • compositions described herein may be formed as, and/or used as, pharmaceutically acceptable salts.
  • pharmaceutical acceptable salts include, but are not limited to: (1) acid addition salts, formed by reacting the free base form of the compound with a pharmaceutically acceptable: inorganic acid, such as, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, metaphosphoric acid, and the like; or with an organic acid, such as, for example, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, trifluoroacetic acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1
  • compounds described herein may coordinate with an organic base, such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine.
  • compounds described herein may form salts with amino acids such as, but not limited to, arginine, lysine, and the like.
  • Acceptable inorganic bases used to form salts with compounds that include an acidic proton include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
  • compounds described herein are prepared as a sodium salt.
  • a reference to a pharmaceutically acceptable salt includes the solvent addition forms or crystal forms thereof, particularly solvates or polymorphs.
  • Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein can be conveniently prepared or formed during the processes described herein.
  • the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
  • Compounds described herein such as a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII), may be in various forms, including but not limited to, amorphous forms, milled forms and nano-particulate forms.
  • compounds described herein include crystalline forms, also known as polymorphs. Polymorphs include the different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, melting points, density, hardness, crystal shape, optical properties, stability, and solubility. Various factors such as the recrystallization solvent, rate of crystallization, and storage temperature may cause a single crystal form to dominate.
  • alkyl group refers to an aliphatic hydrocarbon group.
  • the alkyl group may be a saturated alkyl group (which means that it does not contain any carbon-carbon double bonds or carbon-carbon triple bonds) or the the alkyl group may be an unsaturated alkyl group (which means that it contains at least one carbon-carbon double bonds or carbon-carbon triple bond).
  • the alkyl moiety, whether saturated or unsaturated, may be branched, or straight chain.
  • the "alkyl” group may have 1 to 10 carbon atoms (whenever it appears herein, a numerical range such as “1 to 10" refers to each integer in the given range; e.g., "1 to 10 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although the present definition also covers the occurrence of the term "alkyl” where no numerical range is designated).
  • the alkyl group of the compounds described herein may be designated as "C 1 -C6 alkyl" or similar designations.
  • -C6 alkyl indicates that there are one, two , three, four, five, or six carbon atoms in the alkyl chain.
  • the alkyl is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.
  • Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tertiary butyl, pentyl, neopentyl, hexyl, allyl, but- 2-enyl, but-3-enyl, and the like.
  • an alkyl is a Ci-C 6 alkyl.
  • alkylene refers to a divalent alkyl radical. Any of the above mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl.
  • an alkelene is a Ci-C6alkylene.
  • an alkylene is a Ci-C 4 alkylene.
  • an alkylene is methylene, ethylene, propylene or butylene.
  • Typical alkylene groups include, but are not limited to, -CH 2 -, -CH(CH 3 )-, -C(CH 3 ) 2 -, -CH 2 CH 2 -, -CH 2 CH(CH 3 )-, - CH 2 C(CH 3 ) 2 -, -CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH 2 CH 2 -, and the like.
  • alkoxy refers to a (alkyl)O- group, where alkyl is as defined herein.
  • aromatic refers to a planar ring having a delocalized ⁇ -electron system containing 4n+2 ⁇ electrons, where n is an integer. Aromatic rings can be formed from five, six, seven, eight, nine, ten, or more than ten atoms. Aromatics are optionally substituted.
  • aromatic includes both carbocyclic aryl ("aryl”, e.g., phenyl) and heterocyclic aryl (or “heteroaryl” or
  • heterocyclic groups ⁇ e.g., pyridine).
  • the term includes monocyclic or fused-ring polycyclic ⁇ i.e., rings which share adjacent pairs of carbon atoms) groups.
  • carbocyclic or “carbocycle” refers to a ring or ring system where the atoms forming the backbone of the ring are all carbon atoms. The term thus distinguishes carbocyclic from heterocyclic rings in which the ring backbone contains at least one atom which is different from carbon.
  • aryl refers to an aromatic ring wherein each of the atoms forming the ring is a carbon atom.
  • Aryl rings are formed by five, six, seven, eight, nine, or more than nine carbon atoms.
  • Aryl groups are optionally substituted.
  • an aryl is a phenyl or a naphthalenyl.
  • an aryl is a phenyl.
  • an aryl is a C6-Cioaryl.
  • an aryl group can be a monoradical or a diradical (i.e., an arylene group).
  • Examplary arylenes include, but are not limited to, phenyl- 1 ,2-ene, phenyl- 1 ,3-ene, and phenyl- 1 ,4-ene.
  • cycloalkyl refers to a monocyclic or polycyclic aliphatic, non-aromatic radical, wherein each of the atoms forming the ring (i.e. skeletal atoms) is a carbon atom. Cycloalkyls may be saturated, or partially unsaturated. Cycloalkyls may be fused with an aromatic ring, and the point of attachment is at a carbon that is not an aromatic ring carbon atom. Cycloalkyl groups include groups having from 3 to 10 ring atoms.
  • cycloalkyl groups are selected from among cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Cycloalkyl groups may be substituted or unsubstituted.
  • a cycloalkyl group can be a monoradical or a diradical (i.e., an cycloalkylene group, such as, but not limited to, cyclopropan-l,l-diyl, cyclobutan- 1 , 1 -diyl, cyclopentan-l,l-diyl, cyclohexan- 1 , 1 -diyl, cyclohexan- 1,4-diyl, cycloheptan- 1 , 1 -diyl, and the like).
  • a cycloalkyl is a C 3 - C 6 cycloalkyl.
  • halo or, alternatively, "halogen” or “halide” means fluoro, chloro, bromo or iodo.
  • haloalkyl refers to an alkyl group in which one or more hydrogen atoms are replaced by one or more halide atoms.
  • a haloalkyl is a Ci-C 4 haloalkyl.
  • haloalkylene refers to an alkylene group in which one or more hydrogen atoms are replaced by one or more halide atoms.
  • a haloalkylene is a Ci-Cehaloalkylene.
  • a haloalkylene is a Ci-C 4 haloalkylene.
  • fluoroalkyl refers to an alkyl in which one or more hydrogen atoms are replaced by a fluorine atom.
  • a fluoralkyl is a Ci-C 4 fluoroalkyl.
  • fluoroalkylene refers to an alkylene in which one or more hydrogen atoms are replaced by a fluorine atom.
  • a fluoralkylene is a Ci-C 6 fluoroalkylene.
  • a fluoralkylene is a Ci-C 4 fluoroalkylene.
  • heteroalkyl refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g. NH, Nalkyl), or sulfur.
  • a heteroalkyl is a Ci-C 6 heteroalkyl.
  • heteroalkyl refers to an alkyl group in which one skeletal atom of the alkyl is oxygen, nitrogen (e.g. NH, Nalkyl), or sulfur.
  • heteroalkylene refers to an alkylene group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g. , oxygen, nitrogen (e.g. NH, Nalkyl), or sulfur.
  • heteroalkylene refers to an alkylene group in which one skeletal atom of the alkylene is O, NH, or S.
  • a heteroalkylene is a Ci-C 6 heteroalkylene.
  • a heteroalkylene is a Ci-C 4 heteroalkylene.
  • Examplary heteroalkylenes include, but are not limited to, -OCH 2 -, -OCH(CH 3 )-, -OC(CH 3 ) 2 -, -OCH 2 CH 2 -, -CH 2 0-, -CH(CH 3 )0-, -C(CH 3 ) 2 0-, - CH 2 CH 2 0-, -CH 2 OCH 2 -, -CH 2 OCH 2 CH 2 -, -CH 2 CH 2 OCH 2 -, -SCH 2 -, -SCH(CH 3 )-, -SC(CH 3 ) 2 -, -SCH 2 CH 2 -, -CH 2 S-, -CH(CH 3 )S-, -C(CH 3 ) 2 S-, -CH 2 CH 2 S-, -CH 2 SCH 2 -, -CH 2 SCH 2 CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 SCH 2 -, -S0 2
  • heterocycle refers to heteroaromatic rings (also known as heteroaryls) and heterocycloalkyl rings (also known as heteroalicyclic groups) containing one to four heteroatoms in the ring(s), where each heteroatom in the ring(s) is selected from O, S and N, wherein each heterocyclic group has from 4 to 10 atoms in its ring system, and with the proviso that the any ring does not contain two adjacent O or S atoms.
  • Non-aromatic heterocyclic groups also known as heterocycloalkyls
  • the heterocyclic groups include benzo-fused ring systems.
  • An example of a 3-membered heterocyclic group is aziridinyl.
  • An example of a 4- membered heterocyclic group is azetidinyl.
  • An example of a 5-membered heterocyclic group is thiazolyl.
  • An example of a 6-membered heterocyclic group is pyridyl, and an example of a 10- membered heterocyclic group is quinolinyl.
  • non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6-tetrahydropyridinyl, pyrrolin-2-yl, pyrrolin-3-yl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxo
  • aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinox
  • the foregoing groups may be C-attached or N-attached where such is possible.
  • a group derived from pyrrole may be pyrrol- 1-yl (N-attached) or pyrrol-3-yl (C-attached).
  • a group derived from imidazole may be imidazol- 1 -yl or imidazol- 3-yl (both N-attached) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C-attached).
  • heteroaryl or, alternatively, “heteroaromatic” refers to an aryl group that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur.
  • heteroaryl groups include the following moieties:
  • a heteroaryl contains 0-3 N atoms. In another aspect, a heteroaryl contains 1-3 N atoms.
  • a heteroaryl contains 0-3 N atoms, 0-1 O atoms, and 0-1 S atoms.
  • a heteroaryl is a monocyclic or bicyclic heteroaryl.
  • heteroaryl is a Ci-Cgheteroaryl.
  • monocyclic heteroaryl is a Ci-Csheteroaryl.
  • monocyclic heteroaryl is a 5-membered or 6-membered heteroaryl.
  • bicyclic heteroaryl is a Ce-Cgheteroaryl.
  • a heteroaryl group can be a monoradical or a diradical (i.e., a heteroarylene group).
  • heterocycloalkyl or “heteroalicyclic” group refers to a cycloalkyl group that includes at least one heteroatom selected from nitrogen, oxygen and sulfur.
  • the radicals may be fused with an aryl or heteroaryl.
  • heterocycloalkyl groups also referred to as non-aromatic heterocycles, include:
  • the heterocycloalkyl is selected from oxazolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, and indolinyl.
  • the term heteroalicyclic also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides.
  • a heterocycloalkyl is a C2-Cioheterocycloalkyl.
  • a heterocycloalkyl is a C4-Cioheterocycloalkyl.
  • a heterocycloalkyl is a C4-Cioheterocycloalkyl.
  • heterocycloalkyl is a C2-C 6 heterocycloalkyl. In one aspect, a heterocycloalkyl contains 0-2 N atoms. In another aspect, a heterocycloalkyl contains 0-2 N atoms, 0-2 O atoms or 0-1 S atoms.
  • bond refers to a chemical bond between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure.
  • bond when a group described herein is a bond, the referenced group is absent thereby allowing a bond to be formed between the remaining identified groups.
  • membered ring includes any cyclic structure.
  • membered is meant to denote the number of skeletal atoms that constitute the ring.
  • cyclohexyl, pyridinyl, pyranyl and thiopyranyl are 6-membered rings and cyclopentyl, pyrrolyl, furanyl, and thienyl are 5-membered rings.
  • moiety refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule.
  • carboxylic acid bioisostere refers to a functional group or moiety that exhibits similar physical, biological and/or chemical properties as a carboxylic acid moiety.
  • carboxylic acid bioisosteres examples include, but are not limited to,
  • the term "optionally substituted” or “substituted” means that the referenced group may be substituted with one or more additional group(s) individually and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, cyano, halo, nitro, haloalkyl, fluoroalkyl, fluoroalkoxy, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof.
  • substituents are selected from halogen, -CN, -NH 2 , -OH, -N(CH 3 ) 2 , alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone.
  • an optional substituent is selected from halogen, -CN, -NH 2 , -OH, -NH(CH 3 ), -N(CH 3 ) 2 , -CH 3 , -CH 2 CH 3 , -CF 3 , -OCH 3 , - OCH 2 CH 3 , and -OCF 3 .
  • the compounds presented herein possess one or more stereocenters and each center independently exists in either the R or S configuration.
  • the compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof.
  • Stereoisomers are obtained, if desired, by methods such as, stereoselective synthesis and/or the separation of stereoisomers by chiral chromatographic columns.
  • the methods and formulations described herein include the use of N-oxides (if appropriate), crystalline forms (also known as polymorphs), or pharmaceutically acceptable salts of compounds having the structure of Formula (I), (II), (III), (IV), (V), (VI), or (VII), as well as active metabolites of these compounds having the same type of activity.
  • compounds may exist as tautomers. All tautomers are included within the scope of the compounds presented herein.
  • the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In other embodiments, the compounds described herein exist in unsolvated form.
  • the term "acceptable" with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.
  • module means to interact with a target either directly or indirectly so as to alter the activity of the target, including, by way of example only, to enhance the activity of the target, to inhibit the activity of the target, to limit the activity of the target, or to extend the activity of the target.
  • modulator refers to a molecule that interacts with a target either directly or indirectly.
  • the interactions include, but are not limited to, the interactions of an agonist, partial agonist, an inverse agonist and antagonist.
  • a modulator is an antagonist.
  • agonist refers to a molecule such as a compound, a drug, an enzyme activator or a hormone modulator that binds to a specific receptor and triggers a response in the cell.
  • An agonist mimics the action of an endogenous ligand (such as LPA, prostaglandin, hormone or neurotransmitter) that binds to the same receptor.
  • Antagonist refers to a molecule such as a compound, which diminishes, inhibits, or prevents the action of another molecule or the activity of a receptor site. Antagonists include, but are not limited to, competitive antagonists, non-competitive antagonists, uncompetitive antagonists, partial agonists and inverse agonists.
  • LPA-dependent refers to conditions or disorders that would not occur, or would not occur to the same extent, in the absence of LPA.
  • LPA-mediated refers to refers to conditions or disorders that might occur in the absence of LPA but can occur in the presence of LPA.
  • co-administration are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.
  • an “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
  • an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms.
  • An appropriate “effective” amount in any individual case may be determined using techniques, such as a dose escalation study.
  • the terms “enhance” or “enhancing,” as used herein, means to increase or prolong either in potency or duration a desired effect.
  • the term “enhancing” refers to the ability to increase or prolong, either in potency or duration, the effect of other therapeutic agents on a system.
  • An “enhancing-effective amount,” as used herein, refers to an amount adequate to enhance the effect of another therapeutic agent in a desired system.
  • a "metabolite” of a compound disclosed herein is a derivative of that compound that is formed when the compound is metabolized.
  • active metabolite refers to a biologically active derivative of a compound that is formed when the compound is metabolized.
  • metabolic refers to the sum of the processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes) by which a particular substance is changed by an organism.
  • enzymes may produce specific structural alterations to a compound.
  • cytochrome P450 catalyzes a variety of oxidative and reductive reactions
  • uridine diphosphate glucuronyltransferases catalyze the transfer of an activated glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines and free sulphydryl groups.
  • Metabolites of the compounds disclosed herein are optionally identified either by administration of compounds to a host and analysis of tissue samples from the host, or by incubation of compounds with hepatic cells in vitro and analysis of the resulting compounds.
  • the term "pharmaceutical combination” as used herein, means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non- fixed combinations of the active ingredients.
  • the term "fixed combination” means that the active ingredients, e.g. a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • non- fixed combination means that the active ingredients, e.g. a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and a co-agent, are administered to a patient as separate entities either
  • cocktail therapy e.g. the administration of three or more active ingredients.
  • subject or “patient” encompasses mammals and non-mammals.
  • mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
  • the mammal is a human.
  • Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ophthalmic, pulmonary, transmucosal, transdermal, vaginal, otic, nasal, and topical administration.
  • parenteral delivery includes
  • a compound as described herein is administered in a local rather than systemic manner, for example, via injection of the compound directly into an organ, often in a depot preparation or sustained release formulation.
  • long acting for example, via injection of the compound directly into an organ, often in a depot preparation or sustained release formulation.
  • formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with organ-specific antibody.
  • the liposomes are targeted to and taken up selectively by the organ.
  • the compound as described herein is provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation. In yet other embodiments, the compound described herein is administered topically.
  • the compounds described herein are formulated into pharmaceutical compositions.
  • Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • a summary of pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A.
  • compositions that include a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and at least one pharmaceutically acceptable inactive ingredient.
  • the compounds described herein are administered as pharmaceutical compositions in which a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is mixed with other active ingredients, as in combination therapy.
  • the pharmaceutical compositions include other medicinal or pharmaceutical agents, carriers, adjuvants, preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, and/or buffers.
  • the pharmaceutical compositions include other therapeutically valuable substances.
  • a pharmaceutical composition refers to a mixture of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with other chemical components (i.e. pharmaceutically acceptable inactive ingredients), such as carriers, excipients, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combination thereof.
  • the pharmaceutical composition facilitates administration of the compound to an organism.
  • therapeutically effective amounts of compounds described herein are administered in a pharmaceutical composition to a mammal having a disease, disorder, or condition to be treated.
  • the mammal is a human.
  • a therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors.
  • the compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.
  • the pharmaceutical formulations described herein are administered to a subject by appropriate administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes.
  • the pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
  • compositions including a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
  • the pharmaceutical compositions will include at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as an active ingredient in free-acid or free-base form, or in a pharmaceutically acceptable salt form.
  • the methods and pharmaceutical compositions described herein include the use of N-oxides (if appropriate), crystalline forms, amorphous phases, as well as active metabolites of these compounds having the same type of activity.
  • compounds described herein exist in unsolvated form or in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
  • pharmaceutically acceptable solvents such as water, ethanol, and the like.
  • the solvated forms of the compounds presented herein are also considered to be disclosed herein.
  • compositions provided herein include one or more preservatives to inhibit microbial activity.
  • Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.
  • formulations described herein benefit from antioxidants, metal chelating agents, thiol containing compounds and other general stabilizing agents.
  • stabilizing agents include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02%) w/v polysorbate 80, (g) 0.001%) to about 0.05%o w/v.
  • polysorbate 20 (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (1) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.
  • compositions described herein which include a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are formulated into any suitable dosage form, including but not limited to, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations.
  • aqueous oral dispersions liquids, gels, syrups, elixirs, slurries, suspensions, solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed
  • compositions for oral use are obtained by mixing one or more solid excipient with one or more of the compounds described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as:
  • polyvinylpyrrolidone PVP or povidone
  • calcium phosphate a polyvinylpyrrolidone
  • disintegrating agents such as the cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • dyestuffs or pigments are added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • compositions that are administered orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push- fit capsules contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds are dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In some embodiments, stabilizers are added.
  • solid oral soage forms are prepared by mixing a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with one or more of the following: antioxidants, flavoring agents, and carrier materials such as binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents.
  • antioxidants such as binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents.
  • the solid dosage forms disclosed herein are in the form of a tablet, (including a suspension tablet, a fast-melt tablet, a bite-disintegration tablet, a rapid-disintegration tablet, an effervescent tablet, or a caplet), a pill, a powder, a capsule, solid dispersion, solid solution, bioerodible dosage form, controlled release formulations, pulsatile release dosage forms,
  • the pharmaceutical formulation is in the form of a powder. In still other embodiments, the pharmaceutical formulation is in the form of a tablet. In other embodiments, pharmaceutical formulations of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are in the form of a capsule.
  • solid dosage forms e.g., tablets, effervescent tablets, and capsules
  • solid dosage forms are prepared by mixing particles of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with one or more pharmaceutical excipients to form a bulk blend composition.
  • the bulk blend is readily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules.
  • the individual unit dosages include film coatings.
  • Conventional formulation techniques include, e.g., one or a combination of methods: (1) dry mixing, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion.
  • Other methods include, e.g., spray drying, pan coating, melt granulation, granulation, fluidized bed spray drying or coating (e.g., wurster coating), tangential coating, top spraying, tableting, extruding and the like.
  • Suitable carriers for use in the solid dosage forms described herein include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, sodium caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose, microcrystalline cellulose, lactose, mannitol and the like.
  • Suitable filling agents for use in the solid dosage forms described herein include, but are not limited to, lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starches, pregelatinized starch, hydroxypropylmethycellulose (HPMC), hydroxypropylmethycellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.
  • Suitable disintegrants for use in the solid dosage forms described herein include, but are not limited to, natural starch such as corn starch or potato starch, a pregelatinized starch, or sodium starch glycolate, a cellulose such as methylcrystalline cellulose, methylcellulose, microcrystalline cellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium
  • a cross-linked starch such as sodium starch glycolate
  • a cross-linked polymer such as crospovidone
  • a cross-linked polyvinylpyrrolidone alginate such as alginic acid or a salt of alginic acid such as sodium alginate
  • a gum such as agar,
  • Binders impart cohesiveness to solid oral dosage form formulations: for powder filled capsule formulation, they aid in plug formation that can be filled into soft or hard shell capsules and for tablet formulation, they ensure the tablet remaining intact after compression and help assure blend uniformity prior to a compression or fill step.
  • Materials suitable for use as binders in the solid dosage forms described herein include, but are not limited to, carboxymethylcellulose,
  • pregelatinized starch tragacanth, dextrin, a sugar, such as sucrose, glucose, dextrose, molasses, mannitol, sorbitol, xylitol, lactose, a natural or synthetic gum such as acacia, tragacanth, ghatti gum, mucilage of isapol husks, starch, polyvinylpyrrolidone, larch arabogalactan, polyethylene glycol, waxes, sodium alginate, and the like.
  • a sugar such as sucrose, glucose, dextrose, molasses, mannitol, sorbitol, xylitol, lactose
  • a natural or synthetic gum such as acacia, tragacanth, ghatti gum, mucilage of isapol husks, starch, polyvinylpyrrolidone, larch arabogalactan, polyethylene glycol,
  • binder levels of 20-70% are used in powder- filled gelatin capsule formulations. Binder usage level in tablet formulations varies whether direct compression, wet granulation, roller compaction, or usage of other excipients such as fillers which itself can act as moderate binder. Binder levels of up to 70% in tablet formulations is common.
  • Suitable lubricants or glidants for use in the solid dosage forms described herein include, but are not limited to, stearic acid, calcium hydroxide, talc, corn starch, sodium stearyl fumerate, alkali- metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc, stearic acid, sodium stearates, magnesium stearate, zinc stearate, waxes, Stearowet ® , boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol or a methoxypolyethylene glycol such as CarbowaxTM, PEG 4000, PEG 5000, PEG 6000, propylene glycol, sodium oleate, glyceryl behenate, glyceryl palmitostearate, glyceryl benzoate, magnesium or sodium lauryl sulfate, and the like.
  • stearic acid calcium hydroxide, talc,
  • Suitable diluents for use in the solid dosage forms described herein include, but are not limited to, sugars (including lactose, sucrose, and dextrose), polysaccharides (including dextrates and maltodextrin), polyols (including mannitol, xylitol, and sorbitol), cyclodextrins and the like.
  • Suitable wetting agents for use in the solid dosage forms described herein include, for example, oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate,
  • triethanolamine oleate polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, quaternary ammonium compounds (e.g., Polyquat 10 ® ), sodium oleate, sodium lauryl sulfate, magnesium stearate, sodium docusate, triacetin, vitamin E TPGS and the like.
  • quaternary ammonium compounds e.g., Polyquat 10 ®
  • sodium oleate sodium lauryl sulfate
  • magnesium stearate sodium docusate
  • triacetin vitamin E TPGS and the like.
  • Suitable surfactants for use in the solid dosage forms described herein include, for example, sodium lauryl sulfate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, polysorbates, polaxomers, bile salts, glyceryl monostearate, copolymers of ethylene oxide and propylene oxide, e.g., Pluronic ® (BASF), and the like.
  • Suitable suspending agents for use in the solid dosage forms described here include, but are not limited to, polyvinylpyrrolidone, e.g., polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, polyethylene glycol, e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400, vinyl pyrrolidone/vinyl acetate copolymer (S630), sodium
  • Suitable antioxidants for use in the solid dosage forms described herein include, for example, e.g., butylated hydroxytoluene (BHT), sodium ascorbate, and tocopherol.
  • BHT butylated hydroxytoluene
  • sodium ascorbate sodium ascorbate
  • tocopherol sodium ascorbate
  • additives used in the solid dosage forms described herein there is considerable overlap between additives used in the solid dosage forms described herein.
  • the above-listed additives should be taken as merely exemplary, and not limiting, of the types of additives that can be included in solid dosage forms of the pharmaceutical compositions described herein.
  • the amounts of such additives can be readily determined by one skilled in the art, according to the particular properties desired.
  • Compressed tablets are solid dosage forms prepared by compacting the bulk blend of the formulations described above.
  • tablets will include one or more flavoring agents.
  • the tablets will include a film surrounding the final compressed tablet.
  • the film coating can provide a delayed release of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) from the formulation.
  • the film coating aids in patient compliance (e.g., Opadry ® coatings or sugar coating). Film coatings including Opadry ® typically range from about 1% to about 3% of the tablet weight.
  • a capsule may be prepared, for example, by placing the bulk blend of the formulation of the compound described above, inside of a capsule.
  • the formulations nonaqueous suspensions and solutions
  • the formulations are placed in a soft gelatin capsule.
  • the formulations are placed in standard gelatin capsules or non-gelatin capsules such as capsules comprising HPMC.
  • the formulation is placed in a sprinkle capsule, wherein the capsule is swallowed whole or the capsule is opened and the contents sprinkled on food prior to eating.
  • the particles of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and one or more excipients are dry blended and compressed into a mass, such as a tablet, having a hardness sufficient to provide a pharmaceutical composition that substantially disintegrates within less than about 30 minutes, less than about 35 minutes, less than about 40 minutes, less than about 45 minutes, less than about 50 minutes, less than about 55 minutes, or less than about 60 minutes, after oral administration, thereby releasing the formulation into the gastrointestinal fluid.
  • a powder including a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated to include one or more pharmaceutical excipients and flavors.
  • a powder is prepared, for example, by mixing the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and optional pharmaceutical excipients to form a bulk blend composition.
  • Additional embodiments also include a suspending agent and/or a wetting agent. This bulk blend is uniformly subdivided into unit dosage packaging or multi-dosage packaging units.
  • effervescent powders are also prepared. Effervescent salts have been used to disperse medicines in water for oral administration.
  • the pharmaceutical solid oral dosage forms are formulated to provide a controlled release of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • Controlled release refers to the release of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) from a dosage form in which it is incorporated according to a desired profile over an extended period of time.
  • Controlled release profiles include, for example, sustained release, prolonged release, pulsatile release, and delayed release profiles.
  • controlled release compositions allow delivery of an agent to a subject over an extended period of time according to a predetermined profile.
  • Such release rates can provide therapeutically effective levels of agent for an extended period of time and thereby provide a longer period of pharmacologic response while minimizing side effects as compared to conventional rapid release dosage forms. Such longer periods of response provide for many inherent benefits that are not achieved with the corresponding short acting, immediate release preparations.
  • the solid dosage forms described herein are formulated as enteric coated delayed release oral dosage forms, i.e., as an oral dosage form of a pharmaceutical composition as described herein which utilizes an enteric coating to affect release in the small intestine or large intestine.
  • the enteric coated dosage form is a compressed or molded or extruded tablet/mold (coated or uncoated) containing granules, powder, pellets, beads or particles of the active ingredient and/or other composition components, which are themselves coated or uncoated.
  • the enteric coated oral dosage form is in the form of a capsule containing pellets, beads or granules, which include a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII), that are coated or uncoated.
  • Coatings should be applied to a sufficient thickness such that the entire coating does not dissolve in the gastrointestinal fluids at pH below about 5, but does dissolve at pH about 5 and above. Coatings are typically selected from any of the following:
  • Shellac - this coating dissolves in media of pH >7;
  • Acrylic polymers - examples of suitable acrylic polymers include methacrylic acid copolymers and ammonium methacrylate copolymers.
  • the Eudragit series E, L, S, RL, RS and NE are available as solubilized in organic solvent, aqueous dispersion, or dry powders.
  • the Eudragit series RL, NE, and RS are insoluble in the gastrointestinal tract but are permeable and are used primarily for colonic targeting.
  • the Eudragit series E dissolve in the stomach.
  • the Eudragit series L, L-30D and S are insoluble in stomach and dissolve in the intestine; Poly Vinyl Acetate Phthalate (PVAP) - PVAP dissolves in pH >5, and it is much less permeable to water vapor and gastric fluids.
  • PVAP Poly Vinyl Acetate Phthalate
  • the formulations described herein are delivered using a pulsatile dosage form.
  • a pulsatile dosage form is capable of providing one or more immediate release pulses at predetermined time points after a controlled lag time or at specific sites. Exemplary pulsatile dosage forms and methods of their manufacture are disclosed in U.S. Pat. Nos. 5,011,692, 5,017,381, 5,229,135, 5,840,329 and 5,837,284.
  • the pulsatile dosage form includes at least two groups of particles, (i.e. multiparticulate) each containing the formulation described herein.
  • the first group of particles provides a substantially immediate dose of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) upon ingestion by a mammal.
  • the first group of particles can be either uncoated or include a coating and/or sealant.
  • the second group of particles comprises coated particles.
  • the coating on the second group of particles provides a delay of from about 2 hours to about 7 hours following ingestion before release of the second dose. Suitable coatings for pharmaceutical compositions are described herein or known in the art.
  • pharmaceutical formulations include particles of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and at least one dispersing agent or suspending agent for oral administration to a subject.
  • the formulations may be a powder and/or granules for suspension, and upon admixture with water, a substantially uniform suspension is obtained.
  • liquid formulation dosage forms for oral administration are in the form of aqueous suspensions selected from the group including, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups. See, e.g., Singh et al.., Encyclopedia of Pharmaceutical Technology, 2nd Ed., pp. 754-757 (2002).
  • the liquid dosage forms include additives, such as: (a) disintegrating agents; (b) dispersing agents; (c) wetting agents; (d) at least one preservative, (e) viscosity enhancing agents, (f) at least one sweetening agent, and (g) at least one flavoring agent.
  • the aqueous dispersions can further include a crystalline inhibitor.
  • compositions optionally include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride.
  • acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids
  • bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane
  • buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride.
  • acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.
  • compositions optionally include one or more salts in an amount required to bring osmolality of the composition into an acceptable range.
  • salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.
  • compositions optionally include one or more preservatives to inhibit microbial activity.
  • Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.
  • the aqueous suspensions and dispersions described herein remain in a homogenous state, as defined in The USP Pharmacists' Pharmacopeia (2005 edition, chapter 905), for at least 4 hours.
  • an aqueous suspension is re-suspended into a homogenous suspension by physical agitation lasting less than 1 minute.
  • no agitation is necessary to maintain a homogeneous aqueous dispersion.
  • disintegrating agents for use in the aqueous suspensions and dispersions include, but are not limited to, a starch, e.g., a natural starch such as corn starch or potato starch, a
  • pregelatinized starch, or sodium starch glycolate a cellulose such as methylcrystalline cellulose, methylcellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium
  • a cross-linked starch such as sodium starch glycolate
  • a cross-linked polymer such as crospovidone
  • a cross-linked polyvinylpyrrolidone alginate such as alginic
  • the dispersing agents suitable for the aqueous suspensions and dispersions described herein include, for example, hydrophilic polymers, electrolytes, Tween ® 60 or 80, PEG, polyvinylpyrrolidone, and the carbohydrate-based dispersing agents such as, for example, hydroxypropylcellulose and hydroxypropyl cellulose ethers, hydroxypropyl methylcellulose and hydroxypropyl methylcellulose ethers, carboxymethylcellulose sodium, methylcellulose,
  • the dispersing agent is selected from a group not comprising one of the following agents: hydrophilic polymers; electrolytes; Tween ® 60 or 80; PEG;
  • PVP polyvinylpyrrolidone
  • hydroxypropyl methylcellulose and hydroxypropyl methylcellulose ethers carboxymethylcellulose sodium; methylcellulose; hydroxyethylcellulose; hydroxypropylmethyl-cellulose phthalate;
  • hydroxypropylmethyl-cellulose acetate stearate non-crystalline cellulose
  • magnesium aluminum silicate triethanolamine
  • PVA polyvinyl alcohol
  • 4-(l,l,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde poloxamers
  • poloxamines poloxamines
  • wetting agents suitable for the aqueous suspensions and dispersions described herein include, but are not limited to, cetyl alcohol, glycerol monostearate, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens ® such as e.g., Tween 20 ® and Tween 80 ® , and polyethylene glycols, oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium oleate, sodium lauryl sulfate, sodium docusate, triacetin, vitamin E TPGS, sodium
  • taurocholate taurocholate, simethicone, phosphotidylcholine and the like
  • Suitable preservatives for the aqueous suspensions or dispersions described herein include, for example, potassium sorbate, parabens (e.g., methylparaben and propylparaben), benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl alcohol or benzyl alcohol, phenolic compounds such as phenol, or quaternary compounds such as
  • Preservatives are incorporated into the dosage form at a concentration sufficient to inhibit microbial growth.
  • Suitable viscosity enhancing agents for the aqueous suspensions or dispersions described herein include, but are not limited to, methyl cellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, Plasdon ® S-630, carbomer, polyvinyl alcohol, alginates, acacia, chitosans and combinations thereof.
  • concentration of the viscosity enhancing agent will depend upon the agent selected and the viscosity desired.
  • sweetening agents suitable for the aqueous suspensions or dispersions described herein include, for example, acacia syrup, acesulfame K, alitame, aspartame, chocolate, cinnamon, citrus, cocoa, cyclamate, dextrose, fructose, ginger, glycyrrhetinate, glycyrrhiza (licorice) syrup, monoammonium glyrrhizinate (MagnaSweet ® ), maltol, mannitol, menthol, neohesperidine DC, neotame, Prosweet ® Powder, saccharin, sorbitol, stevia, sucralose, sucrose, sodium saccharin, saccharin, aspartame, acesulfame potassium, mannitol, sucralose, tagatose, thaumatin, vanilla, xylitol, or any combination thereof.
  • acacia syrup a
  • the liquid formulations also include inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers.
  • emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1 ,3-butyleneglycol, dimethylformamide, sodium lauryl sulfate, sodium doccusate, cholesterol, cholesterol esters, taurocholic acid, phosphotidylcholine, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
  • Formulations that include a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. See, for example, Ansel, H. C. et ah, Pharmaceutical Dosage Forms and Drug Delivery Systems, Sixth Ed. (1995). Preferably these compositions and formulations are prepared with suitable nontoxic pharmaceutically acceptable ingredients.
  • nasal dosage forms generally contain large amounts of water in addition to the active ingredient. Minor amounts of other ingredients such as pH adjusters, emulsifiers or dispersing agents, preservatives, surfactants, gelling agents, or buffering and other stabilizing and solubilizing agents are optionally present.
  • the nasal dosage form should be isotonic with nasal secretions.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated for use as an aerosol, a mist or a powder.
  • Pharmaceutical compositions described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane,
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound described herein and a suitable powder base such as lactose or starch.
  • buccal formulations that include a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are administered using a variety of formulations known in the art.
  • formulations include, but are not limited to, U.S. Pat. Nos. 4,229,447, 4,596,795, 4,755,386, and 5,739,136.
  • the buccal dosage forms described herein can further include a bioerodible
  • compositions may take the form of tablets, lozenges, or gels formulated in a conventional manner.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is prepared as transdermal dosage forms.
  • the transdermal formulations described herein include at least three components: (1) a formulation of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII); (2) a penetration enhancer; and (3) an aqueous adjuvant.
  • the transdermal formulations include additional components such as, but not limited to, gelling agents, creams and ointment bases, and the like.
  • the transdermal formulation further include a woven or non-woven backing material to enhance absorption and prevent the removal of the transdermal formulation from the skin.
  • the transdermal formulations described herein can maintain a saturated or supersaturated state to promote diffusion into the skin.
  • formulations suitable for transdermal administration of compounds described herein employ transdermal delivery devices and transdermal delivery patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive.
  • patches are constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • transdermal delivery of the compounds described herein can be accomplished by means of iontophoretic patches and the like.
  • transdermal patches provide controlled delivery of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
  • transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated into a pharmaceutical composition suitable for intramuscular, subcutaneous, or intravenous injection.
  • formulations suitable for intramuscular, subcutaneous, or intravenous injection include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • aqueous and non-aqueous carriers examples include water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, cremophor and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
  • suitable aqueous and non-aqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, cremophor and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of
  • Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • isotonic agents such as sugars, sodium chloride, and the like.
  • Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
  • compounds described herein are formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
  • physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • appropriate formulations include aqueous or nonaqueous solutions, preferably with physiologically compatible buffers or excipients. Such excipients are known.
  • Parenteral injections may involve bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the pharmaceutical composition described herein may be in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient is in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • compositions provided herein can also include an mucoadhesive polymer, selected from among, for example, carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.
  • an mucoadhesive polymer selected from among, for example, carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.
  • the compounds described herein may be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments.
  • Such pharmaceutical compounds can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, and the like.
  • a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the preparation of medicaments for the treatment of LPA-dependent or LPA-mediated diseases or conditions.
  • a method for treating any of the diseases or conditions described herein in a subject in need of such treatment involves administration of pharmaceutical compositions that include at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) or a
  • compositions containing the compound(s) described herein are administered for prophylactic and/or therapeutic treatments.
  • the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest at least one of the symptoms of the disease or condition. Amounts effective for this use depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician. Therapeutically effective amounts are optionally determined by methods including, but not limited to, a dose escalation clinical trial.
  • compositions containing the compounds described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder or condition. Such an amount is defined to be a "prophylactically effective amount or dose.”
  • prophylactically effective amount or dose the precise amounts also depend on the patient's state of health, weight, and the like. When used in a patient, effective amounts for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician.
  • prophylactic treatments include admistering to a mammal, who previously experienced at least one symtom of the disease being treated and is currently in remission, a pharmaceutical composition comprising a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in order to prevent a return of the symptoms of the disease or condition.
  • the administration of the compounds are administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.
  • the dose of drug being administered may be temporarily reduced or temporarily suspended for a certain length of time ⁇ i.e., a "drug holiday").
  • the length of the drug holiday is between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, or more than 28 days.
  • the dose reduction during a drug holiday is, by way of example only, by 10%- 100%, including by way of example only 10%), 15%, 20%), 25%o, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.
  • the dose of drug being administered may be temporarily reduced or temporarily suspended for a certain length of time ⁇ i.e., a "drug diversion").
  • the length of the drug diversion is between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, or more than 28 days.
  • the dose reduction during a drug diversion is, by way of example only, by 10%o-100%), including by way of example only 10%), 15%), 20%), 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.
  • the normal dosing schedule is optionally reinstated.
  • a maintenance dose is administered if necessary. Subsequently, in specific embodiments, the dosage or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In certain embodiments, however, the patient requires intermittent treatment on a long-term basis upon any recurrence of symptoms.
  • the amount of a given agent that corresponds to such an amount varies depending upon factors such as the particular compound, disease condition and its severity, the identity ⁇ e.g., weight, sex) of the subject or host in need of treatment, but can nevertheless be determined according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated.
  • doses employed for adult human treatment are typically in the range of O.Olmg- 5000 mg per day.
  • doses employed for adult human treatment are from about lmg to about 1000 mg per day.
  • the desired dose is conveniently presented in a single dose or in divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub-doses per day.
  • the daily dosages appropriate for the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) described herein are from about 0.01 to about 10 mg/kg per body weight.
  • an indicated daily dosage in a large mammal including, but not limited to, humans, is in the range from about 0.5 mg to about 1000 mg, conveniently administered in divided doses, including, but not limited to, up to four times a day.
  • the daily dosage is administered in extended release form.
  • suitable unit dosage forms for oral administration comprise from about 1 to 500 mg active ingredient.
  • the daily dosage or the amount of active in the dosage form are lower or higher than the ranges indicated herein, based on a number of variables in regard to an individual treatment regime.
  • the daily and unit dosages are altered depending on a number of variables including, but not limited to, the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.
  • Toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LD 50 and the ED 50 .
  • the dose ratio between the toxic and therapeutic effects is the therapeutic index and it is expressed as the ratio between LD5 0 and ED5 0 .
  • the data obtained from cell culture assays and animal studies are used in formulating the
  • the daily dosage amount of the compounds described herein lies within a range of circulating concentrations that include the ED5 0 with minimal toxicity. In certain embodiments, the daily dosage range and/or the unit dosage amount varies within this range depending upon the dosage form employed and the route of administration utilized.
  • any of the aforementioned aspects involving the prevention or treatment of LPA-mediated diseases or conditions are further embodiments comprising identifying patients by screening for LPA receptor gene SNPs.
  • a SNP located in the promoter region of LPAx showed significant association with knee osteoarthritis in two independent populations (Mototani et al. Hum. Mol. Genetics, vol. 17, no. 12, 2008). Patients can be further selected based on increased LPA receptor expression in the tissue of interest.
  • CLL chronic lymphocytic leukemia
  • LPA can protect some CLL cells from apoptosis and the cells that are protected by LPA have high levels of LPAi mRNA.
  • CLL patients are selected based on the expression of the LPA1R. LPA receptor expression are determined by methods including, but not limited to, northern blotting, western blotting, quantitative PCR (qPCR), flow cytometry, autoradiography (using a small molecule radioligand or PET ligand).
  • patients are selected based on the concentration of serum or tissue LPA measured by mass spectrometry.
  • LPA concentrations are high in ovarian cancer ascites and in some breast cancer effusions.
  • patients are selected based on a combination of the above markers (increased LPA concentrations and increased LPA receptor expression).
  • the patient benefits by administration of a local wound-healing agent (at the site of the wound) in combination with the co-existing administration of a compound of Formula (I), (II), (III),
  • the therapeutic effectiveness of one of the compounds described herein is enhanced by administration of an adjuvant ⁇ i.e., by itself the adjuvant may have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced).
  • the benefit experienced by a patient is increased by administering one of the compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is co-administered with a second therapeutic agent, wherein the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and the second therapeutic agent modulate different aspects of the disease, disorder or condition being treated, thereby providing a greater overall benefit than administration of either therapeutic agent alone.
  • the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.
  • different therapeutically-effective dosages of the compounds disclosed herein will be utilized in formulating pharmaceutical composition and/or in treatment regimens when the compounds disclosed herein are administered in combination with one or more additional agent, such as an additional therapeutically effective drug, an adjuvant or the like.
  • a combination treatment regimen encompasses treatment regimens in which administration of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is initiated prior to, during, or after treatment with a second agent described herein, and continues until any time during treatment with the second agent or after termination of treatment with the second agent.
  • Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical
  • compositions and methods for combination therapy are provided herein.
  • the pharmaceutical compositions disclosed herein are used to treat LPA-dependent or LPA-mediated conditions.
  • the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought is modified in accordance with a variety of factors. These factors include the disease, disorder or condition from which the subject suffers, as well as the age, weight, sex, diet, and medical condition of the subject. Thus, in some instances, the dosage regimen actually employed varies and, in some embodiments, deviates from the dosage regimens set forth herein.
  • dosages of the co-administered compounds vary depending on the type of co-drug employed, on the specific drug employed, on the disease or condition being treated and so forth.
  • the compound provided herein when co-administered with one or more other therapeutic agents, is administered either simultaneously with the one or more other therapeutic agents, or sequentially.
  • the multiple therapeutic agents are administered in any order or even simultaneously. If administration is simultaneous, the multiple therapeutic agents are, by way of example only, provided in a single, unified form, or in multiple forms (e.g., as a single pill or as two separate pills). In one embodiment, one of the therapeutic agents is given in multiple doses, and in another, two (or more if present) are given as multiple doses. In some embodiments of non-simultaneous administration, the timing between the multiple doses vary from more than zero weeks to less than four weeks. In addition, the combination methods, compositions and formulations are not to be limited to the use of only two agents; the use of multiple therapeutic combinations is also envisioned.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and combination therapies are administered before, during or after the occurrence of a disease or condition, and the timing of administering the composition containing a compound varies.
  • the compounds described herein are used as a prophylactic and are administered continuously to subjects with a propensity to develop conditions or diseases in order to prevent the occurrence of the disease or condition.
  • the compounds and compositions are administered to a subject during or as soon as possible after the onset of the symptoms.
  • a compound described herein is administered as soon as is practicable after the onset of a disease or condition is detected or suspected, and for a length of time necessary for the treatment of the disease.
  • the length required for treatment varies, and the treatment length is adjusted to suit the specific needs of each subject.
  • a compound described herein or a formulation containing the compound is administered for at least 2 weeks, about 1 month to about 5 years.
  • therapies which combine a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with inhibitors of LP A synthesis or LPA receptor antagonists, either acting at the same or other points in the LPA synthesis or signalling pathway, are encompassed herein for treating LPA-dependent or LPA-mediated diseases or conditions.
  • methods for treatment of LPA-dependent or LPA- mediated conditions or diseases comprises administration to a mammal a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in combination with at least one additional agent selected, by way of example only, alemtuzumab, arsenic trioxide, asparaginase (pegylated or non-), bevacizumab, cetuximab, platinum-based compounds such as cisplatin, cladribine, daunorubicin/doxorubicin/idarubicin, irinotecan, fludarabine, 5-fluorouracil, gemtuzumab, methotrexate, PaclitaxelTM, taxol, temozolomide, thioguanine, or classes of drugs including hormones (an antiestrogen, an antiandrogen, or gonadotropin
  • the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is
  • anti-cancer agents are proapoptotic agents.
  • anti-cancer agents include, but are not limited to, any of the following: gossypol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis- inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib, geldanamycin, 17-N-Allylamino- 17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, or
  • TaxolTM paclitaxel
  • TaxotereTM analogs of TaxolTM, such as TaxotereTM.
  • anti-cancer agents for use in combination with a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) include inhibitors of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; mTOR inhibitors; and antibodies (e.g., rituxan).
  • mitogen-activated protein kinase signaling e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002
  • Syk inhibitors e.g., mTOR inhibitors
  • antibodies e.g., rituxan
  • anti-cancer agents for use in combination with a compound of Formula (I), (II), (III),
  • (IV), (V), (VI), or (VII) include one or more of the following: Adriamycin, Dactinomycin,
  • adozelesin aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide;
  • batimastat batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine;
  • daunorubicin hydrochloride decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate;
  • diaziquone diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate;
  • enloplatin enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; trasrabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin II (including recombinant interleukin II, or rlL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl; interferon alfa-n3; interferon beta-1
  • masoprocol maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopunne; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane;
  • mitoxantrone hydrochloride mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine;
  • alkylating agents include alkylating agents, antimetabolites, natural products, or hormones, e.g., nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, ete.), or triazenes
  • nitrogen mustards e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.
  • alkyl sulfonates e.g., busulfan
  • nitrosoureas e.g., carmustine, lomusitne, ete.
  • triazenes e.g., triazenes
  • antimetabolites include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g., mercaptopunne, thioguanine, pentostatin).
  • folic acid analog e.g., methotrexate
  • pyrimidine analogs e.g., Cytarabine
  • purine analogs e.g., mercaptopunne, thioguanine, pentostatin
  • Examples of natural products for use in combination with a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) include but are not limited to vinca alkaloids (e.g., vinblastin, vincristine), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon alpha).
  • vinca alkaloids e.g., vinblastin, vincristine
  • epipodophyllotoxins e.g., etoposide
  • antibiotics e.g., daunorubicin, doxorubicin, bleomycin
  • enzymes e.g., L-asparaginase
  • biological response modifiers e.g., interferon alpha
  • alkylating agents for use in combination with a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) include, but are not limited to, nitrogen mustards (e.g.,
  • methylmelamines e.g., hexamethlymelamine, thiotepa
  • alkyl sulfonates e.g., busulfan
  • nitrosoureas e.g., carmustine, lomusitne, semustine, streptozocin, etc.
  • triazenes decarbazine, ete.
  • antimetabolites include, but are not limited to folic acid analog (e.g.,
  • methotrexate methotrexate
  • pyrimidine analogs e.g., fluorouracil, floxouridine, Cytarabine
  • purine analogs e.g., mercaptopurine, thioguanine, pentostatin.
  • (I), (II), (III), (IV), (V), (VI), or (VII) include, but are not limited to, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate,
  • adrenocorticosteroids e.g., prednisone
  • progestins e.g., hydroxyprogesterone caproate, megestrol acetate
  • estrogens e.g., diethlystilbestrol, ethinyl estradiol
  • antiestrogen e.g., tamoxifen
  • androgens e.g., testosterone propionate, fluoxymesterone
  • antiandrogen e.g., fiutamide
  • gonadotropin releasing hormone analog e.g., leuprolide
  • platinum coordination complexes e.g., cisplatin, carboblatin
  • anthracenedione e.g., mitoxantrone
  • substituted urea e.g., hydroxyurea
  • methyl hydrazine derivative e.g., procarbazine
  • adrenocortical suppressant e.g., mitotane, aminoglutethimide
  • Discodermolide ABT-751, Altorhyrtins (such as Altorhyrtin A and Altorhyrtin C), Spongistatins (such as Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride, Epothilones (such as Epothilone A, Epothilone B, Epothilone C, Epothilone D, Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B, 21- hydroxyepothilone D, 26-fluoroepothilone, Auristatin PE, Soblidotin, Vincristine sulfate
  • Cryptophycin 52 Vitilevuamide, Tubulysin A, Canadensol, Centaureidin, Oncocidin Al Fijianolide B, Laulimalide, Narcosine, Nascapine, Hemiasterlin, Vanadocene acetylacetonate, Indanocine Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, lsoeleutherobin A, and Z- Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, Diazonamide A, Taccalonolide A, Diozostatin, (-)-Phenylahistin, Myoseverin B, Resverastatin phosphate sodium.
  • Eleutherobins such as Desmethyleleutherobin, Desaetyleleutherobin, lsoeleutherobin A, and Z- Eleutherobin
  • Caribaeoside Cariba
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is coadministered with thrombolytic agents (e.g., alteplase anistreplase, streptokinase, urokinase, or tissue plasminogen activator), heparin, tinzaparin, warfarin, dabigatran (e.g., dabigatran etexilate), factor Xa inhibitors (e.g., fondaparinux, draparinux, rivaroxaban, DX-9065a, otamixaban, LY517717, or YM150), ticlopidine, clopidogrel, CS-747 (prasugrel, LY640315), ximelagatran, or BIBR 1048.
  • thrombolytic agents e.g., alteplase anistreplase, streptokinase,
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is to treat or reduce fibrosis in a mammal.
  • Immunosuppressive therapy is clinically used to treat or prevent the rejection of transplanted organs and tissues (e.g. bone marrow, heart, kidney, liver); treatment of autoimmune diseases or diseases that are most likely of autoimmune origin (e.g. rheumatoid arthritis, myasthenia gravis, systemic lupus erythematosus, Crohn's disease, and ulcerative colitis); and treatment of some other non-autoimmune inflammatory diseases (e.g. long term allergic asthma control), and in the treatment of fibrotic conditions.
  • organs and tissues e.g. bone marrow, heart, kidney, liver
  • autoimmune diseases or diseases that are most likely of autoimmune origin e.g. rheumatoid arthritis, myasthenia gravis, systemic lupus erythematosus, Crohn's disease, and ulcerative colitis
  • some other non-autoimmune inflammatory diseases e.g. long term allergic asthma control
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is adminsitered with corticosteroids.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is adminsitered with an a therapeutic agent selected from among: Calcineurin inhibitors (such as, but not limited to, cyclosporin, tacrolimus); mTOR inhibitors (such as, but not limited to, sirolimus, everolimus); anti-proliferatives (such as, but not limited to, azathioprine, mycophenolic acid); corticosteroids (such as, but not limited to, prednisone, cortisone acetate, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate,
  • Other therapeutic agents include, but are not limited to: cyclophosphamide, penicillamine, cyclosporine, nitrosoureas, cisplatin, carboplatin, oxaliplatin, methotrexate, azathioprine, mercaptopurine, pyrimidine analogues, protein synthesis inhibitors, dactinomycin, anthracyclines, mitomycin C, bleomycin, mithramycin, Atgarr R) , Thymoglobuline ® , OKT3 ® , basiliximab, daclizumab, cyclosporin, tacrolimus, sirolimus, Interferons (IFN- ⁇ , IFN- ⁇ ), opioids, TNF binding proteins (infliximab, etanercept, adalimumab, golimumab), leflunomide, gold thioglucose, gold thiomalate, aurof
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered in combination with Cyclosporin A (CsA) or tacrolimus (FK506).
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered to a mammal in combination with an anti-inflammatory agent including, but not limited to, non-steroidal antiinflammatory drugs (NSAIDs) and corticosteroids (glucocorticoids).
  • NSAIDs non-steroidal antiinflammatory drugs
  • corticosteroids corticosteroids
  • NSAIDs include, but are not limited to: aspirin, salicylic acid, gentisic acid, choline magnesium salicylate, choline salicylate, choline magnesium salicylate, choline salicylate, magnesium salicylate, sodium salicylate, diflunisal, carprofen, fenoprofen, fenoprofen calcium, flurobiprofen, ibuprofen, ketoprofen, nabutone, ketolorac, ketorolac tromethamine, naproxen, oxaprozin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, meclofenamate, meclofenamate sodium, mefenamic acid, piroxicam, meloxicam, COX-2 specific inhibitors (such as, but not limited to, celecoxib, rofecoxib, valdecoxib, parecoxib, etori
  • Corticosteroids include, but are not limited to: betamethasone, prednisone, alclometasone, aldosterone, amcinonide, beclometasone, betamethasone, budesonide, ciclesonide, clobetasol, clobetasone, clocortolone, cloprednol, cortisone, cortivazol, deflazacort, deoxycorticosterone, desonide, desoximetasone, desoxycortone, dexamethasone, diflorasone, diflucortolone, difluprednate, fluclorolone, fludrocortisone, fludroxycortide, flumetasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin, fluocortolone, fluorometholone, fluperolone, fluprednidene, flutica
  • meprednisone methylprednisolone, methylprednisolone aceponate, mometasone furoate, paramethasone, prednicarbate, prednisone/prednisolone, rimexolone, tixocortol, triamcinolone, and ulobetasol.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered in combination with leukotriene receptor antagonists including, but are not limited to, BAY u9773 (see EP 00791576; published 27 Aug 1997), DUO-LT (Tsuji et al, Org. Biomol. Chem., 1, 3139-3141, 2003), zafirlukast, montelukast, prankulast, and derivatives or analogs thereof.
  • methods for treatment of LPA-dependent or LPA- mediated conditions or diseases comprises administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one additional agent selected, by way of example only, HMG-CoA reductase inhibitors (e.g., statins in their lactonized or dihydroxy open acid forms and pharmaceutically acceptable salts and esters thereof, including but not limited to lovastatin; simvastatin; dihydroxy open-acid simvastatin, particularly the ammonium or calcium salts thereof; pravastatin, particularly the sodium salt thereof; fluvastatin, particularly the sodium salt thereof; atorvastatin, particularly the calcium salt thereof; nisvastatin, also referred to as NK-104; rosuvastatin); agents that have both lipid-altering effects and other pharmaceutical activities; HMG-CoA synthase inhibitors; cholesterol absorption inhibitors such as ezetimibe; cholesterol este
  • PPARa agonists such as clofibrate, fenofibrate including micronized fenofibrate, and gemfibrozil
  • PPAR dual ⁇ / ⁇ agonists such as 5-[(2, 4-dioxo-5- thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]-benzamide, known as KRP-
  • vitamin B6 also known as pyridoxine
  • the pharmaceutically acceptable salts thereof such as the HC1 salt
  • vitamin B 12 also known as cyanocobalamin
  • folic acid or a pharmaceutically acceptable salt or ester thereof such as the sodium salt and the methylglucamine salt
  • anti-oxidant vitamins such as vitamin C and E and beta carotene
  • beta-blockers angiotensin II antagonists such as losartan
  • angiotensin converting enzyme inhibitors such as enalapril and captopril
  • calcium channel blockers such as nifedipine and diltiazam
  • endothelian antagonists agents that enhance ABC1 gene expression
  • bisphosphonate compounds such as alendronate sodium
  • cyclooxygenase-2 inhibitors such as rofecoxib and celecoxib.
  • methods for treatment of LPA-dependent or LPA- mediated conditions or diseases comprises administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one additional agent selected from, by way of example only, COX-2 inhibitors; nitric oxide synthase inhibitors, such as N-(3-(aminomethyl)benzyl) acetamidine; Rho kinase inhibitors, such as fasudil; angiotension II type-1 receptor antagonists, including candesartan, losartan, irbesartan, eprosartan, telmisartan and valsartan; glycogen synthase kinase 3 inhibitors; sodium or calcium channel blockers, including crobenetine; p38 MAP kinase inhibitors, including SKB 239063;
  • thromboxane AX- synthetase inhibitors including isbogrel, ozagrel, ridogrel and dazoxiben; statins (HMG CoA reductase inhibitors), including lovastatin, simvastatin, dihydroxy open-acid simvastatin, pravastatin, fluvastatin, atorvastatin, nisvastatin, and rosuvastatin; neuroprotectants, including free radical scavengers, calcium channel blockers, excitatory amino acid antagonists, growth factors, antioxidants, such as edaravone, vitamin C, TROLOXTM, citicoline and minicycline, and reactive astrocyte inhibitors, such as (2R)-2-propyloctanoic acid; beta andrenergic blockers, such as propranolol, nadolol, timolol, pindolol, labetalol, metoprolol, atenolol, es
  • NMDA receptor antagonists including memantine; NR2B antagonists, such as traxoprodil; 5-HT1A agonists; receptor platelet fibrinogen receptor antagonists, including tirofiban and lamifiban;
  • thrombin inhibitors include argatroban; antihypertensive agents, such as enalapril; vasodilators, such as cyclandelate; nociceptin antagonists; DPIV antagonists; GABA 5 inverse agonists; and selective androgen receptor modulators.
  • methods for treatment of LPA-dependent or LPA- mediated conditions or diseases comprises administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one additional agent selected from, by way of example only,
  • dimethylsulfoxide dimethylsulfoxide, omalizumab, and pentosan polysulfate.
  • methods for treating LPA-dependent or LPA- mediated conditions or diseases comprises administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one agent used in the treatment of respiratory conditions.
  • respiratory disorders e.g., asthma, COPD and rhinitis
  • Agents used in the treatment of respiratory conditions include, but are not limited to, bronchodilators (e.g., sympathomimetic agents and xanthine derivatives), leukotriene receptor antagonists, leukotriene formation inhibitors, leukotriene modulators, nasal decongestants, respiratory enzymes, lung surfactants, antihistamines (e.g., mepyramine (pyrilamine), antazoline, diphenhydramine, carbinoxamine, doxylamine, clemastine, dimenhydrinate, pheniramine, chlorphenamine (chlorpheniramine), dexchlorpheniramine, brompheniramine, triprohdine, cetirizine, cyclizine, chlorcyclizine, hydroxyzine, meclizine, loratadine, desloratidine, promethazine, alimemazine (trimeprazine), cyproheptadine, azatadine, ketotifen, a
  • FLAP 5-lipoxygenase-activating protein
  • methods for treating LPA-dependent or LPA- mediated conditions or diseases comprises
  • methods for treating LPA-dependent or LPA-mediated conditions or diseases comprise administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one additional agent selected from, but not limited to, epinephrine, isoproterenol, orciprenaline, bronchodilators, glucocorticoids, leukotriene modifiers, mast-cell stabilizers, xanthines, anticholinergics, ⁇ -2 agonists, FLAP inhibitors, FLAP modulators or 5-LO inhibitors, ⁇ -2 agonists include, but are not limited to, short-acting ⁇ -2 agonists (e.g., salbutamol (albuterol), levalbuterol, terbutaline, pirbuterol, procaterol, metaproterenol, fenoterol and bitolterol mesylate) and long-acting ⁇
  • ⁇ -2 agonists include, but are not limited to, short-acting ⁇ -2 agonists (
  • FLAP inhibitors and/or FLAP modulators include, but are not limited to, 3 - [3 -tert-butylsulfanyl- 1 - [4-(6-methoxy-pyridin-3 -yl)-benzyl] -5-(pyridin-2-ylmethoxy)- 1 H-indol- 2-yl]-2,2-dimethyl-propionic acid, 3-[3-iert-butylsulfanyl-l-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5- methyl-pyridin-2-ylmethoxy)-lH-indol-2-yl]-2,2-dimethyl-propionic acid, MK-886, MK-0591, BAY-xl005 and compounds found in US 2007/0225285, US 2007/0219206, US 2007/0173508, US 2007/0123522 and US 2007/0105866 (each of which are hereby
  • Glucocorticoids include, but are not limited to, beclometasone, budesonide, ciclesonide, fluticasone and mometasone.
  • Anticholinergics include, but are not limited to, ipratropium and tiotropium.
  • Mast cell stabilizers include, but are not limited to, cromoglicate and nedocromil.
  • Xanthines include, but are not limited to, amminophylline, theobromine and theophylline.
  • Leukotriene antagonists include, but are not limited to, montelukast, tomelukast, pranlukast and zafirlukast.
  • 5-LO inhibitors include, but are not limited to, zileuton, VIA-2291 (ABT761), AZ-4407 and ZD-2138 and compounds found in US 2007/0149579, WO2007/016784.
  • methods for treating LPA-dependent or LPA-mediated conditions or diseases comprises administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one additional agent selected from, by way of example only, antihistamines, leukotriene antagonists, corticosteroids and decongestants.
  • Leukotriene antagonists include, but are not limited to, montelukast, tomelukast, pranlukast and zafirlukast.
  • LPA receptor antagonists described herein are admistered in combination with one or more agents used to treat used to treat asthma, including, but not limited to: combination inhalers (fluticasone and salmeterol oral inhalation (e.g. Advair)); inhaled Beta-2 agonists (albuterol inhaler; albuterol nebulizer solution; formoterol; isoproterenol oral inhalation; levalbuterol;
  • combination inhalers fluticasone and salmeterol oral inhalation (e.g. Advair)
  • inhaled Beta-2 agonists albuterol inhaler; albuterol nebulizer solution; formoterol; isoproterenol oral inhalation; levalbuterol;
  • metaproterenol inhalation pirbuterol acetate oral inhalation; salmeterol aerosol inhalation; salmeterol powder inhalation; terbutaline inhaler); inhaled corticosteroids (beclomethasone oral inhalation; budesonide inhalation solution; budesonide inhaler; flunisolide oral inhalation; fluticasone inhalation aerosol; fluticasone powder for oral inhalation; mometasone inhalation powder; triamcinolone oral inhalation); leukotriene modifiers (montelukast; zafirlukast; zileuton); mast cell stabilizers (cromolyn inhaler; nedocromil oral inhalation); monoclonal antibodies (omalizumab); oral Beta-2 agonists (albuterol oral syrup; albuterol oral tablets; metaproterenol; terbutaline); bronchodilator
  • aminophylline (aminophylline; oxtriphylline; theophylline).
  • LPA receptor anatogonists described herein are admistered in combination with one or more agents used to treat allergy, including, but not limited to: antihistamine and decongestant combinations (cetirizine and pseudoephednne; desloratadine and pseudoephedrine ER; fexofenadine and pseudoephedrine; loratadine and pseudoephedrine); antihistamines (azelastine nasal spray; brompheniramine; brompheniramine oral suspension; carbinoxamine; cetirizine;
  • chlorpheniramine clemastine; desloratadine; dexchlorpheniramine ER; dexchlorpheniramine oral syrup; diphenhydramine oral; fexofenadine; loratadine; promethazine); decongestants
  • nasal corticosteroids beclomethasone nasal inhalation; budesonide nasal inhaler; flunisolide nasal inhalation; fluticasone nasal inhalation; mometasone nasal spray; triamcinolone nasal inhalation; triamcinolone nasal spray); nasal decongestants (phenylephrine); nasal mast cell stabilizers (cromolyn nasal spray).
  • LPA receptor anatogonists described herein are admistered in combination with one or more agents used to treat chronic obstructive pulmonary disease (COPD), including, but
  • albuterol and ipratropium e.g. Combivent, DuoNeb
  • fluticasone and salmeterol oral inhalation e.g. Advair
  • corticosteroids diexamethasone tablets; fludrocortisone acetate; hydrocortisone tablets; methylprednisolone; prednisolone liquid; prednisone oral; triamcinolone oral
  • inhaled Beta-2 Agonists albuterol inhaler; albuterol nebulizer solution; formoterol; isoproterenol oral inhalation; levalbuterol; metaproterenol inhalation; pirbuterol acetate oral inhalation; salmeterol aerosol inhalation; salmeterol powder inhalation; terbutaline inhaler
  • Beta-2 agonists albuterol oral syrup; albuterol oral tablets; metaproterenol; terbutaline); bronchodilator (aminophylline; oxtriphylline; theophylline).
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered to a patient in combination with inhaled corticosteroids.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered to a patient in combination with beta2-adrenergic receptor agonists.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered to a patient in combination with short acting beta2-adrenergic receptor agonists.
  • a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered to a patient in combination with long-acting beta2-adrenergic receptor agonists.
  • kits and articles of manufacture are also described herein.
  • Such kits can comprise a carrier, package, or container that is
  • each of the container(s) comprising one of the separate elements to be used in a method described herein.
  • Suitable containers include, for example, bottles, vials, syringes, and test tubes.
  • the containers are formed from any acceptable material including, e.g., glass or plastic.
  • the container(s) can comprise one or more compounds described herein, optionally in a composition or in combination with another agent as disclosed herein.
  • the container(s) optionally have a sterile access port (for example the container can be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • kits optionally comprising a compound with an identifying description or label or instructions relating to its use in the methods described herein.
  • a kit will typically comprise one or more additional containers, each with one or more of various materials (such as reagents, optionally in concentrated form, and/or devices) desirable from a commercial and user standpoint for use of a compound described herein.
  • materials include, but not limited to, buffers, diluents, filters, needles, syringes; carrier, package, container, vial and/or tube labels listing contents and/or instructions for use, and package inserts with instructions for use.
  • a set of instructions will also typically be included.
  • a label can be on or associated with the container.
  • a label can be on a container when letters, numbers or other characters forming the label are attached, molded or etched into the container itself; a label can be associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert.
  • a label can be used to indicate that the contents are to be used for a specific therapeutic application. The label can also indicate directions for use of the contents, such as in the methods described herein.
  • Step 3 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid methyl ester
  • Step 6 iV-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-phenyl-propionamide
  • Step 7 4'-[3-Methyl-4-(3-phenyl-propionylamino)-isoxazol-5-yl]-biphenyl-3-carboxylic acid
  • N-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-phenyl-propionamide (0.100 g, 0.26 mmol)
  • 3-carboxyphenylboronic acid 0.052 g, 0.31 mmol
  • tetrakis(triphenylphosphine)palladium(0) 0.030 g, 0.03 mmol
  • potassium carbonate 0.072 g, 0.52 mmol
  • Step 1 [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-carbamic acid tert-but l ester
  • 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid (1.6 g, 6.0 mmol), diphenylphosphoryl azide (1.6 g, 6.0 mmol), and triethylamine (1.3 mL, 9.3 mmol) were combined in i-BuOH and refluxed overnight. After cooling, the mixture was concentrated and the residue was partitioned between EtOAc and 3 ⁇ 40. The organic layer was separated and concentrated, and the residue was purified by silica gel chromatography (16-18% EtOAc in hexanes) to give the title compound.
  • Step 3 l-Benzyl-3-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-urea
  • Step 4 4'-[4-(3-Benzyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-3-carboxylic acid [0474] Prepared according to the procedure described in Example 1 , Step 7, using l-benzyl-3-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-urea and 3-carboxyphenylboronic acid.
  • Step 1 l-(4-Bromo-phenyl)-cyclopropanecarbonitrile
  • Step 2 l-(4-Bromo-phenyl)-cyclopropanecarboxylic acid
  • Step 3 l-(4-Bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester
  • Step 4 l-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester
  • Step 5 l-[4'-(4-teri-Butoxycarbonylamino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
  • Step 6 l-[4'-(4-Amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
  • Step 7 l- ⁇ 4'-[3-Methyl-4-(3-methyl-butyrylamino)-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid ethyl ester
  • Step 8 l- ⁇ 4'-[3-Methyl-4-(3-methyl-butyrylamino)-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid
  • Step 1 l- ⁇ 4'-[3-Methyl-4-(3-phenyl-propionylamino)-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid ethyl ester
  • Step 2 l- ⁇ 4'-[3-Methyl-4-(3-phenyl-propionylamino)-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid
  • Step 1 l- ⁇ 4'-[3-Methyl-4-(2-phenoxy-acetylamino)-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid ethyl ester
  • Step 2 l- ⁇ 4'-[3-Methyl-4-(2-phenoxy-acetylamino)-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid
  • Step 1 l- ⁇ 4'-[4-(3-Benzyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid ethyl ester
  • Step 2 l- ⁇ 4'-[4-(3-Benzyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid
  • Step 1 l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-teri-butyl-urea
  • Step 2 l- ⁇ 4'-[4-(3-teri-Butyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid ethyl ester
  • Step 3 l- ⁇ 4'-[4-(3-teri-Butyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid
  • Step 1 3-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-l-isopropyl-l-methyl-urea
  • Step 2 l- ⁇ 4'-[4-(3-Isopropyl-3-methyl-ureido)-3-methyl-isoxazol-5-yl]-biphi
  • cyclopropanecarboxylic acid ethyl ester [0493] Prepared according to the procedure described in Example 3, Step 5, using 3-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]- 1 -isopropyl- 1 -methyl-urea and 1 -[4-(4,4,5,5-tetramethyl- [l ,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
  • Step 3 l- ⁇ 4'-[4-(3-Isopropyl-3-methyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid
  • Step 1 3-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-l-methyl-l-((R)-l-phenyl-ethyl)-urea
  • Step 2 l-(4'- ⁇ 3-Methyl-4-[3-methyl-3-((R)-l-phenyl-ethyl)-ureido]-isoxazol-5-yl ⁇ -biphenyl-4- yl)-cyclopropanecarboxylic acid ethyl ester
  • Step 3 l-(4'- ⁇ 3-Methyl-4-[3-methyl-3-((R)-l-phenyl-ethyl)-ureido]-isoxazol-5-yl ⁇ -biphenyl-4- yl)-cyclopropanecarboxylic acid
  • Step 1 l- ⁇ 4'-[3-Methyl-4-(3-phenyl-butylamino)-isoxazol-5-yl]-biphenyl-4-yl ⁇ - cyclopropanecarboxylic acid
  • Step 1 l-(4'- ⁇ 3-Methyl-4-[3-((R)-l-phenyl-ethyl)-ureido]-isoxazol-5-yl ⁇ -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
  • Step 2 l-(4'- ⁇ 3-Methyl-4-[3-((R)-l-phenyl-ethyl)-ureido]-isoxazol-5-yl ⁇ -biphenyl-4-yl)- cyclopropanecarboxylic acid
  • Step 1 l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-(2-fluoro-benzyl)-urea
  • Step 2 l-(4'- ⁇ 4-[3-(2-Fluoro-benzyl)-ureido]-3-methyl-isoxazol-5-yl ⁇ -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Description

COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
RELATED APPLICATIONS
[001] This application claims benefit of U.S. Provisional Application No. 61/247,861, entitled "COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS" filed on October 1, 2009, which is herein incorporated by reference.
FIELD OF THE INVENTION
[002] Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders or conditions associated with one or more of the lysophosphatidic acid (LPA) receptors.
BACKGROUND OF THE INVENTION
[003] Lysophospho lipids are membrane-derived bioactive lipid mediators. Lysophospho lipids affect fundamental cellular functions that include proliferation, differentiation, survival, migration, adhesion, invasion, and morphogensis. These functions influence many biological processes that include, but are not limited to, neurogensis, angiogenesis, wound healing, fibrosis, immunity, and carcinogenesis.
[004] Lysophosphatidic acid (LPA) is a lysophospholipid that has been shown to act through sets of specific G protein-coupled receptors (GPCRs) in an autocrine and paracrine fashion. LPA binding to its cognate GPCRs (LPAi, LPA2, LPA3, LPA4, LPA5, LPA6) activates intracellular signaling pathways to produce a variety of biological responses. Antagonists of the LPA receptors find use in the treatment of diseases, disorders or conditions in which LPA plays a role. SUMMARY OF THE INVENTION
[005] In one aspect, presented herein are compounds of Formula (I) that inhibit the physiological activity of lysophosphatidic acid (LPA), and therefore, are useful as agents for the treatment or prevention of diseases in which inhibition of the physiological activity of LPA is useful, such as diseases in which an LPA receptor participates, is involved in the etiology or pathology of the disease, or is otherwise associated with at least one symptom of the disease. In a related aspect, such compounds are useful as agents for the treatment or prevention of side effects, complications, or adverse events associated with the use of a different therapeutic agent or therapeutic action (e.g., radiation, surgery, etc) used in treating a disease or condition.
[006] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is useful for the treatment of fibrosis of organs (liver, kidney, lung, heart and the like), liver diseases (acute hepatatis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, non- alcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like), cell proliferative disease (cancer (solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL) and the like) and invasive metastasis of cancer cell, and the like), inflammatory disease (psoriasis, nephropathy, pneumonia and the like), gastrointestinal tract disease (irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion, and the like), renal disease, urinary tract- associated disease (benign prostatic hyperplasia or symptoms associated with neuropathic bladder disease, spinal cord tumor, hernia of intervertebral disk, spinal canal stenosis, symptoms derived from diabetes, lower urinary tract disease (obstruction of lower urinary tract, and the like), inflammatory disease of lower urinary tract, dysuria, frequent urination, and the like), pancreas disease, abnormal angiogenesis-associated disease (arterial obstruction and the like), scleroderma, brain-associated disease (cerebral infarction, cerebral hemorrhage, and the like), neuropathic pain, peripheral neuropathy, and the like, ocular disease (age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreoretinopathy (PVR), cicatricial pemphigoid, glaucoma filtration surgery scarring, and the like). In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of fibrotic diseases or conditions.
[007] In one aspect, described herein are compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII), pharmaceutically acceptable salts, pharmaceutically acceptable solvates, and prodrugs thereof. In one aspect, compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII), are antagonists of at least one of the LPA receptors selected from LPAi, LPA2, LPA3, LPA4; LPA5 and LPA6. In one embodiment, compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) are antagonists of LPAi. In one embodiment, compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) are antagonists of LPAi and/or LPA3. In some embodiments, compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) are antagonists of LPAi and/or LPA2. In some embodiments, compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) are selective antagonists for one of the LPA receptors relative to the other LPA receptors. In some embodiments, such a selective antagonist is selective for the LPAi receptor. In some embodiments, such a selective antagonist is selective for the LPA2 receptor. In some embodiments, such a selective antagonist is selective for the LPA3 receptor.
[008] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of diseases, disorders, or conditions in which activation of at least one LPA receptor by LPA contributes to the symptomology or progression of the disease, disorder or condition. These diseases, disorders, or conditions may arise from one or more of a genetic, iatrogenic,
immunological, infectious, metabolic, oncological, toxic, surgical, and/or traumatic etiology. In one aspect, the methods, compounds, pharmaceutical compositions, and medicaments described herein comprise antagonists of LPA receptors. In one aspect, the methods, compounds, pharmaceutical compositions, and medicaments described herein comprise antagonists of LPAi. [009] In one aspect, provided herein is a compound of Formula (I), or a pharmaceutically acceptable solvate, a pharmaceutically acce table salt, a prodrug, or a metabolite thereof:
Figure imgf000004_0001
Formula (I)
and R5 is H, Ci-C4alkyl, or Ci-C4fluoroalkyl; or
Figure imgf000004_0002
, and R3 is H, Ci-C4alkyl, or Ci-C4fluoroalkyl;
m is 0, 1 or 2; n is 0, 1 or 2;
L1 is absent, Ci-C4alkylene, Ci-C4fluoroalkylene, C3-C6cycloalkylene, -C3-C6cycloalkylene- Ci-C4alkylene-, or -[C(Rla)(Rlb)]q-; q is 1, 2 or 3;
Rla and Rlb are each independently selected from H, Ci-C4alkyl and substituted or unsubstituted benzyl;
R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, -C(=0)NH-OH, -C(=0)NH-CN, -CN, P(=0)(OH)2, P(=0)(ORD)2, -OP03H2, -S02NHC(=0)RE, tetrazolyl, -C(=NH)NH2, - C(=NH)NHC(=0)RE, or carboxylic acid bioisostere; RD is H or C C6alkyl; RE is C
C6alkyl or a substituted or unsubstituted phenyl;
L3 is a substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted Ci-
C6fluoroalkylene, or substituted or unsubstituted Ci-C6heteroalkylene, where if L3 is substituted then L3 is substituted with 1, 2 or 3 R13; each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy, Ci-C4fluoroalkoxy and a substituted or unsubstituted phenyl; or
L3 is -ΙΛΧ1-!.5-;
L4is absent or a substituted or unsubstituted Ci-C4alkylene, where if L4 is substituted then L4 is substituted with 1, 2, or 3 R14; each R14 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy;
X1 is a absent, -0-, -S-, -S(O)-, -S(0)2-, -NR7-, -C(0)NR8-, -NR8C(=0)-, -
NR8C(=0)CH20-, -NR8C(=0)-CH(CH3)0-, -NR8C(=0)-C(CH3)20-, -N(R8)S(=0)2- -S(=0)2N(R8)-, -C(=0)-, -OC(=0)-, -C(=0)0-, -OC(=0)0-, -OC(=0)N(R8)-, - NR8C(=0)0-, or -NR8C(=0)N(R8)-; provided that when L4 is absent then X1 is not - NR8C(=0)0-;
R7 is H, -S(=0)2R10, -S(=0)2N(R9)2, -C(=0)R10, -C02R9, -C(=0)N(R9)2, C C4alkyl, Ci-C4fluoroalkyl, or Ci-C4heteroalkyl;
R8 is H, Ci-C4alkyl, or Ci-C4fmoroalkyl;
L5 is absent or a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1, 2, or 3 R15; each R15 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy;
R6 is Ci-C6alkyl, Ci-C6fluoroalkyl, substituted or unsubstituted C3-Ci0cycloalkyl, a
substituted or unsubstituted C3-Cioheterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted monocyclic heteroaryl, or a substituted or unsubstituted bicyclic heteroaryl, wherein if R6 is substituted then R6 is substituted with 1 , 2 or 3 Rc;
each of RA, RB, and Rc are independently selected from halogen, -CN, -N02, -OH, -OR , - SR9, -S(=0)R10, -S(=0)2R10, -N(R9)S(=0)2R10, -S(=0)2N(R9)2, -C(=0)R10, -OC(=0)R10,
-C02R9, -OC02R10, -N(R9)2, -C(=0)N(R9)2, -OC(=0)N(R9)2, -NR9C(=0)N(R9)2, - NR9C(=0)R10, -NR9C(=0)OR10, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, d- C4alkoxy, and Ci-C4heteroalkyl;
each R9 is independently selected from H, Ci-Ci2alkyl, Ci-C6heteroalkyl, Ci-C6fluoroalkyl, a substituted or unsubstituted C3-C6cycloalkyl, a substituted or unsubstituted C2-
Ceheterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted monocyclic heteroaryl, -Ci-C4alkylene-(substituted or unsubstituted C3-C6cycloalkyl), - Ci-C4alkylene-(substituted or unsubstituted C2-C6heterocycloalkyl), -Ci-C4alkylene- (substituted or unsubstituted phenyl), or -Ci-C4alkylene-(substituted or unsubstituted heteroaryl); or
two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted heterocycle;
R10 is selected from Ci-C6alkyl, Ci-C6heteroalkyl, Ci-C6fluoroalkyl, a substituted or
unsubstituted C3-C6cycloalkyl, a substituted or unsubstituted C2-C6heterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted monocyclic heteroaryl, -Ci-C4alkylene-(substituted or unsubstituted C3- C6cycloalkyl), -Ci-C4alkylene-(substituted or unsubstituted C2-C6heterocycloalkyl), -Cr C4alkylene-(substituted or unsubstituted phenyl), and -Ci-C4alkylene-(substituted or unsubstituted heteroaryl).
[010] For any and all of the embodiments, substituents are selected from among from a subset of the listed alternatives. For example, in some embodiments, R1 is -C02RD or -C(=0)NHS02RE. In some embodiments, R1 is -C02RD. In some embodiments, R1 is -CO2H. In some embodiments, R1 is -C(=0)NHS02RE. In some embodiments, RE is Ci-C6 alkyl. In some embodiments, RE is -CH3 or - CH2CH3. In some embodiments, RD is H, -CH3 or -CH2CH3. In some embodiments, RD is H.
[Oil] In some embodiments, the compound has the structure of Formula (II):
Figure imgf000006_0001
wherein,
R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, -CN, or tetrazolyl;
RD is H or Ci-C6alkyl;
REis Ci-C6alkyl or a substituted or unsubstituted phenyl;
L1 is absent, Ci-C4alkylene, Ci-C4fluoroalkylene, C3-C6cycloalkylene, -C3-C6cycloalkylene-
Ci-C4alkylene-, -Ci-C4alkylene-C3-C6cycloalkylene-, or -C(Rla)(Rlb)-;
Rla and Rlb are each independently selected from H, Ci-C4alkyl and benzyl; each RA is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci-C4fluoroalkyl, C
C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
each RB is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-
C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
R5 is H or Ci-C4alkyl;
m is 0 or 1 ; n is 0 or 1.
[012] In some embodiments, the compound has the structure of Formula (III):
Figure imgf000006_0002
Formula (III)
-C(=0)NHS02RE, -C(=0)N(RD)2, -CN, or tetrazolyl;
IT is H or Ci-C6alkyl;
REis Ci-C6alkyl or a substituted or unsubstituted phenyl;
L1 is absent, Ci-C4alkylene, C3-C6cycloalkylene, -C3-C6cycloalkylene-Ci-C4alkylene-, -Cr
C4alkylene-C3-C6cycloalkylene-, or -C(Rla)(Rlb)-;
Rla and Rlb are each independently selected from H, Ci-C4alkyl and benzyl; each RA is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci-C4fluoroalkyl, C C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
each R is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci- C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
R3 is H or Ci-C4alkyl;
m is 0 or 1 ; n is 0 or 1.
[013] In some embodiments, L1 is absent, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH(CH2CH3)-, -
C(CH2CH3)2-, -CH(CH(CH3)2)-, -CH2CH2-, -CH2CH2CH2-, -C≡C-, -CH(CH2phenyl)-, cyclopropyl- 1,1-diyl, cyclopropyl-l,2-diyl, cyclobutyl- 1 , 1 -diyl, cyclopentyl- 1 , 1 -diyl, cyclohexyl-l,l-diyl, - C(CH2CH2)CH2- or -CH2C(CH2CH2)-.
[014] In some embodiments, R1 is -C02RD or -C(=0)NHS02RE; L1 is absent, -CH2-, -CH(CH3)-, - C(CH3)2-, -CH2CH2-, -CH2CH2CH2-, cyclopropyl- 1 , 1 -diyl, cyclopropyl- 1 ,2-diyl, cyclobutyl- 1 , 1 -diyl, cyclopentyl- 1,1 -diyl, cyclohexyl- 1 , 1 -diyl, -C(CH2CH2)CH2- or -CH2C(CH2CH2)-; R6 is C3- C6cycloalkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic heteroaryl, wherein if R6 is substituted then R6 is substituted with 1, 2 or 3 Rc; each Rc is
independently selected from halogen, -CN, -OH, -OR9, -S(=0)2R10, -C(=0)R10, -C02R9, -N(R9)2, - C(=0)N(R9)2, -NR9C(=0)R10, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl.
[015] In some embodiments, L1 is -CH2-, cyclopropyl- 1 , 1 -diyl, or -C(CH2CH2)CH2-; L3 is a substituted or unsubstituted C3-C6alkylene, substituted or unsubstituted C3-C6fluoroalkylene, or substituted or unsubstituted C3-C6heteroalkylene, where if L3 is substituted then L3 is substituted with 1, 2 or 3 R13; each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci- C4alkoxy, Ci-C4fluoroalkoxy and phenyl.
[016] In some embodiments, L3 is a substituted or unsubstituted C3-C4alkylene, substituted or unsubstituted C3-C4fluoroalkylene, -(substituted or unsubstituted C3-C4alkylene)-0-, -(substituted or unsubstituted Ci-C3alkylene)-0-(substituted or unsubstituted Ci-C3alkylene)-, -0-(substituted or unsubstituted C3-C4alkylene)-, -(substituted or unsubstituted C3-C4alkylene)-S-, -(substituted or unsubstituted Ci-C3alkylene)-S-(substituted or unsubstituted Ci-C3alkylene)-, -S-(substituted or unsubstituted C3-C4alkylene)-, -(substituted or unsubstituted C3-C4alkylene)-NH-, -(substituted or unsubstituted Ci-C3alkylene)-NH-(substituted or unsubstituted Ci-C3alkylene)-, -NH-(substituted or unsubstituted C3-C4alkylene)-; where if L3 is substituted then L3 is substituted with 1 or 2 R13.
[017] In some embodiments, L3 is a substituted or unsubstituted C3-C4alkylene, substituted or unsubstituted C3-C4fluoroalkylene, -(substituted or unsubstituted Ci-C3alkylene)-0-(substituted or unsubstituted Ci-C3alkylene)-, -(substituted or unsubstituted Ci-C3alkylene)-S-(substituted or unsubstituted Ci-C3alkylene)-, -NH-(substituted or unsubstituted C3-C4alkylene)-; where if L3 is substituted then L3 is substituted with 1 or 2 R13.
[018] In some embodiments, R1 is -C02RD or -C(=0)NHS02RE; L1 is -CH2-, cyclopropyl- 1 , 1 -diyl, or -C(CH2CH2)CH2-; L3 is -^-X^L5-; L4 is a substituted or unsubstituted Ci-C4alkylene, where if L4 is substituted then L4 is substituted with 1 or 2 R14; each R14 is independently selected from F, -CH3, -CH2CH3, -CF3, hydroxyl, -OCH3, -OCH2CH3, and -OCF3; X1 is -0-, -S-, -S(O)-, -S(0)2-, -NR7-, - C(0)NR8-, -NR8C(=0)-, -NR8C(=0)CH20-, -NR8C(=0)-CH(CH3)0-, -NR8C(=0)-C(CH3)20-, - C(=0)-, -OC(=0)-, -C(=0)0-, -OC(=0)0-, -OC(=0)N(R8)-, -NR8C(=0)0-, or -NR8C(=0)N(R8)-; R7 is H, -C(=0)R10, or Ci-C4alkyl; R8 is H, or Ci-C4alkyl; L5 is absent or a substituted or
unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1 or 2 R15; each R15 is independently selected from F, -CH3, -CH2CH3, -CF3, hydroxyl, -OCH3, -OCH2CH3, and -OCF3.
[019] In some embodiments, L5 is a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1 or 2 R15; each R15 is independently selected from F, -CH3, - CH2CH3, -CF3, hydroxyl, -OCH3, -OCH2CH3, and -OCF3.
[020] In some embodiments, X1 is -0-, -S-, or -NR7-.
[021] In some embodiments, R1 is -C02RD or -C(=0)NHS02RE; L1 is -CH2-, cyclopropyl- 1 , 1 -diyl, or -C(CH2CH2)CH2-; L3 is -L4-Xx-L5-; L4 is absent; X1 is -NR7-; R7 is H or C C4alkyl; L5 is absent or a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1 or 2 R15; each R15 is independently selected from F, -CH3, -CH2CH3, -CF3, hydroxyl, -OCH3, - OCH2CH3, and -OCF3.
[022] In some embodiments, the compound has a structure of Formula (VI), or a pharmaceutically acceptable salt thereof:
Figure imgf000009_0001
Formula (VI)
wherein,
R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, or tetrazolyl;
RD is H or C C6alkyl;
RE is Ci-C6alkyl, C3-C6cycloalkyl, or substituted or unsubstituted phenyl;
L3 is a substituted or unsubstituted C3-C6alkylene, a substituted or unsubstituted C3-
C6fluoroalkylene, or a substituted or unsubstituted C3-C6heteroalkylene, where if L3 is substituted then L3 is substituted with 1 , 2 or 3 R13; each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, and -OH;
each of RA, RB, and Rc are independently selected from H, halogen, -CN, -N02, -OH, -OR9, -
N(R9)2, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-
C4heteroalkyl;
R5 is H or C C4alkyl;
each R9 is independently selected from H, Ci-C6alkyl, Ci-C6fiuoroalkyl, a substituted or unsubstituted phenyl, or -CH2-(substituted or unsubstituted phenyl); or
two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted Ci-Csheterocycle;
m is 0 or 1 ; n is 0 or 1 ; p is 0, 1 , or 2.
[023] In some embodiments, the compound has a structure of Formula (VII), or a pharmaceutically acceptable salt thereof:
Figure imgf000010_0001
Formula (VII)
wherein,
R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, or tetrazolyl;
RD is H or Ci-C6alkyl;
RE is Ci-C6alkyl, C3-C6cycloalkyl, or substituted or unsubstituted phenyl;
L3 is a substituted or unsubstituted C3-C6alkylene, a substituted or unsubstituted C3-
C6fluoroalkylene, or a substituted or unsubstituted C3-C6heteroalkylene, where if L3 is substituted then L3 is substituted with 1 , 2 or 3 R13; each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, and -OH;
each of RA, RB, and Rc are independently selected from H, halogen, -CN, -N02, -OH, -OR9, -
N(R9)2, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and C
C4heteroalkyl;
R3 is H or Ci-C4alkyl;
each R9 is independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, a substituted or unsubstituted phenyl, or -CH2-(substituted or unsubstituted phenyl); or
two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted Ci-C5heterocycle;
m is 0 or 1 ; n is 0 or 1 ; p is 0, 1 , or 2.
[024] In some embodiments, R1 is -C02RD, or -C(=0)NHS02RE; RD is H or C C4alkyl; RE is d- C4alkyl; L3 is a substituted or unsubstituted C3-C4alkylene, a substituted or unsubstituted C3- C4fluoroalkylene, or a substituted or unsubstituted C3-C6heteroalkylene; where if L3 is substituted then L3 is substituted with 1 , 2 or 3 R13; each R13 is independently selected from F, -CH3, -CH2CH3, - CF3, and -OH; m is 0; n is 0.
[025] In some embodiments, L3 is a substituted or unsubstituted butylene, a substituted or unsubstituted fluorobutylene, or a substituted or unsubstituted difluorobutylene; where if L3 is substituted then L3 is substituted with 1 or 2 R13.
[026] In some embodiments, L3 is a substituted or unsubstituted C3-C6heteroalkylene; where if L3 is substituted then L3 is substituted with 1 or 2 R13. [027] In some embodiments, L3 is -(substituted or unsubstituted C3-C4alkylene)-0-, -(substituted or unsubstituted Ci-C3alkylene)-0-(substituted or unsubstituted Ci-C3alkylene)-, -0-(substituted or unsubstituted C3-C4alkylene)-, -(substituted or unsubstituted C3-C4alkylene)-S-, -(substituted or unsubstituted Ci-C3alkylene)-S-(substituted or unsubstituted Ci-C3alkylene)-, -S-(substituted or unsubstituted C3-C4alkylene)-, -(substituted or unsubstituted C3-C4alkylene)-NH-, -(substituted or unsubstituted Ci-C3alkylene)-NH-(substituted or unsubstituted Ci-C3alkylene)-, or -NH-(substituted or unsubstituted C3-C4alkylene)-.
[028] In some embodiments, L3 is -NH-(substituted or unsubstituted C3-C4alkylene); where if L3 is substituted then L3 is substituted with R13. In some embodiments, L3 is -NH-(substituted or unsubstituted propylene); where if L3 is substituted then L3 is substituted with R13.
[029] In some embodiments, L3 is -(substituted or unsubstituted Ci-C3alkylene)-0-(substituted or unsubstituted Ci-C3alkylene)-, or -(substituted or unsubstituted Ci-C3alkylene)-S-(substituted or unsubstituted Ci-C3alkylene)-; where if L3 is substituted then L3 is substituted with R13.
[030] In some embodiments, L3 is -(substituted or unsubstituted ethylene)-0-(substituted or unsubstituted methylene)-, or -(substituted or unsubstituted ethylene)-S-(substituted or unsubstituted methylene)-; where if L3 is substituted then L3 is substituted with R13.
or
Figure imgf000011_0001
. In some embodiments, R 6 is
[032] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[033] In one aspect, provided is a compound presented in Table 1 or Table 2, or a pharmaceutically acceptable salt thereof.
[034] In some embodiments, the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is an antagonist of a LP A receptor. In some embodiments, the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is an antagonist of LPAi. In some embodiments, the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is an antagonist of LPA2. In some embodiments, the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is an antagonist of LPA3.
[035] In some embodiments, presented herein are compounds selected from active metabolites, tautomers, pharmaceutically acceptable solvates, pharmaceutically acceptable salts or prodrugs of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
[036] In some embodiments, provided is a pharmaceutical composition comprising a
therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII). In some embodiments, the pharmaceutical composition also contains at least one pharmaceutically acceptable inactive ingredient.
[037] In some embodiments, provided is a pharmaceutical composition comprising a
therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable inactive ingredient. In one aspect, the pharmaceutical composition is formulated for intravenous injection, subcutaneous injection, oral administration, inhalation, nasal administration, topical administration, ophthalmic administration or otic administration. In some embodiments, the pharmaceutical composition is a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop or an ear drop.
[038] In some embodiments, the pharmaceutical composition further comprises one or more additional therapeutically active agents selected from: corticosteroids, immunosuppresants, analgesics, anti-cancer agent, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, monoacylglycerol kinase inhibitors, phospholipase Ai inhibitors, phospholipase A2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, decongestants, antihistamines, mucolytics,
anticholinergics, antitussives, expectorants, and β-2 agonists.
[039] In some embodiments, provided is a method comprising administering a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) to a human with a LPA-dependent or LPA-mediated disease or condition. In some embodiments, the human is already being administered one or more additional therapeutically active agents other than a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII). In some embodiments, the method further comprises administering one or more additional therapeutically active agents other than a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
[040] In some embodiments, the one or more additional therapeutically active agents other than a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are selected from: corticosteroids, immunosuppresants, analgesics, anti-cancer agent, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, monoacylglycerol kinase inhibitors, phospholipase Ai inhibitors, phospholipase A2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, decongestants, antihistamines, mucolytics, anticholinergics, antitussives, expectorants, and β-2 agonists.
[041] Pharmaceutical formulations described herein are administerable to a subject in a variety of ways by multiple administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical or transdermal administration routes. The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
[042] In some embodiments, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered orally.
[043] In some embodiments, a compounds of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered topically. In such embodiments, the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, shampoos, scrubs, rubs, smears, medicated sticks, medicated bandages, balms, creams or ointments. Such pharmaceutical compounds can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives. In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered topically to the skin.
[044] In another aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered by inhalation. In one embodiment, a compound of Formula (I) is administered by inhalation that directly targets the pulmonary system.
[045] In another aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated for intranasal adminstration. Such formulations include nasal sprays, nasal mists, and the like.
[046] In another aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated as eye drops.
[047] In another aspect is the use of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the manufacture of a medicament for treating a disease, disorder or conditions in which the activity of at least one LPA receptor contributes to the pathology and/or symptoms of the disease or condition. In one embodiment of this aspect, the LPA is selected from LPAl5 LPA2, LPA3, LPA4, LPA5 and LPA6. In one aspect, the LPA receptor is LPAi. In one aspect, the disease or condition is any of the diseases or conditions specified herein.
[048] In any of the aforementioned aspects are further embodiments in which: (a) the effective amount of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is systemically administered to the mammal; and/or (b) the effective amount of the compound is administered orally to the mammal; and/or (c) the effective amount of the compound is intravenously administered to the mammal; and/or (d) the effective amount of the compound is administered by inhalation; and/or (e) the effective amount of the compound is administered by nasal administration; or and/or (f) the effective amount of the compound is administered by injection to the mammal; and/or (g) the effective amount of the compound is administered topically to the mammal; and/or (h) the effective amount of the compound is administered by ophthalmic administration; and/or (i) the effective amount of the compound is administered rectally to the mammal; and/or (j) the effective amount is adminstered non-systemically or locally to the mammal.
[049] In any of the aforementioned aspects are further embodiments comprising single
administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered once; (ii) the compound is administered to the mammal multiple times over the span of one day; (iii) continually; or (iv) continuously.
[050] In any of the aforementioned aspects are further embodiments comprising multiple administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered continuously or intermittently: as in a a single dose; (ii) the time between multiple administrations is every 6 hours; (iii) the compound is administered to the mammal every 8 hours; (iv) the compound is administered to the mammal every 12 hours; (v) the compound is administered to the mammal every 24 hours. In further or alternative embodiments, the method comprises a drug holiday, wherein the administration of the compound is temporarily suspended or the dose of the compound being administered is temporarily reduced; at the end of the drug holiday, dosing of the compound is resumed. In one embodiment, the length of the drug holiday varies from 2 days to 1 year.
[051] Also provided is a method of inhibiting the physiological activity of LP A in a mammal comprising administering a therapuetically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
[052] In one aspect, provided is a medicament for treating a LPA-dependent or LPA-mediated disease or condition in a mammal comprising a therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
[053] In some cases disclosed herein is the use of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the manufacture of a medicament for the treatment of a LPA-dependent or LPA- mediated disease or condition.
[054] In some cases disclosed herein is the use of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the treatment or prevention of a LPA-dependent or LPA-mediated disease or condition.
[055] In one aspect, is a method for treating or preventing a LPA-dependent or LPA-mediated disease or condition in a mammal comprising administering a therapuetically effective amount of a compound of Formula (I), (II), (III), (LV), (V), (VI), or (VII).
[056] In one aspect, LPA-dependent or LPA-mediated diseases or conditions include, but are not limited to, fibrosis of organs or tissues, scarring, liver diseases, dermatological conditions, cancer, cardiovascular disease, respiratory diseases or conditions, inflammatory disease, gastrointestinal tract disease, renal disease, urinary tract-associated disease, inflammatory disease of lower urinary tract, dysuria, frequent urination, pancreas disease, arterial obstruction, cerebral infarction, cerebral hemorrhage, pain, peripheral neuropathy, and fibromyalgia.
[057] In one aspect, the LPA-dependent or LPA-mediated disease or condition is a respiratory disease or condition. In some embodiments, the respiratory disease or condition is asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary arterial hypertension or acute respiratory distress syndrome.
[058] In some embodiments, the LPA-dependent or LPA-mediated disease or condition is selected from idiopathic pulmonary fibrosis; other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, langerhans cell granulomatosis, lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease); radiation induced fibrosis; chronic obstructive pulmonary disease (COPD); scleroderma; bleomycin induced pulmonary fibrosis; chronic asthma; silicosis; asbestos induced pulmonary fibrosis; acute respiratory distress syndrome (ARDS); kidney fibrosis;
tubulointerstitium fibrosis; glomerular nephritis; focal segmental glomerular sclerosis; IgA nephropathy; hypertension; Alport; gut fibrosis; liver fibrosis; cirrhosis; alcohol induced liver fibrosis; toxic/drug induced liver fibrosis; hemochromatosis; nonalcoholic steatohepatitis (NASH); biliary duct injury; primary biliary cirrhosis; infection induced liver fibrosis; viral induced liver fibrosis; and autoimmune hepatitis; corneal scarring; hypertrophic scarring; Duputren disease, keloids, cutaneous fibrosis; cutaneous scleroderma; spinal cord injury/fibrosis; myelofibrosis;
vascular restenosis; atherosclerosis; arteriosclerosis; Wegener's granulomatosis; Peyronie's disease, chronic lymphocytic leukemia, tumor metastasis, transplant organ rejection, endometreosis, neonatal respiratory distress syndrome and neuropathic pain.
[059] In one aspect, the LPA-dependent or LPA-mediated disease or condition is described herein.
[060] In one aspect, provided is a method for the treatment or prevention of organ fibrosis in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) or a pharmaceutically acceptable salt thereof to a mammal in need thereof.
[061] In one aspect, the organ fibrosis comprises lung fibrosis, renal fibrosis, or hepatic fibrosis.
[062] In one aspect, provided is a method of improving lung function in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) or a pharmaceutically acceptable salt thereof to the mammal in need thereof. In one aspect, the mammal has been diagnosed as having lung fibrosis.
[063] In one aspect, compounds disclosed herein are used to treat idiopathic pulmonary fibrosis (usual interstitial pneumonia) in a mammal. [064] In some embodiments, compounds disclosed herein are used to treat diffuse parenchymal interstitial lung diseases in mammal: iatrogenic drug induced, occupational/environmental (Farmer lung), granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease (scleroderma and others), alveolar proteinosis, langerhans cell granulonmatosis,
lymphangioleiomyomatosis, Hermansky-Pudlak Syndrome, Tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease.
[065] In some embodiments, compounds disclosed herein are used to treat post-transplant fibrosis associated with chronic rejection in a mammal: Bronchiolitis obliterans for lung transplant.
[066] In some embodiments, compounds disclosed herein are used to treat cutaneous fibrosis in a mammal: cutaneous scleroderma, Dupuytren disease, keloids.
[067] In one aspect, compounds disclosed herein are used to treat hepatic fibrosis with or without cirrhosis in a mammal: toxic/drug induced (hemochromatosis), alcoholic liver disease, viral hepatitis (hepatitis B virus, hepatitis C virus, HCV), nonalcoholic liver disease (NASH), metabolic and autoimmune.
[068] In one aspect, compounds disclosed herein are used to treat renal fibrosis in a mammal: tubulointerstitium fibrosis, glomerular sclerosis.
[069] In any of the aforementioned aspects involving the treatment of LPA dependent diseases or conditions are further embodiments comprising administering at least one additional agent in addition to the administartion of a compound having the structure of Formula (I), (II), (III), (IV), (V), (VI), or (VII). In various embodiments, each agent is administered in any order, including simultaneously.
[070] In any of the embodiments disclosed herein, the mammal is a human.
[071] In some embodiments, compounds provided herein are administered to a human.
[072] In some embodiments, compounds provided herein are orally administered.
[073] In some embodiments, compounds provided herein are used as antagonists of at least one
LPA receptor. In some embodiments, compounds provided herein are used for inhibiting the activity of at least one LPA receptor or for the treatment of a disease or condition that would benefit from inhibition of the activity of at least one LPA receptor. In one aspect, the LPA receptor is LPAi.
[074] In other embodiments, compounds provided herein are used for the formulation of a medicament for the inhibition of LPAi activity.
[075] Articles of manufacture, which include packaging material, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII), within the packaging material, and a label that indicates that the compound or composition, or pharmaceutically acceptable salt, tautomers, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, is used for inhibiting the activity of at least one LPA receptor, or for the treatment, prevention or amelioration of one or more symptoms of a disease or condition that would benefit from inhibition of the activity of at least one LPA receptor, are provided.
[076] Other objects, features and advantages of the compounds, methods and compositions described herein will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments, are given by way of illustration only, since various changes and modifications within the spirit and scope of the instant disclosure will become apparent to those skilled in the art from this detailed description DETAILED DESCRIPTION OF THE INVENTION
[077] Lysophospho lipids are membrane-derived bioactive lipid mediators. Lysophospho lipids include, but are not limited to, lysophosphatidic acid (l-acyl-2-hydroxy-s«-glycero-3 -phosphate; LPA), sphingosine 1 -phosphate (SIP), lysophosphatidylcholine (LPC), and
sphingosylphosphorylcholine (SPC). Lysophospholipids affect fundamental cellular functions that include cellular proliferation, differentiation, survival, migration, adhesion, invasion, and
morphogensis. These functions influence many biological processes that include neurogensis, angiogenesis, wound healing, immunity, and carcinogenesis.
[078] LPA acts through sets of specific G protein-coupled receptors (GPCRs) in an autocrine and paracrine fashion. LPA binding to its cognate GPCRs (LPAi, LPA2, LPA3, LPA4, LPA5, LPA6) activates intracellular signaling pathways to produce a variety of biological responses.
[079] Lysophospholipids, such as LPA, are quantitatively minor lipid species compared to their major phospholipid counterparts (e.g., phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin). LPA has a role as a biological effector molecule, and has a diverse range of physiological actions such as, but not limited to, effects on blood pressure, platelet activation, and smooth muscle contraction, and a variety of cellular effects, which include cell growth, cell rounding, neurite retraction, and actin stress fiber formation and cell migration. The effects of LPA are predominantly receptor mediated.
[080] Activation of the LPA receptors (LPAi, LPA2, LPA3, LPA4, LPA5, LPA6) with LPA mediates a range of downstream signaling cascades. These include, but are not limited to, mitogen-activated protein kinase (MAPK) activation, adenylyl cyclase (AC) inhibition/activation, phospho lipase C
(PLC) activation/Ca2+ mobilization, arachidonic acid release, Akt/PKB activation, and the activation of small GTPases, Rho, ROCK, Rac, and Ras. Other pathways that are affected by LPA receptor activation include, but are not limited to, cyclic adenosine monophosphate (cAMP), cell division cycle 42/GTP -binding protein (Cdc42) , proto-oncogene serine/threonine-protein kinase Raf (c- RAF), proto-oncogene tyrosine-protein kinase Src (c-src), extracellular signal-regulated kinase
(ERK), focal adhesion kinase (FAK), guanine nucleotide exchange factor (GEF), glycogen synthase kinase 3b (GSK3b), c-jun amino-terminal kinase (JNK), MEK, myosin light chain II (MLC II), nuclear factor kB (NF-kB), N-methyl-D-aspartate (NMD A) receptor activation, phosphatidylinositol 3-kinase (PI3K), protein kinase A (PKA), protein kinase C (PKC), ras-related C3 botulinum toxin substrate 1 (RACl). The actual pathway and realized end point are dependent on a range of variables that include receptor usage, cell type, expression level of a receptor or signaling protein, and LPA concentration. Nearly all mammalian cells, tissues and organs co-express several LPA-receptor subtypes, which indicates that LPA receptors signal in a cooperative manner. LPAi, LPA2, and LP A3 share high amino acid sequence similarity.
[081] LPA is produced from activated platelets, activated adipocytes, neuronal cells, and other cell types. Serum LPA is produced by multiple enzymatic pathways that involve monoacylglycerol kinase, phospholipase Ai, secretory phospholipase A2, and lysophospholipase D (lysoPLD), including autotaxin. Several enzymes are involved in LPA degradation: lysophospholipase, lipid phosphate phosphatase, and LPA acyl transferase such as endophilin. LPA concentrations in human serum are estimated to be 1-5 μΜ. Serum LPA is bound to albumin, low-density lipoproteins, or other proteins, which possibly protect LPA from rapid degradation. LPA molecular species with different acyl chain lengths and saturation are naturally occurring, including 1-palmitoyl (16:0), 1- palmitoleoyl (16: 1), 1-stearoyl (18:0), 1-oleoyl (18: 1), 1-linoleoyl (18:2), and 1 -arachidonyl (20:4) LPA. Quantitatively minor alkyl LPA has biological activities similar to acyl LPA, and different LPA species activate LPA receptor subtypes with varied efficacies.
LPA RECEPTORS
[082] LPAi (previously called VZG-l/EDG-2/mrecl .3) couples with three types of G proteins, Gi/0, Gq, and G12/13. Through activation of these G proteins, LPA induces a range of cellular responses through LPAi including but not limited to: cell proliferation, serum-response element (SRE) activation, mitogen-activated protein kinase (MAPK) activation, adenylyl cyclase (AC) inhibition, phospholipase C (PLC) activation, Ca2+ mobilization, Akt activation, and Rho activation.
[083] Wide expression of LPAi is observed in adult mice, with clear presence in testis, brain, heart, lung, small intestine, stomach, spleen, thymus, and skeletal muscle. Similarly, human tissues also express LPAi; it is present in brain, heart, lung, placenta, colon, small intestine, prostate, testis, ovary, pancreas, spleen, kidney, skeletal muscle, and thymus.
[084] LPA2 (EDG-4) also couples with three types of G proteins, Gi/0, Gq, and G12/13, to mediate LPA-induced cellular signaling. Expression of LPA2 is observed in the testis, kidney, lung, thymus, spleen, and stomach of adult mice and in the human testis, pancreas, prostate, thymus, spleen, and peripheral blood leukocytes. Expression of LPA2 is upregulated in various cancer cell lines, and several human LPA2 transcriptional variants with mutations in the 3 '-untranslated region have been observed. Targeted deletion of LPA2 in mice has not shown any obvious phenotypic abnormalities, but has demonstrated a significant loss of normal LPA signaling (e.g., PLC activation, Ca2+ mobilization, and stress fiber formation) in primary cultures of mouse embryonic fibroblasts (MEFs). Creation of lpa\(-l-) Ipal (-/-) double-null mice has revealed that many LPA-induced responses, which include cell proliferation, AC inhibition, PLC activation, Ca2+ mobilization, TNK and Akt activation, and stress fiber formation, are absent or severely reduced in double-null MEFs. All these responses, except for AC inhibition (AC inhibition is nearly abolished in LPAi (-/-) MEFs), are only partially affected in either LPAi (-/-) or LPA2 (-/-) MEFs. LPA2 contributes to normal LPA-mediated signaling responses in at least some cell types (Choi et al, Biochemica et Biophysica Acta 2008, 1781 , p531-539).
[085] LPA3 (EDG-7) is distinct from LPAi and LPA2 in its ability to couple with GyQ and Gq but not G12/13 and is much less responsive to LPA species with saturated acyl chains. LPA3 can mediate pleiotropic LPA-induced signaling that includes PLC activation, Ca2+ mobilization, AC
inhibition/activation, and MAPK activation. Overexpression of LPA3 in neuroblastoma cells leads to neurite elongation, whereas that of LPAi or LPA2 results in neurite retraction and cell rounding when stimulated with LPA. Expression of LPA3 is observed in adult mouse testis, kidney, lung, small intestine, heart, thymus, and brain. In humans, it is found in the heart, pancreas, prostate, testis, lung, ovary, and brain (frontal cortex, hippocampus, and amygdala).
[086] LPA4 (p2y9/GPR23) is of divergent sequence compared to LPAi, LPA2, and LPA3 with closer similarity to the platelet-activating factor (PAF) receptor. LPA4 mediates LPA induced Ca2+ mobilization and cAMP accumulation, and functional coupling to the G protein Gs for AC activation, as well as coupling to other G proteins. The LPA gene is expressed in the ovary, pancreas, thymus, kidney and skeletal muscle.
[087] LPA5 (GPR92) is a member of the purinocluster of GPCRs and is structurally most closely related to LPA4. LPA5 is expressed in human heart, placenta, spleen, brain, lung and gut. LPA5 also shows very high expression in the CD8+ lymphocyte compartment of the gastrointestinal tract.
[088] LPA6 (p2y5) is a member of the purinocluster of GPCRs and is structurally most closely related to LPA4. LPA6 is an LPA receptor coupled to the G12/13-Rho signaling pathways and is expressed in the inner root sheaths of human hair follicles.
Illustrative Biological Activity
Wound Healing
[089] Normal wound healing occurs by a highly coordinated sequence of events in which cellular, soluble factors and matrix components act in concert to repair the injury. The healing response can be described as taking place in four broad, overlapping phases— hemostasis, inflammation, proliferation, and remodeling. Many growth factors and cytokines are released into a wound site to initiate and perpetuate wound healing processes.
[090] When wounded, damaged blood vessels activate platelets. The activated platelets play pivotal roles in subsequent repair processes by releasing bioactive mediators to induce cell proliferation, cell migration, blood coagulation, and angiogenesis. LPA is one such mediator that is released from activated platelets; this induces platelet aggregation along with mitogenic/migration effects on the surrounding cells, such as endothelial cells, smooth muscle cells, fibroblasts, and keratinocytes.
[091] Topical application of LPA to cutaneous wounds in mice promotes repair processes (wound closure and increased neoepithelial thickness) by increasing cell proliferation/ migration without affecting secondary inflammation.
[092] Activation of dermal fibroblasts by growth factors and cytokines leads to their subsequent migration from the edges of the wound into the provisional matrix formed by the fibrin clot whereupon the fibroblasts proliferate and start to restore the dermis by secreting and organizing the characteristic dermal extracellular matrix (ECM). The increasing number of fibroblasts within the wound and continuous precipitation of ECM enhances matrix rigidity by applying small tractional forces to the newly formed granulation tissue. The increase in mechanical stress, in conjunction with transforming growth factor β (TGFP), induces a-smooth muscle actin (a-SMA) expression and the subsequent transformation of fibroblasts into myofibroblasts. Myofibroblasts facilitate granulation tissue remodeling via myofibroblast contraction and through the production of ECM components.
[093] LPA regulates many important functions of fibroblasts in wound healing, including proliferation, migration, differentiation and contraction. Fibroblast proliferation is required in wound healing in order to fill an open wound. In contrast, fibrosis is characterized by intense proliferation and accumulation of myofibroblasts that actively synthesize ECM and proinflammatory cytokines. LPA can either increase or suppress the proliferation of cell types important in wound healing, such as epithelial and endothelial cells (EC), macrophages, keratinocytes, and fibroblasts. A role for LPAi in LPA-induced proliferation was provided by the observation that LPA-stimulated proliferation of fibroblasts isolated from LPAi receptor null mice was attenuated (Mills et al, Nat Rev. Cancer 2003; 3: 582-591). LPA induces cytoskeletal changes that are integral to fibroblast adhesion, migration, differentiation and contraction.
Fibrosis
[094] Tissue injury initiates a complex series of host wound-healing responses; if successful, these responses restore normal tissue structure and function. If not, these responses can lead to tissue fibrosis and loss of function.
[095] For the majority of organs and tissues the development of fibrosis involves a multitude of events and factors. Molecules involved in the development of fibrosis include proteins or peptides (profibrotic cytokines, chemokines, metalloproteinases etc.) and phospholipids. Phospholipids involved in the development of fibrosis include platelet activating factor (PAF), phosphatidyl choline, sphingosine- 1 phosphate (SIP) and lysophosphatidic acid (LPA).
[096] A number of muscular dystrophies are characterized by a progressive weakness and wasting of musculature, and by extensive fibrosis. It has been shown that LPA treatment of cultured myoblasts induced significant expression of connective tissue growth factor (CTGF). CTGF subsequently induces collagen, fibronectin and integrin expression and induces dedifferentiation of these myoblasts. Treatment of a variety of cell types with LPA induces reproducible and high level induction of CTGF (J.P. Pradere, et al., LPAi receptor activation promotes renal interstitial fibrosis, J. Am. Soc. Nephrol. 18 (2007) 3110-3118; N. Wiedmaier, et al., Int J Med Microbiol; 298(3-4):231- 43, 2008). CTGF is a profibrotic cytokine, signaling down-stream and in parallel with TGF .
[097] CTGF expression by gingival epithelial cells, which are involved in the development of gingival fibromatosis, was found to be exacerbated by LPA treatment (A. Kantarci, et al., J. Pathol. 210 (2006) 59-66).
[098] LPA is associated with the progression of liver fibrosis. In vitro, LPA induces stellate cell and hepatocyte proliferation. These activated cells are the main cell type responsible for the accumulation of ECM in the liver. Furthermore, LPA plasma levels rise during CCl4-induced liver fibrosis in rodents, or in hepatitis C virus-induced liver fibrosis in human (N. Watanabe, et ah, Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity, Life Sci. 81 (2007) 1009-1015; N.Watanabe, et al., J. Clin. Gastroenterol. 41 (2007) 616-623).
[099] An increase of phospholipid concentrations in the bronchoalveolar lavage fluid in rabbits and rodents injected with bleomycin has been reported (K. Kuroda, et al., Phospholipid concentration in lung lavage fluid as biomarker for pulmonary fibrosis, Inhal. Toxicol. 18 (2006) 389-393; K.
Yasuda, et al., Lung 172 (1994) 91-102).
[0100] LPA is associated with heart disease and mycocardial remodeling. Serum LPA levels are increased after myocardial infarction in patients and LPA stimulates rat cardiac fibroblast proliferation and collagen production (Chen et al. FEBS Lett. 2006 Aug 21;580(19):4737-45).
Pulmonary Fibrosis
[0101] In the lung, aberrant wound healing responses to injury contribute to the pathogenesis of fibrotic lung diseases. Fibrotic lung diseases, such as idiopathic pulmonary fibrosis (IPF), are associated with high morbidity and mortality.
[0102] LPA is an important mediator of fibroblast recruitment in pulmonary fibrosis. LPA and LPAi play key pathogenic roles in pulmonary fibrosis. Fibroblast chemoattractant activity plays an important role in the lungs in patients with pulmonary fibrosis. Profibrotic effects of LPAi -receptor stimulation is explained by LPAi -receptor-mediated vascular leakage and increased fibroblast recruitment, both profibrotic events. The LPA-LPAi pathway has a role in mediating fibroblast migration and vascular leakage in IPF. The end result is the aberrant healing process that
characterises this fibrotic condition.
[0103] The LPAi receptor is the LPA receptor most highly expressed on fibroblasts obtained from patients with IPF. Furthermore, BAL obtained from IPF patients induced chemotaxis of human foetal lung fibroblasts that was blocked by the dual LPAi- LP A3 receptor antagonist Ki 16425. In an experimental bleomycin-induced lung injury mouse model, it was shown that LPA levels were high in bronchoalveolar lavage samples compared with unexposed controls. LPAx knockout mice are protected from fibrosis after bleomycin challenge with reduced fibroblast accumulation and vascular leakage. In human subjects with IPF, high LPA levels were observed in bronchoalveolar lavage samples compared with healthy controls. Increased fibroblast chemotactic activity in these samples was inhibited by the Ki 16425 indicating that fibroblast migration is mediated by the LPA-LPA receptor(s) pathway (Tager et al. Nature Medicine, vol. 14, no. 1, 45-54, 2008).
[0104] The LPA-LPAx pathway is crucial in fibroblast recruitment and vascular leakage in pulmonary fibrosis .
[0105] Activation of latent TGF-β by the avP6 integrin plays a critical role in the development of lung injury and fibrosis (Munger et al. Cell, vol. 96, 319-328, 1999). LPA induces avP6-mediated TGF-β activation on human lung epithelial cells (Xu et al. Am. J. Pathology, vol. 174, no. 2, 1264- 1279, 2009). The LPA-induced avP6-mediated TGF-β activation is mediated by the LPA2 receptor. Expression of the LPA2 receptor is increased in epithelial cells and mesenchymal cells in areas of lung fibrosis from IPF patients compared to normal human lung tissue. The LPA-LPA2 pathway contributes to the activation of the TGF-β pathway in pulmonary fibrosis. In some embodiments, compounds that inhibit LPA2 show efficacy in the treatment of lung fibrosis. In some embodiments, compounds that inhibit both LPAI and LPA2 show improved efficacy in the treatment of lung fibrosis compared to compounds which inhibit only LPAI or LPA2.
Renal Fibrosis
[0106] LPA and LPAi are involved in the etiology of kidney fibrosis. LPA has effetcs on both proliferation and contraction of glomerular mesangial cells and thus has been implicated in proliferative glomerulonephritis (C.N. Inoue, et ah, Clin. Sci. (Colch.) 96, 431- 436, 1999). In an animal model of renal fibrosis, unilateral ureteral obstruction (UUO), it was found that renal LPA receptors are expressed under basal conditions with an expression order of
Figure imgf000022_0001
This model mimics in an accelerated manner the development of renal fibrosis including renal inflammation, fibroblast activation and accumulation of extracellular matrix in the tubulointerstitium. UUO significantly induced LPAx -receptor expression. This was paralleled by renal LPA production (3.3 fold increase) in conditioned media from kidney explants. Contralateral kidneys exhibited no significant changes in LPA release and LPA-receptors expression. This shows that a prerequisite for an action of LPA in fibrosis is met: production of a ligand (LPA) and induction of one of its receptors (the LPAi receptor) (J.P. Pradere et al., Biochimica et Biophysica Acta (2008), doi: 10.1016/j.bbalip.2008.04.001). [0107] In mice invalidated for the LPAi receptor (LPAi (-/-), the development of renal fibrosis was significantly attenuated. UUO mice treated with the LPA receptor antagonist Ki 16425 closely resembled the LPAi (-/-) mice.
[0108] LPA can participate in intraperitonial accumulation of monocyte/macrophages and that LPA can induce expression of the profibrotic cytokine CTGF in primary cultures of human fibroblasts (J.S. Ko ,et al., J. Clin. Invest. 102 (1998) 716-727).
[0109] LPA treatment of a mouse epithelial renal cell line, MCT, induced a rapid increase in the expression of the profibrotic cytokine CTGF. CTGF plays a crucial role in UUO-induced
tubulointerstitial fibrosis (TIF), and is involved in the profibrotic activity of TGF . This induction was almost completely suppressed by co-treatment with the LPA-receptor antagonist Ki 16425. In one aspect, the profibrotic activity of LPA in kidney results from a direct action of LPA on kidney cells involving induction of CTGF.
Hepatic fibrosis
[0110] LPA is implicated in liver disease and fibrosis. Plasma LPA levels and serum autotoxin (enzyme responsible for LPA production) are elevated in hepatitis patients and animal models of liver injury in correlation with increased fibrosis. LPA also regulates liver cell function. LPAi and LPA2 receptors are expressed by mouse hepatic stellate cells and LPA stimulates migration of hepatic myofibroblasts.
Ocular Fibrosis
[0111] LPA is in involved in wound healing in the eye. LPAi and LPA3 receptors are detectable in the normal rabbit corneal epithelial cells, keratocytes and endothelial cells and LPAi and LP A3 expression are increased in corneal epithelial cells following injury.
[0112] LPA and its homologues are present in the aqueous humor and the lacrimal gland fluid of the rabbit eye and these levels are increased in a rabbit corneal injury model.
[0113] LPA induces actin stress fiber formation in rabbit corneal endothelial and epithelial cells and promotes contraction corneal fibroblasts. LPA also stimulates proliferation of human retinal pigmented epithelial cells
Cardiac fibrosis
[0114] LPA is implicated in myocardial infarction and cardiac fibrosis. Serum LPA levels are increased in patients following mycocardial infarction (MI) and LPA stimulates proliferation and collagen production (fibrosis) by rat cardiac fibroblasts. Both LPAI and LP A3 receptors are highly expressed in human heart tissue.
Treatment of Fibrosis
[0115] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to treat or prevent fibrosis in a mammal. In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to treat fibrosis of an organ or tissue in a mammal. In one aspect is a method for preventing a fibrosis condition in a mammal, the method comprising administering to the mammal at risk of developing one or more fibrosis conditions a therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII). In one aspect, the mammal has been exposed to one or more environmental conditions that are known to increase the risk of fibrosis of an organ or tissue. In one aspect, the mammal has been exposed to one or more environmental conditions that are known to increase the risk of lung, liver or kidney fibrosis. In one aspect, the mammal has a genetic predisposition of developing fibrosis of an organ or tissue. In one aspect, a compound of Formula (I),
(II) , (III), (IV), (V), (VI), or (VII) is adminstered to a mammal to prevent or minimize scarring following injury. In one aspect, injury includes surgery.
[0116] The terms "fibrosis" or "fibrosing disorder," as used herein, refers to conditions that are associated with the abnormal accumulation of cells and/or fibronectin and/or collagen and/or increased fibroblast recruitment and include but are not limited to fibrosis of individual organs or tissues such as the heart, kidney, liver, joints, lung, pleural tissue, peritoneal tissue, skin, cornea, retina, musculoskeletal and digestive tract.
[0117] Exemplary diseases, disorders, or conditions that involve fibrosis include, but are not limited to: Lung diseases associated with fibrosis, e.g., idiopathic pulmonary fibrosis, pulmonary fibrosis secondary to systemic inflammatory disease such as rheumatoid arthritis, scleroderma, lupus, cryptogenic fibrosing alveolitis, radiation induced fibrosis, chronic obstructive pulmonary disease (COPD), scleroderma, chronic asthma, silicosis, asbestos induced pulmonary or pleural fibrosis, acute lung injury and acute respiratory distress (including bacterial pneumonia induced, trauma induced, viral pneumonia induced, ventilator induced, non-pulmonary sepsis induced, and aspiration induced); Chronic nephropathies associated with injury/fibrosis (kidney fibrosis), e.g.,
glomerulonephritis secondary to systemic inflammatory diseases such as lupus and scleroderma, diabetes,, glomerular nephritis, focal segmental glomerular sclerosis, IgA nephropathy, hypertension, allograft and Alport; Gut fibrosis, e.g., scleroderma, and radiation induced gut fibrosis; Liver fibrosis, e.g., cirrhosis, alcohol induced liver fibrosis, nonalcoholic steatohepatitis (NASH), biliary duct injury, primary biliary cirrhosis, infection or viral induced liver fibrosis (e.g., chronic HCV infection), and autoimmune hepatitis; Head and neck fibrosis, e.g., radiation induced; Corneal scarring, e.g., LASIK (laser-assisted in situ keratomileusis), corneal transplant, and trabeculectomy; Hypertrophic scarring and keloids, e.g., burn induced or surgical; and Other fibrotic diseases, e.g., sarcoidosis, scleroderma, spinal cord injury/fibrosis, myelofibrosis, vascular restenosis,
atherosclerosis, arteriosclerosis, Wegener's granulomatosis, mixed connective tissue disease, and Peyronie's disease.
[0118] In one aspect, a mammal suffering from one of the following non-limiting exemplary diseases, disorders, or conditions will benefit from therapy with a compound of Formula (I), (II),
(III) , (IV), (V), (VI), or (VII): atherosclerosis, thrombosis, heart disease, vasculitis, formation of scar tissue, restenosis, phlobitis, COPD (chronic obstructive pulmonary disease), pulmonary hypertension, pulmonary fibrosis, pulmonary inflammation, bowel adhesions, bladder fibrosis and cystitis, fibrosis of the nasal passages, sinusitis, inflammation mediated by neutrophils, and fibrosis mediated by fibroblasts.
[0119] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is adminstered to a mammal with fibrosis of an organ or tissue or with a predisposition of developing fibrosis of an organ or tissue with one or more other agents that are used to treat fibrosis. In one aspect, the one or more agents include corticosteroids. In one aspect, the one or more agents include
immunosuppresants. In one aspect, the one or more agents include B-cell antagonists. In one aspect, the one or more agents include uteroglobin.
[0120] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to treat a dermatological disorders in a mammal. The term "dermatological disorder," as used herein refers to a skin disorder. Such dermatological disorders include, but are not limited to, proliferative or inflammatory disorders of the skin such as, atopic dermatitis, bullous disorders, collagenoses, psoriasis, psoriatic lesions, scleroderma, dermatitis, contact dermatitis, eczema, urticaria, rosacea, wound healing, scarring, hypertrophic scarring, keloids, Kawasaki Disease, rosacea, Sjogren-Larsso Syndrome, urticaria. In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to treat systemic sclerosis.
Pain
[0121] Since LPA is released following tissue injury, LPAi plays an important role in the initiation of neuropathic pain. LPAi, unlike LPA2 or LP A3, is expressed in both dorsal root ganglion (DRG) and dorsal root neurons. Using the antisense oligodeoxynucleotide (AS-ODN) for LPAi and LPAi- null mice, it was found that LPA-induced mechanical allodynia and hyperalgesia is mediated in an LPAi -dependent manner. LPAi and downstream Rho-ROCK activation play a role in the initiation of neuropathic pain signaling. Pretreatment with Clostridium botulinum C3 exoenzyme (BoTXC3, Rho inhibitor) or Y-27632 (ROCK inhibitor) completely abolished the allodynia and hyperalgesia in nerve-injured mice. LPA also induced demyelination of the dorsal root, which was prevented by BoTXC3. The dorsal root demyelination by injury was not observed in LPAi -null mice or AS-ODN injected wild-type mice. LPA signaling appears to induce important neuropathic pain markers such as protein kinase Cy (PKCy) and a voltage-gated calcium channel α2δ1 subunit (Caa281) in an LPAi and Rho-dependent manner (M. Inoue, et ah, Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling, Nat. Med. 10 (2004) 712-718).
[0122] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of pain in a mammal. In one aspect, the pain is acute pain or chronic pain. In another aspect, the pain is neuropathic pain. [0123] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of fibromylagia. In one aspect, fibromyalgia stems from the formation of fibrous scar tissue in contractile (voluntary) muscles. Fibrosis binds the tissue and inhibits blood flow, resulting in pain. Cancer
[0124] Lysophospho lipid receptor signaling plays a role in the etiology of cancer. Lysophosphatidic acid (LPA) and its G protein-coupled receptors (GPCRs) LPAl5 LPA2, and/or LPA3 play a role in the development of several types of cancers. The initiation, progression and metastasis of cancer involve several concurrent and sequential processes including cell proliferation and growth, survival and anti-apoptosis, migration of cells, penetration of foreign cells into defined cellular layers and/or organs, and promotion of angiogenesis. The control of each of these processes by LPA signaling in physiological and pathophysiological conditions underscores the potential therapeutic usefulness of modulating LPA signaling pathways for the treatment of cancer, especially at the level of the LPA receptors or ATX/lysoPLD. Autotaxin (ATX) is a prometastatic enzyme initially isolated from the conditioned medium of human melanoma cells that stimulates a myriad of biological activities, including angiogenesis and the promotion of cell growth, migration, survival, and differentiation through the production of LPA (Mol Cancer Ther 2008;7(10):3352-62).
[0125] LPA signals through its own GPCRs leading to activation of multiple downstream effector pathways. Such downstream effector pathways play a role in cancer. LPA and its GPCRs are linked to cancer through major oncogenic signaling pathways.
[0126] LPA contributes to tumorigenesis by increasing motility and invasiveness of cells. LPA has been implicated in the initiation or progression of ovarian cancer. LPA is present at significant concentrations (2-80 μΜ) in the ascitic fluid of ovarian cancer patients. Ovarian cancer cells constitutively produce increased amounts of LPA as compared to normal ovarian surface epithelial cells, the precursor of ovarian epithelial cancer. Elevated LPA levels are also detected in plasma from patients with early-stage ovarian cancers compared with controls. LPA receptors (LPA2 and LPA3) are also overexpressed in ovarian cancer cells as compared to normal ovarian surface epithelial cells. LPA stimulates Cox-2 expression through transcriptional activation and post- transcriptional enhancement of Cox-2 mRNA in ovarian cancer cells. Prostaglandins produced by Cox-2 have been implicated in a number of human cancers and pharmacological inhibition of Cox-2 activity reduces colon cancer development and decreases the size and number of adenomas in patients with familial adenomatous polyposis. LPA has also been implicated in the initiation or progression of prostate cancer, breast cancer, melanoma, head and neck cancer, bowel cancer (colorectal cancer), thyroid cancer and other cancers (Gardell et al, Trends in Molecular Medicine, vol. 12, no. 2, p 65-75, 2006; Ishii et al, Annu. Rev. Biochem, 73, 321-354, 2004; Mills et al, Nat. Rev. Cancer, 3, 582-591, 2003; Murph et ah, Biochimica et Biophysica Acta, 1781, 547-557, 2008). [0127] The cellular responses to LPA are mediated through the lysophosphatidic acid receptors. For example, LPA receptors mediate both migration of and invasion by pancreatic cancer cell lines: an antagonist of LPA χ and LPA3 (Ki 16425) and LPAx -specific siRNA effectively blocked in vitro migration in response to LPA and peritoneal fluid (ascites) from pancreatic cancer patients; in addition, Ki 16425 blocked the LPA-induced and ascites-induced invasion activity of a highly peritoneal metastatic pancreatic cancer cell line (Yamada et al, J. Biol. Chem., 279, 6595-6605, 2004).
[0128] Colorectal carcinoma cell lines show significant expression of LPAi mRNA and respond to LPA by cell migration and production of angiogenic factors. Overexpression of LPA receptors has a role in the pathogenesis of thyroid cancer. LP A3 was originally cloned from prostate cancer cells, concordant with the ability of LPA to induce autocrine proliferation of prostate cancer cells.
[0129] LPA has stimulatory roles in cancer progression in many types of cancer. LPA is produced from and induces proliferation of prostate cancer cell lines. LPA induces human colon carcinoma DLD 1 cell proliferation, migration, adhesion, and secretion of angiogenic factors through LPAi signalling. In other human colon carcinoma cells lines (HT29 and WiDR), LPA enhances cell proliferation and secretion of angiogenic factors. In other colon cancer cell lines, LPA2 and LPA3 receptor activation results in proliferation of the cells. The genetic or pharmacological manipulation of LPA metabolism, specific blockade of receptor signaling, and/or inhibition of downstream signal transduction pathways, represent approaches for cancer therapies.
[0130] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of cancer. In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of malignant and benign proliferative disease. In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to prevent or reduce proliferation of tumor cells, invasion and metastasis of carcinomas, pleural mesothelioma (Yamada, Cancer Sci., 2008, 99(8), 1603-1610) or peritoneal mesothelioma, cancer pain, bone metastases (Boucharaba et al, J. Clin. Invest., 2004, 114(12), 1714-1725; Boucharaba et al, Proc. Natl. acad. Sci., 2006, 103(25) 9643-9648). In one aspect is a method of treating cancer in a mammal, the method comprising administering to the mammal a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and a second therapeutic agent, wherein the second therapeutic agent is an anti-cancer agent.
[0131] The term "cancer," as used herein refers to an abnormal growth of cells which tend to proliferate in an uncontrolled way and, in some cases, to metastasize (spread). The types of cancer include, but is not limited to, solid tumors (such as those of the bladder, bowel, brain, breast, endometrium, heart, kidney, lung, lymphatic tissue (lymphoma), ovary, pancreas or other endocrine organ (thyroid), prostate, skin (melanoma or basal cell cancer) or hematological tumors (such as the leukemias) at any stage of the disease with or without metastases. [0132] Additional non-limiting examples of cancers include, acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer,
craniopharyngioma, cutaneous T-Cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, Acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Burkitt lymphoma, cutaneous T-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, chronic myelogenous leukemia, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, kaposi, Sezary syndrome, skin cancer, small cell Lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, T-cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia, Wilms tumor.
[0133] The increased concentrations of LPA and vesicles in ascites from ovarian cancer patients and breast cancer effussions indicate that it could be an early diagnostic marker, a prognostic indicator or an indicator of response to therapy (Mills et al, Nat. Rev. Cancer., 3, 582-591, 2003; Sutphen et ah, Cancer Epidemiol. Biomarkers Prev . 13, 1185-1191, 2004). LPA concentrations are consistently higher in ascites samples than in matched plasma samples.
Respiratory and Allergic Disorders
[0134] In one aspect, LPA is a contributor to the pathogenesis of respiratory diseases. In one aspect the respiratory disease is asthma. Proinflammatory effects of LPA include degranulation of mast cells, contraction of smooth-muscle cells and release of cytokines from dendritic cells. Airway smooth muscle cells, epithelial cells and lung fibroblasts all show responses to LPA. LPA induces the secretion of IL-8 from human bronchial epithelial cells. IL-8 is found in increased concentrations in BAL fluids from patients with asthma, chronic obstructive lung disease, pulmonary sarcoidosis and acute respiratory distress syndrome and 11-8 has been shown to exacerbate airway inflammation and airway remodeling of asthmatics. LPA1, LPA2 and LP A3 receptors have all been shown to contribute to the LPA-induced IL-8 production. Studies cloning multiple GPCRs that are activated by LPA allowed the demonstration of the presence of mRNA for the LPAi, LPA2 and LPA3 in the lung (J.J.A. Contos, et al, Mol. Pharmacol. 58, 1188-1196, 2000).
[0135] The release of LPA from platelets activated at a site of injury and its ability to promote fibroblast proliferation and contraction are features of LPA as a mediator of wound repair. In the context of airway disease, asthma is an inflammatory disease where inappropriate airway "repair" processes lead to structural "remodeling" of the airway. In asthma, the cells of the airway are subject to ongoing injury due to a variety of insults, including allergens, pollutants, other inhaled environmental agents, bacteria and viruses, leading to the chronic inflammation that characterizes asthma.
[0136] In one aspect, in the asthmatic individual, the release of normal repair mediators, including LPA, is exaggerated or the actions of the repair mediators are inappropriately prolonged leading to inappropriate airway remodeling. Major structural features of the remodeled airway observed in asthma include a thickened lamina reticularis (the basement membrane-like structure just beneath the airway epithelial cells), increased numbers and activation of myofibroblasts, thickening of the smooth muscle layer, increased numbers of mucus glands and mucus secretions, and alterations in the connective tissue and capillary bed throughout the airway wall. In one aspect, LPA contributes to these structural changes in the airway. In one aspect, LPA is involved in acute airway
hyperresponsiveness in asthma. The lumen of the remodeled asthmatic airway is narrower due to the thickening of the airway wall, thus decreasing airflow. In one aspect, LPA contributes to the long- term structural remodeling and the acute hyperresponsiveness of the asthmatic airway. In one aspect, LPA contributes to the hyper-responsiveness that is a primary feature of acute exacerbations of asthma.
[0137] In addition to the cellular responses mediated by LPA, several of the LPA signaling pathway components leading to these responses are relevant to asthma. EGF receptor upregulation is induced by LPA and is also seen in asthmatic airways (M. Amishima, et ah, Am. J. Respir. Crit. Care Med. 157, 1907- 1912, 1998). Chronic inflammation is a contributor to asthma, and several of the transcription factors that are activated by LPA are known to be involved in inflammation (Ediger et al, Eur Respir J 21 :759-769, 2003).
[0138] In one aspect, the fibroblast proliferation and contraction and extracellular matrix secretion stimulated by LPA contributes to the fibroproliferative features of other airway diseases, such as the peribronchiolar fibrosis present in chronic bronchitis, emphysema, and interstitial lung disease. Emphysema is also associated with a mild fibrosis of the alveolar wall, a feature which is believed to represent an attempt to repair alveolar damage. In another aspect, LPA plays a role in the fibrotic interstitial lung diseases and obliterative bronchiolitis, where both collagen and myofibroblasts are increased. In another aspect, LPA is involved in several of the various syndromes that constitute chronic obstructive pulmonary disease.
[0139] Administration of LPA in vivo induces airway hyper-responsiveness, itch-scratch responses, infiltration and activation of eosinophils and neutrophils, vascular remodeling, and nociceptive flexor responses. LPA also induces histamine release from mouse and rat mast cells. In an acute allergic reaction, histamine induces various responses, such as contraction of smooth muscle, plasma exudation, and mucus production. Plasma exudation is important in the airway, because the leakage and subsequent airway-wall edema contribute to the development of airway hyperresponsiveness. Plasma exudation progresses to conjunctival swelling in ocular allergic disorder and nasal blockage in allergic rhinitis (Hashimoto et ah, J Pharmacol Sci 100, 82 - 87, 2006). In one aspect, plasma exudation induced by LPA is mediated by histamine release from mast cells via one or more LPA receptors. In one aspect, the LPA receptor(s) include LPAi and/or LPA3. In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of various allergic disorders in a mammal. In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of respiratory diseases, disorders or conditions in a mammal. In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of asthma in a mammal. In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the treatment of chronic asthma in a mammal.
[0140] The term "respiratory disease," as used herein, refers to diseases affecting the organs that are involved in breathing, such as the nose, throat, larynx, eustachian tubes, trachea, bronchi, lungs, related muscles (e.g., diaphram and intercostals), and nerves. Respiratory diseases include, but are not limited to, asthma, adult respiratory distress syndrome and allergic (extrinsic) asthma, non- allergic (intrinsic) asthma, acute severe asthma, chronic asthma, clinical asthma, nocturnal asthma, allergen-induced asthma, aspirin-sensitive asthma, exercise-induced asthma, isocapnic
hyperventilation, child-onset asthma, adult-onset asthma, cough- variant asthma, occupational asthma, steroid-resistant asthma, seasonal asthma, seasonal allergic rhinitis, perennial allergic rhinitis, chronic obstructive pulmonary disease, including chronic bronchitis or emphysema, pulmonary hypertension, interstitial lung fibrosis and/or airway inflammation and cystic fibrosis, and hypoxia.
[0141] The term "asthma" as used herein refers to any disorder of the lungs characterized by variations in pulmonary gas flow associated with airway constriction of whatever cause (intrinsic, extrinsic, or both; allergic or non-allergic). The term asthma may be used with one or more adjectives to indicate cause.
[0142] In one aspect, presented herein is the use of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the treatment or prevention of chronic obstructive pulmonary disease in a mammal comprising administering to the mammal at least once an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII). In addition, chronic obstructive pulmonary disease includes, but is not limited to, chronic bronchitis or emphysema, pulmonary hypertension, interstitial lung fibrosis and/or airway inflammation, and cystic fibrosis.
Nervous System
[0143] The nervous system is a major locus for LPAi expression; there it is spatially and temporally regulated throughout brain development. Oligodendrocytes, the myelinating cells in the central nervous system (CNS), express LPAi in mammals. In addition, Schwann cells, the myelinating cells of the peripheral nervous system, also express LPAi, which is involved in regulating Schwann cell survival and morphology. These observations identify important functions for receptor-mediated LPA signaling in neurogenesis, cell survival, and myelination.
[0144] Exposure of peripheral nervous system cell lines to LPA produces a rapid retraction of their processes resulting in cell rounding, which was, in part, mediated by polymerization of the actin cytoskeleton. In one aspect, LPA causes neuronal degeneration under pathological conditions when the blood-brain barrier is damaged and serum components leak into the brain (Moolenaar, Curr. Opin. Cell Biol. 7:203-10, 1995). Immortalized CNS neuroblast cell lines from the cerebral cortex also display retraction responses to LPA exposure through Rho activation and actomyosin interactions. In one aspect, LPA is associated with post-ischemic neural damage (J. Neurochem. 61 , 340, 1993; J. Neurochem., 70:66, 1998).
[0145] In one aspect, provided is a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) for use in the treatment or prevention of a nervous system disorder in a mammal. The term "nervous system disorder," as used herein, refers to conditions that alter the structure or function of the brain, spinal cord or peripheral nervous system, including but not limited to Alzheimer's Disease, cerebral edema, cerebral ischemia, stroke, multiple sclerosis, neuropathies, Parkinson's Disease, those found after blunt or surgical trauma (including post-surgical cognitive dysfunction and spinal cord or brain stem injury), as well as the neurological aspects of disorders such as degenerative disk disease and sciatica. [0146] In one aspect, provided is a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) for use in the treatment or prevention of a CNS disorder in a mammal. CNS disorders include, but are not limited to, multiple sclerosis, Parkinson's disease, Alzheimer's disease, stroke, cerebral ischemia, retinal ischemia, post-surgical cognitive dysfunction, migraine, peripheral neuropathy/neuropathic pain, spinal cord injury, cerebral edema and head injury.
Cardiovascular Disorders
[0147] Cardiovascular phenotypes observed after targeted deletion of lysophospho lipid receptors reveal important roles for lysophospho lipid signaling in the development and maturation of blood vessels, formation of atherosclerotic plaques and maintenance of heart rate (Ishii, I. et al. Annu. Rev. Biochem. 73, 321-354, 2004). Angiogenesis, the formation of new capillary networks from preexisting vasculature, is normally invoked in wound healing, tissue growth and myocardial angiogenesis after ischemic injury. Peptide growth factors (e.g. vascular endothelial growth factor (VEGF)) and lysophospholipids control coordinated proliferation, migration, adhesion,
differentiation and assembly of vascular endothelial cells (VECs) and surrounding vascular smooth- muscle cells (VSMCs). In one aspect, dysregulation of the processes mediating angiogenesis leads to atherosclerosis, hypertension, tumor growth, rheumatoid arthritis and diabetic retinopathy (Osborne, N. and Stainier, D.Y. Annu. Rev. Physiol. 65, 23-43, 2003).
[0148] Downstream signaling pathways evoked by lysophospholipid receptors include Rac- dependent lamellipodia formation (e.g. LPAi) and Rho-dependent stress-fiber formation (e.g. LPAi), which is important in cell migration and adhesion. Dysfunction of the vascular endothelium can shift the balance from vasodilatation to vasoconstriction and lead to hypertension and vascular remodeling, which are risk factors for atherosclerosis (Maguire, J.J. et al., Trends Pharmacol. Sci. 26, 448-454, 2005).
[0149] LPA contributes to both the early phase (barrier dysfunction and monocyte adhesion of the endothelium) and the late phase (platelet activation and intra-arterial thrombus formation) of atherosclerosis, in addition to its overall progression. In the early phase, LPA from numerous sources accumulates in lesions and activates its cognate GPCRs (LPAi and LPA3) expressed on platelets (Siess, W. Biochim. Biophys. Acta 1582, 204-215, 2002; Rother, E. et al. Circulation 108, 741-747, 2003). This triggers platelet shape change and aggregation, leading to intra-arterial thrombus formation and, potentially, myocardial infarction and stroke. In support of its atherogenic activity, LPA can also be a mitogen and motogen to VSMCs and an activator of endothelial cells and macrophages. In one aspect, mammals with cardiovascular disease benefit from LPA receptor antagonists that prevent thrombus and neointima plaque formation.
[0150] The specific effects of LPA are receptor-mediated.
[0151] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to treat or prevent cardiovascular disease in mammal. [0152] The term "cardiovascular disease," as used herein refers to diseases affecting the heart or blood vessels or both, including but not limited to: arrhythmia (atrial or ventricular or both);
atherosclerosis and its sequelae; angina; cardiac rhythm disturbances; myocardial ischemia;
myocardial infarction; cardiac or vascular aneurysm; vasculitis, stroke; peripheral obstructive arteriopathy of a limb, an organ, or a tissue; reperfusion injury following ischemia of the brain, heart or other organ or tissue; endotoxic, surgical, or traumatic shock; hypertension, valvular heart disease, heart failure, abnormal blood pressure; shock; vasoconstriction (including that associated with migraines); vascular abnormality, inflammation, insufficiency limited to a single organ or tissue..
[0153] In one aspect, provided herein are methods for preventing or treating vasoconstriction, atherosclerosis and its sequelae myocardial ischemia, myocardial infarction, aortic aneurysm, vasculitis and stroke comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) or pharmaceutical composition or medicament thereof.
[0154] In one aspect, provided herein are methods for reducing cardiac reperfusion injury following myocardial ischemia and/or endotoxic shock comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
[0155] In one aspect, provided herein are methods for reducing the constriction of blood vessels in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
[0156] In one aspect, provided herein are methods for lowering or preventing an increase in blood pressure of a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
Inflammation
[0157] LPA has been shown to regulate immunological responses by modulating activities/functions of immune cells such as T-/B-lymphocytes and macrophages. In activated T cells, LPA activates IL- 2 production/cell proliferation through LPAx (Gardell et al, TRENDS in Molecular Medicine Vol.12 No.2 February 2006). Expression of LPA-induced inflammatory response genes is mediated by LPAi and LPA3 (Biochem Biophys Res Commun. 363(4): 1001-8, 2007). In addition, LPA modulates the chemotaxis of inflammatory cells {Biochem Biophys Res Commun., 1993, 15; 193(2), 497). The proliferation and cytokine-secreting activity in response to LPA of immune cells ( J. Imuunol. 1999, 162, 2049), platelet aggregation activity in response to LPA, acceleration of migration activity in monocytes, activation of NF-κΒ in fibroblast, enhancement of fibronectin-binding to the cell surface, and the like are known. Thus, LPA is associated with various inflammatory/immune diseases .
[0158] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used to treat or prevent inflammation in a mammal. In one aspect, antagonists of LPAi and/or LP A3 find use in the treatment or prevention of inflammatory/immune disorders in a mammal. In one aspect, the antagonist of LPA i is a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
[0159] Examples of inflammatory/immune disorders include psoriasis, rheumatoid arthritis, vasculitis, inflammatory bowel disease, dermatitis, osteoarthritis, asthma, inflammatory muscle disease, allergic rhinitis, vaginitis, interstitial cystitis, scleroderma, eczema, allogeneic or xenogeneic transplantation (organ, bone marrow, stem cells and other cells and tissues) graft rejection, graft- versus-host disease, lupus erythematosus, inflammatory disease, type I diabetes, pulmonary fibrosis, dermatomyositis, Sjogren's syndrome, thyroiditis (e.g., Hashimoto's and autoimmune thyroiditis), myasthenia gravis, autoimmune hemolytic anemia, multiple sclerosis, cystic fibrosis, chronic relapsing hepatitis, primary biliary cirrhosis, allergic conjunctivitis and atopic dermatitis.
Other Diseases, Disorders or Conditions
[0160] In accordance with one aspect, are methods for treating, preventing, reversing, halting or slowing the progression of LPA-dependent or LPA-mediated diseases or conditions once it becomes clinically evident, or treating the symptoms associated with or related to LPA-dependent or LPA- mediated diseases or conditions, by administering to the mammal a compound of Formula (I), (II),
(III) , (IV), (V), (VI), or (VII). In certain embodiments, the subject already has a LPA-dependent or LPA-mediated disease or condition at the time of administration, or is at risk of developing a LPA- dependent or LPA-mediated disease or condition.
[0161] In certain aspects, the activity of LPAi in a mammal is directly or indirectly modulated by the administration of (at least once) a therapeutically effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII). Such modulation includes, but is not limited to, reducing and/or inhibiting the activity of LPAi. In additional aspects, the activity of LPA in a mammal is directly or indirectly modulated, including reducing and/or inhibiting, by the
administration of (at least once) a therapeutically effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII). Such modulation includes, but is not limited to, reducing and/or inhibiting the amount and/or activity of a LPA receptor. In one aspect, the LPA receptor is LPAi.
[0162] In one aspect, LPA has a contracting action on bladder smooth muscle cell isolated from bladder, and promotes growth of prostate-derived epithelial cell {The Journal of Urology , 1999, vol. 162, pp. 1779-1784; The Journal of Urology , 2000, vol. 163, pp. 1027-1032). In another aspect,
LPA contracts the urinary tract and prostate in vitro and increases intraurethral pressure in vivo (WO 02/062389).
[0163] In certain aspects, are methods for preventing or treating eosinophil and/or basophil and/or dendritic cell and/or neutrophil and/or monocyte and/or T-cell recruitment comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III),
(IV) , (V), (VI), or (VII). [0164] In certain aspects, are methods for the treatment of cystitis, including, e.g., interstitial cystitis, comprising administering at least once to the mammal a therapeutically effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
[0165] In accordance with one aspect, methods described herein include the diagnosis or determination of whether or not a patient is suffering from a LPA-dependent or LPA-mediated disease or condition by administering to the subject a therapeutically effective amount of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and determining whether or not the patient responds to the treatment.
[0166] In one aspect provided herein are compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII), pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and
pharmaceutically acceptable solvates thereof, which are antagonists of LPAi, and are used to treat patients suffering from one or more LPA-dependent or LPA-mediated conditions or diseases, including, but not limited to, lung fibrosis, kindney fibrosis, liver fibrosis, scarring, asthma, rhinitis, chronic obstructive pulmonary disease, pulmonary hypertension, interstitial lung fibrosis, arthritis, allergy, psoriasis, inflammatory bowel disease, adult respiratory distress syndrome, myocardial infarction, aneurysm, stroke, cancer, pain, proliferative disorders and inflammatory conditions. In some embodiments, LPA-dependent conditions or diseases include those wherein an absolute or relative excess of LP A is present and/or observed.
[0167] In any of the aforementioned aspects the LPA-dependent or LPA-mediated diseases or conditions include, but are not limited to, organ fibrosis, asthma, allergic disorders, chronic obstructive pulmonary disease, pulmonary hypertension, lung or pleural fibrosis, peritoneal fibrosis, arthritis, allergy, cancer, cardiovascular disease, ult respiratory distress syndrome, myocardial infarction, aneurysm, stroke, and cancer.
[0168] In one aspect, compounds of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are used to improve the corneal sensitivity decrease caused by corneal operations such as laser-assisted in situ keratomileusis (LASIK) or cataract operation, corneal sensitivity decrease caused by corneal degeneration, and dry eye symptom caused thereby.
[0169] In one aspect, presented herein is the use of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the treatment or prevention of ocular inflammation and allergic conjunctivitis, vernal keratoconjunctivitis, and papillary conjunctivitis in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
[0170] In one aspect, presented herein is the use of a compound of Formula (I), (II), (III), (IV), (V),
(VI), or (VII) in the treatment or prevention of Sjogren disease or inflammatory disease with dry eyes in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII). [0171] In one aspect, LPA and LPA receptors (e.g. LPAi) are involved in the pathogenesis of osteoarthritis (Kotani et al, Hum. Mol. Genet., 2008, 17, 1790-1797). In one aspect, presented herein is the use of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the treatment or prevention of osteoarthritis in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
[0172] In one aspect, LPA receptors (e.g. LPAl 5 LPA3) contribute to the pathogenesis of rheumatoid arthritis (Zhao et al, Mol. Pharmacol., 2008, 73(2), 587-600). In one aspect, presented herein is the use of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the treatment or prevention of rheumatoid arthritis in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
[0173] In one aspect, LPA receptors (e.g. LPAi) contribute to adipogenesis. (Simon et al, J.Biol. Chem., 2005, vol. 280, no. 15, p.14656). In one aspect, presented herein is the use of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in the promotion of adipose tissue formation in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), (II), (III), (LV), (V), (VI), or (VII).
Compounds
[0174] In one aspect, compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII), including pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically acceptable solvates thereof, antagonize or modulate LPAi and are used to treat patients suffering from LPAi -dependent or LPA mediated conditions or diseases.
[0175] In one aspect, provided herein is a compound of Formula (I), or a pharmaceutically acceptable solvate, a pharmaceutically acceptable salt, a prodrug, or a metabolite thereof:
Figure imgf000036_0001
wherein
R3 is , and Pv5 is H, Ci-C4alkyl, or Ci-C4fluoroalkyl; or
Pv5 is
Figure imgf000036_0002
, and Pv3 is H, Ci-C4alkyl, or Ci-C4fluoroalkyl;
m is 0, 1 or 2; n is 0, 1 or 2; L1 is absent, Ci-C4alkylene, Ci-C4fiuoroalkylene, C3-C6cycloalkylene, -C3-C6cycloalkylene- Ci-C4alkylene-, or -[C(Rla)(Rlb)]q-; q is 1,2 or 3;
Rla and Rlb are each independently selected from H, Ci-C4alkyl and substituted or unsubstituted benzyl;
R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, -C(=0)NH-OH, -C(=0)NH-CN, -CN,
P(=0)(OH)2, P(=0)(ORD)2, -OP03H2, -S02NHC(=0)RE, tetrazolyl, -C(=NH)NH2, - C(=NH)NHC(=0)RE, or carboxylic acid bioisostere; RD is H or Ci-C6alkyl; RE is C C6alkyl or a substituted or unsubstituted phenyl;
L3 is a substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted C
C6fluoroalkylene, or substituted or unsubstituted Ci-Ceheteroalkylene, where if L3 is substituted then L3 is substituted with 1 to 3 R13; each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy; or L3 is -ΙΛΧ1-!.5-;
L4is absent or a substituted or unsubstituted Ci-C4alkylene, where if L4 is substituted then L4 is substituted with 1 to 3 R14; each R14 is independently selected from F, Ci-
C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy, Ci-C4fluoroalkoxy and a substituted or unsubstituted phenyl;
X1 is a absent, -0-, -S-, -S(O)-, -S(0)2-, -NR7-, -C(0)NR8-, -NR8C(=0)-, -
NR8C(=0)CH20-, -NR8C(=0)-CH(CH3)0-, -NR8C(=0)-C(CH3)20-, -N(R8)S(=0)2-, -S(=0)2N(R8)-, -C(=0)-, -OC(=0)-, -C(=0)0-, -OC(=0)0-, -OC(=0)N(R8)-, -
NR8C(=0)0-, or -NR8C(=0)N(R8)-; provided that when L4 is absent then X1 is not - NR8C(=0)0-;
R7 is H, -S(=0)2R10, -S(=0)2N(R9)2, -C(=0)R10, -C02R9, -C(=0)N(R9)2, C C4alkyl,
Ci-C4fluoroalkyl, or Ci-C4heteroalkyl;
R8 is H, Ci-C4alkyl, or Ci-C4fluoroalkyl;
L5 is absent or a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1 to 3 R15; each R15 is independently selected from F, Ci-
C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy;
R6 is Ci-C6alkyl, Ci-C6fluoroalkyl, substituted or unsubstituted C3-Ci0cycloalkyl, a
substituted or unsubstituted C3-Cioheterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted monocyclic heteroaryl, or a substituted or unsubstituted bicyclic heteroaryl, wherein if R6 is substituted then R6 is substituted with 1 to 3 Rc;
each of RA, RB, and Rc are independently selected from halogen, -CN, -N02, -OH, -OR , - SR9, -S(=0)R10, -S(=0)2R10, -N(R9)S(=0)2R10, -S(=0)2N(R9)2, -C(=0)R10, -OC(=0)R10,
-C02R9, -OC02R10, -N(R9)2, -C(=0)N(R9)2, -OC(=0)N(R9)2, -NR9C(=0)N(R9)2, - NR9C(=0)R10, -NR9C(=0)OR10, d-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, d- C4alkoxy, and Ci-C4heteroalkyl;
each R9 is independently selected from H, Ci-C6alkyl, Ci-C6heteroalkyl, Ci-C6fluoroalkyl, a substituted or unsubstituted C3-C6cycloalkyl, a substituted or unsubstituted C2- Ceheterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted monocyclic heteroaryl, -Ci-C4alkylene-(substituted or unsubstituted C3-C6cycloalkyl), - Ci-C4alkylene-(substituted or unsubstituted C2-C6heterocycloalkyl), -Ci-C4alkylene- (substituted or unsubstituted phenyl), or -Ci-C4alkylene-(substituted or unsubstituted heteroaryl); or
two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted heterocycle;
R10 is selected from Ci-C6alkyl, Ci-C6heteroalkyl, Ci-C6fluoroalkyl, a substituted or
unsubstituted C3-C6cycloalkyl, a substituted or unsubstituted C2-C6heterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted monocyclic heteroaryl, -Ci-C4alkylene-(substituted or unsubstituted C3- C6cycloalkyl), -Ci-C4alkylene-(substituted or unsubstituted C2-C6heterocycloalkyl), -Ci- C4alkylene-(substituted or unsubstituted phenyl), and -Ci-C4alkylene-(substituted or unsubstituted heteroaryl).
[0176] For any and all of the embodiments, substituents are selected from among from a subset of the listed alternatives. For example, in some embodiments, R1 is -C02RD, -C(=0)NHS02RE, - C(=0)N(RD)2, -CN, or tetrazolyl. In some embodiments, R1 is -C02RD, -C(=0)NHS02RE, or tetrazolyl. In some embodiments, R1 is -C02RD or -C(=0)NHS02RE In some embodiments, R is -C02RD. In some embodiments, R1 is -C(=0)NHS02RE. In some embodiments, R1 is carboxylic acid bioisostere. In some embodiments, RE is Ci-C6alkyl. In some embodiments, R1 is -CO2H or - C02 RD). In some embodiments, RD is H -CH3, or -CH2CH3. In some embodiments, R1 is -CO2H.
Figure imgf000038_0001
Ci-C4alkyl. In some embodiments, R5 is H, -CH3, or -CH2CH3. In some embodiments, R5 is -CH3, or -CH2CH3. In some embodiments, R5 is -CH3. In some embodiments, R5 is H. In some embodiments, R5 is -H, -CH3 or -CH2CH3; R1 is -C02RD; RD is H or Ci-C6alkyl.
[0178] In some embodiments, the compound of Formula (I) has the structure of Formula (II):
Figure imgf000039_0001
[0179] In some embodiments, the compound of Formula (II) has the following structure:
[0180] In some embodiments, R5 is R3 is H, Ci-C4 alkyl, or Ci-C4
fluoroalkyl. In some embodiments, R
Figure imgf000039_0002
5 is . In some embodiments, R is
Ci-C4alkyl. In some embodiments, R3 is H, -CH3, or -CH2CH3. In some embodiments, R3 is or -CH2CH3. In some embodiments, R3 is -CH3. In some embodiments, R3 is H. In some embodiments, R3 is -H, -CH3 or -CH2CH3; R1 is -C02RD; RD is H or C C6alkyl.
[0181] In some embodiments, the compound of Formula (I) has the structure of Formula (III)
Figure imgf000039_0003
[0182] In some embodiments, the compound of Formula III) has the following structure:
Figure imgf000040_0001
[0183] In some embodiments, each R is independently selected from halogen, -CN, -OH, - C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl. In some embodiments, each RAis independently selected from halogen, -CN, -OH, -CH3, -CH2CH3, -CF3, - OCF3, -OCH3 and -OCH2CH3. In some embodiments, each RAis independently halogen, -CN, -OH, -CH3, -CH2CH3, -CF3, -OCF3, -OCH3 or -OCH2CH3. In some embodiments, each RA is independently halogen, -OH, or -CH3.
[0184] In some embodiments, each RB is independently selected from halogen, -CN, -OH, Ci- C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl. In some embodiments, each RB is independently selected from halogen, -CN, -OH, -CH3, -CH2CH3, -CF3, - OCF3, -OCH3 and -OCH2CH3. In some embodiments, each RB is independently halogen, -CN, -OH, - CH3, -CH2CH3, -CF3, -OCF3, -OCH3 or -OCH2CH3. In some embodiments, each RB is independently halogen, -OH, or -CH3.
[0185] In some embodiments, L1 is absent, Ci-C4alkylene, C3-C6cycloalkylene, -C3-
C6cycloalkylene-Ci-C4alkylene-, or -C(Rla)(Rlb)-; Rla and Rlb are each independently selected from H, Ci-C4alkyl and benzyl. In some embodiments, L1 is Ci-C4alkylene, C3-C6cycloalkylene, -C3- C6cycloalkylene-Ci-C4alkylene-, -Ci-C4alkylene-C3-C6cycloalkylene- or -C(Rla)(Rlb)-.
[0186] In some embodiments, R6 is substituted with 1, 2 or 3 Rc. In some embodiments, R6 is substituted with 1 or 2 Rc. In some embodiments, R6 is substituted with Rc. In some embodiments, R6 is unsubstituted. In some embodiments, if R6 is substituted then R6 is substituted with 1, 2 or 3 Rc. In some embodiments, if R6 is substituted then R6 is substituted with 1 or 2 Rc. In some
embodiments, if R6 is substituted then R6 is substituted with Rc. In some embodiments, R6 is unsubstituted.
[0187] In some embodiments, each Rc is independently selected from halogen, -CN, -OH, -OR9, - SR9, -S(=0)R10, -S(=0)2R10, -C(=0)R10, -C02R9, -N(R9)2, -C(=0)N(R9)2, d-C4alkyl, C
C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl. In some embodiments, each Rc is independently selected from halogen, -CN, -OH, -S(=0)2CH3, -C(=0)CH3, -C02H, -C02CH3, - C02CH2CH3, -NH2, -NH(CH3), -N(CH3)2, -C(=0)NH2, -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -CH2CF3, -OCF3, -OCH3, -OCH2CH3, -CH2OCH3, -CH2OCH2CH3, or -CH2N(CH3)2. In some embodiments, each Rcis halogen, -CN, -OH, -CH3, -CH2CH3, -CF3, -OCF3, -OCH3, -OCH2CH3, - CH2OCH3, -CH2OCH2CH3, or -CH2N( CH3)2. In some embodiments, each Rc is independently selected from halogen, -OH, -CN, -CH3, -CH2CH3, -CF3, -OCF3, -OCH3 and -OCH2CH3.
[0188] In some embodiments, R6 is Ci-C6alkyl, Ci-C6fluoroalkyl, substituted or unsubstituted C3- Ciocycloalkyl, a substituted or unsubstituted C3-Cioheterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted monocyclic heteroaryl, or a substituted or unsubstituted bicyclic heteroaryl. In some embodiments, R6 is substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted phenyl, or a substituted or
unsubstituted monocyclic heteroaryl. In some embodiments, R6 is a substituted or unsubstituted phenyl or a substituted or unsubstituted monocyclic heteroaryl. In some embodiments, R6 is a substituted or unsubstituted phenyl.
[0189] In some embodiments, R6 is C3-C6cycloalkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic heteroaryl, wherein if R6 is substituted then R6 is substituted with 1 to 3 Rc; each Rc is independently selected from H, halogen, -CN, -N02, -OH, Ci-C4alkyl, C C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl.
[0190] In some embodiments, R6 is a substituted or unsubstituted phenyl, wherein if R6 is substituted then R6 is substituted with 1 to 3 Rc.
[0191] In some embodiments, L1 is absent, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH2CH2-, cyclopropyl- 1,1 -diyl, cyclopropyl- 1 ,2-diyl, cyclobutyl- 1,1 -diyl, cyclopentyl- 1 , 1 -diyl, cyclohexyl- 1 , 1 - diyl, or -C(CH2CH2)CH2-.
[0192] In some embodiments, L1 is -CH(CH3)-, -C(CH3)2-, cyclopropyl- 1,1 -diyl, cyclopropyl- 1 ,2- diyl, cyclobutyl- 1,1 -diyl, cyclopentyl- 1 , 1 -diyl, cyclohexyl- 1,1 -diyl, or -C(CH2CH2)CH2-.
[0193] In some embodiments, L1 is cyclopropyl- 1,1 -diyl, cyclopropyl- 1 ,2-diyl, or -C(CH2CH2)CH2-. In some embodiments, L1 is cyclopropyl- 1,1 -diyl.
[0194] In some embodiments, each R9 is independently selected from H, Ci-C6alkyl, C3- C6cycloalkyl, a substituted or unsubstituted phenyl, and -CH2-(substituted or unsubstituted phenyl); or two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted heterocycle; R10 is selected from Ci-C6alkyl, C3-
C6cycloalkyl, a substituted or unsubstituted phenyl, and -CH2-(substituted or unsubstituted phenyl).
[0195] In some embodiments, L3 is substituted with 1, 2 or 3 R13. In some embodiments, L3 is substituted with 1 or 2 R13. In some embodiments, L3 is substituted with R13. In some embodiments, L3 is unsubstituted. In some embodiments, if L3 is substituted then L3 is substituted with 1, 2 or 3 R13. In some embodiments, if L3 is substituted then L3 is substituted with 1 or 2 R13. In some
embodiments, if L3 is substituted then L3 is substituted with R13. In some embodiments, L3 is unsubstituted. In some embodiments, each R13 is independently selected from F, Ci-C4alkyl, Ci- C4fluoroalkyl, hydroxyl, Ci-C4alkoxy, Ci-C4fluoroalkoxy and a substituted or unsubstituted phenyl. In some embodiments, each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy, and Ci-C4iluoroalkoxy. In some embodiments, each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, and -OH. In some embodiments, each R13 is independently selected from F, Ci-C4alkyl, and -OH. In some embodiments, each R13 is
independently selected from Ci-C4alkyl, and -OH. In some embodiments, each R13 is independently selected from F, -CH3, -CH2CH3, -CF3, and -OH. In some embodiments, each R13 is independently selected from F, -CH3, and -OH. In some embodiments, each R13 is independently selected from - CH3, and -OH. In some embodiments, R13 is F, -CH3, -CH2CH3, -CF3, or -OH. In some
embodiments, R13 is F, -CH3, -CH2CH3, or -OH. In some embodiments, R13 is -CH3 or -OH. In some embodiments, R13 is Ci-C4alkyl, or -OH.
[0196] In some embodiments, L3 is a substituted or unsubstituted C3-C6alkylene, substituted or unsubstituted C3-C6fluoroalkylene, or substituted or unsubstituted C3-C6heteroalkylene, where if L3 is substituted then L3 is substituted with 1 to 3 R13; each R13 is independently selected from F, Ci-
C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy.
[0197] In some embodiments, L3 is a substituted or unsubstituted C3-C6alkylene, where if L3 is substituted then L3 is substituted with 1 to 3 R13; each R13 is independently selected from F, Ci-
C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy.
[0198] In some embodiments, L3 is a substituted or unsubstituted C3-C6fluoroalkylene, where if L3 is substituted then L3 is substituted with 1 to 3 R13; each R13 is independently selected from F, Ci-
C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy.
[0199] In some embodiments, L3 is a substituted or unsubstituted C3-C6heteroalkylene, where if L3 is substituted then L3 is substituted with 1 to 3 R13; each R13 is independently selected from F, Ci- C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy.
[0200] In some embodiments, L3 is a substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted Ci-C6fluoroalkylene, substituted or unsubstituted -Ci-C6alkylene-0-, substituted or unsubstituted -Ci-C3alkylene-0-Ci-C3alkylene-, substituted or unsubstituted -0-Ci-C6alkylene-, substituted or unsubstituted -Ci-C6alkylene-S-, substituted or unsubstituted -Ci-C3alkylene-S-Cr C3alkylene-, substituted or unsubstituted -S-Ci-C6alkylene-, substituted or unsubstituted -Ci- C6alkylene-SO-, substituted or unsubstituted -Ci-C3alkylene-SO-Ci-C3alkylene-, substituted or unsubstituted -SO-Ci-C6alkylene-, substituted or unsubstituted -Ci-C6alkylene-S02-, substituted or unsubstituted -Ci-C3alkylene-S02-Ci-C3alkylene-, substituted or unsubstituted -S02-Ci-C6alkylene-, substituted or unsubstituted -Ci-C6alkylene-NH-, substituted or unsubstituted -Ci-C3alkylene-NH-Ci- C3alkylene-, substituted or unsubstituted -NH-Ci-C6alkylene-, substituted or unsubstituted -Ci-
C4alkylene-NCH3-, substituted or unsubstituted -Ci-C2alkylene-NCH3-Ci-C2alkylene-, substituted or unsubstituted -NCH3-Ci-C4alkylene-, substituted or unsubstituted -Ci-C4alkylene-NCH2CH3-, substituted or unsubstituted -Ci-C2alkylene-NCH2CH3-Ci-C2alkylene-, or substituted or
unsubstituted -NCH2CH3-Ci-C4alkylene-; where if L3 is substituted then L3 is substituted with 1 or 2 R13; each R13 is independently selected from F, -CH3, -CF3, hydroxyl, -OCH3, and -OCF3.
[0201] In some embodiments, L3 is a substituted or unsubstituted Ci-C4alkylene, substituted or unsubstituted Ci-C4fluoroalkylene, substituted or unsubstituted -Ci-C4alkylene-0-, substituted or unsubstituted -Ci-C3alkylene-0-Ci-C3alkylene-, substituted or unsubstituted -0-Ci-C4alkylene-, substituted or unsubstituted -Ci-C4alkylene-S-, substituted or unsubstituted -Ci-C3alkylene-S-Ci- C3alkylene-, substituted or unsubstituted -S-Ci-C4alkylene-, substituted or unsubstituted -C
C4alkylene-NH-, substituted or unsubstituted -Ci-C3alkylene-NH-Ci-C3alkylene-, substituted or unsubstituted -NH-Ci-C4alkylene-; where if L3 is substituted then L3 is substituted with 1 or 2 R13; each R13 is independently selected from F, -CH3, -CF3, and hydroxyl.
[0202] In some embodiments, L3 is a substituted or unsubstituted C3-C4alkylene, substituted or unsubstituted C3-C4fluoroalkylene, substituted or unsubstituted -C2-C4alkylene-0-, substituted or unsubstituted -Ci-C3alkylene-0-Ci-C3alkylene-, substituted or unsubstituted -0-C2-C4alkylene-, substituted or unsubstituted -C2-C4alkylene-S-, substituted or unsubstituted -Ci-C3alkylene-S-Ci- C3alkylene-, substituted or unsubstituted -S-C2-C4alkylene-, substituted or unsubstituted -C2- C4alkylene-NH-, substituted or unsubstituted -Ci-C3alkylene-NH-Ci-C3alkylene-, substituted or unsubstituted -NH-C2-C4alkylene-; where if L3 is substituted then L3 is substituted with 1 or 2 R13; each R13 is independently selected from F, -CH3, -CF3, and hydroxyl.
[0203] In some embodiments, L3 is a substituted or unsubstituted C4alkylene or substituted or unsubstituted C4fluoroalkylene; where if L3 is substituted then L3 is substituted with 1 or 2 R13; each R13 is independently selected from F, -CH3, -CF3,and hydroxyl.
[0204] In some embodiments, L3 is a substituted or unsubstituted -Ci-C4alkylene-0-, substituted or unsubstituted -Ci-C3alkylene-0-Ci-C3alkylene-, substituted or unsubstituted -0-Ci-C4alkylene-, substituted or unsubstituted -Ci-C4alkylene-S-, substituted or unsubstituted -Ci-C3alkylene-S-Cr C3alkylene-, substituted or unsubstituted -S-Ci-C4alkylene-, substituted or unsubstituted -Ci- C4alkylene-NH-, substituted or unsubstituted -Ci-C3alkylene-NH-Ci-C3alkylene-, substituted or unsubstituted -NH-Ci-C4alkylene-; where if L3 is substituted then L3 is substituted with 1 or 2 R13; each R13 is independently selected from F, -CH3, -CF3, and hydroxyl.
[0205] In some embodiments, L3 is a substituted or unsubstituted -C2-C4alkylene-0-, substituted or unsubstituted -Ci-C3alkylene-0-Ci-C3alkylene-, substituted or unsubstituted -0-C2-C4alkylene-, substituted or unsubstituted -C2-C4alkylene-S-, substituted or unsubstituted -Ci-C3alkylene-S-Ci- C3alkylene-, substituted or unsubstituted -S-C2-C4alkylene-, substituted or unsubstituted -C2- C4alkylene-NH-, substituted or unsubstituted -Ci-C3alkylene-NH-Ci-C3alkylene-, substituted or unsubstituted -NH-C2-C4alkylene-; where if L3 is substituted then L3 is substituted with 1 or 2 R13; each R13 is independently selected from F, -CH3, -CF3, and hydroxyl.
[0206] In some embodiments, L3 is a substituted or unsubstituted -Ci-C4alkylene-0-, substituted or unsubstituted -Ci-C3alkylene-0-Ci-C3alkylene-, or substituted or unsubstituted -0-Ci-C4alkylene-; where if L is substituted then L is substituted with 1 or 2 R ; each R is independently selected from F, -CH3, -CF3, and hydroxyl.
[0207] In some embodiments, L3 is a substituted or unsubstituted -C2-C4alkylene-0-, substituted or unsubstituted -Ci-C3alkylene-0-Ci-C3alkylene-, or substituted or unsubstituted -0-C2-C4alkylene-; where if L is substituted then L is substituted with 1 or 2 R ; each R is independently selected from F, -CH3, -CF3, and hydroxyl.
[0208] In some embodiments, L3 is a substituted or unsubstituted -Ci-C4alkylene-S-, substituted or unsubstituted -Ci-C3alkylene-S-Ci-C3alkylene-, or substituted or unsubstituted -S-Ci-C4alkylene-; where if L is substituted then L is substituted with 1 or 2 R ; each R is independently selected from F, -CH3, -CF3, and hydroxyl.
[0209] In some embodiments, L3 is a substituted or unsubstituted -C2-C4alkylene-S-, substituted or unsubstituted -Ci-C3alkylene-S-Ci-C3alkylene-, or substituted or unsubstituted -S-C2-C4alkylene-; where if L is substituted then L is substituted with 1 or 2 R ; each R is independently selected from F, -CH3, -CF3, and hydroxyl.
[0210] In some embodiments, L3 is a substituted or unsubstituted -Ci-C4alkylene-NH-, substituted or unsubstituted -Ci-C3alkylene-NH-Ci-C3alkylene-, substituted or unsubstituted -NH-Cr
C4alkylene-; where if L is substituted then L is substituted with 1 or 2 R ; each R is
independently selected from F, -CH3, -CF3, and hydroxyl. In some embodiments, L3 is a substituted or unsubstituted -C2-C4alkylene-NH-, substituted or unsubstituted -Ci-C3alkylene-NH-Ci- C3alkylene-, substituted or unsubstituted -NH-C2-C4alkylene-; where if L3 is substituted then L3 is substituted with 1 or 2 R13; each R13 is independently selected from F, -CH3, -CF3, and hydroxyl.
[0211] In some embodiments, L3 is a substituted or unsubstituted C3-C4alkylene, a substituted or unsubstituted C3-C4fluoroalkylene, or a substituted or unsubstituted C3-C6heteroalkylene.
[0212] In some embodiments, L3 is a substituted or unsubstituted propylene, a substituted or unsubstituted propenylene, a substituted or unsubstituted butylene, a substituted or unsubstituted butenylene, a substituted or unsubstituted pentylene, a substituted or unsubstituted pentenylene. In some embodiments, L3 is a substituted or unsubstituted butylene, a substituted or unsubstituted butenylene, a substituted or unsubstituted fluorobutylene, a substituted or unsubstituted
fluorobutenylene, a substituted or unsubstituted difluorobutylene or a substituted or unsubstituted difluorobutenylene. In some embodiments, L3 is a substituted or unsubstituted butylene, a substituted or unsubstituted fluorobutylene, or a substituted or unsubstituted difluorobutylene. [0213] In some embodiments, L3 is a substituted or unsubstituted C3-C6heteroalkylene. In some embodiments, L3 is a substituted or unsubstituted C3-C4heteroalkylene.
[0214] In some embodiments, L3 is -(substituted or unsubstituted C3-C4alkylene)-0-, -(substituted or unsubstituted Ci-C3alkylene)-0-(substituted or unsubstituted Ci-C3alkylene)-, -0-(substituted or unsubstituted C3-C4alkylene)-, -(substituted or unsubstituted C3-C4alkylene)-S-, -(substituted or unsubstituted Ci-C3alkylene)-S-(substituted or unsubstituted Ci-C3alkylene)-, -S-(substituted or unsubstituted C3-C4alkylene)-, -(substituted or unsubstituted C3-C4alkylene)-NH-, -(substituted or unsubstituted Ci-C3alkylene)-NH-(substituted or unsubstituted Ci-C3alkylene)-, or -NH-(substituted or unsubstituted C3-C4alkylene)-.
[0215] In some embodiments, L3 is -NH-(substituted or unsubstituted C3-C4alkylene).
[0216] In some embodiments, L3 is -(substituted or unsubstituted Ci-C3alkylene)-0-(substituted or unsubstituted Ci-C3alkylene)-, or -(substituted or unsubstituted Ci-C3alkylene)-S-(substituted or unsubstituted Ci-C3alkylene)-. In some embodiments, L3 is -(substituted or unsubstituted ethylene)- 0-(substituted or unsubstituted methylene)-, or -(substituted or unsubstituted ethylene)-S-(substituted or unsubstituted methylene)- .
[0217] In some embodiments, L3 is -ΐ Χ1-!,5-.
[0218] In some embodiments, L4is absent or a substituted or unsubstituted Ci-C4alkylene, where if L4 is substituted then L4 is substituted with 1 or 2 R14; each R14 is independently selected from F, - CH3, -CF3, hydroxyl, -OCH3, and -OCF3; X1 is -0-, -S-, -S(O)-, -S(0)2-, -NR7-, -C(0)NR8-, - NR8C(=0)-, -NR8C(=0)CH20-, -NR8C(=0)-CH(CH3)0-, -NR8C(=0)-C(CH3)20-, -C(=0)-, -
OC(=0)-, -C(=0)0-, -OC(=0)0-, -OC(=0)N(R8)-, -NR8C(=0)0-, or -NR8C(=0)N(R8)-; R7 is H, - C(=0)R10, or Ci-C4alkyl; R8 is H, or Ci-C4alkyl; L5 is absent or a substituted or unsubstituted Ci- C4alkylene, where if L5 is substituted then L5 is substituted with 1 or 2 R15; each R15 is independently selected from F, -CH3, -CF3, hydroxyl, -OCH3, and -OCF3.
[0219] In some embodiments, X1 is -0-, -S-, -NR7-, -C(0)NR8-, -NR8C(=0)-, -C(=0)-, - OC(=0)N(R8)-, -NR8C(=0)0-, or -NR8C(=0)N(R8)-.
[0220] In some embodiments, L4is absent; L5 is a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1 or 2 R15; each R15 is independently selected from F, - CH3, -CF3, hydroxyl, -OCH3, and -OCF3.
[0221] In some embodiments, L4is absent; L5 is a substituted or unsubstituted C2-C4alkylene, where if L5 is substituted then L5 is substituted with 1 or 2 R15; each R15 is independently selected from F, - CH3, -CF3, or hydroxyl.
[0222] In some embodiments, L4is a substituted or unsubstituted Ci-C4alkylene, where if L4 is substituted then L4 is substituted with 1 or 2 R14; each R14 is independently selected from F, -CH3, - CF3, hydroxyl, -OCH3, and -OCF3; L5 is absent. [0223] In some embodiments, L4 is a substituted or unsubstituted C2-C4alkylene, where if L4 is substituted then L4 is substituted with 1 or 2 R14; each R14 is independently selected from F, -CH3, - CF3, or hydroxyl; L5 is absent.
[0224] In some embodiments, L4 is a substituted or unsubstituted C2-C4alkylene, where if L4 is substituted then L4 is substituted with 1 or 2 R14; each R14 is independently selected from F, -CH3, -
CF3, or hydroxyl; L5 is a substituted or unsubstituted C2-C4alkylene, where if L5 is substituted then L5 is substituted with 1 or 2 R15; each R15 is independently selected from F, -CH3, -CF3, or hydroxyl.
[0225] In some embodiments, X1 is -0-, -S-, or -NR7-.
[0226] In some embodiments, m is 0 or 1. In some embodiments, n is 0 or 1.
[0227] In some embodiments, m is 0. In some embodiments, n is 0.
[0228] In some embodiments, the compound of Formula (I) has the structure of Formula (IV), or a pharmaceutically acceptable solvate, or a pharmaceutically acceptable salt, or a prodrug, or a metabolite thereof:
Figure imgf000046_0001
Formula (IV)
L1 is absent, Ci-C4alkylene, C3-C6cycloalkylene, -C3-C6cycloalkylene-Ci-C4alkylene-, or -
C(Rla)(Rlb)-;
Rla and Rlb are each independently selected from H, Ci-C4alkyl and substituted or unsubstituted benzyl;
L4 absent or a substituted or unsubstituted Ci-C4alkylene, where if L4 is substituted then L4 is substituted with 1 to 3 R ; each R is independently selected from H, F, Ci-C4alkyl, C C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy;
X1 is a absent, -0-, -S-, -S(O)-, -S(0)2-, -NR7-, -C(0)NR8-, -NR8C(=0)-, -N(R8)S(=0)2-, - S(=0)2N(R8)-, -C(=0)-, -OC(=0)-, -C(=0)0-, -OC(=0)0-, -OC(=0)N(R8)-, - NR8C(=0)0-, or -NR8C(=0)N(R8)-;
R7 is H, -S(=0)2R10, -S(=0)2N(R9)2, -C(=0)R10, -C02R9, -C(=0)N(R9)2, d-C4alkyl, C
C4fluoroalkyl, or Ci-C4heteroalkyl;
R8 is H, Ci-C4alkyl, or Ci-C4fluoroalkyl; L5 absent or a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1 to 3 R15; each R15 is independently selected from F, Ci-C4alkyl, d- C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy;
m is 0, 1, or 2; n is 0, 1, or 2; p is 0, 1, or 2
each of RA, RB, and Rc are independently selected from H, halogen, -CN, -N02, -OH, -OR9, - N(R9)2, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and C C4heteroalkyl;
each R9 is independently selected from H, Ci-C6alkyl, Ci-C6fiuoroalkyl, a substituted or unsubstituted phenyl, or -CH2-(substituted or unsubstituted phenyl); or
two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted heterocycle;
R10 is selected from Ci-C6alkyl, Ci-C6fluoroalkyl, C3-C6cycloalkyl, and a substituted or unsubstituted phenyl.
[0229] In some embodiments, the compound of Formula (I) has a structure of Formula (V), or a pharmaceutically acceptable solvate, or a pharmaceutically acceptable salt, or a prodrug, or a metabolite thereof:
Figure imgf000047_0001
Formula (V)
L1 is absent, Ci-C4alkylene, C3-C6cycloalkylene, -C3-C6cycloalkylene-Ci-C4alkylene-, or - C(Rla)(Rlb)-;
Rla and Rlb are each independently selected from H, Ci-C4alkyl and substituted or unsubstituted benzyl;
L4 absent or a substituted or unsubstituted Ci-C4alkylene, where if L4 is substituted then L4 is substituted with 1 to 3 R14; each R14 is independently selected from H, F, Ci-C4alkyl, C
C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy;
X1 is a absent, -0-, -S-, -S(O)-, -S(0)2-, -NR7-, -C(0)NR8-, -NR8C(=0)-, -N(R8)S(=0)2-, -
S(=0)2N(R8)-, -C(=0)-, -OC(=0)-, -C(=0)0-, -OC(=0)0-, -OC(=0)N(R8)-, -
NR8C(=0)0-, or -NR8C(=0)N(R8)-;
R7 is H, -S(=0)2R10, -S(=0)2N(R9)2, -C(=0)R10, -C02R9, -C(=0)N(R9)2, d-C4alkyl, d- C4fluoroalkyl, or Ci-C4heteroalkyl; R8 is H, Ci-C4alkyl, or Ci-C4fluoroalkyl;
L5 absent or a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1 to 3 R15; each R15 is independently selected from F, Ci-C4alkyl, C
C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy;
m is 0, 1, or 2; n is 0, 1, or 2; p is 0, 1, or 2;
each of RA, RB, and Rc are independently selected from H, halogen, -CN, -N02, -OH, -OR9, -
N(R9)2, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-
C4heteroalkyl;
each R9 is independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, a substituted or unsubstituted phenyl, or -CH2-(substituted or unsubstituted phenyl); or
two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted heterocycle;
R10 is selected from Ci-C6alkyl, Ci-C6fluoroalkyl, C3-C6cycloalkyl, and a substituted or
unsubstituted phenyl.
[0230] In some embodiments, L1 is Ci-C4alkylene, C3-C6cycloalkylene, -C3-C6cycloalkylene-Ci- C4alkylene-, or -C(Rla)(Rlb)-.
[0231] In some embodiments, L1 is -CH2-, -CH(CH3)-, -CH(substituted or unsubstituted benzyl)-, - C(CH3)2-, -CH2CH2-, -CH2CH2CH2-, cyclopropyl- 1 , 1 -diyl, cyclopropyl- 1 ,2-diyl, cyclobutyl- 1 , 1 -diyl, cyclopentyl-l,l-diyl, cyclohexyl- 1 , 1 -diyl, or -C(CH2CH2)CH2-.
[0232] In some embodiments, L1 is -CH(CH3)-, -CH(substituted or unsubstituted benzyl)-, - C(CH3)2-, cyclopropyl- 1,1 -diyl, cyclopropyl- 1 ,2-diyl, or -C(CH2CH2)CH2-.
[0233] In some embodiments, L1 is cyclopropyl- 1,1 -diyl, cyclopropyl- 1 ,2-diyl, or -C(CH2CH2)CH2-.
[0234] In some embodiments, L1 is C3-C6cycloalkylene, or -C3-C6cycloalkylene-Ci-C4alkylene.
[0235] In some embodiments, L1 is C3-C6cycloalkylene.
[0236] In some embodiments, L1 is cyclopropyl- 1,1 -diyl, cyclopropyl- 1 ,2-diyl, cyclobutyl- 1,1 -diyl, cyclopentyl- 1 , 1 -diyl, cyclohexyl- 1 , 1 -diyl.
[0237] In some embodiments, L4is absent or a substituted or unsubstituted Ci-C4alkylene, where if L4 is substituted then L4 is substituted with 1 or 2 R14; each R14 is independently selected from F, - CH3, -CF3, hydroxyl, -OCH3, and -OCF3; X1 is -0-, -S-, -S(O)-, -S(0)2-, -NR7-, -C(0)NR8-, - NR8C(=0)-, -NR8C(=0)CH20-, -NR8C(=0)-CH(CH3)0-, -NR8C(=0)-C(CH3)20-, -C(=0)-, -
OC(=0)N(R8)-, -NR8C(=0)0-, or -NR8C(=0)N(R8)-; R7 is H, -C(=0)R10, or Ci-C4alkyl; R8 is H, or Ci-C4alkyl; L5 is absent or a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1 or 2 R15; each R15 is independently selected from F, -CH3, -CF3, hydroxyl, -OCH3, and -OCF3.
[0238] In some embodiments, X1 is -0-, -S-, -NR7-, -C(0)NR8-, -NR8C(=0)-, -C(=0)-, -
OC(=0)N(R8)-, -NR8C(=0)0-, or -NR8C(=0)N(R8)-. [0239] In some embodiments, L4is absent.
[0240] In some embodiments, L5 is a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1 or 2 R15; each R15 is independently selected from F, -CH3, - CF3, hydroxyl, -OCH3, and -OCF3.
[0241] In some embodiments, L4is a substituted or unsubstituted Ci-C4alkylene, where if L4 is substituted then L4 is substituted with 1 or 2 R14; each R14 is independently selected from F, -CH3, -
CF3, hydroxyl, -OCH3, and -OCF3.
[0242] In some embodiments, L5 is absent.
[0243] In some embodiments, L4is a substituted or unsubstituted Ci-C4alkylene, where if L4 is substituted then L4 is substituted with 1 or 2 R14; each R14 is independently selected from F, -CH3, - CF3, or hydroxyl. In some embodiments, L5 is a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1 or 2 R15; each R15 is independently selected from F, - CH3, -CF3, or hydroxyl.
[0244] In some embodiments, X1 is -0-, -S-, or -NR7-. In some embodiments, X1 is -O- or -S-. In some embodiments, X1 is -NR7-.
[0245] In some embodiments, each of RA, RB, and Rc are independently selected from H, halogen, -
CN, -N02, -OH, -NH2, -CH3, -CF3, -OCF3, and -OCH3.
[0246] In some embodiments, m is 0 or 1; n is 0 or 1. In some embodiments, m is 0. In some embodiments, n is 0.
[0247] In some embodiments, p is 0 or 1. In some embodiments, p is 1 or 2. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
[0248] In some embodiments, each Rc is independently selected from H, halogen, -CN, -OH, -CH3, - CF3, -OCF3, and -OCH3.
[0249] In some embodiments, the compound of Formula (I) has a structure of Formula (VI), or a pharmaceutically acceptable salt thereof:
Figure imgf000049_0001
Formula (VI)
wherein, R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, or tetrazolyl;
RD is H or Ci-C6alkyl;
RE is Ci-C6alkyl, C3-C6cycloalkyl, or substituted or unsubstituted phenyl;
L3 is a substituted or unsubstituted C3-C6alkylene, a substituted or unsubstituted C3-
C6fluoroalkylene, or a substituted or unsubstituted C3-C6heteroalkylene, where if L3 is substituted then L3 is substituted with 1 , 2 or 3 R13; each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, and -OH;
each of RA, RB, and Rc are independently selected from H, halogen, -CN, -N02, -OH, -OR9, -
N(R9)2, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and C
C4heteroalkyl;
R5 is H or Ci-C4alkyl;
each R9 is independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, a substituted or unsubstituted phenyl, or -CH2-(substituted or unsubstituted phenyl); or
two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted Ci-Csheterocycle;
m is 0 or 1 ;
n is 0 or 1 ;
p is 0, 1 , or 2.
[0250] In some embodiments, the compound of Formula (I) has a structure of Formula (VII), or a pharmaceutically acceptable salt thereof:
Figure imgf000050_0001
wherein,
R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, or tetrazolyl;
RD is H or Ci-C6alkyl;
RE is Ci-C6alkyl, C3-C6cycloalkyl, or substituted or unsubstituted phenyl;
L3 is a substituted or unsubstituted C3-C6alkylene, a substituted or unsubstituted C3-
C6fluoroalkylene, or a substituted or unsubstituted C3-C6heteroalkylene, where if L3 is substituted then L3 is substituted with 1 , 2 or 3 R13; each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, and -OH;
each of RA, RB, and Rc are independently selected from H, halogen, -CN, -N02, -OH, -OR9, -
N(R9)2, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-
C4heteroalkyl;
R3 is H or C C4alkyl;
each R9 is independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, a substituted or unsubstituted phenyl, or -CH2-(substituted or unsubstituted phenyl); or
two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted Ci-Csheterocycle;
m is 0 or 1 ;
n is 0 or 1 ;
p is 0, 1 , or 2.
[0251] In some embodiments, the compound of Formula (I) has one of the following structures:
Figure imgf000051_0001
[0252] In one aspect, R6 is as described in Table 1 and/or 2. In one aspect, L1 is as described in Table 1 and/or 2. In one aspect, L3 is as described in Table 1 and/or 2. In one aspect, RE is as described in Table 2.
[0253] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds. [0254] In one aspect, compounds of Formula (I) include, but are not limited to, those described in Table 1 and Table 2:
Table 1:
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
*mass spectrometric data
Table 2
Figure imgf000065_0002
Figure imgf000065_0003
Figure imgf000066_0001
*mass spectrometric data
Synthesis of Compounds
[0255] Compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) described herein are synthesized using standard synthetic techniques or using methods known in the art in combination with methods described herein. In additions, solvents, temperatures and other reaction conditions presented herein may vary.
[0256] The starting material used for the synthesis of the compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) are either synthesized or obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, Fluka, Acros Organics, Alfa Aesar, and the like. The compounds described herein, and other related compounds having different substituents are synthesized using techniques and materials described herein or otherwise known, including those found in March, ADVANCED ORGANIC CHEMISTRY 4th Ed., (Wiley 1992); Carey and Sundberg, ADVANCED ORGANIC CHEMISTRY 4th Ed., Vols. A and B (Plenum 2000, 2001), and Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS 3rd Ed., (Wiley 1999). General methods for the preparation of compounds can be modified by the use of appropriate reagents and conditions for the introduction of the various moieties found in the formulae as provided herein. [0257] In some embodiments, the compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) are prepared as outlined in the following Schemes.
Scheme 1:
Figure imgf000067_0001
[0258] In one aspect, the synthesis of compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) described herein begins with the reaction of an alkyl acetoacetate with methylamine to provide a compound of structure l-II. Compounds of structure l-II are reacted with a substituted or unsubstituted 4-halo-benzoyl chloride (structure l-III) to provide compounds of structure 1-IV.
[0259] Treatment of compounds of structure 1-IV with hydroxyl amine and acetic acid provides isoxazoles of structure 1-V. Hydrolysis of the ester group of isoxazoles of structure 1-V provides carboxylic acids of structure 1-VI. A Curtius rearrangement of carboxylic acids of structure 1-VI in the presence of hydroxy compounds of structure 1-VII provides carbamate compounds of structure 1-VIII. Deprotection of the tert-butoxycarbonyl group provides amines of structure 1-IX which are further functionalized into a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII). In some embodiments, compounds of 1-V are reduced to the alcohol and then further functionalized into a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII).
[0260] In one aspect, ureas of structure 2-V are prepared as outlined in Scheme 2.
Scheme 2
Figure imgf000068_0001
[0261] A Curtius rearrangement of carboxylic acids of structure 2-1 in the presence of tert-butanol provides carbamate compounds of structure 2-II. Removal of the tert-butyl group with acid provides amines of structure 2-III Amines of structure 2-III are reacted with isocyantes of structure 2-IV to provide ureas of structure 2-V. Ureas of structure 2-V are used in the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein.
[0262] Common methods for the synthesis of isocyanates include the Curtius rearrangement of acyl azides and the Lossen rearrangement of hydroxamic acids. The synthesis of ureas include the following procedures: C. Han, J. A. Porco, Jr, Org. Lett., 2007, 9, 1517-1520; H. Lebel, O. Leogane,
Org. Lett., 2006, 8, 5717-5720; M. B. Bertrand, J. P. Wolfe, Tetrahedron, 2005, 61 , 6447-6459; M.
McLaughlin, M. Palucki, I. W. Davies, Org. Lett., 2006, 8, 331 1-3314; J. A. Fritz, et al., Org. Lett.,
2006, 8, 2531-2534; L. Marinescu, et al, J. Org. Chem., 2003, 68, 9453-9455; S.-H. Lee, et al.,
Tetrahedron, 2004, 60, 3439-3443.
[0263] In one aspect, amides of structure 3-III are prepared as outlined in Scheme 3.
Scheme 3
Figure imgf000068_0002
[0264] Amines of structure 2-III are reacted with acid chlorides of structure 3-II to provide amides of structure 3-III. Amides of structure 3-III are used in the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein.
[0265] In some embodiments, amines of structure 2-III are reacted with, but not limited to, a carboxylic acid (R6-L5-C02H) and coupling reagent such as EDC EDC, DCC, BOP, HATU or the like, or a carboxylic acid activated ester or an acid chloride (i.e. compound of structure 3-II), in the presence of a suitable base and a suitable solvent to afford compounds of structure 3-III.
[0266] In one aspect, amines of structure 3-III are prepared as outlined in Scheme 3.
Scheme 4
Figure imgf000069_0001
[0267] Amines of structure 2-III are reacted with aldehydes of structure 4-II under reductive amination conditions to provide amines of structure 4-III. Secondary amines of structure 4-III are optionally reacted with acid chlorides, alkyl chlorides, and the like, or reacted with aldehydes (R7- C(=0)H) under reductive amination conditions to provide compounds of structure 4-IV. Compounds of structure 4-IV are used in the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein.
[0268] In some embodiments, amines, amides, carbamates, and ureas are prepared as shown below. Scheme 5
Figure imgf000069_0002
[0269] Oxidation of the alcohol of 1-X provides aldehydes of structure 5-1. Reductive amination of the aldehydes with amines (e.g. R6-L5-NH2) provides secondary amines of structure 5-III.
Alkylation, acetylation, and the like, of the secondary amines, provides compounds of structure 5-IV. Alternatively, reductive amination of aldehydes 5-1 with amines R7-NH2 provides amines of structure 5-V. In some embodiments, R7 is a protecting group that is optionally removed. Reaction of amines of structure 5-V with acid chlorides, isocyantes, or chloro formates provides compounds of structure 5-VI, where Y is, absent, O, or NH. Compounds of structure 5-IV and 5-VI are used in the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein. [0270] In some embodiments, olefination of the aldehydes of structure 4-1 provides isoxazoles are olefinated to provide compounds of structure 8-1, where L3 comprises an alkenylene.
[0271] In some embodiments, ethers and thioethers are prepared as shown in Scheme 6.
Scheme 6
Figure imgf000070_0001
[0272] Alkylation of alcohols of structure 1-X then provides compounds of structure 6-1.
Alternatively, alcohols of structure 1-X are brominated, chlorinated, or activated with an activating agent (e.g. tosyl chloride, mesyl chloride and the like) and then reacted with alcohols or thiol compounds to provide compounds of structure 6-III. Compounds of structure 6-1 and 6-III are used in the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein.
[0273] In some embodiments, alcohols of structure 1-X are used to prepare esters, carbamates, carbonates and the like as shown in scheme 7.
Scheme 7.
Figure imgf000070_0002
[0274] Reaction of alcohols of structure 1-X are reacted with acid chlorides, isocyantes, and chloroformates and the like to provide compounds of structure 7-1, where Y is absent, O, or NH. Compounds of structure 7-1 are used in the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein. [0275] In one aspect, metal mediated couplings are used to provide a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described in Scheme 8, Scheme 9, Scheme 10, and Scheme 11. Scheme 8
Figure imgf000071_0001
8- II I
[0276] In one aspect, a Suzuki reaction between compounds of structure 8-1 and compounds of structure 8-II is used to provide compounds of structure 8-III. Other metal mediated coupling reactions contemplated for the preparation of compounds of structure 8-III include, but are not limited to Suzuki reactions, Stille cross couplings, Negishi couplings, Kumada couplings, Ullmann reactions, Hiyama Coupling, and variants thereof (Metal-Catalyzed Cross-Coupling Reactions, Armin de Meijere (Editor), Francois Diederich (Editor), John Wiley & Sons; 2nd edition, 2004; Ozdemir, et al, Tetrahedron, 2005, 61, 9791-9798; Ackermann, et al, Org. Lett., 2006, 8, 3457- 3460; Blakey, et al, J. Am. Chem. Soc, 2003, 125, 6046-6047; Dai, et al, Org. Lett., 2004, 6, 221- 224; Yoshikai, et al, J. Am. Chem. Soc, 2005, 127, 17978-17979; Tang, et al, J. Org. Chem., 2006, 71, 2167-2169; Murata, et al, Synthesis, 2001, 2231-2233).
[0277] In one aspect, the coupling partners in the metal mediated reaction condition includes those outlined in Scheme 9.
Scheme 9
Figure imgf000072_0001
[0278] In one aspect, halides of structure 8-1 are reacted with a borylating agent using transition metal mediated reaction conditions to form boronate compounds of structure 9-1. Boronate compounds of structure 9-1 are reacted with compounds of structure 9-III under palladium mediated coupling conditions to form biphenyl aldehydes of structure 9-IV.
[0279] In yet another aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is prepared as outlined in Scheme 10.
Scheme 10
Figure imgf000072_0002
[0280] Following the same procedures as described in Scheme 1, compounds of structure 10-1 are used to prepare a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII). In one aspect, compounds of structure 10-1 are prepared using the methodology described herein or known in the art.
[0281] A non-limiting example of the synthesis of compounds of structure 10-1 is shown in Scheme 11.
Scheme 11
Figure imgf000073_0001
[0282] In some embodiments, the isoxazole in any of the schemes described herein are prepared as outlined in Scheme 12.
Scheme 12
Figure imgf000073_0002
[0283] In some embodiments, the synthesis of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) described herein begins with the reaction of an alkyl acetoacetate with methylamine to provide a compound of structure 12-11. Reaction of 12-11 provides compounds 12-IV which are then treated with hydroxylamine to provide isoxazoles of structure 12-V. Isoxazoles of structure 12-V are then elaborated into a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as described herein. [0284] Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[0285] A detailed description of techniques applicable to the creation of protecting groups and their removal are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference for such disclosure.
Further Forms of Compounds
[0286] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) possess one or more stereocenters and each stereocenter exists independently in either the R or S configuration. The compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. The compounds and methods provided herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof. In certain embodiments, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds/salts, separating the diastereomers and recovering the optically pure enantiomers. In some embodiments, resolution of enantiomers is carried out using covalent diastereomeric derivatives of the compounds described herein. In another embodiment, diastereomers are seprated by separation/resolution techniques based upon differences in solubility. In other embodiments, separation of steroisomers is performed by chromatography or by the forming diastereomeric salts and separation by recrystallization, or chromatography, or any combination thereof. Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981. In one aspect, stereoisomers are obtained by stereoselective synthesis.
[0287] The methods and compositions described herein include the use of amorphous forms as well as crystalline forms (also known as polymorphs). In one aspect, compounds described herein are in the form of pharmaceutically acceptable salts. As well, active metabolites of these compounds having the same type of activity are included in the scope of the present disclosure. In addition, the compounds described herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the compounds presented herein are also considered to be disclosed herein.
[0288] In some embodiments, compounds described herein are prepared as prodrugs. A "prodrug" refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. In some embodiments, the design of a prodrug increases the effective water solubility. An example, without limitation, of a prodrug is a compound described herein, which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide
(polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of the compound. In certain embodiments, a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound.
[0289] In one aspect, prodrugs are designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug. By virtue of knowledge of pharmacokinetic,
pharmacodynamic processes and drug metabolism in vivo, once a pharmaceutically active compound is known, the design prodrugs of the compound is possible, (see, for example, Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392; Silverman (1992), The Organic Chemistry of Drug Design and Drug Action, Academic Press, Inc., San Diego, pages 352-401, Rooseboom et ah, Pharmacological Reviews, 56:53-102, 2004; Aesop Cho, "Recent Advances in Oral Prodrug Discovery", Annual Reports in Medicinal Chemistry, Vol. 41, 395-407, 2006; T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series).
[0290] Prodrug forms of the herein described compounds, wherein the prodrug is metabolized in vivo to produce a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as set forth herein are included within the scope of the claims. In some cases, some of the herein-described compounds may be a prodrug for another derivative or active compound.
[0291] In some embodiments, sites on the aromatic ring portion of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are susceptible to various metabolic reactions Therefore incorporation of appropriate substituents on the aromatic ring structures will reduce, minimize or eliminate this metabolic pathway. In specific embodiments, the appropriate substituent to decrease or eliminate the susceptibility of the aromatic ring to metabolic reactions is, by way of example only, a halogen, or an alkyl group.
[0292] In another embodiment, the compounds described herein are labeled isotopically (e.g. with a radioisotope) or by another other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
[0293] Compounds described herein include isotopically-labeled compounds, which are identical to those recited in the various formulae and structures presented herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the present compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, such as, for example, ¾, 3H, 13C, 14C, 15N, 180, 170, 35S, 18F, 36C1. In one aspect, isotopically-labeled compounds described herein, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. In one aspect, substitution with isotopes such as deuterium affords certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements.
[0294] In additional or further embodiments, the compounds described herein are metabolized upon administration to an organism in need to produce a metabolite that is then used to produce a desired effect, including a desired therapeutic effect.
[0295] "Pharmaceutically acceptable," as used herein, refers a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively nontoxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
[0296] The term "pharmaceutically acceptable salt" refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. In some embodiments, pharmaceutically acceptable salts are obtained by reacting a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with acids. Pharmaceutically acceptable salts are also obtained by reacting a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with a base to form a salt.
[0297] Compounds described herein may be formed as, and/or used as, pharmaceutically acceptable salts. The type of pharmaceutical acceptable salts, include, but are not limited to: (1) acid addition salts, formed by reacting the free base form of the compound with a pharmaceutically acceptable: inorganic acid, such as, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, metaphosphoric acid, and the like; or with an organic acid, such as, for example, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, trifluoroacetic acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-
2- ene-l-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-l-carboxylic acid),
3- phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, butyric acid, phenylacetic acid, phenylbutyric acid, valproic acid, and the like; (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion (e.g.
lithium, sodium, potassium), an alkaline earth ion (e.g. magnesium, or calcium), or an aluminum ion. In some cases, compounds described herein may coordinate with an organic base, such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine. In other cases, compounds described herein may form salts with amino acids such as, but not limited to, arginine, lysine, and the like. Acceptable inorganic bases used to form salts with compounds that include an acidic proton, include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. In some embodiments, compounds described herein are prepared as a sodium salt.
[0298] It should be understood that a reference to a pharmaceutically acceptable salt includes the solvent addition forms or crystal forms thereof, particularly solvates or polymorphs. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein can be conveniently prepared or formed during the processes described herein. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
[0299] Compounds described herein, such as a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII), may be in various forms, including but not limited to, amorphous forms, milled forms and nano-particulate forms. In addition, compounds described herein include crystalline forms, also known as polymorphs. Polymorphs include the different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, melting points, density, hardness, crystal shape, optical properties, stability, and solubility. Various factors such as the recrystallization solvent, rate of crystallization, and storage temperature may cause a single crystal form to dominate.
[0300] Throughout the specification, groups and substituents thereof can be chosen by one skilled in the field to provide stable moieties and compounds.
Certain Terminology
[0301] Unless otherwise stated, the following terms used in this application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology are employed. In this application, the use of "or" or "and" means "and/or" unless stated otherwise. Furthermore, use of the term "including" as well as other forms, such as "include", "includes," and "included," is not limiting. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0302] An "alkyl" group refers to an aliphatic hydrocarbon group. The alkyl group may be a saturated alkyl group (which means that it does not contain any carbon-carbon double bonds or carbon-carbon triple bonds) or the the alkyl group may be an unsaturated alkyl group (which means that it contains at least one carbon-carbon double bonds or carbon-carbon triple bond). The alkyl moiety, whether saturated or unsaturated, may be branched, or straight chain.
[0303] The "alkyl" group may have 1 to 10 carbon atoms (whenever it appears herein, a numerical range such as "1 to 10" refers to each integer in the given range; e.g., "1 to 10 carbon atoms" means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although the present definition also covers the occurrence of the term "alkyl" where no numerical range is designated). The alkyl group of the compounds described herein may be designated as "C1-C6 alkyl" or similar designations. By way of example only, " -C6 alkyl" indicates that there are one, two , three, four, five, or six carbon atoms in the alkyl chain. In one aspect the alkyl is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tertiary butyl, pentyl, neopentyl, hexyl, allyl, but- 2-enyl, but-3-enyl, and the like. In one aspect, an alkyl is a Ci-C6alkyl.
[0304] The term "alkylene" refers to a divalent alkyl radical. Any of the above mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl. In one aspect, an alkelene is a Ci-C6alkylene. In another apsect, an alkylene is a Ci-C4alkylene. In some embodiments, an alkylene is methylene, ethylene, propylene or butylene. Typical alkylene groups include, but are not limited to, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH(CH3)-, - CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, and the like.
[0305] An "alkoxy" group refers to a (alkyl)O- group, where alkyl is as defined herein.
[0306] The term "alkylamine" refers to the -N(alkyl)xHy group, where x and y are selected from the group x=l, y=l and x=2, y=0. In some embodiments, when x=2 and y=0, the alkyl groups taken together with the ntrogen atom to which they are attached form a cyclic ring system.
[0307] The term "aromatic" refers to a planar ring having a delocalized π-electron system containing 4n+2 π electrons, where n is an integer. Aromatic rings can be formed from five, six, seven, eight, nine, ten, or more than ten atoms. Aromatics are optionally substituted. The term "aromatic" includes both carbocyclic aryl ("aryl", e.g., phenyl) and heterocyclic aryl (or "heteroaryl" or
"heteroaromatic") groups {e.g., pyridine). The term includes monocyclic or fused-ring polycyclic {i.e., rings which share adjacent pairs of carbon atoms) groups. [0308] The term "carbocyclic" or "carbocycle" refers to a ring or ring system where the atoms forming the backbone of the ring are all carbon atoms. The term thus distinguishes carbocyclic from heterocyclic rings in which the ring backbone contains at least one atom which is different from carbon.
[0309] As used herein, the term "aryl" refers to an aromatic ring wherein each of the atoms forming the ring is a carbon atom. Aryl rings are formed by five, six, seven, eight, nine, or more than nine carbon atoms. Aryl groups are optionally substituted. In one aspect, an aryl is a phenyl or a naphthalenyl. In one aspect, an aryl is a phenyl. In one aspect, an aryl is a C6-Cioaryl. Depending on the structure, an aryl group can be a monoradical or a diradical (i.e., an arylene group). Examplary arylenes include, but are not limited to, phenyl- 1 ,2-ene, phenyl- 1 ,3-ene, and phenyl- 1 ,4-ene.
The term "cycloalkyl" refers to a monocyclic or polycyclic aliphatic, non-aromatic radical, wherein each of the atoms forming the ring (i.e. skeletal atoms) is a carbon atom. Cycloalkyls may be saturated, or partially unsaturated. Cycloalkyls may be fused with an aromatic ring, and the point of attachment is at a carbon that is not an aromatic ring carbon atom. Cycloalkyl groups include groups having from 3 to 10 ring atoms. In some embodiments, cycloalkyl groups are selected from among cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Cycloalkyl groups may be substituted or unsubstituted. Depending on the structure, a cycloalkyl group can be a monoradical or a diradical (i.e., an cycloalkylene group, such as, but not limited to, cyclopropan-l,l-diyl, cyclobutan- 1 , 1 -diyl, cyclopentan-l,l-diyl, cyclohexan- 1 , 1 -diyl, cyclohexan- 1,4-diyl, cycloheptan- 1 , 1 -diyl, and the like). In one aspect, a cycloalkyl is a C3- C6cycloalkyl.
[0310] The term "halo" or, alternatively, "halogen" or "halide" means fluoro, chloro, bromo or iodo.
[0311] The term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by one or more halide atoms. In one aspect, a haloalkyl is a Ci-C4haloalkyl.
[0312] The term "haloalkylene" refers to an alkylene group in which one or more hydrogen atoms are replaced by one or more halide atoms. In one aspect, a haloalkylene is a Ci-Cehaloalkylene. In another aspect, a haloalkylene is a Ci-C4haloalkylene.
[0313] The term "fluoroalkyl" refers to an alkyl in which one or more hydrogen atoms are replaced by a fluorine atom. In one aspect, a fluoralkyl is a Ci-C4fluoroalkyl.
[0314] The term "fluoroalkylene" refers to an alkylene in which one or more hydrogen atoms are replaced by a fluorine atom. In one aspect, a fluoralkylene is a Ci-C6fluoroalkylene. In another aspect, a fluoralkylene is a Ci-C4fluoroalkylene.
[0315] The term "heteroalkyl" refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g. NH, Nalkyl), or sulfur. In one aspect, a heteroalkyl is a Ci-C6heteroalkyl. In some embodiments, heteroalkyl refers to an alkyl group in which one skeletal atom of the alkyl is oxygen, nitrogen (e.g. NH, Nalkyl), or sulfur. [0316] The term "heteroalkylene" refers to an alkylene group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g. , oxygen, nitrogen (e.g. NH, Nalkyl), or sulfur. In some embodiments, heteroalkylene refers to an alkylene group in which one skeletal atom of the alkylene is O, NH, or S. In one aspect, a heteroalkylene is a Ci-C6heteroalkylene. In another aspect, a heteroalkylene is a Ci-C4heteroalkylene. Examplary heteroalkylenes include, but are not limited to, -OCH2-, -OCH(CH3)-, -OC(CH3)2-, -OCH2CH2-, -CH20-, -CH(CH3)0-, -C(CH3)20-, - CH2CH20-, -CH2OCH2-, -CH2OCH2CH2-, -CH2CH2OCH2-, -SCH2-, -SCH(CH3)-, -SC(CH3)2-, - SCH2CH2-, -CH2S-, -CH(CH3)S-, -C(CH3)2S-, -CH2CH2S-, -CH2SCH2-, -CH2SCH2CH2-, - CH2CH2SCH2-, -S02CH2-, -S02CH(CH3)-, -S02C(CH3)2-, -S02CH2CH2-, -CH2S02-, -CH(CH3)S02- , -C(CH3)2S02-, -CH2CH2S02-, -CH2S02CH2-, -CH2S02CH2CH2-, -CH2CH2S02CH2-, -NHCH2-, - NHCH(CH3)-, -NHC(CH3)2-, -NHCH2CH2-, -NHCH2CH2CH2-,-CH2NH-, -CH(CH3)NH-, - C(CH3)2NH-, -CH2CH2NH-, -CH2CH2CH2NH-, -CH2NHCH2-, -CH2NHCH2CH2-, -CH2CH2NHCH2- , and the like.
[0317] The term "heterocycle" or "heterocyclic" refers to heteroaromatic rings (also known as heteroaryls) and heterocycloalkyl rings (also known as heteroalicyclic groups) containing one to four heteroatoms in the ring(s), where each heteroatom in the ring(s) is selected from O, S and N, wherein each heterocyclic group has from 4 to 10 atoms in its ring system, and with the proviso that the any ring does not contain two adjacent O or S atoms. Non-aromatic heterocyclic groups (also known as heterocycloalkyls) include groups having only 3 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system. The heterocyclic groups include benzo-fused ring systems. An example of a 3-membered heterocyclic group is aziridinyl. An example of a 4- membered heterocyclic group is azetidinyl. An example of a 5-membered heterocyclic group is thiazolyl. An example of a 6-membered heterocyclic group is pyridyl, and an example of a 10- membered heterocyclic group is quinolinyl. Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6-tetrahydropyridinyl, pyrrolin-2-yl, pyrrolin-3-yl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1 ,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3- azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl. Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. The foregoing groups may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol- 1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be imidazol- 1 -yl or imidazol- 3-yl (both N-attached) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C-attached). The heterocyclic groups include benzo-fused ring systems. Non-aromatic heterocycles may ber substituted with one or two oxo (=0) moieties, such as pyrrolidin-2-one.
[0318] The terms "heteroaryl" or, alternatively, "heteroaromatic" refers to an aryl group that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur. Illustrative examples of heteroaryl groups include the following moieties:
Figure imgf000081_0001
include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl, and furazanyl. In one aspect, a heteroaryl contains 0-3 N atoms. In another aspect, a heteroaryl contains 1-3 N atoms. In another aspect, a heteroaryl contains 0-3 N atoms, 0-1 O atoms, and 0-1 S atoms. In another aspect, a heteroaryl is a monocyclic or bicyclic heteroaryl. In one aspect, heteroaryl is a Ci-Cgheteroaryl. In one aspect, monocyclic heteroaryl is a Ci-Csheteroaryl. In one aspect, monocyclic heteroaryl is a 5-membered or 6-membered heteroaryl. In one aspect, bicyclic heteroaryl is a Ce-Cgheteroaryl. Depending on the structure, a heteroaryl group can be a monoradical or a diradical (i.e., a heteroarylene group).
[0319] A "heterocycloalkyl" or "heteroalicyclic" group refers to a cycloalkyl group that includes at least one heteroatom selected from nitrogen, oxygen and sulfur. The radicals may be fused with an aryl or heteroaryl. Illustrative examples of heterocycloalkyl groups, also referred to as non-aromatic heterocycles, include:
Figure imgf000082_0001
and the like. In some embodiments, the heterocycloalkyl is selected from oxazolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, and indolinyl. The term heteroalicyclic also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides. In one aspect, a heterocycloalkyl is a C2-Cioheterocycloalkyl. In another aspect, a heterocycloalkyl is a C4-Cioheterocycloalkyl. In another aspect, a
heterocycloalkyl is a C2-C6heterocycloalkyl. In one aspect, a heterocycloalkyl contains 0-2 N atoms. In another aspect, a heterocycloalkyl contains 0-2 N atoms, 0-2 O atoms or 0-1 S atoms.
[0320] The term "bond" or "single bond" refers to a chemical bond between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure. In one aspect, when a group described herein is a bond, the referenced group is absent thereby allowing a bond to be formed between the remaining identified groups.
[0321] The term "membered ring" includes any cyclic structure. The term "membered" is meant to denote the number of skeletal atoms that constitute the ring. Thus, for example, cyclohexyl, pyridinyl, pyranyl and thiopyranyl are 6-membered rings and cyclopentyl, pyrrolyl, furanyl, and thienyl are 5-membered rings.
[0322] The term "moiety" refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule.
[0323] As used herein, "carboxylic acid bioisostere" refers to a functional group or moiety that exhibits similar physical, biological and/or chemical properties as a carboxylic acid moiety.
Examples of carboxylic acid bioisosteres include, but are not limited to,
Figure imgf000082_0002
[0324] The term "optionally substituted" or "substituted" means that the referenced group may be substituted with one or more additional group(s) individually and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, cyano, halo, nitro, haloalkyl, fluoroalkyl, fluoroalkoxy, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof. By way of example an optional substituents may be halide, -CN, -N02, or LSRS, wherein each Ls is independently selected from a bond, -0-, -C(=0)-, -C(=0)0-, -S-, -S(=0)-, - S(=0)2-, -NH-, -NHC(=0)-, -C(=0)NH-, S(=0)2NH-, -NHS(=0)2, -OC(=0)NH-, -NHC(=0)0-, or - (Ci-C6 alkylene)-; and each Rs is selected from H, alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl. The protecting groups that may form the protective derivatives of the above substituents may be found in sources such as Greene and Wuts, above. In some embodiments, optional substituents are selected from halogen, -CN, -NH2, -OH, -N(CH3)2, alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone. In some embodiments, an optional substituents is halogen, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, alkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, -S-alkyl, or -S(=0)2alkyl. In some embodiments, an optional substituent is selected from halogen, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, -CH3, -CH2CH3, -CF3, -OCH3, - OCH2CH3, and -OCF3. In some embodiments, substituted groups are substituted with one or two of the preceding groups. In some embodiments, substituted groups are substituted with one of the preceding groups. In some embodiments, an optional substituent on an aliphatic carbon atom (acyclic or cyclic, saturated or unsaturated carbon atoms, excluding aromatic carbon atoms) includes oxo (=0).
[0325] In certain embodiments, the compounds presented herein possess one or more stereocenters and each center independently exists in either the R or S configuration. The compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. Stereoisomers are obtained, if desired, by methods such as, stereoselective synthesis and/or the separation of stereoisomers by chiral chromatographic columns.
[0326] The methods and formulations described herein include the use of N-oxides (if appropriate), crystalline forms (also known as polymorphs), or pharmaceutically acceptable salts of compounds having the structure of Formula (I), (II), (III), (IV), (V), (VI), or (VII), as well as active metabolites of these compounds having the same type of activity. In some situations, compounds may exist as tautomers. All tautomers are included within the scope of the compounds presented herein. In specific embodiments, the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In other embodiments, the compounds described herein exist in unsolvated form. [0327] The term "acceptable" with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.
[0328] The term "modulate," as used herein, means to interact with a target either directly or indirectly so as to alter the activity of the target, including, by way of example only, to enhance the activity of the target, to inhibit the activity of the target, to limit the activity of the target, or to extend the activity of the target.
[0329] The term "modulator," as used herein, refers to a molecule that interacts with a target either directly or indirectly. The interactions include, but are not limited to, the interactions of an agonist, partial agonist, an inverse agonist and antagonist. In one embodiment, a modulator is an antagonist.
[0330] The term "agonist," as used herein, refers to a molecule such as a compound, a drug, an enzyme activator or a hormone modulator that binds to a specific receptor and triggers a response in the cell. An agonist mimics the action of an endogenous ligand (such as LPA, prostaglandin, hormone or neurotransmitter) that binds to the same receptor.
[0331] The term "antagonist," as used herein, refers to a molecule such as a compound, which diminishes, inhibits, or prevents the action of another molecule or the activity of a receptor site. Antagonists include, but are not limited to, competitive antagonists, non-competitive antagonists, uncompetitive antagonists, partial agonists and inverse agonists.
[0332] The term "LPA-dependent", as used herein, refers to conditions or disorders that would not occur, or would not occur to the same extent, in the absence of LPA.
[0333] The term "LPA-mediated", as used herein, refers to refers to conditions or disorders that might occur in the absence of LPA but can occur in the presence of LPA.
[0334] The terms "co-administration" or the like, as used herein, are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.
[0335] The terms "effective amount" or "therapeutically effective amount," as used herein, refer to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate "effective" amount in any individual case may be determined using techniques, such as a dose escalation study.
[0336] The terms "enhance" or "enhancing," as used herein, means to increase or prolong either in potency or duration a desired effect. Thus, in regard to enhancing the effect of therapeutic agents, the term "enhancing" refers to the ability to increase or prolong, either in potency or duration, the effect of other therapeutic agents on a system. An "enhancing-effective amount," as used herein, refers to an amount adequate to enhance the effect of another therapeutic agent in a desired system.
[0337] The terms "kit" and "article of manufacture" are used as synonyms.
[0338] A "metabolite" of a compound disclosed herein is a derivative of that compound that is formed when the compound is metabolized. The term "active metabolite" refers to a biologically active derivative of a compound that is formed when the compound is metabolized. The term
"metabolized," as used herein, refers to the sum of the processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes) by which a particular substance is changed by an organism. Thus, enzymes may produce specific structural alterations to a compound. For example, cytochrome P450 catalyzes a variety of oxidative and reductive reactions while uridine diphosphate glucuronyltransferases catalyze the transfer of an activated glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines and free sulphydryl groups.
Metabolites of the compounds disclosed herein are optionally identified either by administration of compounds to a host and analysis of tissue samples from the host, or by incubation of compounds with hepatic cells in vitro and analysis of the resulting compounds.
[0339] The term "pharmaceutical combination" as used herein, means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non- fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non- fixed combination" means that the active ingredients, e.g. a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and a co-agent, are administered to a patient as separate entities either
simultaneously, concurrently or sequentially with no specific intervening time limits, wherein such administration provides effective levels of the two compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients.
[0340] The term "subject" or "patient" encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. In one embodiment, the mammal is a human.
[0341] The terms "treat," "treating" or "treatment," as used herein, include any one of the following
(or combination thereof): alleviating, abating or ameliorating at least one symptom of a disease disease or condition, preventing additional symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically. Routes of Administration
[0342] Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ophthalmic, pulmonary, transmucosal, transdermal, vaginal, otic, nasal, and topical administration. In addition, by way of example only, parenteral delivery includes
intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections.
[0343] In certain embodiments, a compound as described herein is administered in a local rather than systemic manner, for example, via injection of the compound directly into an organ, often in a depot preparation or sustained release formulation. In specific embodiments, long acting
formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Furthermore, in other embodiments, the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with organ-specific antibody. In such
embodiments, the liposomes are targeted to and taken up selectively by the organ. In yet other embodiments, the compound as described herein is provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation. In yet other embodiments, the compound described herein is administered topically. Pharmaceutical Compositions/Formulations
[0344] In some embodiments, the compounds described herein are formulated into pharmaceutical compositions. Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. A summary of pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkinsl999), herein incorporated by reference for such disclosure.
[0345] Provided herein are pharmaceutical compositions that include a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and at least one pharmaceutically acceptable inactive ingredient. In some embodiments, the compounds described herein are administered as pharmaceutical compositions in which a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is mixed with other active ingredients, as in combination therapy. In other embodiments, the pharmaceutical compositions include other medicinal or pharmaceutical agents, carriers, adjuvants, preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, and/or buffers. In yet other embodiments, the pharmaceutical compositions include other therapeutically valuable substances.
[0346] A pharmaceutical composition, as used herein, refers to a mixture of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with other chemical components (i.e. pharmaceutically acceptable inactive ingredients), such as carriers, excipients, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combination thereof. The pharmaceutical composition facilitates administration of the compound to an organism. In practicing the methods of treatment or use provided herein, therapeutically effective amounts of compounds described herein are administered in a pharmaceutical composition to a mammal having a disease, disorder, or condition to be treated. In some embodiments, the mammal is a human. A therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. The compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.
[0347] The pharmaceutical formulations described herein are administered to a subject by appropriate administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes. The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
[0348] Pharmaceutical compositions including a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
[0349] The pharmaceutical compositions will include at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) as an active ingredient in free-acid or free-base form, or in a pharmaceutically acceptable salt form. In addition, the methods and pharmaceutical compositions described herein include the use of N-oxides (if appropriate), crystalline forms, amorphous phases, as well as active metabolites of these compounds having the same type of activity. In some
embodiments, compounds described herein exist in unsolvated form or in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the compounds presented herein are also considered to be disclosed herein.
[0350] In certain embodiments, compositions provided herein include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.
[0351] In some embodiments, formulations described herein benefit from antioxidants, metal chelating agents, thiol containing compounds and other general stabilizing agents. Examples of such stabilizing agents, include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02%) w/v polysorbate 80, (g) 0.001%) to about 0.05%o w/v. polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (1) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.
[0352] The pharmaceutical compositions described herein, which include a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are formulated into any suitable dosage form, including but not limited to, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations.
[0353] Pharmaceutical preparations for oral use are obtained by mixing one or more solid excipient with one or more of the compounds described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as:
polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. If desired, disintegrating agents are added, such as the cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. In some embodiments, dyestuffs or pigments are added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
[0354] Pharmaceutical preparations that are administered orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push- fit capsules contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In some embodiments, stabilizers are added.
[0355] All formulations for oral administration are in dosages suitable for such administration.
[0356] In one aspect, solid oral soage forms are prepared by mixing a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with one or more of the following: antioxidants, flavoring agents, and carrier materials such as binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents.
[0357] In some embodiments, the solid dosage forms disclosed herein are in the form of a tablet, (including a suspension tablet, a fast-melt tablet, a bite-disintegration tablet, a rapid-disintegration tablet, an effervescent tablet, or a caplet), a pill, a powder, a capsule, solid dispersion, solid solution, bioerodible dosage form, controlled release formulations, pulsatile release dosage forms,
multiparticulate dosage forms, beads, pellets, granules. In other embodiments, the pharmaceutical formulation is in the form of a powder. In still other embodiments, the pharmaceutical formulation is in the form of a tablet. In other embodiments, pharmaceutical formulations of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are in the form of a capsule.
[0358] In some embodiments, solid dosage forms, e.g., tablets, effervescent tablets, and capsules, are prepared by mixing particles of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with one or more pharmaceutical excipients to form a bulk blend composition. The bulk blend is readily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules. In some embodiments, the individual unit dosages include film coatings. These formulations are
manufactured by conventional formulation techniques.
[0359] Conventional formulation techniques include, e.g., one or a combination of methods: (1) dry mixing, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion. Other methods include, e.g., spray drying, pan coating, melt granulation, granulation, fluidized bed spray drying or coating (e.g., wurster coating), tangential coating, top spraying, tableting, extruding and the like.
[0360] Suitable carriers for use in the solid dosage forms described herein include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, sodium caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose, microcrystalline cellulose, lactose, mannitol and the like.
[0361] Suitable filling agents for use in the solid dosage forms described herein include, but are not limited to, lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starches, pregelatinized starch, hydroxypropylmethycellulose (HPMC), hydroxypropylmethycellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.
[0362] Suitable disintegrants for use in the solid dosage forms described herein include, but are not limited to, natural starch such as corn starch or potato starch, a pregelatinized starch, or sodium starch glycolate, a cellulose such as methylcrystalline cellulose, methylcellulose, microcrystalline cellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium
carboxymethylcellulose, cross-linked carboxymethylcellulose, or cross-linked croscarmellose, a cross-linked starch such as sodium starch glycolate, a cross-linked polymer such as crospovidone, a cross-linked polyvinylpyrrolidone, alginate such as alginic acid or a salt of alginic acid such as sodium alginate, a gum such as agar, guar, locust bean, Karaya, pectin, or tragacanth, sodium starch glycolate, bentonite, sodium lauryl sulfate, sodium lauryl sulfate in combination starch, and the like.
[0363] Binders impart cohesiveness to solid oral dosage form formulations: for powder filled capsule formulation, they aid in plug formation that can be filled into soft or hard shell capsules and for tablet formulation, they ensure the tablet remaining intact after compression and help assure blend uniformity prior to a compression or fill step. Materials suitable for use as binders in the solid dosage forms described herein include, but are not limited to, carboxymethylcellulose,
methylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, hydroxyethylcellulose, hydroxypropylcellulose, ethylcellulose, and microcrystalline cellulose, microcrystalline dextrose, amylose, magnesium aluminum silicate, polysaccharide acids, bentonites, gelatin, polyvinylpyrrolidone/vinyl acetate copolymer, crospovidone, povidone, starch,
pregelatinized starch, tragacanth, dextrin, a sugar, such as sucrose, glucose, dextrose, molasses, mannitol, sorbitol, xylitol, lactose, a natural or synthetic gum such as acacia, tragacanth, ghatti gum, mucilage of isapol husks, starch, polyvinylpyrrolidone, larch arabogalactan, polyethylene glycol, waxes, sodium alginate, and the like.
[0364] In general, binder levels of 20-70% are used in powder- filled gelatin capsule formulations. Binder usage level in tablet formulations varies whether direct compression, wet granulation, roller compaction, or usage of other excipients such as fillers which itself can act as moderate binder. Binder levels of up to 70% in tablet formulations is common.
[0365] Suitable lubricants or glidants for use in the solid dosage forms described herein include, but are not limited to, stearic acid, calcium hydroxide, talc, corn starch, sodium stearyl fumerate, alkali- metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc, stearic acid, sodium stearates, magnesium stearate, zinc stearate, waxes, Stearowet®, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol or a methoxypolyethylene glycol such as Carbowax™, PEG 4000, PEG 5000, PEG 6000, propylene glycol, sodium oleate, glyceryl behenate, glyceryl palmitostearate, glyceryl benzoate, magnesium or sodium lauryl sulfate, and the like.
[0366] Suitable diluents for use in the solid dosage forms described herein include, but are not limited to, sugars (including lactose, sucrose, and dextrose), polysaccharides (including dextrates and maltodextrin), polyols (including mannitol, xylitol, and sorbitol), cyclodextrins and the like.
[0367] Suitable wetting agents for use in the solid dosage forms described herein include, for example, oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate,
triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, quaternary ammonium compounds (e.g., Polyquat 10®), sodium oleate, sodium lauryl sulfate, magnesium stearate, sodium docusate, triacetin, vitamin E TPGS and the like.
[0368] Suitable surfactants for use in the solid dosage forms described herein include, for example, sodium lauryl sulfate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, polysorbates, polaxomers, bile salts, glyceryl monostearate, copolymers of ethylene oxide and propylene oxide, e.g., Pluronic® (BASF), and the like.
[0369] Suitable suspending agents for use in the solid dosage forms described here include, but are not limited to, polyvinylpyrrolidone, e.g., polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, polyethylene glycol, e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400, vinyl pyrrolidone/vinyl acetate copolymer (S630), sodium
carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, polysorbate-80, hydroxyethylcellulose, sodium alginate, gums, such as, e.g., gum tragacanth and gum acacia, guar gum, xanthans, including xanthan gum, sugars, cellulosics, such as, e.g., sodium
carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose,
hydroxypropylmethylcellulose, hydroxyethylcellulose, polysorbate-80, sodium alginate,
polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone and the like.
[0370] Suitable antioxidants for use in the solid dosage forms described herein include, for example, e.g., butylated hydroxytoluene (BHT), sodium ascorbate, and tocopherol.
[0371] It should be appreciated that there is considerable overlap between additives used in the solid dosage forms described herein. Thus, the above-listed additives should be taken as merely exemplary, and not limiting, of the types of additives that can be included in solid dosage forms of the pharmaceutical compositions described herein. The amounts of such additives can be readily determined by one skilled in the art, according to the particular properties desired.
[0372] Compressed tablets are solid dosage forms prepared by compacting the bulk blend of the formulations described above.
[0373] In various embodiments, tablets will include one or more flavoring agents. [0374] In other embodiments, the tablets will include a film surrounding the final compressed tablet. In some embodiments, the film coating can provide a delayed release of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) from the formulation. In other embodiments, the film coating aids in patient compliance (e.g., Opadry® coatings or sugar coating). Film coatings including Opadry® typically range from about 1% to about 3% of the tablet weight.
[0375] A capsule may be prepared, for example, by placing the bulk blend of the formulation of the compound described above, inside of a capsule. In some embodiments, the formulations (nonaqueous suspensions and solutions) are placed in a soft gelatin capsule. In other embodiments, the formulations are placed in standard gelatin capsules or non-gelatin capsules such as capsules comprising HPMC. In other embodiments, the formulation is placed in a sprinkle capsule, wherein the capsule is swallowed whole or the capsule is opened and the contents sprinkled on food prior to eating.
[0376] In various embodiments, the particles of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and one or more excipients are dry blended and compressed into a mass, such as a tablet, having a hardness sufficient to provide a pharmaceutical composition that substantially disintegrates within less than about 30 minutes, less than about 35 minutes, less than about 40 minutes, less than about 45 minutes, less than about 50 minutes, less than about 55 minutes, or less than about 60 minutes, after oral administration, thereby releasing the formulation into the gastrointestinal fluid.
[0377] In other embodiments, a powder including a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated to include one or more pharmaceutical excipients and flavors. Such a powder is prepared, for example, by mixing the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and optional pharmaceutical excipients to form a bulk blend composition. Additional embodiments also include a suspending agent and/or a wetting agent. This bulk blend is uniformly subdivided into unit dosage packaging or multi-dosage packaging units.
[0378] In still other embodiments, effervescent powders are also prepared. Effervescent salts have been used to disperse medicines in water for oral administration.
[0379] In some embodiments, the pharmaceutical solid oral dosage forms are formulated to provide a controlled release of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII). Controlled release refers to the release of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) from a dosage form in which it is incorporated according to a desired profile over an extended period of time. Controlled release profiles include, for example, sustained release, prolonged release, pulsatile release, and delayed release profiles. In contrast to immediate release compositions, controlled release compositions allow delivery of an agent to a subject over an extended period of time according to a predetermined profile. Such release rates can provide therapeutically effective levels of agent for an extended period of time and thereby provide a longer period of pharmacologic response while minimizing side effects as compared to conventional rapid release dosage forms. Such longer periods of response provide for many inherent benefits that are not achieved with the corresponding short acting, immediate release preparations.
[0380] In some embodiments, the solid dosage forms described herein are formulated as enteric coated delayed release oral dosage forms, i.e., as an oral dosage form of a pharmaceutical composition as described herein which utilizes an enteric coating to affect release in the small intestine or large intestine. In one aspect, the enteric coated dosage form is a compressed or molded or extruded tablet/mold (coated or uncoated) containing granules, powder, pellets, beads or particles of the active ingredient and/or other composition components, which are themselves coated or uncoated. In one aspect, the enteric coated oral dosage form is in the form of a capsule containing pellets, beads or granules, which include a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII), that are coated or uncoated.
[0381] Any coatings should be applied to a sufficient thickness such that the entire coating does not dissolve in the gastrointestinal fluids at pH below about 5, but does dissolve at pH about 5 and above. Coatings are typically selected from any of the following:
[0382] Shellac - this coating dissolves in media of pH >7; Acrylic polymers - examples of suitable acrylic polymers include methacrylic acid copolymers and ammonium methacrylate copolymers. The Eudragit series E, L, S, RL, RS and NE (Rohm Pharma) are available as solubilized in organic solvent, aqueous dispersion, or dry powders. The Eudragit series RL, NE, and RS are insoluble in the gastrointestinal tract but are permeable and are used primarily for colonic targeting. The Eudragit series E dissolve in the stomach. The Eudragit series L, L-30D and S are insoluble in stomach and dissolve in the intestine; Poly Vinyl Acetate Phthalate (PVAP) - PVAP dissolves in pH >5, and it is much less permeable to water vapor and gastric fluids.
[0383] Conventional coating techniques such as spray or pan coating are employed to apply coatings. The coating thickness must be sufficient to ensure that the oral dosage form remains intact until the desired site of topical delivery in the intestinal tract is reached.
[0384] In other embodiments, the formulations described herein are delivered using a pulsatile dosage form. A pulsatile dosage form is capable of providing one or more immediate release pulses at predetermined time points after a controlled lag time or at specific sites. Exemplary pulsatile dosage forms and methods of their manufacture are disclosed in U.S. Pat. Nos. 5,011,692, 5,017,381, 5,229,135, 5,840,329 and 5,837,284. In one embodiment, the pulsatile dosage form includes at least two groups of particles, (i.e. multiparticulate) each containing the formulation described herein. The first group of particles provides a substantially immediate dose of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) upon ingestion by a mammal. The first group of particles can be either uncoated or include a coating and/or sealant. In one aspect, the second group of particles comprises coated particles. The coating on the second group of particles provides a delay of from about 2 hours to about 7 hours following ingestion before release of the second dose. Suitable coatings for pharmaceutical compositions are described herein or known in the art.
[0385] In some embodiments, pharmaceutical formulations are provided that include particles of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and at least one dispersing agent or suspending agent for oral administration to a subject. The formulations may be a powder and/or granules for suspension, and upon admixture with water, a substantially uniform suspension is obtained.
[0386] In one aspect, liquid formulation dosage forms for oral administration are in the form of aqueous suspensions selected from the group including, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups. See, e.g., Singh et al.., Encyclopedia of Pharmaceutical Technology, 2nd Ed., pp. 754-757 (2002). In addition to the particles of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII), the liquid dosage forms include additives, such as: (a) disintegrating agents; (b) dispersing agents; (c) wetting agents; (d) at least one preservative, (e) viscosity enhancing agents, (f) at least one sweetening agent, and (g) at least one flavoring agent. In some embodiments, the aqueous dispersions can further include a crystalline inhibitor.
[0387] Furthermore, pharmaceutical compositions optionally include one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.
[0388] Additionally, pharmaceutical compositions optionally include one or more salts in an amount required to bring osmolality of the composition into an acceptable range. Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.
[0389] Other pharmaceutical compositions optionally include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.
[0390] In one embodiment, the aqueous suspensions and dispersions described herein remain in a homogenous state, as defined in The USP Pharmacists' Pharmacopeia (2005 edition, chapter 905), for at least 4 hours. In one embodiment, an aqueous suspension is re-suspended into a homogenous suspension by physical agitation lasting less than 1 minute. In still another embodiment, no agitation is necessary to maintain a homogeneous aqueous dispersion. [0391] Examples of disintegrating agents for use in the aqueous suspensions and dispersions include, but are not limited to, a starch, e.g., a natural starch such as corn starch or potato starch, a
pregelatinized starch, or sodium starch glycolate; a cellulose such as methylcrystalline cellulose, methylcellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium
carboxymethylcellulose, cross-linked carboxymethylcellulose, or cross-linked croscarmellose; a cross-linked starch such as sodium starch glycolate; a cross-linked polymer such as crospovidone; a cross-linked polyvinylpyrrolidone; alginate such as alginic acid or a salt of alginic acid such as sodium alginate; a gum such as agar, guar, locust bean, Karaya, pectin, or tragacanth; sodium starch glycolate; bentonite; a natural sponge; a surfactant; a resin such as a cation-exchange resin; citrus pulp; sodium lauryl sulfate; sodium lauryl sulfate in combination starch; and the like.
[0392] In some embodiments, the dispersing agents suitable for the aqueous suspensions and dispersions described herein include, for example, hydrophilic polymers, electrolytes, Tween ® 60 or 80, PEG, polyvinylpyrrolidone, and the carbohydrate-based dispersing agents such as, for example, hydroxypropylcellulose and hydroxypropyl cellulose ethers, hydroxypropyl methylcellulose and hydroxypropyl methylcellulose ethers, carboxymethylcellulose sodium, methylcellulose,
hydroxyethylcellulose, hydroxypropylmethyl-cellulose phthalate, hydroxypropylmethyl-cellulose acetate stearate, noncrystalline cellulose, magnesium aluminum silicate, tnethanolamine, polyvinyl alcohol (PVA), polyvinylpyrrolidone/vinyl acetate copolymer, 4-(l,l,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers; and poloxamines. In other embodiments, the dispersing agent is selected from a group not comprising one of the following agents: hydrophilic polymers; electrolytes; Tween® 60 or 80; PEG;
polyvinylpyrrolidone (PVP); hydroxypropylcellulose and hydroxypropyl cellulose ethers;
hydroxypropyl methylcellulose and hydroxypropyl methylcellulose ethers; carboxymethylcellulose sodium; methylcellulose; hydroxyethylcellulose; hydroxypropylmethyl-cellulose phthalate;
hydroxypropylmethyl-cellulose acetate stearate; non-crystalline cellulose; magnesium aluminum silicate; triethanolamine; polyvinyl alcohol (PVA); 4-(l,l,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde; poloxamers; or poloxamines.
[0393] Wetting agents suitable for the aqueous suspensions and dispersions described herein include, but are not limited to, cetyl alcohol, glycerol monostearate, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens® such as e.g., Tween 20® and Tween 80®, and polyethylene glycols, oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium oleate, sodium lauryl sulfate, sodium docusate, triacetin, vitamin E TPGS, sodium
taurocholate, simethicone, phosphotidylcholine and the like
[0394] Suitable preservatives for the aqueous suspensions or dispersions described herein include, for example, potassium sorbate, parabens (e.g., methylparaben and propylparaben), benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl alcohol or benzyl alcohol, phenolic compounds such as phenol, or quaternary compounds such as
benzalkonium chloride. Preservatives, as used herein, are incorporated into the dosage form at a concentration sufficient to inhibit microbial growth.
[0395] Suitable viscosity enhancing agents for the aqueous suspensions or dispersions described herein include, but are not limited to, methyl cellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, Plasdon® S-630, carbomer, polyvinyl alcohol, alginates, acacia, chitosans and combinations thereof. The concentration of the viscosity enhancing agent will depend upon the agent selected and the viscosity desired.
[0396] Examples of sweetening agents suitable for the aqueous suspensions or dispersions described herein include, for example, acacia syrup, acesulfame K, alitame, aspartame, chocolate, cinnamon, citrus, cocoa, cyclamate, dextrose, fructose, ginger, glycyrrhetinate, glycyrrhiza (licorice) syrup, monoammonium glyrrhizinate (MagnaSweet®), maltol, mannitol, menthol, neohesperidine DC, neotame, Prosweet® Powder, saccharin, sorbitol, stevia, sucralose, sucrose, sodium saccharin, saccharin, aspartame, acesulfame potassium, mannitol, sucralose, tagatose, thaumatin, vanilla, xylitol, or any combination thereof.
[0397] In some embodiments, the liquid formulations also include inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers. Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1 ,3-butyleneglycol, dimethylformamide, sodium lauryl sulfate, sodium doccusate, cholesterol, cholesterol esters, taurocholic acid, phosphotidylcholine, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
[0398] Representative intranasal formulations are described in, for example, U.S. Pat. Nos.
4,476,1 16, 5,1 16,817 and 6,391 ,452. Formulations that include a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. See, for example, Ansel, H. C. et ah, Pharmaceutical Dosage Forms and Drug Delivery Systems, Sixth Ed. (1995). Preferably these compositions and formulations are prepared with suitable nontoxic pharmaceutically acceptable ingredients. These ingredients are known to those skilled in the preparation of nasal dosage forms and some of these can be found in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, 21st edition, 2005. The choice of suitable carriers is dependent upon the exact nature of the nasal dosage form desired, e.g., solutions, suspensions, ointments, or gels. Nasal dosage forms generally contain large amounts of water in addition to the active ingredient. Minor amounts of other ingredients such as pH adjusters, emulsifiers or dispersing agents, preservatives, surfactants, gelling agents, or buffering and other stabilizing and solubilizing agents are optionally present. Preferably, the nasal dosage form should be isotonic with nasal secretions.
[0399] For administration by inhalation, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated for use as an aerosol, a mist or a powder. Pharmaceutical compositions described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane,
tnchlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound described herein and a suitable powder base such as lactose or starch.
[0400] Buccal formulations that include a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) are administered using a variety of formulations known in the art. For example, such formulations include, but are not limited to, U.S. Pat. Nos. 4,229,447, 4,596,795, 4,755,386, and 5,739,136. In addition, the buccal dosage forms described herein can further include a bioerodible
(hydrolysable) polymeric carrier that also serves to adhere the dosage form to the buccal mucosa. For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, or gels formulated in a conventional manner.
[0401] In some embodiments, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is prepared as transdermal dosage forms. In one embodiments, the transdermal formulations described herein include at least three components: (1) a formulation of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII); (2) a penetration enhancer; and (3) an aqueous adjuvant. In some embodiments the transdermal formulations include additional components such as, but not limited to, gelling agents, creams and ointment bases, and the like. In some embodiments, the transdermal formulation further include a woven or non-woven backing material to enhance absorption and prevent the removal of the transdermal formulation from the skin. In other embodiments, the transdermal formulations described herein can maintain a saturated or supersaturated state to promote diffusion into the skin.
[0402] In one aspect, formulations suitable for transdermal administration of compounds described herein employ transdermal delivery devices and transdermal delivery patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive. In one aspect, such patches are constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. Still further, transdermal delivery of the compounds described herein can be accomplished by means of iontophoretic patches and the like. In one aspect, transdermal patches provide controlled delivery of the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII). In one aspect, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
[0403] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated into a pharmaceutical composition suitable for intramuscular, subcutaneous, or intravenous injection. In one aspect, formulations suitable for intramuscular, subcutaneous, or intravenous injection include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, cremophor and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. In some embodiments, formulations suitable for subcutaneous injection also contain additives such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. In some cases it is desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
[0404] For intravenous injections, compounds described herein are formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. For other parenteral injections, appropriate formulations include aqueous or nonaqueous solutions, preferably with physiologically compatible buffers or excipients. Such excipients are known.
[0405] Parenteral injections may involve bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The pharmaceutical composition described herein may be in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. In one aspect, the active ingredient is in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0406] In certain embodiments, delivery systems for pharmaceutical compounds may be employed, such as, for example, liposomes and emulsions. In certain embodiments, compositions provided herein can also include an mucoadhesive polymer, selected from among, for example, carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.
[0407] In some embodiments, the compounds described herein may be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments. Such pharmaceutical compounds can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
[0408] In some embodiments, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, and the like. In suppository forms of the compositions, a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.
Methods of Dosing and Treatment Regimens
[0409] In one embodiment, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is used in the preparation of medicaments for the treatment of LPA-dependent or LPA-mediated diseases or conditions. In addition, a method for treating any of the diseases or conditions described herein in a subject in need of such treatment, involves administration of pharmaceutical compositions that include at least one compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) or a
pharmaceutically acceptable salt, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, in therapeutically effective amounts to said subject.
[0410] In certain embodiments, the compositions containing the compound(s) described herein are administered for prophylactic and/or therapeutic treatments. In certain therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest at least one of the symptoms of the disease or condition. Amounts effective for this use depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician. Therapeutically effective amounts are optionally determined by methods including, but not limited to, a dose escalation clinical trial.
[0411] In prophylactic applications, compositions containing the compounds described herein are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder or condition. Such an amount is defined to be a "prophylactically effective amount or dose." In this use, the precise amounts also depend on the patient's state of health, weight, and the like. When used in a patient, effective amounts for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician. In one aspect, prophylactic treatments include admistering to a mammal, who previously experienced at least one symtom of the disease being treated and is currently in remission, a pharmaceutical composition comprising a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in order to prevent a return of the symptoms of the disease or condition.
[0412] In certain embodiments wherein the patient's condition does not improve, upon the doctor's discretion the administration of the compounds are administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.
[0413] In certain embodiments wherein a patient's status does improve, the dose of drug being administered may be temporarily reduced or temporarily suspended for a certain length of time {i.e., a "drug holiday"). In specific embodiments, the length of the drug holiday is between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, or more than 28 days. The dose reduction during a drug holiday is, by way of example only, by 10%- 100%, including by way of example only 10%), 15%, 20%), 25%o, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.
[0414] In certain embodiments in which the patient is presented with a situation in which the activity of LPA needs to be enhanced, for example, to assist with wound healing, the dose of drug being administered may be temporarily reduced or temporarily suspended for a certain length of time {i.e., a "drug diversion"). In specific embodiments, the length of the drug diversion is between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, or more than 28 days. The dose reduction during a drug diversion is, by way of example only, by 10%o-100%), including by way of example only 10%), 15%), 20%), 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%. Once the situation requiring enhanced activity of LPA is alleviated, the normal dosing schedule is optionally reinstated.
[0415] Once improvement of the patient's conditions has occurred, a maintenance dose is administered if necessary. Subsequently, in specific embodiments, the dosage or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In certain embodiments, however, the patient requires intermittent treatment on a long-term basis upon any recurrence of symptoms.
[0416] The amount of a given agent that corresponds to such an amount varies depending upon factors such as the particular compound, disease condition and its severity, the identity {e.g., weight, sex) of the subject or host in need of treatment, but can nevertheless be determined according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, the condition being treated, and the subject or host being treated. In general, however, doses employed for adult human treatment are typically in the range of O.Olmg- 5000 mg per day. In one aspect, doses employed for adult human treatment are from about lmg to about 1000 mg per day. In one embodiment, the desired dose is conveniently presented in a single dose or in divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub-doses per day.
[0417] In one embodiment, the daily dosages appropriate for the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) described herein are from about 0.01 to about 10 mg/kg per body weight. In specific embodiments, an indicated daily dosage in a large mammal, including, but not limited to, humans, is in the range from about 0.5 mg to about 1000 mg, conveniently administered in divided doses, including, but not limited to, up to four times a day. In one embodiment, the daily dosage is administered in extended release form. In certain embodiments, suitable unit dosage forms for oral administration comprise from about 1 to 500 mg active ingredient. In other embodiments, the daily dosage or the amount of active in the dosage form are lower or higher than the ranges indicated herein, based on a number of variables in regard to an individual treatment regime. In various embodiments, the daily and unit dosages are altered depending on a number of variables including, but not limited to, the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.
[0418] Toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LD50 and the ED50. The dose ratio between the toxic and therapeutic effects is the therapeutic index and it is expressed as the ratio between LD50 and ED50. In certain embodiments, the data obtained from cell culture assays and animal studies are used in formulating the
therapeutically effective daily dosage range and/or the therapeutically effective unit dosage amount for use in mammals, including humans. In some embodiments, the daily dosage amount of the compounds described herein lies within a range of circulating concentrations that include the ED50 with minimal toxicity. In certain embodiments, the daily dosage range and/or the unit dosage amount varies within this range depending upon the dosage form employed and the route of administration utilized.
Patient Selection
[0419] In any of the aforementioned aspects involving the prevention or treatment of LPA-mediated diseases or conditions are further embodiments comprising identifying patients by screening for LPA receptor gene SNPs. A SNP located in the promoter region of LPAx showed significant association with knee osteoarthritis in two independent populations (Mototani et al. Hum. Mol. Genetics, vol. 17, no. 12, 2008). Patients can be further selected based on increased LPA receptor expression in the tissue of interest. For example, chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD19+/CD5+ B -lymphocytes in the peripheral blood, bone marrow and lymphoid organs which occurs as a result of a block in B-lymphocyte apoptosis. LPA can protect some CLL cells from apoptosis and the cells that are protected by LPA have high levels of LPAi mRNA. In some embodiments, CLL patients are selected based on the expression of the LPA1R. LPA receptor expression are determined by methods including, but not limited to, northern blotting, western blotting, quantitative PCR (qPCR), flow cytometry, autoradiography (using a small molecule radioligand or PET ligand). In some embodiments, patients are selected based on the concentration of serum or tissue LPA measured by mass spectrometry. LPA concentrations are high in ovarian cancer ascites and in some breast cancer effusions. In some embodiments, patients are selected based on a combination of the above markers (increased LPA concentrations and increased LPA receptor expression).
Combination Treatments
[0420] In certain instances, it is appropriate to administer at least one compound of Formula (I), (II),
(III) , (IV), (V), (VI), or (VII) in combination with another therapeutic agent. By way of example only, if one of the side effects experienced by a patient upon receiving one of the compounds herein is inflammation, then it may be appropriate to administer an anti-inflammatory agent in combination with the initial therapeutic agent. Or in another example, a patient is presented with a situation in which antagonism of LPA receptors provides potential harm, for example, if the patient is wounded, antagonism of LPA receptors may lead to a delay in wound healing. In such an event, in certain embodiments, the patient benefits by administration of a local wound-healing agent (at the site of the wound) in combination with the co-existing administration of a compound of Formula (I), (II), (III),
(IV) , (V), (VI), or (VII).
[0421] Or, in one embodiment, the therapeutic effectiveness of one of the compounds described herein is enhanced by administration of an adjuvant {i.e., by itself the adjuvant may have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced). Or, in some embodiments, the benefit experienced by a patient is increased by administering one of the compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
[0422] In one specific embodiment, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is co-administered with a second therapeutic agent, wherein the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and the second therapeutic agent modulate different aspects of the disease, disorder or condition being treated, thereby providing a greater overall benefit than administration of either therapeutic agent alone.
[0423] In any case, regardless of the disease, disorder or condition being treated, the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit. [0424] In certain embodiments, different therapeutically-effective dosages of the compounds disclosed herein will be utilized in formulating pharmaceutical composition and/or in treatment regimens when the compounds disclosed herein are administered in combination with one or more additional agent, such as an additional therapeutically effective drug, an adjuvant or the like.
Therapeutically-effective dosages of drugs and other agents for use in combination treatment regimens can be determined by means similar to those set forth hereinabove for the actives themselves. Furthermore, the methods of prevention/treatment described herein encompasses the use of metronomic dosing, i.e., providing more frequent, lower doses in order to minimize toxic side effects. In some embodiments, a combination treatment regimen encompasses treatment regimens in which administration of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is initiated prior to, during, or after treatment with a second agent described herein, and continues until any time during treatment with the second agent or after termination of treatment with the second agent. It also includes treatments in which a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and the second agent being used in combination are administered simultaneously or at different times and/or at decreasing or increasing intervals during the treatment period. Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical
management of the patient.
[0425] Compositions and methods for combination therapy are provided herein. In accordance with one aspect, the pharmaceutical compositions disclosed herein are used to treat LPA-dependent or LPA-mediated conditions.
[0426] It is understood that the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought, is modified in accordance with a variety of factors. These factors include the disease, disorder or condition from which the subject suffers, as well as the age, weight, sex, diet, and medical condition of the subject. Thus, in some instances, the dosage regimen actually employed varies and, in some embodiments, deviates from the dosage regimens set forth herein.
[0427] For combination therapies described herein, dosages of the co-administered compounds vary depending on the type of co-drug employed, on the specific drug employed, on the disease or condition being treated and so forth. In additional embodiments, when co-administered with one or more other therapeutic agents, the compound provided herein is administered either simultaneously with the one or more other therapeutic agents, or sequentially.
[0428] In combination therapies, the multiple therapeutic agents (one of which is one of the compounds described herein) are administered in any order or even simultaneously. If administration is simultaneous, the multiple therapeutic agents are, by way of example only, provided in a single, unified form, or in multiple forms (e.g., as a single pill or as two separate pills). In one embodiment, one of the therapeutic agents is given in multiple doses, and in another, two (or more if present) are given as multiple doses. In some embodiments of non-simultaneous administration, the timing between the multiple doses vary from more than zero weeks to less than four weeks. In addition, the combination methods, compositions and formulations are not to be limited to the use of only two agents; the use of multiple therapeutic combinations is also envisioned.
[0429] A compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) and combination therapies are administered before, during or after the occurrence of a disease or condition, and the timing of administering the composition containing a compound varies. Thus, in one embodiment, the compounds described herein are used as a prophylactic and are administered continuously to subjects with a propensity to develop conditions or diseases in order to prevent the occurrence of the disease or condition. In another embodiment, the compounds and compositions are administered to a subject during or as soon as possible after the onset of the symptoms. In specific embodiments, a compound described herein is administered as soon as is practicable after the onset of a disease or condition is detected or suspected, and for a length of time necessary for the treatment of the disease. In some embodiments, the length required for treatment varies, and the treatment length is adjusted to suit the specific needs of each subject. For example, in specific embodiments, a compound described herein or a formulation containing the compound is administered for at least 2 weeks, about 1 month to about 5 years.
[0430] By way of example, therapies which combine a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with inhibitors of LP A synthesis or LPA receptor antagonists, either acting at the same or other points in the LPA synthesis or signalling pathway, are encompassed herein for treating LPA-dependent or LPA-mediated diseases or conditions.
Exemplary Agents for use in Combination
[0431] In another embodiment described herein, methods for treatment of LPA-dependent or LPA- mediated conditions or diseases, such as proliferative disorders, including cancer, comprises administration to a mammal a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) in combination with at least one additional agent selected, by way of example only, alemtuzumab, arsenic trioxide, asparaginase (pegylated or non-), bevacizumab, cetuximab, platinum-based compounds such as cisplatin, cladribine, daunorubicin/doxorubicin/idarubicin, irinotecan, fludarabine, 5-fluorouracil, gemtuzumab, methotrexate, Paclitaxel™, taxol, temozolomide, thioguanine, or classes of drugs including hormones (an antiestrogen, an antiandrogen, or gonadotropin releasing hormone analogues, interferons such as alpha interferon, nitrogen mustards such as busulfan or melphalan or mechlorethamine, retinoids such as tretinoin, topoisomerase inhibitors such as irinotecan or topotecan, tyrosine kinase inhibitors such as gefinitinib or imatinib, or agents to treat signs or symptoms induced by such therapy including allopurinol, filgrastim, granisetron/ ondansetron/palonosetron, dronabinol.
[0432] In one aspect, the compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is
administered or formulated in combination with one or more anti-cancer agents. In some embodiments, one or more of the anti-cancer agents are proapoptotic agents. Examples of anti-cancer agents include, but are not limited to, any of the following: gossypol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis- inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib, geldanamycin, 17-N-Allylamino- 17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, or
PD 184352, Taxol™ (paclitaxel), and analogs of Taxol™, such as Taxotere™. Compounds that have the basic taxane skeleton as a common structure feature, have also been shown to have the ability to arrest cells in the G2-M phases due to stabilized microtubules and may be useful for treating cancer in combination with the compounds described herein.
[0433] Further examples of anti-cancer agents for use in combination with a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) include inhibitors of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; mTOR inhibitors; and antibodies (e.g., rituxan).
[0434] Other anti-cancer agents for use in combination with a compound of Formula (I), (II), (III),
(IV), (V), (VI), or (VII) include one or more of the following: Adriamycin, Dactinomycin,
Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine;
adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide;
amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin;
batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine;
daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate;
diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate;
dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin;
enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin II (including recombinant interleukin II, or rlL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl; interferon alfa-n3; interferon beta-1 a; interferon gamma-1 b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride;
masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopunne; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane;
mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine;
rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium;
sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin;
teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole;
zeniplatin; zinostatin; zorubicin hydrochloride.
[0435] Yet other anticancer agents for use in combination with a compound of Formula (I), (II),
(III), (IV), (V), (VI), or (VII) include alkylating agents, antimetabolites, natural products, or hormones, e.g., nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, ete.), or triazenes
(decarbazine, etc.). Examples of antimetabolites include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g., mercaptopunne, thioguanine, pentostatin).
[0436] Examples of natural products for use in combination with a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) include but are not limited to vinca alkaloids (e.g., vinblastin, vincristine), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon alpha).
[0437] Examples of alkylating agents for use in combination with a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) include, but are not limited to, nitrogen mustards (e.g.,
mechloroethamine, cyclophosphamide, chlorambucil, meiphalan, etc.), ethylenimine and
methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes (decarbazine, ete.). Examples of antimetabolites include, but are not limited to folic acid analog (e.g.,
methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin.
[0438] Examples of hormones and antagonists for use in combination with a compound of Formula
(I), (II), (III), (IV), (V), (VI), or (VII) include, but are not limited to, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate,
medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., fiutamide), gonadotropin releasing hormone analog (e.g., leuprolide). Other agents that can be used in the methods and compositions described herein for the treatment or prevention of cancer include platinum coordination complexes (e.g., cisplatin, carboblatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide).
[0439] Examples of anti-cancer agents which act by arresting cells in the G2-M phases due to stabilized microtubules include without limitation the following marketed drugs and drugs in development: Erbulozole, Dolastatin 10, Mivobulin isethionate, Vincristine, NSC-639829,
Discodermolide, ABT-751, Altorhyrtins (such as Altorhyrtin A and Altorhyrtin C), Spongistatins (such as Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride, Epothilones (such as Epothilone A, Epothilone B, Epothilone C, Epothilone D, Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B, 21- hydroxyepothilone D, 26-fluoroepothilone, Auristatin PE, Soblidotin, Vincristine sulfate,
Cryptophycin 52, Vitilevuamide, Tubulysin A, Canadensol, Centaureidin, Oncocidin Al Fijianolide B, Laulimalide, Narcosine, Nascapine, Hemiasterlin, Vanadocene acetylacetonate, Indanocine Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, lsoeleutherobin A, and Z- Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, Diazonamide A, Taccalonolide A, Diozostatin, (-)-Phenylahistin, Myoseverin B, Resverastatin phosphate sodium.
[0440] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is coadministered with thrombolytic agents (e.g., alteplase anistreplase, streptokinase, urokinase, or tissue plasminogen activator), heparin, tinzaparin, warfarin, dabigatran (e.g., dabigatran etexilate), factor Xa inhibitors (e.g., fondaparinux, draparinux, rivaroxaban, DX-9065a, otamixaban, LY517717, or YM150), ticlopidine, clopidogrel, CS-747 (prasugrel, LY640315), ximelagatran, or BIBR 1048. Immunosuppresants
[0441] In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is to treat or reduce fibrosis in a mammal. In one aspect, a compound of Formula (I), (II), (III), (IV), (V), (VI), or
(VII) is administered in combination with one or more immunosuppresants. Immunosuppressive therapy is clinically used to treat or prevent the rejection of transplanted organs and tissues (e.g. bone marrow, heart, kidney, liver); treatment of autoimmune diseases or diseases that are most likely of autoimmune origin (e.g. rheumatoid arthritis, myasthenia gravis, systemic lupus erythematosus, Crohn's disease, and ulcerative colitis); and treatment of some other non-autoimmune inflammatory diseases (e.g. long term allergic asthma control), and in the treatment of fibrotic conditions. [0442] In some embodiments, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is adminsitered with corticosteroids. In some embodiments, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is adminsitered with an a therapeutic agent selected from among: Calcineurin inhibitors (such as, but not limited to, cyclosporin, tacrolimus); mTOR inhibitors (such as, but not limited to, sirolimus, everolimus); anti-proliferatives (such as, but not limited to, azathioprine, mycophenolic acid); corticosteroids (such as, but not limited to, prednisone, cortisone acetate, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone, hydrocortisone); antibodies (such as, but not limited to, monoclonal anti-IL-2Ra receptor antibodies (basiliximab, daclizumab), polyclonal anti-T-cell antibodies (anti-thymocyte globulin (ATG), anti-lymphocyte globulin (ALG)), B-cell antagonists, rituximab, natalizumab.
[0443] Other therapeutic agents include, but are not limited to: cyclophosphamide, penicillamine, cyclosporine, nitrosoureas, cisplatin, carboplatin, oxaliplatin, methotrexate, azathioprine, mercaptopurine, pyrimidine analogues, protein synthesis inhibitors, dactinomycin, anthracyclines, mitomycin C, bleomycin, mithramycin, Atgarr R), Thymoglobuline®, OKT3®, basiliximab, daclizumab, cyclosporin, tacrolimus, sirolimus, Interferons (IFN-β, IFN-γ), opioids, TNF binding proteins (infliximab, etanercept, adalimumab, golimumab), leflunomide, gold thioglucose, gold thiomalate, aurofin, sulfasalazine, hydroxychloroquinine, minocycline, rapamicin, mycophenolic acid, mycophenolate mofetil, FTY720, as well as those listed in US 7,060,697.
[0444] In one embodiment, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered in combination with Cyclosporin A (CsA) or tacrolimus (FK506). In one embodiment, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered to a mammal in combination with an anti-inflammatory agent including, but not limited to, non-steroidal antiinflammatory drugs (NSAIDs) and corticosteroids (glucocorticoids).
[0445] NSAIDs include, but are not limited to: aspirin, salicylic acid, gentisic acid, choline magnesium salicylate, choline salicylate, choline magnesium salicylate, choline salicylate, magnesium salicylate, sodium salicylate, diflunisal, carprofen, fenoprofen, fenoprofen calcium, flurobiprofen, ibuprofen, ketoprofen, nabutone, ketolorac, ketorolac tromethamine, naproxen, oxaprozin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, meclofenamate, meclofenamate sodium, mefenamic acid, piroxicam, meloxicam, COX-2 specific inhibitors (such as, but not limited to, celecoxib, rofecoxib, valdecoxib, parecoxib, etoricoxib, lumiracoxib, CS-502, JTE-522, L- 745,337 and NS398).
[0446] Corticosteroids, include, but are not limited to: betamethasone, prednisone, alclometasone, aldosterone, amcinonide, beclometasone, betamethasone, budesonide, ciclesonide, clobetasol, clobetasone, clocortolone, cloprednol, cortisone, cortivazol, deflazacort, deoxycorticosterone, desonide, desoximetasone, desoxycortone, dexamethasone, diflorasone, diflucortolone, difluprednate, fluclorolone, fludrocortisone, fludroxycortide, flumetasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin, fluocortolone, fluorometholone, fluperolone, fluprednidene, fluticasone, formocortal, halcinonide, halometasone, hydrocortisone/cortisol, hydrocortisone aceponate, hydrocortisone buteprate, hydrocortisone butyrate, loteprednol, medrysone,
meprednisone, methylprednisolone, methylprednisolone aceponate, mometasone furoate, paramethasone, prednicarbate, prednisone/prednisolone, rimexolone, tixocortol, triamcinolone, and ulobetasol.
[0447] In one embodiment, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered in combination with leukotriene receptor antagonists including, but are not limited to, BAY u9773 (see EP 00791576; published 27 Aug 1997), DUO-LT (Tsuji et al, Org. Biomol. Chem., 1, 3139-3141, 2003), zafirlukast, montelukast, prankulast, and derivatives or analogs thereof.
Other Combination Therapies
[0448] In another embodiment described herein, methods for treatment of LPA-dependent or LPA- mediated conditions or diseases, such as atherosclerosis, comprises administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one additional agent selected, by way of example only, HMG-CoA reductase inhibitors (e.g., statins in their lactonized or dihydroxy open acid forms and pharmaceutically acceptable salts and esters thereof, including but not limited to lovastatin; simvastatin; dihydroxy open-acid simvastatin, particularly the ammonium or calcium salts thereof; pravastatin, particularly the sodium salt thereof; fluvastatin, particularly the sodium salt thereof; atorvastatin, particularly the calcium salt thereof; nisvastatin, also referred to as NK-104; rosuvastatin); agents that have both lipid-altering effects and other pharmaceutical activities; HMG-CoA synthase inhibitors; cholesterol absorption inhibitors such as ezetimibe; cholesterol ester transfer protein (CETP) inhibitors, for example JTT-705 and CP529, 414; squalene epoxidase inhibitors; squalene synthetase inhibitors (also known as squalene synthase inhibitors); acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitors including selective inhibitors of ACAT- 1 or ACAT-2 as well as dual inhibitors of ACAT- 1 and-2; microsomal triglyceride transfer protein (MTP) inhibitors; probucol; niacin; bile acid sequestrants; LDL (low density lipoprotein) receptor inducers; platelet aggregation inhibitors, for example glycoprotein Ilb/IIIa fibrinogen receptor antagonists and aspirin; human peroxisome proliferator activated receptor gamma (PPARy) agonists, including the compounds commonly referred to as glitazones, for example troglitazone, pioglitazone and rosiglitazone and including those compounds included within the structural class known as thiazolidinediones as well as those PPARy agonists outside the
thiazolidinedione structural class; PPARa agonists such as clofibrate, fenofibrate including micronized fenofibrate, and gemfibrozil ; PPAR dual α/γ agonists such as 5-[(2, 4-dioxo-5- thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]-benzamide, known as KRP-
297; vitamin B6 (also known as pyridoxine) and the pharmaceutically acceptable salts thereof such as the HC1 salt; vitamin B 12 (also known as cyanocobalamin); folic acid or a pharmaceutically acceptable salt or ester thereof such as the sodium salt and the methylglucamine salt; anti-oxidant vitamins such as vitamin C and E and beta carotene; beta-blockers; angiotensin II antagonists such as losartan; angiotensin converting enzyme inhibitors such as enalapril and captopril ; calcium channel blockers such as nifedipine and diltiazam; endothelian antagonists; agents that enhance ABC1 gene expression; FXR and LXR ligands including both inhibitors and agonists; bisphosphonate compounds such as alendronate sodium; and cyclooxygenase-2 inhibitors such as rofecoxib and celecoxib.
[0449] In another embodiment described herein, methods for treatment of LPA-dependent or LPA- mediated conditions or diseases, such as the therapy of stroke, comprises administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one additional agent selected from, by way of example only, COX-2 inhibitors; nitric oxide synthase inhibitors, such as N-(3-(aminomethyl)benzyl) acetamidine; Rho kinase inhibitors, such as fasudil; angiotension II type-1 receptor antagonists, including candesartan, losartan, irbesartan, eprosartan, telmisartan and valsartan; glycogen synthase kinase 3 inhibitors; sodium or calcium channel blockers, including crobenetine; p38 MAP kinase inhibitors, including SKB 239063;
thromboxane AX- synthetase inhibitors, including isbogrel, ozagrel, ridogrel and dazoxiben; statins (HMG CoA reductase inhibitors), including lovastatin, simvastatin, dihydroxy open-acid simvastatin, pravastatin, fluvastatin, atorvastatin, nisvastatin, and rosuvastatin; neuroprotectants, including free radical scavengers, calcium channel blockers, excitatory amino acid antagonists, growth factors, antioxidants, such as edaravone, vitamin C, TROLOX™, citicoline and minicycline, and reactive astrocyte inhibitors, such as (2R)-2-propyloctanoic acid; beta andrenergic blockers, such as propranolol, nadolol, timolol, pindolol, labetalol, metoprolol, atenolol, esmolol and acebutolol;
NMDA receptor antagonists, including memantine; NR2B antagonists, such as traxoprodil; 5-HT1A agonists; receptor platelet fibrinogen receptor antagonists, including tirofiban and lamifiban;
thrombin inhibitors; antithrombotics, such as argatroban; antihypertensive agents, such as enalapril; vasodilators, such as cyclandelate; nociceptin antagonists; DPIV antagonists; GABA 5 inverse agonists; and selective androgen receptor modulators.
[0450] In another embodiment described herein, methods for treatment of LPA-dependent or LPA- mediated conditions or diseases, such as the therapy of interstitial cystitis, comprises administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one additional agent selected from, by way of example only,
dimethylsulfoxide, omalizumab, and pentosan polysulfate.
[0451] In yet another embodiment described herein, methods for treating LPA-dependent or LPA- mediated conditions or diseases, such as the therapy of respiratory disorders (e.g., asthma, COPD and rhinitis), comprises administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one agent used in the treatment of respiratory conditions. Agents used in the treatment of respiratory conditions include, but are not limited to, bronchodilators (e.g., sympathomimetic agents and xanthine derivatives), leukotriene receptor antagonists, leukotriene formation inhibitors, leukotriene modulators, nasal decongestants, respiratory enzymes, lung surfactants, antihistamines (e.g., mepyramine (pyrilamine), antazoline, diphenhydramine, carbinoxamine, doxylamine, clemastine, dimenhydrinate, pheniramine, chlorphenamine (chlorpheniramine), dexchlorpheniramine, brompheniramine, triprohdine, cetirizine, cyclizine, chlorcyclizine, hydroxyzine, meclizine, loratadine, desloratidine, promethazine, alimemazine (trimeprazine), cyproheptadine, azatadine, ketotifen, acrivastine, astemizole, cetirizine, mizolastine, terfenadine, azelastine, levocabastine, olopatadine, levocetirizine, fexofenadine), mucolytics, corticosteroids, anticholinergics, antitussives, analgesics, expectorants, albuterol, ephedrine, epinephrine, fomoterol, metaproterenol, terbutaline, budesonide, ciclesonide,
dexamethasone, flunisolide, fluticasone propionate, triamcinolone acetonide, ipratropium bromide, pseudoephedrine, theophylline, montelukast, zafirlukast, ambrisentan, bosentan, enrasentan, sitaxsentan, tezosentan, iloprost, treprostinil, pirfenidone, 5-lipoxygenase-activating protein (FLAP) inhibitors, FLAP modulators and 5-LO inhibitors.
[0452] In a specific embodiment described herein, methods for treating LPA-dependent or LPA- mediated conditions or diseases, such as the therapy of asthma and/or COPD, comprises
administration to a patient anti-inflammatory agents. In certain embodiments, methods for treating LPA-dependent or LPA-mediated conditions or diseases, such as the therapy of asthma and/or COPD, comprise administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one additional agent selected from, but not limited to, epinephrine, isoproterenol, orciprenaline, bronchodilators, glucocorticoids, leukotriene modifiers, mast-cell stabilizers, xanthines, anticholinergics, β-2 agonists, FLAP inhibitors, FLAP modulators or 5-LO inhibitors, β-2 agonists include, but are not limited to, short-acting β-2 agonists (e.g., salbutamol (albuterol), levalbuterol, terbutaline, pirbuterol, procaterol, metaproterenol, fenoterol and bitolterol mesylate) and long-acting β-2 agonists (e.g., salmeterol, formoterol, bambuterol and clenbuterol). FLAP inhibitors and/or FLAP modulators include, but are not limited to, 3 - [3 -tert-butylsulfanyl- 1 - [4-(6-methoxy-pyridin-3 -yl)-benzyl] -5-(pyridin-2-ylmethoxy)- 1 H-indol- 2-yl]-2,2-dimethyl-propionic acid, 3-[3-iert-butylsulfanyl-l-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5- methyl-pyridin-2-ylmethoxy)-lH-indol-2-yl]-2,2-dimethyl-propionic acid, MK-886, MK-0591, BAY-xl005 and compounds found in US 2007/0225285, US 2007/0219206, US 2007/0173508, US 2007/0123522 and US 2007/0105866 (each of which are hereby incorporated by reference).
Glucocorticoids include, but are not limited to, beclometasone, budesonide, ciclesonide, fluticasone and mometasone. Anticholinergics include, but are not limited to, ipratropium and tiotropium. Mast cell stabilizers include, but are not limited to, cromoglicate and nedocromil. Xanthines include, but are not limited to, amminophylline, theobromine and theophylline. Leukotriene antagonists include, but are not limited to, montelukast, tomelukast, pranlukast and zafirlukast. 5-LO inhibitors include, but are not limited to, zileuton, VIA-2291 (ABT761), AZ-4407 and ZD-2138 and compounds found in US 2007/0149579, WO2007/016784.
[0453] In another specific embodiment described herein, methods for treating LPA-dependent or LPA-mediated conditions or diseases, such as the therapy of allergic diseases or conditions, comprises administration to a patient compounds, pharmaceutical compositions, or medicaments described herein in combination with at least one additional agent selected from, by way of example only, antihistamines, leukotriene antagonists, corticosteroids and decongestants. Leukotriene antagonists include, but are not limited to, montelukast, tomelukast, pranlukast and zafirlukast.
[0454] In one aspect, LPA receptor antagonists described herein are admistered in combination with one or more agents used to treat used to treat asthma, including, but not limited to: combination inhalers (fluticasone and salmeterol oral inhalation (e.g. Advair)); inhaled Beta-2 agonists (albuterol inhaler; albuterol nebulizer solution; formoterol; isoproterenol oral inhalation; levalbuterol;
metaproterenol inhalation; pirbuterol acetate oral inhalation; salmeterol aerosol inhalation; salmeterol powder inhalation; terbutaline inhaler); inhaled corticosteroids (beclomethasone oral inhalation; budesonide inhalation solution; budesonide inhaler; flunisolide oral inhalation; fluticasone inhalation aerosol; fluticasone powder for oral inhalation; mometasone inhalation powder; triamcinolone oral inhalation); leukotriene modifiers (montelukast; zafirlukast; zileuton); mast cell stabilizers (cromolyn inhaler; nedocromil oral inhalation); monoclonal antibodies (omalizumab); oral Beta-2 agonists (albuterol oral syrup; albuterol oral tablets; metaproterenol; terbutaline); bronchodilator
(aminophylline; oxtriphylline; theophylline).
[0455] In one aspect, LPA receptor anatogonists described herein are admistered in combination with one or more agents used to treat allergy, including, but not limited to: antihistamine and decongestant combinations (cetirizine and pseudoephednne; desloratadine and pseudoephedrine ER; fexofenadine and pseudoephedrine; loratadine and pseudoephedrine); antihistamines (azelastine nasal spray; brompheniramine; brompheniramine oral suspension; carbinoxamine; cetirizine;
chlorpheniramine; clemastine; desloratadine; dexchlorpheniramine ER; dexchlorpheniramine oral syrup; diphenhydramine oral; fexofenadine; loratadine; promethazine); decongestants
(pseudoephedrine); leukotriene modifiers (montelukast; montelukast granules); nasal anticholinergics (ipratropium); nasal corticosteroids (beclomethasone nasal inhalation; budesonide nasal inhaler; flunisolide nasal inhalation; fluticasone nasal inhalation; mometasone nasal spray; triamcinolone nasal inhalation; triamcinolone nasal spray); nasal decongestants (phenylephrine); nasal mast cell stabilizers (cromolyn nasal spray).
[0456] In one aspect, LPA receptor anatogonists described herein are admistered in combination with one or more agents used to treat chronic obstructive pulmonary disease (COPD), including, but
- I l l - not limited to: anticholinergics - ipratropium bromide oral inhalation); combination Inhalers
(albuterol and ipratropium (e.g. Combivent, DuoNeb); fluticasone and salmeterol oral inhalation (e.g. Advair)); corticosteroids (dexamethasone tablets; fludrocortisone acetate; hydrocortisone tablets; methylprednisolone; prednisolone liquid; prednisone oral; triamcinolone oral); inhaled Beta-2 Agonists (albuterol inhaler; albuterol nebulizer solution; formoterol; isoproterenol oral inhalation; levalbuterol; metaproterenol inhalation; pirbuterol acetate oral inhalation; salmeterol aerosol inhalation; salmeterol powder inhalation; terbutaline inhaler); inhaled Corticosteroids
(beclomethasone oral inhalation; budesonide inhalation solution; budesonide inhaler; flunisolide oral inhalation; fluticasone inhalation aerosol; fluticasone powder for oral inhalation; triamcinolone oral inhalation); muko lyrics (guaifenesin); oral Beta-2 agonists (albuterol oral syrup; albuterol oral tablets; metaproterenol; terbutaline); bronchodilator (aminophylline; oxtriphylline; theophylline).
[0457] In one embodiment, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered to a patient in combination with inhaled corticosteroids.
[0458] In one embodiment, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered to a patient in combination with beta2-adrenergic receptor agonists. In one
embodiment, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered to a patient in combination with short acting beta2-adrenergic receptor agonists. In one embodiment, a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is administered to a patient in combination with long-acting beta2-adrenergic receptor agonists.
Kits/Articles of Manufacture
[0459] For use in the therapeutic applications described herein, kits and articles of manufacture are also described herein. Such kits can comprise a carrier, package, or container that is
compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein.
Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers are formed from any acceptable material including, e.g., glass or plastic.
[0460] For example, the container(s) can comprise one or more compounds described herein, optionally in a composition or in combination with another agent as disclosed herein. The container(s) optionally have a sterile access port (for example the container can be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). Such kits optionally comprising a compound with an identifying description or label or instructions relating to its use in the methods described herein.
[0461] A kit will typically comprise one or more additional containers, each with one or more of various materials (such as reagents, optionally in concentrated form, and/or devices) desirable from a commercial and user standpoint for use of a compound described herein. Non-limiting examples of such materials include, but not limited to, buffers, diluents, filters, needles, syringes; carrier, package, container, vial and/or tube labels listing contents and/or instructions for use, and package inserts with instructions for use. A set of instructions will also typically be included.
[0462] A label can be on or associated with the container. A label can be on a container when letters, numbers or other characters forming the label are attached, molded or etched into the container itself; a label can be associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert. A label can be used to indicate that the contents are to be used for a specific therapeutic application. The label can also indicate directions for use of the contents, such as in the methods described herein.
EXAMPLES
[0463] These examples are provided for illustrative purposes only and not to limit the scope of the claims provided herein.
Example 1: Synthesis of 4'-[3-Methyl-4-(3-phenyl-propionylamino)-isoxazol-5-yl]-biphenyl-3- carboxylic acid (Compound 1-1)
Figure imgf000114_0001
Step 1: 3-Methylamino-but-2-enoic acid methyl ester
[0464] To a solution of methyl acetoacetate (29.4 g, 253 mmol) in MeOH (30 mL) was added methylamine (33% w/w in EtOH, 48 mL, 385 mmol) dropwise at room temperature. The reaction was stirred for 1 hour then concentrated and dried to give the title compound as a white crystalline solid.
Figure imgf000114_0002
Step 2: 2-(4-Bromo-benzoyl)-3-oxo-butyric acid methyl ester
[0465] To 3-methylamino-but-2-enoic acid methyl ester (5.0 g, 39.1 mmol) in THF (100 mL) was added pyridine (3.7 mL, 47 mmol). The mixture was cooled to 0 °C and 4-bromobenzoyl chloride (8.55 g, 39.1 mmol) in THF (30 mL) was added dropwise over 2 minutes. The reaction was warmed to room temperature over 1 hour and stirred overnight. Aqueous workup provided the title compound.
Figure imgf000115_0001
Step 3: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid methyl ester
[0466] To a mixture of 2-(4-bromo-benzoyl)-3-oxo-butyric acid methyl ester (11 g, 39 mmol) in acetic acid (50 mL) was added hydroxylamine hydrochloride (2.66 g, 39 mmol) and the reaction was stirred at 115 °C for 1 hour. After cooling, aqueous workup provided the title compound, which was used directly in the hydrolysis step.
Figure imgf000115_0002
Step 4: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid
[0467] 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid methyl ester (39 mmol) in MeOH (50 mL) and ¾0 (10 mL) was treated with lithium hydroxide (2 g, 48 mmol) and the reaction was stirred at 60 °C for 1 hour. The mixture was acidified, and standard workup provided the title compound.
Figure imgf000115_0003
Step 5: 5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylamine
[0468] 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid (1.1 g, 4.1 mmol),
diphenylphosphoryl azide (1.2 mL, 4.3 mmol), and triethylamine (1.14 mL, 8.2 mmol) were combined in toluene and stirred at 120 °C for 25 minutes. After cooling to room temperature, ¾0 (2 mL) in THF (2 mL) was added and the reaction was stirred at 88 °C for 2 hours. The mixture was cooled to room temperature and extracted with EtOAc. The combined organic layers were concentrated to give the title compound.
Figure imgf000116_0001
Step 6: iV-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-phenyl-propionamide
[0469] Hydrocinnamoyl chloride (0.73 mL, 4.9 mmol) was added to a mixture of 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine (4.1 mmol), triethylamine (1.14 mL, 8.2 mmol), and a few drops of DMF in CH2CI2, and the reaction was stirred at room temperature for 2 hours. The mixture was diluted with EtOAc and H20 and the organic layer was separated, washed with brine, and concentrated. The residue was purified by dry-load silica gel chromatography (28-48% EtOAc in hexanes) to give the title compound.
Figure imgf000116_0002
Step 7: 4'-[3-Methyl-4-(3-phenyl-propionylamino)-isoxazol-5-yl]-biphenyl-3-carboxylic acid
[0470] N-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-phenyl-propionamide (0.100 g, 0.26 mmol), 3-carboxyphenylboronic acid (0.052 g, 0.31 mmol), tetrakis(triphenylphosphine)palladium(0) (0.030 g, 0.03 mmol), and potassium carbonate (0.072 g, 0.52 mmol) were combined in 2: 1
DMEiFLO. The mixture was purged with N2 and stirred at 88 °C in a sealed container for 1 hour. After aqueous workup the crude material was purified by preparative HPLC to give the title compound.
Example 2: Synthesis of 4'-[4-(3-Benzyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-3-carboxylic acid (Compound 1-2)
Figure imgf000116_0003
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-carbamic acid tert-but l ester [0471] 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid (1.6 g, 6.0 mmol), diphenylphosphoryl azide (1.6 g, 6.0 mmol), and triethylamine (1.3 mL, 9.3 mmol) were combined in i-BuOH and refluxed overnight. After cooling, the mixture was concentrated and the residue was partitioned between EtOAc and ¾0. The organic layer was separated and concentrated, and the residue was purified by silica gel chromatography (16-18% EtOAc in hexanes) to give the title compound.
Figure imgf000117_0001
Step 2: 5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylamine
[0472] [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-carbamic acid tert-butyl ester (0.38 g, 1.07 mmol) was treated with 50% trifluoroacetic acid in CH2CI2 and stirred for 3 hours. Once no starting material was seen by analytical LCMS, the mixture was concentrated to give the title compound.
Figure imgf000117_0002
Step 3: l-Benzyl-3-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-urea
[0473] Sodium hydride (60% in mineral oil, 0.040 g, 1.00 mmol) was added to a solution of 5-(4- bromo-phenyl)-3-methyl-isoxazol-4-ylamine (0.170 g, 0.67 mmol) in DMF, and the mixture was stirred for 5 minutes at room temperature. Benzyl isocyanate (0.08 mL, 0.67 mmol) was added, and the reaction was stirred at 80 °C for 2 hours. After aqueous workup, the crude material was used directly in the coupling step.
Figure imgf000117_0003
Step 4: 4'-[4-(3-Benzyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-3-carboxylic acid [0474] Prepared according to the procedure described in Example 1 , Step 7, using l-benzyl-3-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-urea and 3-carboxyphenylboronic acid.
Example 3: Synthesis of l-{4'-[3-Methyl-4-(3-methyl-butyrylamino)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compoun -3)
Figure imgf000118_0001
Step 1: l-(4-Bromo-phenyl)-cyclopropanecarbonitrile
[0475] Potassium hydroxide (14.3 g, 255 mmol) was dissolved in H20 (5 mL) and toluene (40 mL). 4-Bromophenylacetonitrile (5.0 g, 25.5 mmol) and tetrabutylammonium bromide (0.41 g, 1.3 mmol) were added, and 1 ,2-dibromoethane (3.25 mL, 38 mmol) was added dropwise over 10 minutes. The reaction was stirred at room temperature for 2 hours and then submitted to standard aqueous workup to give the title compound.
Figure imgf000118_0002
Step 2: l-(4-Bromo-phenyl)-cyclopropanecarboxylic acid
[0476] l-(4-Bromo-phenyl)-cyclopropanecarbonitrile (5 g, 22.5 mmol) and potassium hydroxide (5 g, 89.3 mmol) were combined in ethylene glycol (70 mL), and the reaction was stirred at 180 °C for 4 hours. The mixture was poured into H20, acidified, and filtered to give the title compound.
Figure imgf000118_0003
Step 3: l-(4-Bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester
[0477] l-(4-Bromo-phenyl)-cyclopropanecarboxylic acid (5 g, 20.7 mmol) in EtOH (50 mL) was treated with sulfuric acid (2 mL) and the reaction was stirred at 75 °C for 1 hour. Standard aqueous workup afforded title compound.
Figure imgf000119_0001
Step 4: l-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester
[0478] l-(4-Bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester (3 g, 13. mmol),
bis(pinacolato)diboron (3.37 g, 16.1 mmol), and potassium acetate (2.8 g, 29.0 mmol) were combined in 1,4-dioxane (30 mL) under N2. The solution was purged with N2 for 10 minutes, then (l, -bis(diphenylphosphino)ferrocene)-dichloropalladium(II) (0.50 g, 0.65 mmol) was added and the reaction was heated to 80 °C for 2 hours. After aqueous workup, the crude material was purified by silica gel chromatography (0-30% EtOAc in hexanes) to give the title compound.
Figure imgf000119_0002
Step 5: l-[4'-(4-teri-Butoxycarbonylamino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0479] [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-carbamic acid tert-butyl ester (2.0 g, 5.6 mmol), l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester (1.78 g, 5.6 mmol), tetrakis(triphenylphosphine)palladium(0) (0.65 g, 0.56 mmol), and sodium bicarbonate (1.4 g, 16.8 mmol) were combined in DME (30 mL) and H2O (10 mL) and the mixture was purged with N2. The reaction was stirred at 80 °C overnight, and after aqueous workup the crude material was purified by silica gel chromatography (0-40% EtOAc in hexanes) to give the title compound.
Figure imgf000120_0001
Step 6: l-[4'-(4-Amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0480] l-[4'-(4-iert-Butoxycarbonylamino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester (1.5 g, 3.2 mmol) in CH2CI2 (10 mL) was treated with trifluoroacetic acid (4 mL). The reaction was stirred for 1 hour. The mixture was neutralized and submitted to standard workup to give the title compound.
Figure imgf000120_0002
Step 7: l-{4'-[3-Methyl-4-(3-methyl-butyrylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0481] l-[4'-(4-Amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.10 g, 0.28 mmol) and triethylamine (0.1 mL, 0.66 mmol) were combined in CH2CI2 (2 mL). Isovaleryl chloride (0.04 mL, 0.33 mmol) was added, and the reaction was stirred at room temperature for 1 hour. After aqueous workup, the crude material was purified by silica gel chromatography (0-80% EtOAc in hexanes) to give the title compound.
Figure imgf000121_0001
Step 8: l-{4'-[3-Methyl-4-(3-methyl-butyrylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0482] l-{4'-[3-Methyl-4-(3-methyl-butyrylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (0.060 g, 0.13 mmol) in MeOH and ¾0 was treated with lithium hydroxide (0.100 g, 2.4 mmol) and stirred at 60 °C for 1 hour. The mixture was submitted to standard workup to give the title compound.
Example 4: Synthesis of l-{4'-[3-Methyl-4-(3-phenyl-propionylamino)-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid (Compound 1-4)
Figure imgf000121_0002
Step 1 : l-{4'-[3-Methyl-4-(3-phenyl-propionylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0483] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(4-amino-3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and hydrocinnamoyl chloride.
Figure imgf000122_0001
Step 2: l-{4'-[3-Methyl-4-(3-phenyl-propionylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0484] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (3-phenyl-propionylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. Example 5: Synthesis of l-{4'-[3-Methyl-4-(2-phenoxy-acetylamino)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-5)
Figure imgf000122_0002
Step 1 : l-{4'-[3-Methyl-4-(2-phenoxy-acetylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0485] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(4-amino-3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and phenoxyacetyl chloride.
Figure imgf000123_0001
Step 2: l-{4'-[3-Methyl-4-(2-phenoxy-acetylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0486] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (2-phenoxy-acetylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester. Example 6: Synthesis of l-{4'-[4-(3-Benzyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-6)
Figure imgf000123_0002
Step 1 : l-{4'-[4-(3-Benzyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0487] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(4-amino-3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and benzyl isocyanate.
Figure imgf000123_0003
Step 2: l-{4'-[4-(3-Benzyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0488] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(3- benzyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester. Example 7: Synthesis of l-{4'-[4-(3-teri-Butyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-7)
Figure imgf000124_0001
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-teri-butyl-urea
[0489] 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid (1.0 g, 3.53 mmol) and triethylamine (0.56 mL, 3.9 mmol) were combined in toluene (20 mL). Diphenylphosphoryl azide (0.84 mL, 3.9 mmol) was added and the reaction was stirred at 80 °C for 1 hour. iert-Butylamine (0.38 g, 5.3 mmol) was then added, and the reaction was stirred at 80 °C for 1 hour. Aqueous workup provided the title compound.
Figure imgf000124_0002
Step 2: l-{4'-[4-(3-teri-Butyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0490] Prepared according to the procedure described in Example 3, Step 5, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-3-iert-butyl-urea and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan- 2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000125_0001
Step 3: l-{4'-[4-(3-teri-Butyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0491] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(3-£ert- butyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester. Example 8: Synthesis of l-{4'-[4-(3-Isopropyl-3-methyl-ureido)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-8)
Figure imgf000125_0002
Step 1 : 3-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-l-isopropyl-l-methyl-urea
[0492] Prepared according to the procedure described in Example 7, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carboxylic acid and N-meth lisopropylamine.
Figure imgf000125_0003
Step 2: l-{4'-[4-(3-Isopropyl-3-methyl-ureido)-3-methyl-isoxazol-5-yl]-biphi
cyclopropanecarboxylic acid ethyl ester [0493] Prepared according to the procedure described in Example 3, Step 5, using 3-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]- 1 -isopropyl- 1 -methyl-urea and 1 -[4-(4,4,5,5-tetramethyl- [l ,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000126_0001
Step 3: l-{4'-[4-(3-Isopropyl-3-methyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0494] Prepared according to the procedure described in Example 3, Step 8, using l- {4'-[4-(3- isopropyl-3-methyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 9: Synthesis of l-(4'-{3-Methyl-4-[3-methyl-3-((R)-l-phenyl-ethyl)-ureido]-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-9)
Figure imgf000126_0002
Step 1 : 3-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-l-methyl-l-((R)-l-phenyl-ethyl)-urea
[0495] Prepared according to the procedure described in Example 7, Step 1 , using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carboxylic acid and (R)-(+)-N,a-dimethylbenzylamine.
Figure imgf000126_0003
Step 2: l-(4'-{3-Methyl-4-[3-methyl-3-((R)-l-phenyl-ethyl)-ureido]-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid ethyl ester
[0496] Prepared according to the procedure described in Example 3, Step 5, using 3-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]- 1 -methyl- 1 -((R)-l -phenyl-ethyl)-urea and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000127_0001
Step 3: l-(4'-{3-Methyl-4-[3-methyl-3-((R)-l-phenyl-ethyl)-ureido]-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid
[0497] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{3-methyl-4- [3-methyl-3-((R)- 1 -phenyl-ethyl)-ureido]-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 10: Synthesis of l-{4'-[3-Methyl-4-(3-phenyl-butylamino)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-10)
Figure imgf000127_0002
Step 1: l-{4'-[3-Methyl-4-(3-phenyl-butylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0498] l-[4'-(4-Amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.1 g, 0.27 mmol), 3 -phenyl -butyraldehyde (0.048 g, 0.33 mmol) and sodium
triacetoxyborohydride (0.11 g, 0.54 mmol) were mixed in CH2CI2 and stirred overnight. Lithium hydroxide monohydrate (0.100 g, 2.38 mmol) in MeOH/H20 was added and the reaction stirred at 60 °C for 1 hour. The reaction was submitted to standard aqueous workup to yield the title compound. Example 11: Synthesis of l-(4'-{3-Methyl-4-[3-((R)-l-phenyl-ethyl)-ureido]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-11)
Figure imgf000128_0001
Step 1 : l-(4'-{3-Methyl-4-[3-((R)-l-phenyl-ethyl)-ureido]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0499] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(4-amino-3- methyl-isoxazol-5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid ethyl ester and (R)-(+)-a- methylbenzyl isocyanate.
Figure imgf000128_0002
Step 2: l-(4'-{3-Methyl-4-[3-((R)-l-phenyl-ethyl)-ureido]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0500] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{3-methyl-4- [3-((Pv)- 1 -phenyl-ethyl)-ureido]-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 12: Synthesis of l-(4'-{4-[3-(2-Fluoro-benzyl)-ureido]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-12)
Figure imgf000129_0001
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-(2-fluoro-benzyl)-urea
[0501] Prepared according to the procedure described in Example 7, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carboxylic acid and 2-fluorobenzylamine.
Figure imgf000129_0002
Step 2: l-(4'-{4-[3-(2-Fluoro-benzyl)-ureido]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0502] Prepared according to the procedure described in Example 3, Step 5, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-3-(2-fluoro-benzyl)-urea and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000129_0003
Step 3: l-(4'-{4-[3-(2-Fluoro-benzyl)-ureido]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0503] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[3-(2- fluoro-benzyl)-ureido]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester. Example 13: Synthesis of l-(4'-{3-Methyl-4-[3-(2,2,2-trifluoro-ethyl)-ureido]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-13)
Figure imgf000130_0001
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-(2,2,2-trifluoro-ethyl)-urea
[0504] Prepared according to the procedure described in Example 7, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carboxylic acid and 2,2,2-trifluoroethylamine.
Figure imgf000130_0002
Step 2: l-(4'-{3-Methyl-4-[3-(2,2,2-trifluoro-ethyl)-ureido]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0505] Prepared according to the procedure described in Example 3, Step 5, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-3-(2,2,2-trifluoro-ethyl)-urea and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000130_0003
Step 3: l-(4'-{3-Methyl-4-[3-(2,2,2-trifluoro-ethyl)-ureido]-isoxazol-5-yl}-biphi
cyclopropanecarboxylic acid [0506] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{3-methyl-4- [3-(2,2,2-trifluoro-ethyl)-ureido]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 14: Synthesis of l-{4'-[4-(2-Chloro-phenylmethanesulfonylamino)-3-methyl-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-14)
Figure imgf000131_0001
Step 1: l-{4'-[4-(2-Chloro-phenylmethanesulfonylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester
[0507] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(4-amino-3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2- chlorobenzylsulfonyl chloride.
Figure imgf000131_0002
Step 2: l-{4'-[4-(2-Chloro-phenylmethanesulfonylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid
[0508] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(2- chloro-phenylmethanesulfonylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester.
Example 15: Synthesis of l-(4'-{4-[3-(2-Fluoro-5-trifluoromethyl-benzyl)-ureido]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-15)
Figure imgf000132_0001
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-(2-fluoro-5-trifluoromethyl-benzyl)- urea
[0509] Prepared according to the procedure described in Example 7, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carboxylic acid and 2-fluoro-5-(trifluoromethyl)benzylamine.
Figure imgf000132_0002
Step 2: l-(4'-{4-[3-(2-Fluoro-5-trifluoromethyl-benzyl)-ureido]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0510] Prepared according to the procedure described in Example 3, Step 5, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-3-(2-fluoro-5-trifluoromethyl-benzyl)-urea and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000132_0003
Step 3: l-(4'-{4-[3-(2-Fluoro-5-trifluoromethyl-benzyl)-ureido]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid [0511] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[3-(2- fluoro-5-trifluoromethyl-benzyl)-ureido]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 16: Synthesis of l-(4'-{4-[3-(2,6-Difluoro-benzyl)-ureido]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-16)
Figure imgf000133_0001
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-(2,6-difluoro-benzyl)-urea
[0512] Prepared according to the procedure described in Example 7, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carboxylic acid and 2,6-difluorobenzylamine.
Figure imgf000133_0002
Step 2: l-(4'-{4-[3-(2,6-Difluoro-benzyl)-ureido]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0513] Prepared according to the procedure described in Example 3, Step 5, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-3-(2,6-difluoro-benzyl)-urea and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000134_0001
Step 3: l-(4'-{4-[3-(2,6-Difluoro-benzyl)-ureido]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0514] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[3-(2,6- difluoro-benzyl)-ureido]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 17: Synthesis of l-{4'-[3-Methyl-4-(2-phenoxy-propionylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-17)
Figure imgf000134_0002
Step 1: l-{4'-[3-Methyl-4-(2-phenoxy-propionylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0515] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(4-amino-3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2- phenoxypropionyl chloride.
Figure imgf000135_0001
Step 2: l-{4'-[3-Methyl-4-(2-phenoxy-propionylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0516] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (2-phenoxy-propionylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. Example 18: Synthesis of l-{4'-[4-(3-Benzenesulfonyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid (Compound 1-18)
Figure imgf000135_0002
Step 1 : l-Benzenesulfonyl-3-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-urea
[0517] Prepared according to the procedure described in Example 3, Step 7, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and benzenesulfonyl isocyanate.
Figure imgf000135_0003
Step 2: l-{4'-[4-(3-Benzenesulfonyl-ureido)-3-methyl-isoxazol-5-yl]-biphi
cyclopropanecarboxylic acid ethyl ester [0518] Prepared according to the procedure described in Example 3, Step 5, using 1- benzenesulfonyl-3-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-urea and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000136_0001
Step 3: l-{4'-[4-(3-Benzenesulfonyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0519] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(3- benzenesulfonyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 19: Synthesis of l-{4'-[3-Methyl-4-((R)-l-phenyl-ethylcarbamoyloxymethyl)-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-19)
Figure imgf000136_0002
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl] -methanol
[0520] 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid methyl ester (5 g, 16.8 mmol) and lithium borohydride (1.85 g, 84.1 mmol) were combined in EtOH and stirred at 60 °C. After aqueous workup, the crude material was purified by silica gel chromatography to give the title compound.
Figure imgf000136_0003
Step 2: ((R)-l-Phenyl-ethyl)-carbamic acid 5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl ester
[0521] [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-methanol (0.120 g, 0.45 mmol) and (R)-(+)-a- methylbenzyl isocyanate (0.17 mL, 1.2 mmol) were combined in toluene and stirred overnight at 90 °C. The mixture was diluted with CH2CI2 and purified by silica gel chromatography to give the title compound.
Figure imgf000137_0001
Step 3: l-{4'-[3-Methyl-4-((R)-l-phenyl-ethylcarbamoyloxymethyl)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester
[0522] Prepared according to the procedure described in Example 3, Step 5, using ((R)- 1 -phenyl - ethyl)-carbamic acid 5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl ester and l-[4-(4 ,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000137_0002
Step 4: l-{4'-[3-Methyl-4-((R)-l-phenyl-ethylcarbamoyloxymethyl)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid
[0523] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- ((R)- 1 -phenyl-ethylcarbamoyloxymethyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. Example 20: Synthesis of l-{4'-[3-Methyl-4-(3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-20)
Figure imgf000138_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(3-phenyl-propyl)-amine
[0524] 5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylamine (0.300 g, 1.19 mmol),
hydrocinnamaldehyde (0.192 g, 1.43 mmol), and sodium cyanoborohydride (0.188 g, 2.99 mmol) were combined in CH2C12 and stirred overnight at room temperature. After aqueous workup, the crude material was purified by silica gel chromatography to give the title compound.
Figure imgf000138_0002
Step 2: l-{4'-[3-Methyl-4-(3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0525] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(3-phenyl-propyl)-amine and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000138_0003
Step 3: l-{4'-[3-Methyl-4-(3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0526] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester. Example 21: Synthesis of l-[4'-(4-Benzylcarbamoyloxymethyl-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-21)
Figure imgf000139_0001
Step 1: Benzyl-carbamic acid 5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl ester
[0527] Prepared according to the procedure described in Example 19, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl] -methanol and benzyl isocyanate.
Step 2: l-[4'-(4-Benzylcarbamoyloxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0528] Prepared according to the procedure described in Example 3, Step 5, using benzyl-carbamic acid 5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl ester and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000140_0001
Step 3: l-[4'-(4-Benzylcarbamoyloxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0529] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(4- benzylcarbamoyloxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester.
Example 22: Synthesis of l-{4'-[3-Methyl-4-((S)-l-phenyl-ethylcarbamoyloxymethyl)-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-22)
Figure imgf000140_0002
Step 1: ((S)-l-Phenyl-ethyl)-carbamic acid 5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl ester
[0530] Prepared according to the procedure described in Example 19, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-methanol and (S)-(-)-a-methylbenzyl isocyanate.
Figure imgf000140_0003
Step 2: l-{4'-[3-Methyl-4-((S)-l-phenyl-ethylcarbamoyloxymethyl)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester
[0531] Prepared according to the procedure described in Example 3, Step 5, using ((S)- 1 -phenyl- ethyl)-carbamic acid 5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl ester and l-[4-(4 ,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000141_0001
Step 3: l-{4'-[3-Methyl-4-((S)-l-phenyl-ethylcarbamoyloxymethyl)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid
[0532] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- ((S)- 1 -phenyl-ethylcarbamoyloxymethyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 23: Synthesis of l-[4'-(4-Cyclopentylcarbamoyloxymethyl-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-23)
Figure imgf000141_0002
Step 1: Cyclopentyl-carbamic acid 5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl ester
[0533] Prepared according to the procedure described in Example 19, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-methanol and cyclopentyl isocyanate.
Figure imgf000142_0001
Step 2: l-[4'-(4-Cyclopentylcarbamoyloxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0534] Prepared according to the procedure described in Example 3, Step 5, using cyclopentyl- carbamic acid 5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl ester and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000142_0002
Step 3: l-[4'-(4-Cyclopentylcarbamoyloxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0535] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(4- cyclopentylcarbamoyloxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester.
Example 24: Synthesis of l-(4'-{4-[3-(4-Isopropyl-phenyl)-2-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-24)
Figure imgf000142_0003
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[3-(4-isopropyl-phenyl)-2-methyl-propyl]- amine
[0536] 5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylamine (0.300 g, 1.19 mmol) and 3-(4- isopropylphenyl)isobutyraldehyde (0.272 g, 1.43 mmol) were combined in toluene (3 mL) and stirred at 110 °C for 1 hour. After cooling to room temperature, toluene was removed under vacuum and the mixture was diluted with THF (4 mL). Sodium cyanoborohydride (0.188 g, 2.98 mmol) was added, and the reaction was stirred at room temperature for 1 hour. The mixture was adsorbed onto silica gel and purified by silica gel chromatography to give the title compound.
Figure imgf000143_0001
Step 2: l-(4'-{4-[3-(4-Isopropyl-phenyl)-2-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0537] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(4-isopropyl-phenyl)-2-methyl-propyl]-amine and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000143_0002
Step 3: l-(4'-{4-[3-(4-Isopropyl-phenyl)-2-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0538] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[3-(4- isopropyl-phenyl)-2-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester. Example 25: Synthesis of l-{4'-[3-Methyl-4-(l-methyl-3-phenyl-propylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-25)
Figure imgf000144_0001
Step 1 : l-{4'-[3-Methyl-4-(l-methyl-3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0539] Prepared according to the procedure described in Example 24, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-y -cyclopropanecarboxylic acid ethyl ester and benzylacetone.
Figure imgf000144_0002
Step 2: l-{4'-[3-Methyl-4-(l-methyl-3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0540] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (1 -methyl-3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 26: Synthesis of l-{4'-[3-Methyl-4-(phenethylamino-methyl)-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid (Compound 1-26)
Figure imgf000144_0003
Step 1: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde
[0541] [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-methanol (1.2 g, 4.5 mmol) was treated with 4-methylmorpholine N-oxide (0.786 g, 6.7 mmol) and tetrapropylammonium perruthenate (catalytic) in CH2CI2. Standard workup procedure afforded the title compound.
Figure imgf000145_0001
Step 2: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-phenethyl-amine
[0542] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and 2-phenylethylamine.
Figure imgf000145_0002
Step 3: l-{4'-[3-Methyl-4-(phenethylamino-methyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0543] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-phenethyl-amine and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000145_0003
Step 4: l-{4'-[3-Methyl-4-(phenethylamino-methyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0544] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (phenethylamino-methyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester. Example 27: Synthesis of l-(4'-{4-[(Cyclopropylmethyl-amino)-methyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-27)
Figure imgf000146_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-cyclopropylmethyl-amine
[0545] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and (aminomethyl)cyclopropane.
Figure imgf000146_0002
Step 2: l-(4'-{4-[(Cyclopropylmethyl-amino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0546] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-cyclopropylmethyl-amine and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000147_0001
Step 3: l-(4'-{4-[(Cyclopropylmethyl-amino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0547] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4- [(cyclopropylmethyl-amino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 28: Synthesis of l-(4'-{4-[(Cyclohexylmethyl-amino)-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-28)
Figure imgf000147_0002
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-cyclohexylmethyl-amine
[0548] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and cyclohexanemethylamine.
Figure imgf000147_0003
Step 2: l-(4'-{4-[(Cyclohexylmethyl-amino)-methyl]-3-methyl-isoxazol-5-yl}-biphi
cyclopropanecarboxylic acid ethyl ester [0549] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-cyclohexylmethyl-amine and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000148_0001
Step 3: l-(4'-{4-[(Cyclohexylmethyl-amino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0550] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4- [(cyclohexylmethyl-amino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 29: Synthesis of l-{4'-[4-(Benzylamino-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-29)
Figure imgf000148_0002
Step 1 : Benzyl- [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl] -amine
[0551] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and benzylamine.
Figure imgf000149_0001
Step 2: l-{4'-[4-(Benzylamino-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0552] Prepared according to the procedure described in Example 3, Step 5, using benzyl-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl] -amine and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000149_0002
Step 3: l-{4'-[4-(Benzylamino-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0553] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4- (benzylamino-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 30: Synthesis of l-(4'-{4-[(Acetyl-phenethyl-amino)-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-30)
Figure imgf000149_0003
Step 1 : iV-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-iV-phenethyl-acetamide
[0554] [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-phenethyl-amine (0.055 g, 0.15 mmol), acetyl chloride (0.05 mL, 0.75 mmol), and triethylamine (0.13 mL, 0.95 mmol) were combined and stirred at room temperature for 30 minutes. The mixture was loaded directly onto silica gel and purified by silica gel chromatography (30-50% EtOAc in hexanes) to give the title compound.
Figure imgf000150_0001
Step 2: l-(4'-{4-[(Acetyl-phenethyl-amino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0555] Prepared according to the procedure described in Example 3, Step 5, using N-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-N-phenethyl-acetamide and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000150_0002
Step 3: l-(4'-{4-[(Acetyl-phenethyl-amino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0556] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[(acetyl- phenethyl-amino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 31: Synthesis of l-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-31)
Figure imgf000151_0001
Step 1 : 5-(4-Bromo-phenyl)-3-methyl-4-(4-phenyl-but-l-enyl)-isoxazole
[0557] To a solution of (3-phenylpropyl)triphenylphosphonium bromide (0.956 g, 2.07 mmol) in THF (5 mL) at -78 °C was slowly added n-butyllithium (2.5 M in hexanes, 0.83 mL, 2.07 mmol) and the mixture was stirred for 15 minutes. 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde (0.500 g, 1.88 mmol) in THF (3 mL) was added, and the reaction was warmed to 0°C and stirred for 1 hour. The solution was diluted with 1 N aqueous HC1 and extracted twice with EtOAc. The combined organic layers were dried over Na2S04, decanted, and concentrated. The residue was purified by silica gel chromatography -20% EtOAc in hexanes) to give the title compound.
Figure imgf000151_0002
Step 2: l-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0558] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-3-methyl-4-(4-phenyl-but- 1 -enyl)-isoxazole and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000151_0003
Step 3: l-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0559] l-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (0.072 g, 0.15 mmol) in THF (2 mL) and EtOH (1 mL) was treated with 3 N aqueous NaOH (0.75 mL, 2.25 mmol) and the reaction was stirred at 75 °C overnight. The mixture was acidified with 1 N aqueous HC1 (2.25 mL) and extracted with CH2CI2. The combined organic layers were dried over MgS04, filtered, and concentrated, and the residue was purified by preparative HPLC to give the title compound.
Example 32: Synthesis of l-{4'-[3-Methyl-4-(4-phenyl-butyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-32)
Figure imgf000152_0001
Step 1 : l-{4'-[3-Methyl-4-(4-phenyl-butyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0560] l-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (0.030 g, 0.07 mmol) was dissolved in EtOAc and MeOH. 10% Palladium on carbon (spatula tip) was added, and the reaction was stirred under a balloon of H2 overnight. The mixture was filtered and concentrated to give the title compound.
Example 33: Synthesis of l-(4'-{3-Methyl-4-[(l-phenyl-ethylcarbamoyl)-methyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-33)
Figure imgf000152_0002
Step 1 : 4-Bromomethyl-5-(4-bromo-phenyl)-3-methyl-isoxazole
[0561] [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-methanol (2.88 g, 10.74 mmol) in DME (23 mL) was treated with phosphorus tribromide (1.5 mL, 16.11 mmol) and the reaction was stirred at room temperature for 1 hour. Aqueous workup provided the title compound.
Figure imgf000153_0001
Step 2 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl] -acetonitrile
[0562] To 4-bromomethyl-5-(4-bromo-phenyl)-3-methyl-isoxazole (10.74 mmol) in DMF (30 niL) was added potassium cyanide (0.729 g, 10.74 mmol) and the reaction stirred at 65 °C overnight. After aqueous workup, the crude material was purified by silica gel chromatography (0-70% EtOAc in hexanes) to give the title compound.
Figure imgf000153_0002
Step 3: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl] -acetic acid
[0563] [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetonitrile (1.652 g, 5.96 mmol) in EtOH (9 mL) was treated with 4 N aqueous NaOH (6 mL, 23.85 mmol) and the reaction was stirred at 75 °C for 3 hours. The mixture was acidified with 2 N aqueous HC1 (12 mL) and a precipitate formed as the solution cooled to room temperature. The mixture was filtered and the solid material was dried to give the title compound.
Figure imgf000153_0003
Step 4: 2-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-iV-(l-phenyl-ethyl)-acetamide
[0564] [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid (0.154 g, 0.52 mmol), a- methylbenzylamine (0.07 mL, 0.52 mmol), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.120 g, 0.62 mmol), 1 -hydroxybenzotriazole (0.087 g, 0.62 mmol), and
triethylamine (0.22 mL, 1.56 mmol) were combined in CH2CI2 (1.5 mL). The reaction was stirred at room temperature for 2.5 hours. After aqueous workup the crude material was purified by silica gel chromatography (0-60% EtOAc in hexanes) to give the title compound.
Figure imgf000154_0001
Step 5: l-(4'-{3-Methyl-4-[(l-phenyl-ethylcarbamoyl)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0565] Prepared according to the procedure described in Example 3, Step 5, using 2-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-N-(l-phenyl-ethyl)-acetamide and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000154_0002
Step 6: l-(4'-{3-Methyl-4-[(l-phenyl-ethylcarbamoyl)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0566] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{3-methyl- 4-[(l-phenyl-ethylcarbamoyl)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 34: Synthesis of l-{4'-[4-(2-Benzyloxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compou -34)
Figure imgf000154_0003
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl] -acetic acid ethyl ester
[0567] [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid (0.405 g, 1.37 mmol) in EtOH (4 mL) was treated with thionyl chloride (0.2 mL, 2.73 mmol) and the reaction was stirred at room temperature until no starting material was seen by analytical TLC. After basic workup the crude material was purified by silica gel chromatography (0- 100% EtOAc in hexanes) to give the title compound.
Figure imgf000155_0001
Step 2: 2-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol
[0568] To [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid ethyl ester (1.37 mmol) in THF (3 mL) at 0°C was added lithium aluminum hydride (0.060 g, 1.47 mmol). The reaction was stirred at room temperature for 1 hour. The mixture was diluted with EtOAc and 1 N aqueous HCl, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over MgS04, filtered and concentrated to give the title compound.
Figure imgf000155_0002
Step 3: l-{4'-[4-(2-Hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0569] Prepared according to the procedure described in Example 3, Step 5, using 2-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-ethanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000156_0001
Step 4: l-{4'-[4-(2-Benzyloxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0570] To a solution of l-{4'-[4-(2-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (0.080 g, 0.19 mmol) in DMF (1 mL) was added sodium hydride (60% in mineral oil, 0.010 g, 0.24 mmol), followed by benzyl bromide (0.024 mL, 0.20 mmol), and the reaction was stirred at room temperature for 1 hour. After aqueous workup, the crude material was purified by silica gel chromatography (0- 15% EtOAc in hexanes) to give the title compound.
Figure imgf000156_0002
Step 5: l-{4'-[4-(2-Benzyloxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0571] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(2- benzyloxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. Example 35: Synthesis of l-{4'-[4-(2-Cyclopropylmethoxy-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-35)
Figure imgf000157_0001
Step 1 : l-{4'-[4-(2-Cyclopropylmethoxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0572] To a solution of l-{4'-[4-(2-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (0.144 g, 0.37 mmol) and (bromomethyl)cyclopropane (0.04 mL, 0.44 mmol) in DMF (1.4 mL) as added sodium hydride (60% in mineral oil, 0.022 g, 0.55 mmol) and the reaction was stirred at room temperature. Analytical LCMS indicated that there was a mixture of products, including the hydro lyzed acid, so the mixture was submitted to aqueous workup procedure and purified by silica gel chromatography (0-100% EtOAc in hexanes). Fractions containing the desired product were purified by preparative HPLC to give the title compound.
Example 36: Synthesis of l-{4'-[4-(2-Benzoylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-36)
Figure imgf000157_0002
Step 1 : (E)-3-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl] -acrylic acid methyl ester
[0573] To a solution of sodium hydride (60% in mineral oil, 0.471 g, 11.03 mmol) in THF (10 mL) at 0 °C was added trimethyl phosphonoacetate (1.1 mL, 7.58 mmol). Additional THF (15 mL) was added to facilitate stirring and the solution was warmed to room temperature over 15 minutes. After cooling to 0 °C, 5-(4-bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde (1.834 g, 6.89 mmol) in THF (8 mL) was added and the reaction was stirred at room temperature for 10 minutes. The mixture was extracted with EtOAc and aqueous NH4CI, dried over MgS04, filtered and concentrated. The residue was purified by silica gel chromatography to give the title compound.
Figure imgf000158_0001
Step 2: l-{4'-[4-((E)-2-Methoxycarbonyl-vinyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0574] Prepared according to the procedure described in Example 3, Step 5, using (E)-3-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl] -acrylic acid methyl ester and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000158_0002
Step 3: l-{4'-[4-(2-Methoxycarbonyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0575] 1 - {4'-[4-((E)-2-Methoxycarbonyl-vinyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid ethyl ester (1.249 g, 2.89 mmol) and 10% palladium on carbon (0.135 g) were combined in EtOAc (25 mL) and stirred under ¾ atmosphere for 4 hours. EtOH (25 mL) was added, along with additional 10% palladium on carbon (one spatula), and the reaction was stirred under H2 for 2 days, replacing the balloon of H2 as needed. When no starting material was seen by analytical LCMS, the mixture was filtered through Celite and the filtrate was concentrated to give the title compound.
Figure imgf000159_0001
Step 4: l-{4'-[4-(2-Carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0576] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(2- methoxycarbonyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Figure imgf000159_0002
Step 5: l-{4'-[4-(2-Amino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester
[0577] l-{4'-[4-(2-Carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester (0.825 g, 1.97 mmol), tert-butanol (0.21 mL, 2.16 mmol), diphenylphosphoryl azide (0.47 mL, 2.16 mmol), and triethylamine (0.3 mL, 2.16 mmol) were combined in toluene (8 mL) and stirred at 100 °C for 4 hours. The reaction was cooled to 80 °C and additional iert-butanol (0.21 mL, 2.16 mmol) was added. After stirring overnight at 80 °C, the reaction was cooled to room temperature and submitted to aqueous workup. The crude material was purified by silica gel chromatography (0-100% EtOAc in hexanes). Then, the isolated product was treated with 4 N HC1 in 1 ,4-dioxane and stirred at 60 °C overnight. The solution was filtered and concentrated to give the title compound.
Figure imgf000160_0001
Step 6: l-{4'-[4-(2-Benzoylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0578] l-{4'-[4-(2-Amino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester (0.031 g, 0.08 mmol), benzoyl chloride (0.01 mL, 0.09 mmol), and triethylamine (0.03 mL, 0.24 mmol) were combined in CH2CI2 (0.5 mL) and stirred at room temperature for 1 hour. After aqueous workup, the crude material was purified by silica gel chromatography (0-100% EtOAc in hexanes) to give the title compound.
Figure imgf000160_0002
Step 7: l-{4'-[4-(2-Benzoylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0579] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(2- benzoylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 37: Synthesis of l-{4'-[4-(2-Dibenzylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-37)
Figure imgf000161_0001
Step 1 : l-{4'-[4-(2-Dibenzylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0580] l-{4'-[4-(2-Amino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester (0.131 g, 0.34 mmol) and sodium acetate (0.086 g, 1.01 mmol) were combined in MeOH (1.5 mL). Benzaldehyde (0.04 mL, 0.40 mmol) was added, followed by sodium
cyanoborohydride (0.041 g, 0.60 mmol), and the reaction was stirred at room temperature overnight. After aqueous workup the crude material was purified by silica gel chromatography to give the title compound.
Figure imgf000161_0002
Step 2: l-{4'-[4-(2-Dibenzylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0581] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(2- dibenzylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 38: Synthesis of l-[4'-(3-Methyl-4-phenethylcarbamoyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Compound 1-38)
Figure imgf000162_0001
Step 1: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid phenethyl-amide
[0582] Prepared according to the procedure described in Example 33, Step 4, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carboxylic acid and 2-phenylethylamine.
Figure imgf000162_0002
Step 2: l-[4'-(3-Methyl-4-phenethylcarbamoyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0583] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carboxylic acid phenethyl-amide and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000162_0003
Step 3: l-[4'-(3-Methyl-4-phenethylcarbamoyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0584] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(3-methyl-4- phenethylcarbamoyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester. Example 39: Synthesis of l-{4'-[4-(2-Cyclopropylcarbamoyl-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-39)
Figure imgf000163_0001
Step 1 : l-{4'-[4-(2-Cyclopropylcarbamoyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0585] Prepared according to the procedure described in Example 33, Step 4, using l- {4'-[4-(2- carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and cyclopropylamine.
Figure imgf000163_0002
Step 2: l-{4'-[4-(2-Cyclopropylcarbamoyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0586] Prepared according to the procedure described in Example 3, Step 8, using l- {4'-[4-(2- cyclopropylcarbamoyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 40: Synthesis of l-(4'-{4-[2-(Cyclopropylmethyl-carbamoyl)-ethyl]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-40)
Figure imgf000164_0001
Step 1 : l-(4'-{4-[2-(Cyclopropylmethyl-carbamoyl)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid ethyl ester
[0587] Prepared according to the procedure described in Example 33, Step 4, using l-{4'-[4-(2- carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and (aminomethyl)cyclopropane.
Figure imgf000164_0002
Step 2: l-(4'-{4-[2-(Cyclopropylmethyl-carbamoyl)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid
[0588] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[2- (cyclopropylmethyl-carbamoyl)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 41: Synthesis of l-{4'-[3-Methyl-4-(3-oxo-3-pyrrolidin-l-yl-propyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-41)
Figure imgf000165_0001
Step 1 : l-{4'-[3-Methyl-4-(3-oxo-3-pyrrolidin-l-yl-propyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0589] Prepared according to the procedure described in Example 33, Step 4, using l-{4'-[4-(2- carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and pyrrolidine.
Figure imgf000165_0002
Step 2: l-{4'-[3-Methyl-4-(3-oxo-3-pyrrolidin-l-yl-propyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0590] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (3-oxo-3-pyrrolidin- 1 -yl-propyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 42: Synthesis of l-{4'-[4-(2-Benzylcarbamoyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid (Compound 1-42)
Figure imgf000166_0001
Step 1 : l-{4'-[4-(2-Benzylcarbamoyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0591] Prepared according to the procedure described in Example 33, Step 4, using l-{4'-[4-(2- carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and benzylamine.
Figure imgf000166_0002
Step 2: l-{4'-[4-(2-Benzylcarbamoyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0592] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(2- benzylcarbamoyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 43: Synthesis of l-{4'-[3-Methyl-4-(2-phenylcarbamoyl-ethyl)-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid (Compound 1-43)
Figure imgf000167_0001
Step 1 : l-{4'-[3-Methyl-4-(2-phenylcarbamoyl-ethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0593] Prepared according to the procedure described in Example 33, Step 4, using l-{4'-[4-(2- carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and aniline.
Figure imgf000167_0002
Step 2: l-{4'-[3-Methyl-4-(2-phenylcarbamoyl-ethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0594] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (2-phenylcarbamoyl-ethyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. Example 44: Synthesis of l-[4'-(4-{2-[(2-Fluoro-benzyl)-methyl-carbamoyl]-ethyl}-3-methyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-44)
Figure imgf000168_0001
Step 1 : l-[4'-(4-{2-[(2-Fluoro-benzyl)-methyl-carbamoyl]-ethyl}-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0595] Prepared according to the procedure described in Example 33, Step 4, using l-{4'-[4-(2- carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 2-fluoro-N-methylbenzylamine.
Figure imgf000168_0002
Step 2: l-[4'-(4-{2-[(2-Fluoro-benzyl)-methyl-carbamoyl]-ethyl}-3-methyl-isoxazol-5-yl)- biphenyl-4-yl] -cyclopropanecarboxylic acid
[0596] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(4-{2-[(2- fluoro-benzyl)-methyl-carbamoyl]-ethyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester.
Example 45: Synthesis of l-[4'-(4-Benzyloxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Compound 1-45)
Figure imgf000169_0001
Step 1 : l-[4'-(4-Hydroxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0597] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-methanol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000169_0002
Step 2: l-[4'-(4-Benzyloxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0598] l-[4'-(4-Hydroxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.100 g, 0.265 mmol) and benzyl bromide (0.031 mL, 0.265 mmol) were dissolved in dioxane. Sodium hydride (60% in mineral oil, 0.016 g, 0.398 mmol) was added and the reaction was heated to 60 °C overnight. Upon cooling the reaction was partitioned between EtOAc and ¾0, acidified with 1 N HC1 (aq.) and extracted with EtOAc. After drying the residue was purified by silica gel chromatography (EtOAc/hexanes) to afford the title compound.
Example 46: Synthesis of l-{4'-[4-(2-Chloro-benzyloxymethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-46)
Figure imgf000170_0001
Step 1 : l-{4'-[4-(2-Chloro-benzyloxymethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0599] Prepared according to the procedure described in Example 45, Step 2, using l-[4'-(4- hydroxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and l-bromomethyl-2-chloro-benzene.
Example 47: Synthesis of l-{4'-[3-Methyl-4-(l-phenyl-ethoxymethyl)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-47)
Figure imgf000170_0002
Step 1: l-{4'-[3-Methyl-4-(l-phenyl-ethoxymethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0600] Prepared according to the procedure described in Example 45, Step 2, using l-[4'-(4- hydroxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and (1 -bromo-ethyl)-benzene.
Example 48: Synthesis of l-[4'-(3-Methyl-4-phenethyloxymethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Compound 1-48)
Figure imgf000171_0001
Step 1 : l-[4'-(4-Bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0601] Phosphorus tribromide (0.43 mL, 4.53 mmol) was added to a solution of l-[4'-(4- hydroxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (1.14 g, 3.02 mmol) in DME (30 mL) at 0 °C. The reaction was stirred overnight at room
temperature then cooled to 0 °C and neutralized with saturated aqueous NaHC03 to pH 7. The mixture was partitioned between CH2CI2 and H20 and the aqueous layer was extracted with CH2CI2. The combined organic layers were dried over MgS04, filtered, and concentrated, and the residue was purified by silica gel chromatography to give the title compound.
Figure imgf000171_0002
Step 2: l-[4'-(3-Methyl-4-phenethyloxymethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0602] Sodium hydride (60% in mineral oil, 0.027 g, 0.68 mmol) was added to a solution of l-[4'-(4- bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.200 g, 0.45 mmol) and phenethyl alcohol (0.06 mL, 0.45 mmol) in DMF (5 mL). The reaction was stirred at 55 °C overnight, then partitioned between EtOAc and H20 and acidified with 1 N aqueous HCl. The aqueous layer was extracted with EtOAc, and the combined organic layers were dried over MgS04, filtered and concentrated. The residue was purified by silica gel chromatography to give the title compound. Example 49: Synthesis of l-{4'-[3-Methyl-4-(l-methyl-2-phenyl-ethoxymethyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-49)
Figure imgf000172_0001
Step 1 : l-{4'-[3-Methyl-4-(l-methyl-2-phenyl-ethoxymethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0603] Prepared according to the procedure described in Example 48, Step 2, using l-[4'-(4- bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 1 phenyl-propan-2-ol.
Example 50: Synthesis of l-[4'-(4-Benzylsulfanylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl] cyclopropanecarboxylic acid (Compound 1-50)
Figure imgf000172_0002
Step 1 : l-[4'-(4-Benzylsulfanylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0604] Prepared according to the procedure described in Example 48, Step 2, using l-[4'-(4- bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and benzyl mercaptan.
Figure imgf000173_0001
Step 2: l-[4'-(4-Benzylsulfanylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0605] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(4- benzylsulfanylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester.
Example 51: Synthesis of l-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4- yl]-cyclopropanecarboxylic acid (Compound 1-51)
Figure imgf000173_0002
Step 1: l-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0606] Sodium hydride (60% in mineral oil, 0.070 g, 1.70 mmol) was added to a solution of l-[4'-(4- bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.500 g, 1.13 mmol) and 2-phenylethanethiol (0.15 mL, 1.13 mmol) in DMF. The reaction was stirred at room temperature for 2 hours, and then partitioned between EtOAc and ¾0 and acidified with 1 N aqueous HC1. The aqueous layer was extracted with EtOAc, and the combined organic layers were dried over MgS04, filtered, and concentrated. Analytical LCMS indicated that a mixture of the title compound and the hydrolyzed acid were present, so the crude material was used directly in the hydrolysis step.
Figure imgf000174_0001
Step 2: l-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0607] To 1 -[4'-(3-methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester (1.13 mmol) in MeOH and ¾0 was added lithium hydroxide (excess) and the reaction was stirred at 70 °C for 3 hours. After acidic workup, the crude material was purified by silica gel chromatography to give the title compound.
Example 52: Synthesis of l-[4'-(3-Methyl-4-phenylmethanesulfinylmethyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-52)
Figure imgf000174_0002
Step 1 : l-[4'-(3-Methyl-4-phenylmethanesulfinylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0608] m-Chloroperbenzoic acid (0.024 g, 0.11 mmol) was added to a solution of l-[4'-(4- benzylsulfanylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (0.050 g, 0.11 mmol) in CH2CI2. After stirring for 15 minutes the mixture was concentrated and the residue was purified by preparative HPLC to give the title compound.
Example 53: Synthesis of l-[4'-(3-Methyl-4-phenylmethanesulfonylmethyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-53)
Figure imgf000175_0001
Step 1 : l-[4'-(3-Methyl-4-phenylmethanesulfonylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0609] m-Chloroperbenzoic acid (0.048 g, 0.22 mmol) was added to a solution of l-[4'-(4- benzylsulfanylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (0.050 g, 0.11 mmol) in CH2CI2. After stirring for 15 minutes the mixture was concentrated and the residue was purified by preparative HPLC to give the title compound.
Example 54: Synthesis of l-{4'-[3-Methyl-4-(2-phenyl-ethanesulfinylmethyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-54)
Figure imgf000175_0002
Step 1 : l-{4'-[3-Methyl-4-(2-phenyl-ethanesulfinylmethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0610] m-Chloroperbenzoic acid (0.023 g, 0.11 mmol) was added to a solution of l-[4'-(3-methyl-4- phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (0.050 g, 0.11 mmol) in CH2CI2. After stirring for 15 minutes the mixture was concentrated and the residue was purified by preparative HPLC to give the title compound.
Example 55: Synthesis of l-{4'-[3-Methyl-4-(2-phenyl-ethanesulfonylmethyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-55)
Figure imgf000176_0001
Step 1 : l-{4'-[3-Methyl-4-(2-phenyl-ethanesulfonylmethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0611] m-Chloroperbenzoic acid (0.047 g, 0.21 mmol) was added to a solution of l-[4'-(3-Methyl-4- phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (0.050 g, 0.11 mmol) in CH2CI2. After stirring for 15 minutes, the mixture was concentrated and the residue was purified by preparative HPLC to give the title compound.
Example 56: Synthesis of l-{4'-[3-Methyl-4-(2-phenyl-propoxymethyl)-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid (Compound 1-56)
Figure imgf000176_0002
Step 1 : l-{4'-[3-Methyl-4-(2-phenyl-propoxymethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0612] Prepared according to the procedure described in Example 48, Step 2, using l-[4'-(4- bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2- phenyl-propan- 1 -ol.
Example 57: Synthesis of l-{4'-[4-(Benzyloxycarbonylamino-methyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-57)
Figure imgf000177_0001
Step 1: 4-Azidomethyl-5-(4-bromo-phenyl)-3-methyl-isoxazole
[0613] To 4-bromomethyl-5-(4-bromo-phenyl)-3-methyl-isoxazole (3.68 g, 11.12 mmol) in DMF (30 mL) was added sodium azide (1.83 g, 27.79 mmol) and the reaction was stirred at 80 °C for 1 hour. After aqueous workup, the mixture was concentrated to give the title compound.
Figure imgf000177_0002
Step 2 : C- [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl] -methylamine
[0614] 4-Azidomethyl-5-(4-bromo-phenyl)-3-methyl-isoxazole (3.18 g, 10.85 mmol) in THF (30 mL) and FLO (10 mL) was treated with triphenylphosphine (2.85 g, 10.86 mmol) and the reaction stirred overnight at room temperature. After aqueous workup, the crude material was purified by silica gel chromatography to afford the title compound.
Figure imgf000177_0003
Step 3: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-carbamic acid benzyl ester
[0615] Prepared according to the procedure described in Example 3, Step 7, using C-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl] -methylamine and benzyl chloro formate.
Figure imgf000178_0001
Step 4: l-{4'-[4-(Benzyloxycarbonylamino-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0616] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-carbamic acid benzyl ester and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000178_0002
Step 5: l-{4'-[4-(Benzyloxycarbonylamino-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0617] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4- (benzyloxycarbonylamino-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 58: Synthesis of l-{4'-[3-Methyl-4-(phenylacetylamino-methyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-58)
Figure imgf000179_0001
Step 1 : l-[4'-(4-Aminomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0618] l-{4'-[4-(Benzyloxycarbonylamino-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (0.462 g, 0.90 mmol) was treated with trifluoroacetic acid (10 mL) and the reaction was stirred at 85 °C for 1 hour. The mixture was concentrated to give the title compound.
Figure imgf000179_0002
Step 2: l-{4'-[3-Methyl-4-(phenylacetylamino-methyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0619] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(4- aminomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and phenylacetyl chloride.
Figure imgf000180_0001
Step 3: l-{4'-[3-Methyl-4-(phenylacetylamino-methyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0620] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (phenylacetylamino-methyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester. Example 59: Synthesis of l-{4'-[4-(3-Benzyl-ureidomethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-59)
Figure imgf000180_0002
Step 1 : l-{4'-[4-(3-Benzyl-ureidomethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0621] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(4- aminomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and benzyl isocyanate.
Figure imgf000180_0003
Step 2: l-{4'-[4-(3-Benzyl-ureidomethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0622] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(3- benzyl-ureidomethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 60: Synthesis of l-(4'-{3-Methyl-4-[(3-phenyl-propionylamino)-methyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-60)
Figure imgf000181_0001
Step 1 : l-(4'-{3-Methyl-4-[(3-phenyl-propionylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0623] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(4- aminomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3- phenyl-propionyl chloride.
Figure imgf000181_0002
Step 2: l-(4'-{3-Methyl-4-[(3-phenyl-propionylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0624] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{3-methyl- 4-[(3-phenyl-propionylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 61: Synthesis of l-(4'-{4-[(2-Chloro-phenylmethanesulfonylamino)-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-61)
Figure imgf000182_0001
Step 1: l-(4'-{4-[(2-Chloro-phenylmethanesulfonylamino)-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0625] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(4- aminomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and (2 chloro-phenyl)-methanesulfonyl chloride.
Figure imgf000182_0002
Step 2: l-(4'-{4-[(2-Chloro-phenylmethanesulfonylamino)-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0626] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[(2- chloro-phenylmethanesulfonylamino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 62: Synthesis of l-{4'-[3-Methyl-4-((Z)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-2 yl}-cyclopropanecarboxylic acid (Compo
Figure imgf000182_0003
Step 1: l-(2-Bromo-phenyl)-cyclopropanecarbonitrile
[0627] Prepared according to the procedure described in Example 3, Step 1, using (2-bromo- phenyl)-acetonitrile and 1,2-dibromoethane.
Figure imgf000183_0001
Step 2: l-(2-Bromo-phenyl)-cyclopropanecarboxylic acid
[0628] Prepared according to the procedure described in Example 3, Step 2, using l-(2-bromo- phenyl)-cyclopropanecarbonitrile.
Figure imgf000183_0002
Step 3: l-(2-Bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester
[0629] Prepared according to the procedure described in Example 3, Step 3, using l-(2-bromo- phenyl)-cyclopropanecarboxylic acid.
Figure imgf000183_0003
Step 4: l-[2-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester
[0630] Prepared according to the procedure described in Example 3, Step 4, using l-(2-bromo- phenyl)-cyclopropanecarboxylic acid ethyl ester and bis(pinacolato)diboron.
Figure imgf000183_0004
Step 5: l-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-2-yl}- cyclopropanecarboxylic acid ethyl ester
[0631] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-Bromo- phenyl)-3-methyl-4-(4-phenyl-but- 1 -enyl)-isoxazole and 1 -[2-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000184_0001
Step 6: l-{4'-[3-Methyl-4-((Z)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-2-yl}- cyclopropanecarboxylic acid
[0632] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[3-methyl- 4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-2-yl}-cyclopropanecarboxylic acid ethyl ester. After the reaction the two isomers were separated using preparatory HPLC, and the "Z-" isomer was isolated for this example.
Example 63: Synthesis of l-{4'-[3-Methyl-4-((E)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-2- yl}-cyclopropanecarboxylic acid (C
Figure imgf000184_0002
Step 1 : l-{4'-[3-Methyl-4-((E)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-2-yl}- cyclopropanecarboxylic acid
[0633] Prepared according to the procedure described in Example 62, Step 6, however for this example the "E-" isomer was isolated.
Example 64: Synthesis of l-[4'-(3-Methyl-4-{[(l-phenyl-cyclopropanecarbonyl)-amino]- methyl}-isoxazol-5-yl)-biphenyl-4-yl -cyclopropanecarboxylic acid (Compound 1-64)
Figure imgf000184_0003
Step 1: l-[4'-(3-Methyl-4-{[(l-phenyl-cyclopropanecarbonyl)-amino]-methyl}-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0634] Prepared according to the procedure described in Example 33, Step 4, using l-[4'-(4- aminomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 1 phenyl-cyclopropanecarboxylic acid.
Figure imgf000185_0001
Step 2: l-[4'-(3-Methyl-4-{[(l-phenyl-cyclopropanecarbonyl)-amino]-methyl}-isoxazol-5-yl)- biphenyl-4-yl] -cyclopropanecarboxylic acid
[0635] Prepared according to the procedure described in Example 31, Step 3, using l-[4'-(3 -methyl 4-{[(l-phenyl-cyclopropanecarbonyl)-amino]-methyl}-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester.
Example 65: Synthesis of l-{4'-[4-(Indan-l-ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-65)
Figure imgf000185_0002
Step 1 : 2-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-iV-(R)-indan-l-yl-acetamide
[0636] Prepared according to the procedure described in Example 33, Step 4, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-acetic acid and (R)-indan-l-ylamine.
Figure imgf000186_0001
Step 2: l-{4'-[4-((R)-Indan-l-ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0637] Prepared according to the procedure described in Example 3, Step 5, using 2-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-N-(R)-indan- 1 -yl-acetamide and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000186_0002
Step 3: l-{4'-[4-(Indan-l-ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0638] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-((R)- indan- 1 -ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 66: Synthesis of l-(4'-{4-[2-(l,3-Dihydro-isoindol-2-yl)-2-oxo-ethyl]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-66)
Figure imgf000186_0003
Step 1: 2-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-l-(l,3-dihydro-isoindol-2-yl)-ethanone [0639] Prepared according to the procedure described in Example 33, Step 4, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl] -acetic acid and 2,3-dihydro-lH-isoindole.
Figure imgf000187_0001
Step 2: l-(4'-{4-[2-(l,3-Dihydro-isoindol-2-yl)-2-oxo-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid ethyl ester
[0640] Prepared according to the procedure described in Example 3, Step 5, using 2-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-l-(l ,3-dihydro-isoindol-2-yl)-ethanone and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000187_0002
Step 3: l-(4'-{4-[2-(l,3-Dihydro-isoindol-2-yl)-2-oxo-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid
[0641] Prepared according to the procedure described in Example 31 , Step 3, using l-(4'- {4-[2-(l ,3- dihydro-isoindol-2-yl)-2-oxo-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 67: Synthesis of l-(4'-{3-Methyl-4-[(methyl-phenethyl-amino)-methyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-67)
Figure imgf000188_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-methyl-phenethyl-amine
[0642] 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde (0.150 g, 0.56 mmol) and N-methyl- phenethylamine (0.10 mL, 0.67 mmol) were combined in MeOH and stirred at room temperature overnight. Once no starting material was seen by analytical LCMS, sodium borohydride (0.064 g, 1.69 mmol) was added and the reaction was stirred at room temperature for 1 hour. ¾0 was added and the mixture was extracted with EtOAc. The combined organic layers were dried and
concentrated, and the residue was purified by silica gel chromatography to give the title compound.
Figure imgf000188_0002
Step 2: l-(4'-{3-Methyl-4-[(methyl-phenethyl-amino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0643] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-methyl-phenethyl-amine and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000188_0003
Step 3: l-(4'-{3-Methyl-4-[(methyl-phenethyl-amino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0644] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{3-methyl-4- [(methyl-phenethyl-amino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 68: Synthesis of l-(4'-{4-[(2-Hydroxy-2-phenyl-ethylamino)-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-68)
Figure imgf000189_0001
Step 1: 2-{[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-amino}-l-phenyl-ethanol
[0645] Prepared according to the procedure described in Example 67, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and 2-amino- 1 -phenyl-ethanol.
Figure imgf000189_0002
Step 2: l-(4'-{4-[(2-Hydroxy-2-phenyl-ethylamino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid ethyl ester
[0646] Prepared according to the procedure described in Example 3, Step 5, using 2-{[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-amino} - 1 -phenyl-ethanol and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000190_0001
Step 3: l-(4'-{4-[(2-Hydroxy-2-phenyl-ethylamino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl- yl)-cyclopropanecarboxylic acid
[0647] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[(2- hydroxy-2-phenyl-ethylamino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 69: Synthesis of l-(4'-{3-Methyl-4-[(2-phenyl-propylamino)-methyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-69)
Figure imgf000190_0002
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-(2-phenyl-propyl)-amine
[0648] Prepared according to the procedure described in Example 67, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and 2-phenyl-propylamine.
Figure imgf000190_0003
Step 2: l-(4'-{3-Methyl-4-[(2-phenyl-propylamino)-methyl]-isoxazol-5-yl}-biphi
cyclopropanecarboxylic acid ethyl ester [0649] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-(2-phenyl-propyl)-amine and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000191_0001
Step 3: l-(4'-{3-Methyl-4-[(2-phenyl-propylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0650] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{3-methyl-4- [(2-phenyl-propylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 70: Synthesis of l-[4'-(4-{[Acetyl-(2-phenyl-propyl)-amino]-methyl}-3-methyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-70)
Figure imgf000191_0002
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-(2-phenyl-propyl)-amine
[0651] Prepared according to the procedure described in Example 67, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and β-methylphenethylamine.
Figure imgf000191_0003
Step 2: l-(4'-{3-Methyl-4-[(2-phenyl-propylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0652] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-(2-phenyl-propyl)-amine and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000192_0001
Step 3: l-[4'-(4-{[Acetyl-(2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4- yl]-cyclopropanecarboxylic acid ethyl ester
[0653] Prepared according to the procedure described in Example 3, Step 7, using l-(4'-{3-methyl-4- [(2-phenyl-propylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester and acetyl chloride.
Figure imgf000192_0002
Step 4: l-[4'-(4-{[Acetyl-(2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)-biphi yl]-cyclopropanecarboxylic acid [0654] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(4-{[acetyl- (2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester.
Example 71: Synthesis of l-(4'-{3-Methyl-4-[(methyl-phenylacetyl-amino)-methyl]-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-71)
Figure imgf000193_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-methyl-amine
[0655] Prepared according to the procedure described in Example 67, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and methylamine.
Figure imgf000193_0002
Step 2: l-[4'-(3-Methyl-4-methylaminomethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0656] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-methyl-amine and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000193_0003
Step 3: l-(4'-{3-Methyl-4-[(methyl-phenylacetyl-amino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0657] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(3-methyl-4- methylaminomethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and phenyl-acetyl chloride.
Figure imgf000194_0001
Step 4: l-(4'-{3-Methyl-4-[(methyl-phenylacetyl-amino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0658] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{3-methyl-4- [(methyl-phenylacetyl-amino)-methyl]-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 72: Synthesis of l-[4'-(3-Methyl-4-{[methyl-(2-phenoxy-propionyl)-amino]-methyl}- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-72)
Figure imgf000194_0002
Step 1: l-[4'-(3-Methyl-4-{[methyl-(2-phenoxy-propionyl)-amino]-methyl}-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0659] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(3-methyl-4- methylaminomethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2- phenoxy-propionyl chloride.
Figure imgf000195_0001
Step 2: l-[4'-(3-Methyl-4-{[methyl-(2-phenoxy-propionyl)-amino]-methyl}-isoxazol-5-yl)- biphenyl-4-yl] -cyclopropanecarboxylic acid
[0660] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(3-methyl-4- {[methyl-(2-phenoxy-propionyl)-amino]-methyl}-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester.
Example 73: Synthesis of l-[4'-(4-{[Cyclopropanecarbonyl-(2-phenyl-propyl)-amino]-methyl}- 3-methyl-isoxazol-5-yl)-biphenyl-4- -cyclopropanecarboxylic acid (Compound 1-73)
Figure imgf000195_0002
Step 1: l-[4'-(4-{[Cyclopropanecarbonyl-(2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol- 5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid ethyl ester
[0661] Prepared according to the procedure described in Example 3, Step 7, using l-(4'-{3-Methyl- 4-[(2-phenyl-propylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester and cyclopropanecarbonyl chloride.
Figure imgf000196_0001
Step 2: l-[4'-(4-{[Cyclopropanecarbonyl-(2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol- 5-yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid
[0662] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(4- {[cyclopropanecarbonyl-(2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester.
Example 74: Synthesis of l-[4'-(4-{[Benzoyl-(2-phenyl-propyl)-amino]-methyl}-3-methyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-74)
Figure imgf000196_0002
Step 1: l-[4'-(4-{[Benzoyl-(2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)-biphenyl- 4-yl] -cyclopropanecarboxylic acid ethyl ester
[0663] Prepared according to the procedure described in Example 3, Step 7, using l-(4'-{3-methyl-4- [(2-phenyl-propylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester and benzoyl chloride.
Figure imgf000197_0001
Step 2: l-[4'-(4-{[Benzoyl-(2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)-biphen 4-yl] -cyclopropanecarboxylic acid
[0664] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(4- {[benzoyl-(2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester.
Example 75: Synthesis of l-(4'-{3-Methyl-4-[2-(pyridin-2-ylmethoxy)-ethyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-75)
Figure imgf000197_0002
Step 1: l-(4'-{3-Methyl-4-[2-(pyridin-2-ylmethoxy)-ethyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0665] Prepared according to the procedure described in Example 34, Step 4, using l-{4'-[4-(2- hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and 2-bromomethyl-pyridine.
Figure imgf000198_0001
Step 2: l-(4'-{3-Methyl-4-[2-(pyridin-2-ylmethoxy)-ethyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0666] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{3-methyl- 4-[2-(pyridin-2-ylmethoxy)-ethyl]-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 76: Synthesis of l-(4'-{3-Methyl-4-[2-(pyridin-3-ylmethoxy)-ethyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-76)
Figure imgf000198_0002
Step 1: l-(4'-{3-Methyl-4-[2-(pyridin-3-ylmethoxy)-ethyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0667] Prepared according to the procedure described in Example 34, Step 4, using l-{4'-[4-(2- hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 3-bromomethyl-pyridine.
Figure imgf000199_0001
Step 2: l-(4'-{3-Methyl-4-[2-(pyridin-3-ylmethoxy)-ethyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0668] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{3-methyl- 4-[2-(pyridin-3-ylmethoxy)-ethyl]-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 77: Synthesis of l-(4'-{3-Methyl-4-[2-(pyridin-4-ylmethoxy)-ethyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-77)
Figure imgf000199_0002
Step 1: l-(4'-{3-Methyl-4-[2-(pyridin-4-ylmethoxy)-ethyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0669] Prepared according to the procedure described in Example 34, Step 4, using l-{4'-[4-(2- hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 4-bromomethyl-pyridine.
Figure imgf000200_0001
Step 2: l-(4'-{3-Methyl-4-[2-(pyridin-4-ylmethoxy)-ethyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0670] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{3-methyl- 4-[2-(pyridin-4-ylmethoxy)-ethyl]-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 78: Synthesis of l-(4'-{3-Methyl-4-[2-(l-phenyl-ethoxy)-ethyl]-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid (Compound 1-78)
Figure imgf000200_0002
Step 1: l-(4'-{3-Methyl-4-[2-(l-phenyl-ethoxy)-ethyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0671] Prepared according to the procedure described in Example 34, Step 4, using l-{4'-[4-(2- hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and (1 -bromoethyl)benzene.
Example 79: Synthesis of l-(4'-{4-[2-(2-Chloro-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-79)
Figure imgf000201_0001
Step 1 : l-(4'-{4-[2-(2-Chloro-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0672] Prepared according to the procedure described in Example 34, Step 4, using l-{4'-[4-(2- hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and l-bromomethyl-2-chloro-benzene.
Example 80: Synthesis of l-(4'-{4-[2-(3-Chloro-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-80)
Figure imgf000201_0002
Step 1: l-(4'-{4-[2-(3-Chloro-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0673] Prepared according to the procedure described in Example 34, Step 4, using l-{4'-[4-(2- Hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and l-bromomethyl-3-chloro-benzene.
Example 81: Synthesis of l-(4'-{4-[2-(4-Chloro-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-81)
Figure imgf000202_0001
Step 1 : l-(4'-{4-[2-(4-Chloro-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0674] Prepared according to the procedure described in Example 34, Step 4, using l-{4'-[4-(2- hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and l-bromomethyl-4-chloro-benzene.
Example 82: Synthesis of l-(4'-{3-Methyl-4-[2-(methyl-phenyl-carbamoyl)-ethyl]-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-82)
Figure imgf000202_0002
Step 1 : l-(4'-{3-Methyl-4-[2-(methyl-phenyl-carbamoyl)-ethyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0675] Prepared according to the procedure described in Example 34, Step 4, using THF as the solvent and the following starting materials: l-{4'-[3-methyl-4-(2-phenylcarbamoyl-ethyl)-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid and iodomethane.
Example 83: Synthesis of l-{4'-[4-(2-Benzylsulfanyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-83)
Figure imgf000203_0001
Step 1: Methanesulfonic acid 2-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethyl ester
[0676] To a solution of 2-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol (0.100 g, 0.35 mmol) and triethylamine (0.10 mL, 0.71mmol) in THF at 0 °C was added methanesulfonyl chloride (0.05 mL, 0.62 mmol) and the reaction stirred at 0 °C for 1 hour. The mixture was diluted with H20 and extracted with EtOAc, and the combined organic layers were washed with H 0, saturated aqueous NaHCC>3, and brine. Dried over MgS04, filtered, and concentrated to give the title compound.
Figure imgf000203_0002
Step 2 : 4-(2-Benzylsulfanyl-ethyl)-5-(4-bromo-phenyl)-3-methyl-isoxazole
[0677] Benzyl mercaptan (0.06 mL, 0.45 mmol) and sodium hydroxide (0.030 g, 0.76 mmol) were combined in EtOH. Methanesulfonic acid 2-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethyl ester (0.161 g, 0.45 mmol) was added and the reaction was stirred at 70 °C for 2 hours. The mixture was diluted with EtOAc and H20 and separated. The organic layer was washed with H20 and brine, dried over Na2S04, filtered, and concentrated to give the title compound.
Figure imgf000203_0003
Step 3: l-{4'-[4-(2-Benzylsulfanyl-ethyl)-3-methyl-isoxazol-5-yl]-biphi
cyclopropanecarboxylic acid ethyl ester [0678] Prepared according to the procedure described in Example 3, Step 5, using 4-(2- benzylsulfanyl-ethyl)-5-(4-bromo-phenyl)-3-methyl-isoxazole and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000204_0001
Step 4: l-{4'-[4-(2-Benzylsulfanyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0679] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(2- benzylsulfanyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 84: Synthesis of l-{4'-[3-Methyl-4-(2-phenylmethanesulfinyl-ethyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-84)
Figure imgf000204_0002
Step 1 : l-{4'-[3-Methyl-4-(2-phenylmethanesulfinyl-ethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0680] Prepared according to the procedure described in Example 52, Step 1, using l-{4'-[4-(2- benzylsulfanyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Figure imgf000205_0001
Step 2: l-{4'-[3-Methyl-4-(2-phenylmethanesulfinyl-ethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0681] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (2-phenylmethanesulfinyl-ethyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 85: Synthesis of l-{4'-[3-Methyl-4-(2-phenylmethanesulfonyl-ethyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-85)
Figure imgf000205_0002
Step 1: l-{4'-[3-Methyl-4-(2-phenylmethanesulfonyl-ethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0682] Prepared according to the procedure described in Example 53, Step 1, using l-{4'-[4-(2- benzylsulfanyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Figure imgf000206_0001
Step 2: l-{4'-[3-Methyl-4-(2-phenylmethanesulfonyl-ethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0683] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (2-phenylmethanesulfonyl-ethyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 86: Synthesis of l-{4'-[4-(2-hydroxy-2-phenyl-propoxymethyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-86)
Figure imgf000206_0002
Step 1: l-{4'-[4-(2-Hydroxy-2-phenyl-propoxymethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0684] Prepared according to the procedure described in Example 48, Step 2, using l-[4'-(4- bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2- phenyl-propane- 1 ,2-diol.
Example 87: Synthesis of l-[4'-(3-Methyl-4-{[methyl-(2-phenyl-propyl)-amino]-methyl}- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-87)
Figure imgf000207_0001
Step 1: l-[4'-(3-Methyl-4-{[methyl-(2-phenyl-propyl)-amino]-methyl}-isoxazol-5-yl)-biphenyl-4- yl]-cyclopropanecarboxylic acid ethyl ester
[0685] Prepared according to the procedure described in Example 67, Step 1, using sodium triacetoxyborohydride instead of sodium borohydride and the following starting materials: l-(4'-{3- methyl-4-[(2-phenyl-propylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester and formaldehyde.
Figure imgf000207_0002
Step 2: l-[4'-(3-Methyl-4-{[methyl-(2-phenyl-propyl)-amino]-methyl}-isoxazol-5-yl)-biphenyl-4- yl]-cyclopropanecarboxylic acid
[0686] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(3-methyl-4- {[methyl-(2-phenyl-propyl)-amino]-methyl}-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester.
Example 88: Synthesis of l-{4'-[3-Methyl-4-(2-oxo-4-phenyl-butyl)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-88)
Figure imgf000208_0001
Step 1 : l-{4'-[3-Methyl-4-(3-phenethyl-oxiranyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0687] l-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (0.343 g, 0.718 mmol) and m-chloroperbenzoic acid (0.181 g, 0.79 mmol) were stirred in CH2CI2 overnight. An additional portion of m-chloroperbenzoic acid was added and the reaction stirred overnight again. Standard aqueous workup and silica gel chromatography (0- 100% EtOAc in hexanes) afforded the title compound.
Figure imgf000208_0002
Step 2: l-{4'-[3-Methyl-4-(2-oxo-4-phenyl-butyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0688] To a solution of l-{4'-[3-methyl-4-(3-phenethyl-oxiranyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (0.421 g, 0.85 mmol) in benzene (4.2 mL) was added boron trifluoride diethyl etherate (1 M in Et20, 0.94 mL, 0.94 mmol) and the reaction was stirred for 1 hour. The mixture was diluted with EtOAc and H20, separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound.
Figure imgf000209_0001
Step 3: l-{4'-[3-Methyl-4-(2-oxo-4-phenyl-butyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0689] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (2-oxo-4-phenyl-butyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 89: Synthesis of l-{4'-[4-(2-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-89)
Figure imgf000209_0002
Step 1 : l-{4'-[4-(2-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0690] l-{4'-[3-Methyl-4-(2-oxo-4-phenyl-butyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (0.015 g, 0.03 mmol) in MeOH was treated with sodium borohydride (0.001 g, 0.03 mmol) and stirred at room temperature for 5 minutes. Aqueous workup provided the title compound.
Example 90: Synthesis of l-{4'-[4-(Indan-2-ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-90)
Figure imgf000210_0001
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl] -acetic acid benzyl ester
[0691] Benzyl bromide (0.491 mL, 4.13 mmol) and cesium carbonate (1.68 g, 5.16 mmol) were added to [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-acetic acid (1.02 g, 3.44 mmol) and the reaction stirred at room temperature. After two hours, a second aliquot of benzyl bromide (0.100 mL) was added. When the reaction was complete by analytical LCMS it was submitted to standard aqueous workup to obtain the title compound.
Figure imgf000210_0002
Step 2: l-[4'-(4-Benzyloxycarbonylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0692] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-acetic acid benzyl ester and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000210_0003
Step 3: l-[4'-(4-Carboxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0693] l-[4'-(4-Benzyloxycarbonylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester (0.171 g, 0.35 mmol) was stirred in THF (3 mL) and MeOH (3 niL) and 1 N aqueous NaOH (1 niL) was added. After 1.5 hours the reaction was submitted to standard aqueous workup to afford the title compound.
Figure imgf000211_0001
Step 4: l-{4'-[4-(Indan-2-ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0694] Prepared according to the procedure described in Example 33, Step 4, using l-[4'-(4- carboxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and indan-2-ylamine.
Figure imgf000211_0002
Step 5: l-{4'-[4-(Indan-2-ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0695] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(indan- 2-ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 91: Synthesis of l-[4'-(4-{[(2-Fluoro-benzyl)-methyl-carbamoyl]-methyl}-3-methyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-91)
Figure imgf000212_0001
Step 1: l-[4'-(4-{[(2-Fluoro-benzyl)-methyl-carbamoyl]-methyl}-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0696] Prepared according to the procedure described in Example 33, Step 4, using l-[4'-(4- carboxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and (2-fluoro-benzyl)-methyl-amine.
Figure imgf000212_0002
Step 2: l-[4'-(4-{[(2-Fluoro-benzyl)-methyl-carbamoyl]-methyl}-3-methyl-isoxazol-5-yl)- biphenyl-4-yl] -cyclopropanecarboxylic acid
[0697] Prepared according to the procedure described in Example 31, Step 3, using l-[4'-(4-{[(2- fluoro-benzyl)-methyl-carbamoyl]-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester.
Example 92: Synthesis of l-(4'-{4-[((lS,2R)-2-Hydroxy-indan-l-ylcarbamoyl)-methyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl -cyclopropanecarboxylic acid (Compound 1-92)
Figure imgf000212_0003
Step 1 : l-(4'-{4-[((lS,2R)-2-Hydroxy-indan-l-ylcarbamoyl)-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0698] Prepared according to the procedure described in Example 33, Step 4, using l-[4'-(4- carboxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and (lS,2R)-l-amino-indan-2-ol.
Figure imgf000213_0001
Step 2: l-(4'-{4-[((lS,2R)-2-Hydroxy-indan-l-ylcarbamoyl)-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0699] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4- [((1 S,2Pv)-2-hydroxy-indan- 1 -ylcarbamoyl)-methyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 93: Synthesis of l-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-93)
Figure imgf000213_0002
Step 1: l-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0700] To a solution of l-{4'-[3-methyl-4-(2-oxo-4-phenyl-butyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (0.182 g, 0.37 mmol) in benzene (1.5 mL) was added (diethylamino)sulfur trifluoride (DAST) (0.11 mL, 0.81 mmol). The reaction was stirred overnight at room temperature then at 65 °C for a further 24 hours. Additional (diethylamino)sulfur trifluoride (0.11 mL, 0.81 mmol) was added but no product was observed by analytical LCMS. Bise methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor) (50% in toluene, 5 mL) was then added and the reaction stirred at 65 °C overnight. After cooling to room temperature, the mixture was exctracted with CH2C12 and saturated aqueous NaHC03. The crude material was purified by silica gel chromatography (0-25% EtOAc in hexanes) to give the title compound.
Figure imgf000214_0001
Step 2: l-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0701] Prepared according to the procedure described in Example 3, Step 8, using l- {4'-[4-(2,2- difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 94: Synthesis of l-{4'-[3-Methyl-4-((Z)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-94)
Figure imgf000214_0002
Step 1 : l-{4'-[3-Methyl-4-((Z)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0702] Prepared according to the procedure described in Example 31 , Step 3, using l- {4'-[3-methyl- 4-((Z)-4-phenyl-but- 1 -enyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. After the reaction the crude material was purified by preparatory HPLC to afford two separable isomers, of which the minor product was the title compound. Example 95: Synthesis of l-{4'-[3-Methyl-4-((E)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphi yl}-cyclopropanecarboxylic acid (C
Figure imgf000215_0001
Step 1 : l-{4'-[3-Methyl-4-((E)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0703] Prepared according to the procedure described in Example 94, Step 1, and the major isomer was the title compound.
Example 96: Synthesis of l-[4'-(4-Isobutylsulfanylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4- yl]-cyclopropanecarboxylic acid (Compound 1-96)
Figure imgf000215_0002
Step 1 : l-[4'-(4-Isobutylsulfanylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0704] Prepared according to the procedure described in Example 48, Step 2, using l-[4'-(4- bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2- methyl-propane- 1 -thiol .
Example 97: Synthesis of l-(4'-{3-Methyl-4-[l-(l-phenyl-ethylcarbamoyl)-ethyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-97)
Figure imgf000216_0001
Step 1 : l-{4'-[4-(l-Carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0705] Prepared according to the procedure described in Example 82, Step 1, using l-[4'-(4- benzyloxycarbonylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and iodomethane.
Figure imgf000216_0002
Step 2: l-(4'-{3-Methyl-4-[l-(l-phenyl-ethylcarbamoyl)-ethyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0706] Prepared according to the procedure described in Example 33, Step 4, using l-{4'-[4-(l- carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 1 -phenyl-ethylamine .
Figure imgf000216_0003
Step 3: l-(4'-{3-Methyl-4-[l-(l-phenyl-ethylcarbamoyl)-ethyl]-isoxazol-5-yl}-biphi
cyclopropanecarboxylic acid [0707] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{3-methyl- 4-[ 1 -(1 -phenyl-ethylcarbamoyl)-ethyl]-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 98: Synthesis of l-(4'-{3-Methyl-4-[(2-methyl-2-phenyl-propionylamino)-methyl]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-98)
Figure imgf000217_0001
Step 1 : l-(4'-{3-Methyl-4-[(2-methyl-2-phenyl-propionylamino)-methyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0708] l-[4'-(4-Aminomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.038 g, 0.1 mmol), α,α-dimethylphenylacetic acid (0.020 g, 0.12 mmol), l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC) (0.023 g, 0.12 mmol), 1 -hydroxybenzotriazole (HOBt) (0.016 g, 0.12 mmol), and triethylamine (0.56 mL, 0.4 mmol) were combined in CH2CI2 (1 mL) and stirred at room temperature overnight. The mixture was concentrated and the residue was purified by silica gel chromatography (0-50% EtOAc in hexanes) to give the title compound.
Figure imgf000217_0002
Step 2: l-(4'-{3-Methyl-4-[(2-methyl-2-phenyl-propionylamino)-methyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0709] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{3-methyl-4- [(2-methyl-2-phenyl-propionylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester. Example 99: Synthesis of l-{4'-[4-((S)-Indan-l-ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-99)
Figure imgf000218_0001
Step 1 : 2-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-iV-(S)-indan-l-yl-acetamide
[0710] Prepared according to the procedure described in Example 98, Step 1, using [5-(4 phenyl)-3-methyl-isoxazol-4-yl]-acetic acid and (S)-(+)- 1 -aminoindan.
Figure imgf000218_0002
Step 2: l-{4'-[4-((S)-Indan-l-ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0711] Prepared according to the procedure described in Example 3, Step 5, using 2-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-N-(S)-indan- 1 -yl-acetamide and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000218_0003
Step 3: l-{4'-[4-((S)-Indan-l-ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]-biphi
cyclopropanecarboxylic acid [0712] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-((S)- indan- 1 -ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 100: Synthesis of l-(4'-{3-Methyl-4-[(2-phenoxy-propionylamino)-methyl]-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-100)
Figure imgf000219_0001
Step 1 : l-(4'-{3-Methyl-4-[(2-phenoxy-propionylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0713] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(4- aminomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2- phenoxy-propionyl chloride.
Figure imgf000219_0002
Step 2: l-(4'-{3-Methyl-4-[(2-phenoxy-propionylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0714] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{3-methyl- 4-[(2-phenoxy-propionylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 101: Synthesis of (l-{4'-[3-Methyl-4-((Z)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropyl)-acetic acid (Compound 1-101)
Figure imgf000220_0001
Step 1: [l-(4-Bromo-phenyl)-cyclopropyl]-methanol
[0715] To l-(4-bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester (10.0 g, 37.2 mmol) in THF (100 mL) at 0 °C was added lithium aluminum hydride (2.11 g, 55.7 mmol) and the reaction was stirred for 1 hour at room temperature. The mixture was quenched with 1¾0 (2 mL), followed by 4 N aqueous NaOH (2 mL) and additional 1¾0 (6 mL). After stirring for 15 minutes, the solid precipitate was removed by filtration and the filtrate was concentrated and dried to give the title compound.
Figure imgf000220_0002
Step 2: l-Bromo-4-(l-bromomethyl-cyclopropyl)-benzene
[0716] Prepared according to the procedure described in Example 33, Step 1, using [l-(4-bromo- phenyl)-cyclopropyl]-methanol and phospho de.
Figure imgf000220_0003
Step 3: [l-(4-Bromo-phenyl)-cyclopropyl]-acetonitrile
[0717] Prepared according to the procedure described in Example 33, Step 2, using l-bromo-4-(l- bromomethyl-cyclopropyl)-benzene and potassium cyanide.
Figure imgf000220_0004
Step 4: [l-(4-Bromo-phenyl)-cyclopropyl]-acetic acid
[0718] [l-(4-Bromo-phenyl)-cyclopropyl]-acetonitrile (3.95 g, 16.73 mmol) and potassium hydroxide (3.75 g, 66.92 mmol) were combined in ethylene glycol (24 mL) and stirred at 180 °C overnight. The mixture was acidified with 6 N aqueous HCl and extracted three times with EtOAc. The combined organic layers were dried and concentrated to yield the title compound.
Figure imgf000221_0001
Step 5: [l-(4-Bromo-phenyl)-cyclopropyl]-acetic acid ethyl ester
[0719] [l-(4-Bromo-phenyl)-cyclopropyl]-acetic acid (16.73 mmol) was treated with concentrated sulfuric acid (2 mL) in EtOH at 80 °C overnight. The mixture was concentrated and submitted to standard aqueous workup. The crude material was purified by preparative HPLC to afford the title compound.
Figure imgf000221_0002
Step 6: {l-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropyl}-acetic acid ethyl ester
[0720] Prepared according to the procedure described in Example 3, Step 4, using [l-(4-bromo- phenyl)-cyclopropyl]-acetic acid ethyl ester and bis(pinacolato)diboron.
Figure imgf000221_0003
Step 7: (l-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)- acetic acid ethyl ester
[0721] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-3-methyl-4-(4-phenyl-but- 1 -enyl)-isoxazole and { 1 -[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000222_0001
Step 8: (l-{4'-[3-Methyl-4-((Z)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)- acetic acid
[0722] Prepared according to the procedure described in Example 31, Step 3, using (l-{4'-[3-methyl- 4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid ethyl ester. After the reaction the crude material was purified by preparatory HPLC to afford two separable isomers, of which the minor product was the title compound.
Example 102: Synthesis of (l-{4'-[3-Methyl-4-((E)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropyl)-acetic acid (Compound 1-102)
Figure imgf000222_0002
Step 1 : l-{4'-[3-Methyl-4-((E)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0723] Prepared according to the procedure described in Example 101, Step 8, and the major isomer was the title compound.
Example 103: Synthesis of l-(4'-{3-Methyl-4-[((R)-2-phenyl-propylamino)-methyl]-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-103)
Figure imgf000223_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-((R)-2-phenyl-propyl)-amine
[0724] Prepared according to the procedure described in Example 67, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and (R)-(+)-P-methylphenethylamine.
Figure imgf000223_0002
Step 2: l-(4'-{3-Methyl-4-[((R)-2-phenyl-propylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0725] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-((R)-2-phenyl-propyl)-amine and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000223_0003
Step 3: l-(4'-{3-Methyl-4-[((R)-2-phenyl-propylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0726] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{3-methyl-4- [((R)-2-phenyl-propylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester. Example 104: Synthesis of l-[4'-(4-{[Ethyl-((R)-2-phenyl-propyl)-amino]-methyl} isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-104)
Figure imgf000224_0001
Step 1: l-[4'-(4-{[Ethyl-((R)-2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0727] Prepared according to the procedure described in Example 67, Step 1, using l-(4'-{3-methyl- 4-[((R)-2-phenyl-propylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester and acetaldehyde.
Figure imgf000224_0002
Step 2: l-[4'-(4-{[Ethyl-((R)-2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)- biphenyl-4-yl] -cyclopropanecarboxylic acid
[0728] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(4-{[ethyl- ((R)-2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester.
Example 105: Synthesis of l-[4'-(3-Methyl-4-{2-[(R)-methyl-(l-phenyl-ethyl)-carbamoyl]- ethyl}-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-105)
Figure imgf000225_0001
Step 1 : l-[4'-(3-Methyl-4-{2-[methyl-((R)-l-phenyl-ethyl)-carbamoyl]-ethyl}-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0729] Prepared according to the procedure described in Example 98, Step 1 , using l- {4'-[4-(2- carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and (R)-(+)-N,a-dimethylbenzylamine.
Figure imgf000225_0002
Step 2: l-[4'-(3-Methyl-4-{2-[methyl-((R)-l-phenyl-ethyl)-carbamoyl]-ethyl}-isoxazol-5-yl)- biphenyl-4-yl] -cyclopropanecarboxylic acid
[0730] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(3-methyl-4- (2-[methyl-((R)- 1 -phenyl-ethyl)-carbamoyl]-ethyl} -isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester.
Example 106: Synthesis of l-(4'-{3-Methyl-4-[2-(l-methyl-l-phenyl-ethylcarbamoyl)-ethyl]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-106)
Figure imgf000226_0001
Step 1 : l-(4'-{3-Methyl-4-[2-(l-methyl-l-phenyl-ethylcarbamoyl)-ethyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0731] Prepared according to the procedure described in Example 33, Step 4, using l-{4'-[4-(2- carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 1 -methyl- 1 -phenyl-ethylamine.
Figure imgf000226_0002
Step 2: l-(4'-{3-Methyl-4-[2-(l-methyl-l-phenyl-ethylcarbamoyl)-ethyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0732] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{3-methyl-4- [2-( 1 -methyl- 1 -phenyl-ethylcarbamoyl)-ethyl]-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 107: Synthesis of l-(4'-{4-[3-(l,3-Dihydro-isoindol-2-yl)-3-oxo-propyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-107)
Figure imgf000227_0001
Step 1: l-(4'-{4-[3-(l,3-Dihydro-isoindol-2-yl)-3-oxo-propyl]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid ethyl ester
[0733] Prepared according to the procedure described in Example 33, Step 4, using l-{4'-[4-(2- carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 2,3-dihydro-lH-isoindole.
Figure imgf000227_0002
Step 2: l-(4'-{4-[3-(l,3-Dihydro-isoindol-2-yl)-3-oxo-propyl]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid
[0734] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[3-(l,3- dihydro-isoindol-2-yl)-3-oxo-propyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 108: Synthesis of [4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4- yl]-acetic acid (Compound 1-108)
Figure imgf000228_0001
Step 1 : 5-(4-Bromo-phenyl)-3-methyl-4-phenethylsulfanylmethyl-isoxazole
[0735] Prepared according to the procedure described in Example 51 , Step 1 , using 4-bromomethyl- 5-(4-bromo-phenyl)-3-methyl-isoxazole and 2-phenylethanethiol.
Figure imgf000228_0002
Step 2: [4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-acetic acid ethyl ester
[0736] Prepared according to the procedure described in Example 3, Step 5, using (Ι , - bis(diphenylphosphino)ferrocene)-dichloropalladium(II) as the catalyst and the following starting materials: 5-(4-bromo-phenyl)-3-methyl-4-phenethylsulfanylmethyl-isoxazole and [4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester.
Figure imgf000228_0003
Step 3: [4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-acetic acid
[0737] Prepared according to the procedure described in Example 3, Step 8, using [4'-(3-methyl-4- phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-acetic acid ethyl ester. Example 109: Synthesis of {4'-[3-Methyl-4-(2-phenyl-ethanesulfonylmethyl)-isoxazol-5-yl]- biphenyl-4-yl}-acetic acid (Compound 1-109)
Figure imgf000229_0001
Step 1 : {4'-[3-Methyl-4-(2-phenyl-ethanesulfonylmethyl)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid
[0738] Prepared according to the procedure described in Example 53, Step 1, using [4'-(3-methyl-4- phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-acetic acid.
Example 110: Synthesis of l-{4'-[3-Methyl-4-(4-phenyl-pent-l-enyl)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-110)
Figure imgf000229_0002
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-triphenyl-phosphonium bromide
[0739] 4-Bromomethyl-5-(4-bromo-phenyl)-3-methyl-isoxazole (0.8066 g, 2.44 mmol) and triphenylphosphine (0.7026 g, 2.68 mmol) were combined in toluene (8 mL) and heated to 75 °C for 75 minutes. Analytical LCMS indicated complete conversion so the reaction was cooled, filtered (rinsing with toluene) and concentrated to afford the title compound, which was used in the next step without further purification.
Figure imgf000229_0003
Step 2: 5-(4-Bromo-phenyl)-3-methyl-4-(4-phenyl-pent-l-enyl)-isoxazole [0740] [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-triphenyl-phosphonium bromide (0.2678 g, 0.451 mmol) was dissolved in THF (2.7 mL) at 0 °C. Potassium tert-butoxide (1 M in THF, 0.5 mL, 0.50 mmol) was added and after stirring 15 minutes 3-phenyl-butyraldehyde (0.074 mL, 0.50 mmol) was added and the ice bath was removed. After 15 minutes, analytical LCMS indicated complete reaction. Standard aqueous workup followed by silica gel chromatography (0- 20% EtOAc in hexanes) afforded the
Figure imgf000230_0001
Step 3: l-{4'-[3-Methyl-4-(4-phenyl-pent-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0741] Prepared according to the procedure described in Example 3, Step 5, using
dichlorobis(triphenylphosphine)palladium(II) as the catalyst and the following starting materials: 5- (4-bromo-phenyl)-3-methyl-4-(4-phenyl-pent- 1 -enyl)-isoxazole and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000230_0002
Step 4: l-{4'-[3-Methyl-4-(4-phenyl-pent-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0742] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[3-methyl- 4-(4-phenyl-pent- 1 -enyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. Example 111: Synthesis of l-(4'-{4-[4-(4-Isopropyl-phenyl)-3-methyl-but-l-enyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-111)
Figure imgf000231_0001
Step 1 : 5-(4-Bromo-phenyl)-4-[4-(4-isopropyl-phenyl)-3-methyl-but-l-enyl]-3-methyl-isoxazole
[0743] Prepared according to the procedure described in Example 110, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-triphenyl-phosphonium bromide and 3-(4-isopropyl-phenyl)- 2-methyl-propionaldehyde.
Figure imgf000231_0002
Step 2: l-(4'-{4-[4-(4-Isopropyl-phenyl)-3-methyl-but-l-enyl]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid ethyl ester
[0744] Prepared according to the procedure described in Example 3, Step 5, using
dichlorobis(triphenylphosphine)palladium(II) as the catalyst and the following starting materials: 5- (4-bromo-phenyl)-4-[4-(4-isopropyl-phenyl)-3-methyl-but- 1 -enyl]-3-methyl-isoxazole and 1 -[4- (4,4,5,5-tetramethyl-[l,3,2]dioxabo carboxylic acid ethyl ester.
Figure imgf000231_0003
Step 3: l-(4'-{4-[4-(4-Isopropyl-phenyl)-3-methyl-but-l-enyl]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid [0745] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[4-(4- isopropyl-phenyl)-3-methyl-but-l-enyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 112: Synthesis of l-{4'-[3-Methyl-4-((Z)-4-phenyl-pent-l-enyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-112)
Figure imgf000232_0001
Step 1 : l-{4'-[3-Methyl-4-((Z)-4-phenyl-pent-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0746] Prepared according to the procedure described in Example 110, Step 4, and after the reaction the material was purified by preparatory HPLC to afford two separable isomers, of which the minor product was the title compound.
Example 113: Synthesis of l-{4'-[3-Methyl-4-((E)-4-phenyl-pent-l-enyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-113)
Figure imgf000232_0002
Step 1 : l-{4'-[3-Methyl-4-((E)-4-phenyl-pent-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0747] Prepared according to the procedure described in Example 110, Step 4, and after the reaction the material was purified by preparatory HPLC to afford two separable isomers, of which the major product was the title compound. Example 114: Synthesis of l-{4'-[4-(3-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-114)
Figure imgf000233_0001
Step 1 : l-{4'-[4-(3-Hydroxy-propyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0748] l-{4'-[4-(2-Carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester (0.336 g, 0.8 mmol) and triethylamine (0.145 mL, 1.04 mmol) were dissolved in THF (6.6 mL) under N2 atmosphere and cooled to 0 °C. Isobutyl chloroformate (0.126 mL, 0.96 mmol) was added and the reaction stirred for 40 minutes and was then filtered, rinsing with dioxane and THF, and the filtrate was collected and concentrated. The crude material was dissolved in THF (10 mL), H20 (4.4 mL), and EtOH (1.9 mL), and then sodium borohydride (0.176 g, 4.6 mmol) was added. The reaction was heated to 50 °C for five hours then cooled and submitted to standard aqueous workup. The residue was purified on silica gel (0-80% EtOAc in hexanes) to yield the title compound.
Figure imgf000233_0002
Step 2: l-{4'-[3-Methyl-4-(3-oxo-propyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester
[0749] Prepared according to the procedure described in Example 26, Step 1, using l-{4'-[4-(3- hydroxy-propyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Figure imgf000234_0001
Step 3: l-{4'-[4-(3-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0750] l- {4'-[3-Methyl-4-(3-oxo-propyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester (0.250 g, 0.62 mmol) was dissolved in THF and cooled to 0 °C under N2 atmosphere. Benzylmagnesium bromide (19% in THF, 0.62 mL, 0.62 mmol) was added and the reaction was allowed to slowly warm to room temperature. After 1.5 hours, the reaction was cooled to 0 °C and additional benzylmagnesium bromide (19% in THF, 0.1 mL, 0.10 mmol) was added, and the reaction was stirred for 30 minutes. The mixture was quenched with saturated aqueous NH4CI and extracted with EtOAc. The combined organic layers were dried and concentrated and the residue was purified by silica gel chromatography (0-60%) EtOAc in hexanes) to give the title compound.
Figure imgf000234_0002
Step 4: l-{4'-[4-(3-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0751] Prepared according to the procedure described in Example 31 , Step 3, using l- {4'-[4-(3- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 115: Synthesis of l-{4'-[4-((E)-l-Hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-115)
Figure imgf000235_0001
Step 1: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-but-3-en-l-ol
[0752] 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde (0.375 g, 1.41 mmol) was dissolved in THF (3.75 mL) and cooled to 0 °C under N2 atmosphere. Allylmagnesium bromide (1 M in ΕΪ2Ο, 1.55 mL, 1.55 mmol) was added and the reaction stirred at 0 °C for 1.5 hours. Additional allylmagnesium bromide (1 M in Et20, 0.8 mL, 0.80 mmol) was added, and the reaction was stirred for 30 minutes at 0 °C. The mixture was quenched with saturated aqueous NH4CI and extracted with EtOAc. The combined organic layers were dried and concentrated and the residue was purified by silica gel chromatography (0-50% Et title compound.
Figure imgf000235_0002
Step 2: (E)-l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-but-3-en-l-ol
[0753] l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-but-3-en-l-ol (0.152 g, 0.49 mmol), iodobenzene (0.06 mL, 0.49 mmol), dichlorobis(triphenylphosphine)palladium(II) (0.034 g, 0.05 mmol), and triethylamine (0.68 mL, 4.9 mmol) were combined in DMF (4 mL) and the mixture was purged with N2 (g) for 5 minutes. The reaction was then sealed and stirred at 100 °C overnight. After aqueous workup, the crude material was purified by silica gel chromatography (0-50% EtOAc in hexanes) to give the title compoun
Figure imgf000235_0003
Step 3: l-{4'-[4-((E)-l-Hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0754] Prepared according to the procedure described in Example 3, Step 5, using (E)-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-but-3-en- 1 -ol and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000236_0001
Step 4: l-{4'-[4-((E)-l-Hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0755] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-((E)-l- hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 116: Synthesis of l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-116)
Figure imgf000236_0002
Step 1 : l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0756] Prepared according to the procedure described in Example 32, Step 1, using l-{4'-[4-((E)-l- hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000237_0001
Step 2: l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0757] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 117: Synthesis of l-[4'-(3-Methyl-4-{2-[methyl-((R)-l-phenyl-ethyl)-carbamoyl]- ethyl}-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-117)
Figure imgf000237_0002
Step 1: l-[4'-(3-Methyl-4-{2-[methyl-((S)-l-phenyl-ethyl)-carbamoyl]-ethyl}-isoxazol-5-yl)- biphenyl-4-yl] -cyclopropanecarboxylic acid ethyl ester
[0758] Prepared according to the procedure described in Example 33, Step 4, using l-{4'-[4-(2- carboxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and methyl-((S)- 1 -phenyl-ethyl)-amine.
Figure imgf000238_0001
Step 2: l-[4'-(3-Methyl-4-{2-[methyl-((R)-l-phenyl-ethyl)-carbamoyl]-ethyl}-isoxazol-5-yl)- biphenyl-4-yl] -cyclopropanecarboxylic acid
[0759] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(3-methyl-4- {2-[methyl-((S)- 1 -phenyl-ethyl)-carbamoyl]-ethyl} -isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester.
Example 118: Synthesis of l-[4'-(3-Methyl-4-{2-[methyl-(l-methyl-l-phenyl-ethyl)-carbamoyl]- ethyl}-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-118)
Figure imgf000238_0002
Step 1: l-[4'-(3-Methyl-4-{2-[methyl-(l-methyl-l-phenyl-ethyl)-carbamoyl]-ethyl}-isoxazol-5- yl)-biphenyl-4-yl] -cyclopropanecarboxylic acid
[0760] Prepared according to the procedure described in Example 34, Step 4, using l-(4'-{3-methyl- 4- [2-(l -methyl- 1 -phenyl-ethylcarbamoyl)-ethyl]-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid and iodomethane.
Example 119: Synthesis of l-(4'-{4-[2-(Cyclopropylmethyl-methyl-carbamoyl)-ethyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-119)
Figure imgf000239_0001
Step 1 : l-(4'-{4-[2-(Cyclopropylmethyl-methyl-carbamoyl)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0761] Prepared according to the procedure described in Example 34, Step 4, using l-(4'-{4-[2- (cyclopropylmethyl-carbamoyl)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid and iodomethane.
Example 120: Synthesis of l-{4'-[3-Methyl-4-(2-oxo-2-phenyl-ethylsulfanylmethyl)-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-120)
Figure imgf000239_0002
Step 1: l-[4'-(3-Methyl-4-triisopropylsilanylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0762] l-[4'-(4-Bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (1.0 g, 2.27 mmol) and triisopropylsilanethiol (0.488 mL, 2.27 mmol) were dissolved in DMF (25 mL) and the solution was degassed with N2 for 10 minutes. Cesium carbonate was added and the reaction stirred overnight under N2 atmosphere. Standard aqueous workup afforded a mixture of the desired product plus de-protected free thiol which was taken directly to the next step.
Figure imgf000240_0001
Step 2: l-[4'-(4-Mercaptomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0763] The mixture from Step 1 was dissolved in THF and tetrabutylammonium fluoride (1.0 M in THF, 2.27 mL, 2.27 mmol) was added. The reaction stirred for 5 minutes and was then submitted to standard aqueous workup and purification via silica gel chromatography to yield the title compound.
Figure imgf000240_0002
Step 3: l-{4'-[3-Methyl-4-(2-oxo-2-phenyl-ethylsulfanylmethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0764] Prepared according to the procedure described in Example 3, Step 7, using l-[4'-(4- mercaptomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo- 1 -phenyl-ethanone.
Example 121: Synthesis of l-{4'-[4-(2-Hydroxy-2-methyl-4-phenyl-butyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-121)
Figure imgf000241_0001
Step 1 : l-{4'-[4-(2-Hydroxy-2-methyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0765] Prepared according to the procedure described in Example 115, Step 1, using l-{4'-[3- methyl -4-(2-oxo-4-phenyl-butyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid and methylmagnesium iodide.
Example 122: Synthesis of 2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl- 4-yl]-butyric acid (Compound 1-122)
Figure imgf000241_0002
Step 1: 2-(4-Bromo-phenyl)-butyric acid ethyl ester
[0766] Prepared according to the procedure described in Example 3, Step 3, using 2-(4-bromo- phenyl)-butyric acid.
Figure imgf000241_0003
Step 2: 2 2-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-butyric acid ethyl ester
[0767] Prepared according to the procedure described in Example 3, Step 4, using 2-(4-bromo- phenyl)-butyric acid ethyl ester and bis(pinacolato)diboron.
Figure imgf000242_0001
Step 3: 2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-butyric acid ethyl ester
[0768] Prepared according to the procedure described in Example 108, Step 2, using 5-(4-bromo- phenyl)-3-methyl-4-phenethylsulfanylmethyl-isoxazole and 2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-butyric acid ethyl ester.
Figure imgf000242_0002
Step 4: 2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-butyric acid
[0769] Prepared according to the procedure described in Example 3, Step 8, using 2-[4'-(3-methyl-4- phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-butyric acid ethyl ester.
Example 123: Synthesis of 2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl- 4-yl] -propionic acid (Compound 1-123)
Figure imgf000242_0003
Step 1: 2-(4-Bromo-phenyl)-propionic acid ethyl ester
[0770] (4-Bromo-phenyl)-acetic acid ethyl ester (6 g, 24.7 mmol) was dissolved in THF (60 mL) and cooled to -78 °C. Lithium bis(trimethylsilyl)amide (1 M in THF, 32.11 mL, 32.11 mmol) was added and the reaction stirred at -78 °C for 1 hour. Iodomethane (2.0 mL, 32.11 mmol) in THF (8 mL) was added and the reaction was allowed to warm to room temperature. The reaction was submitted to standard aqueous workup then purified via silica gel chromatography (0-10% EtOAc in hexanes) to afford the title compound.
Figure imgf000243_0001
Step 2: 2-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid ethyl ester
[0771] Prepared according to the procedure described in Example 3, Step 4, using 2-(4-bromo- phenyl)-propionic acid ethyl ester and bis(pinacolato)diboron.
Figure imgf000243_0002
Step 3: 2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-propionic acid ethyl ester
[0772] Prepared according to the procedure described in Example 108, Step 2, using 5-(4-bromo- phenyl)-3-methyl-4-phenethylsulfanylmethyl-isoxazole and 2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid ethyl ester.
Figure imgf000243_0003
Step 4: 2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-propionic acid
[0773] Prepared according to the procedure described in Example 3, Step 8, using 2-[4'-(3-methyl-4- phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-propionic acid ethyl ester.
Example 124: Synthesis of l-{4'-[3-Methyl-4-(4-phenyl-butyryl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-124)
Figure imgf000244_0001
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-one
[0774] l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-but-3-en-l-ol (1.76 g, 5.69 mmol), iodobenzene (0.638 mL, 5.69 mmol), and triethylamine (1.59 mL, 11.38 mmol) were dissolved in ACN (17 mL) and the solution was purged with bubbling N2 (g). Palladium(II) acetate (0.064 g, 0.28 mmol) was added, the reaction vessel was sealed, and the reaction was heated to 85 °C overnight. After cooling, the reaction was submitted to standard aqueous workup then purified on silica gel (0-30% EtOAc in hexanes) to give a separable mixture of two compounds, one of which was the title compound.
Figure imgf000244_0002
Step 2: l-{4'-[3-Methyl-4-(4-phenyl-butyryl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0775] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan- 1 -one and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000245_0001
Step 3: l-{4'-[3-Methyl-4-(4-phenyl-butyryl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0776] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[3-methyl- 4-(4-phenyl-butyryl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 125: Synthesis of {l-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl- 4-yl]-cyclopropyl} -acetic acid (Co
Figure imgf000245_0002
Step 1: {l-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropyl}- acetic acid ethyl ester
[0777] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-3-methyl-4-phenethylsulfanylmethyl-isoxazole and { 1 -[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000245_0003
Step 2: {l-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropyl}- acetic acid
[0778] Prepared according to the procedure described in Example 3, Step 8, using {l-[4'-(3-methyl- 4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropyl} -acetic acid ethyl ester. Example 126: Synthesis of l-{4'-[4-(l-Hydroxy-l-methyl-4-phenyl-butyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-126)
Figure imgf000246_0001
Step 1 : l-{4'-[4-(l-Hydroxy-l-methyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0779] Prepared according to the procedure described in Example 114, Step 3, using l-{4'-[3- methyl-4-(4-phenyl-butyryl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid and methylmagnesium iodide.
Example 127: Synthesis of l-(4'-{4-[2-(Cyclopropyl-methyl-carbamoyl)-ethyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-127)
Figure imgf000246_0002
Step 1 : l-(4'-{4-[2-(Cyclopropyl-methyl-carbamoyl)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid
[0780] Prepared according to the procedure described in Example 34, Step 4, using l-{4'-[4-(2- Cyclopropylcarbamoyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid and iodomethane. Example 128: Synthesis of (trans)-2-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-128)
Figure imgf000247_0001
Step 1: (trans)-2-(4-Bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester
[0781] Copper(II) acetylacetonate (0.156 g, 0.6 mmol) was dissolved in CH2CI2 (40 mL) then phenylhydrazine (3 drops, catalytic amount) was added. After 5 minutes, 4-bromostyrene (2.6 mL, 20 mmol) was added and the reaction was heated to 40 °C. Ethyl diazoacetate (3.1 mL, 30 mmol) in CH2CI2 (40 mL) was slowly added using a syringe pump. The reaction was stirred at 40 °C overnight then cooled and submitted to standard aqueous workup. The crude material was purified on silica gel (0-10% EtOAc in hexanes) two times to afford a separable mixture of two cyclopropyl isomers (cis- and trans-) and the less polar isomer was determined to be the title compound.
Figure imgf000247_0002
Step 2 : (trans)-2- [4-(4,4,5,5-Tetramethyl- [1,3,2] dioxaborolan-2-yl)-phenyl] - cyclopropanecarboxylic acid ethyl ester
[0782] Prepared according to the procedure described in Example 3, Step 4, using (trans)-2-(4- bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester and bis(pinacolato)diboron.
Figure imgf000247_0003
Step 3: (trans)-2-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0783] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-3-methyl-4-(4-phenyl-but- 1 -enyl)-isoxazole and (trans)-2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000248_0001
Step 4: (trans)-2-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0784] Prepared according to the procedure described in Example 3, Step 8, using (trans)-2-{4'-[3- methyl-4-(4-phenyl-but- 1 -enyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 129: Synthesis of (cis)-2-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-129)
Figure imgf000248_0002
Step 1: (cis)-2-(4-Bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester
[0785] Prepared according to the procedure described in Example 128, Step 1, where the more polar isomer was the title compound.
Figure imgf000249_0001
Step 2 : (cis)-2- [4-(4,4,5,5-Tetramethyl- [1,3,2] dioxaborolan-2-yl)-phenyl] - cyclopropanecarboxylic acid ethyl ester
[0786] Prepared according to the procedure described in Example 3, Step 4, using (cis)-2-(4-bromo- phenyl)-cyclopropanecarboxylic acid ethyl ester and bis(pinacolato)diboron.
Figure imgf000249_0002
Step 3: (cis)-2-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0787] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-3-methyl-4-(4-phenyl-but-l-enyl)-isoxazole and (cis)-2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000249_0003
Step 4: (cis)-2-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0788] Prepared according to the procedure described in Example 3, Step 8, using (cis)-2-{4'-[3- methyl-4-(4-phenyl-but- 1 -enyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 130: Synthesis of (trans)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-130)
Figure imgf000250_0001
Step 1 : (trans)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0789] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-3-methyl-4-phenethylsulfanylmethyl-isoxazole and (trans)-2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000250_0002
Step 2: (trans)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0790] Prepared according to the procedure described in Example 3, Step 8, using (trans)-2-[4'-(3- methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester. Example 131: Synthesis of (cis)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-131)
Figure imgf000251_0001
Step 1 : (cis)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0791] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-3-methyl-4-phenethylsulfanylmethyl-isoxazole and (cis)-2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000251_0002
Step 2: (cis)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0792] Prepared according to the procedure described in Example 3, Step 8, using (cis)-2-[4'-(3- methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester.
Example 132: Synthesis of l-{4'-[4-(3-Benzylamino-2-hydroxy-propyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-132)
Figure imgf000252_0001
Step 1: 4-AUyl-5-(4-bromo-phenyl)-3-methyl-isoxazole
[0793] Copper(I) iodide (0.187 g, 0.98 mmol) was suspended in THF (43 mL) then cooled to -40 °C under N2 atmosphere. Vinylmagnesium bromide (1 M in THF, 9.74 mL, 9.74 mmol) was added over the course of 4 minutes and the reaction continued stirring for 18 minutes. Next, 4-bromomethyl-5- (4-bromo-phenyl)-3-methyl-isoxazole (2.15 g, 6.5 mmol) in THF (11 mL) was added over the course of 15 minutes. The reaction was placed in a -20 °C overnight. After warming the reaction was submitted to standard aqueous workup to afford the title compound.
Figure imgf000252_0002
Step 2: l-[4'-(4-AUyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0794] Prepared according to the procedure described in Example 110, Step 3, using 4-allyl-5-(4- bromo-phenyl)-3-methyl-isoxazole and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester.
Figure imgf000252_0003
Step 3: l-[4'-(3-Methyl-4-oxiranylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester [0795] m-Chloroperbenzoic acid (77%, 0.565 g, 2.52 mmol) was washed 4x with a solution of sodium phosphate dibasic (0.1 M aq., 7 mL) then dissolved in CH2CI2 (4 mL). The solution was added to l-[4'-(4-Allyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.244 g, 0.63 mmol) in CH2CI2 (3 mL) followed by sodium phosphate dibasic (0.1 M aq., 7 mL). After 3.5 hours an additional portion of m-chloroperbenzoic acid (0.55 g) was rinsed 4x with sodium phosphate dibasic (0.1 M aq., 7 mL) and added to the reaction and stirring continued overnight. The reaction was then submitted to standard aqueous workup and purified via silica gel chromatography (0-30% EtOAc in hexanes) to give the title compound.
Figure imgf000253_0001
Step 4: l-{4'-[4-(3-Benzylamino-2-hydroxy-propyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0796] l-[4'-(3-Methyl-4-oxiranylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.160 g, 0.40 mmol) was dissolved in N-methylpyrrolidone (5 mL) then benzylamine (0.130 mL, 1.2 mmol) was added. The reaction was heated to 85 °C overnight then cooled and submitted to standard aqueous wo d.
Figure imgf000253_0002
Step 5: l-{4'-[4-(3-Benzylamino-2-hydroxy-propyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0797] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(3- benzylamino-2-hydroxy-propyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester. Example 133: Synthesis of 2-Methyl-2-[4'-(3-methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)- biphenyl-4-yl] -propionic acid (Compound 1-133)
Figure imgf000254_0001
Step 1: 2-Methyl-2-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid methyl ester
[0798] Prepared according to the procedure described in Example 3, Step 4, using 2-(4-bromo- phenyl)-2-methyl-propionic acid methyl ester and bis(pinacolato)diboron.
Figure imgf000254_0002
Step 2: 2-Methyl-2-[4'-(3-methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- propionic acid methyl ester
[0799] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-3-methyl-4-phenethylsulfanylmethyl-isoxazole and 2-methyl-2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid methyl ester.
Figure imgf000254_0003
Step 3: 2-Methyl-2-[4'-(3-methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- propionic acid
[0800] Prepared according to the procedure described in Example 3, Step 8, using 2-methyl-2-[4'-(3- methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-propionic acid.
Example 134: Synthesis of l-[4'-(4-{2-[Hydroxyimino]-4-phenyl-butyl}-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-134)
Figure imgf000255_0001
Step 1 : 5-(4-Bromo-phenyl)-3-methyl-4-(3-phenethyl-oxiranyl)-isoxazole
[0801] Prepared according to the procedure described in Example 132, Step 3, using 5-(4-bromo- phenyl)-3-methyl-4-(4-phenyl-but- 1 -enyl)-isoxazole.
Figure imgf000255_0002
Step 2: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-2-one
[0802] Prepared according to the procedure described in Example 88, Step 2, using 5-(4-bromo- phenyl)-3-methyl-4-(3-phenethyl-oxiranyl)-isoxazole.
Figure imgf000255_0003
Step 3: l-{4'-[3-Methyl-4-(2-oxo-4-phenyl-butyl)-isoxazol-5-yl]-biphi
cyclopropanecarboxylic acid ethyl ester [0803] Prepared according to the procedure described in Example 3, Step 5, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-2-one and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000256_0001
Step 4: l-[4'-(4-{2-[Hydroxyimino]-4-phenyl-butyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0804] l-{4'-[3-Methyl-4-(2-oxo-4-phenyl-butyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (0.0541 g, 0.11 mmol), hydroxylamine hydrochloride (0.009 g, 0.13 mmol), and potassium acetate (0.022 g, 0.22 mmol) were suspended in acetic acid. The reaction was gently heated using a hot air blower until all of the materials went into solution, then stirred at room temperature for 2 days. The reaction mixture was concentrated, dissolved in CH2CI2, then washed with H20 and brine, drie concentrated to afford the title compound.
Figure imgf000256_0002
Step 5: l-[4'-(4-{2-[Hydroxyimino]-4-phenyl-butyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid
[0805] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(4-{2- [hydroxyimino]-4-phenyl-butyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester.
Example 135: Synthesis of (cis)-2-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-135)
Figure imgf000257_0001
Step 1 : 5-(4-Bromo-phenyl)-4-(2,2-difluoro-4-phenyl-butyl)-3-methyl-isoxazole
[0806] Bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor) (50% in THF, 2.11 mL, 4.77 mmol) was added to l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-2-one (0.833 g, 2.2 mmol) in benzene (20 mL) and the reaction was heated to 75 °C for 4 hours. An additional portion of bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor) (50% in THF, 2 mL) was added and the reaction continued heating overnight. Another portion of bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor) (50% in THF, 2 mL) was added and the reaction continued heating overnight. After cooling the reaction was submitted to standard aqueous workup and purified on silica gel. The residue was purified via preparatory HPLC to give the title compound.
Figure imgf000257_0002
Step 2: (cis)-2-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0807] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-4-(2,2-difluoro-4-phenyl-butyl)-3-methyl-isoxazole and (cis)-2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000258_0001
Step 3: (cis)-2-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0808] Prepared according to the procedure described in Example 3, Step 8, using (cis)-2-{4'-[4- (2,2-difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 136: Synthesis of 2-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-propionic acid (Com
Figure imgf000258_0002
Step 1 : 2-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-propionic acid ethyl ester
[0809] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-4-(2,2-difluoro-4-phenyl-butyl)-3-methyl-isoxazole and 2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid ethyl ester.
Figure imgf000259_0001
Step 2: 2-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-propionic acid
[0810] Prepared according to the procedure described in Example 3, Step 8, using 2-{4'-[4-(2,2- difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -propionic acid ethyl ester.
Example 137: Synthesis of 3-Methyl-2-[4'-(3-methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)- biphenyl-4-yl] -butyric acid (Compound 1-137)
Figure imgf000259_0002
Step 1: 2-(4-Bromo-phenyl)-3-methyl-butyric acid ethyl ester
[0811] Ethyl 4-bromophenylacetate (3.0 g, 12.3 mmol) and potassium tert-butoxide (1.38 g, 12.3 mmol) were combined in DMF (35 mL). 2-Iodo-propane (2.09 g, 12.3 mmol) was added and the reaction was stirred at room temperature for 1 hour. Aqueous workup provided the title compound.
Figure imgf000259_0003
Step 2: 3-Methyl-2-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-butyric acid ethyl ester
[0812] Prepared according to the procedure described in Example 3, Step 4, using 2-(4-bromo- phenyl)-3 -methyl-butyric acid ethyl ester and bis(pinacolato)diboron.
Figure imgf000260_0001
Step 3: 3-Methyl-2-[4'-(3-methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- butyric acid ethyl ester
[0813] Prepared according to the procedure described in Example 1, Step 7, using 5-(4-bromo- phenyl)-3-methyl-4-phenethylsulfanylmethyl-isoxazole and 3-methyl-2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-butyric acid ethyl ester.
Figure imgf000260_0002
Step 4: 3-Methyl-2-[4'-(3-methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- butyric acid
[0814] Prepared according to the procedure described in Example 3, Step 8, using 3-methyl-2-[4'-(3- methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-butyric acid ethyl ester.
Example 138: Synthesis of l-(4'-{4-[3-(Acetyl-benzyl-amino)-2-hydroxy-propyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-138)
Figure imgf000261_0001
Step 1 : l-(4'-{4-[3-(Acetyl-benzyl-amino)-2-hydroxy-propyl]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid ethyl ester
[0815] Prepared according to the procedure described in Example 3, Step 7, using l-{4'-[4-(3- benzylamino-2-hydroxy-propyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and acetyl chloride.
Figure imgf000261_0002
Step 2: l-(4'-{4-[3-(Acetyl-benzyl-amino)-2-hydroxy-propyl]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid
[0816] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[3- (acetyl-benzyl-amino)-2-hydroxy-propyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 139: Synthesis of l-(4'-{4-[3-(Benzyl-methanesulfonyl-amino)-propenyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-139)
Figure imgf000262_0001
Step 1 : l-(4'-{4-[3-(Benzyl-methanesulfonyl-amino)-2-hydroxy-propyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0817] Prepared according to the procedure described in Example 3, Step 7, using l-{4'-[4-(3- benzylamino-2-hydroxy-propyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and methanesulfonyl chloride.
Figure imgf000262_0002
Step 2: l-(4'-{4-[3-(Benzyl-methanesulfonyl-amino)-propenyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0818] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[3- (benzyl-methanesulfonyl-amino)-2-hydroxy-propyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 140: Synthesis of (l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-140)
Figure imgf000262_0003
Step 1 : (E)-l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-but-3-en-l-ol [0819] Prepared according to the procedure described in Example 124, Step 1, where the title compound was the other of the two separable compounds isolated.
Figure imgf000263_0001
Step 2: (l-{4'-[4-((E)-l-Hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester
[0820] Prepared according to the procedure described in Example 110, Step 3, using (E)-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-but-3-en-l-ol and {l-[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000263_0002
Step 3: (l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester
[0821] Prepared according to the procedure described in Example 32, Step 1, using (l-{4'-[4-((E)-l- hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid ethyl ester.
Figure imgf000263_0003
Step 4: (l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid
[0822] Prepared according to the procedure described in Example 31 , Step 3 , using (l-{4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropyl)-acetic acid ethyl ester.
Example 141: Synthesis of l-{4'-[4-(2-Benzylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (C
Figure imgf000264_0001
Step 1 : l-{4'-[4-(2-Benzylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0823] Prepared according to the procedure described in Example 67, Step 1, using l-{4'-[4-(2- amino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and benzaldehyde.
Figure imgf000264_0002
Step 2: l-{4'-[4-(2-Benzylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0824] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(2- benzylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. Example 142: Synthesis of l-(4'-{4-[2-(Acetyl-benzyl-amino)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-142)
Figure imgf000265_0001
Step 1 : l-(4'-{4-[2-(Acetyl-benzyl-amino)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[0825] Prepared according to the procedure described in Example 3, Step 7, using l-{4'-[4-(2- benzylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and acetyl chloride.
Figure imgf000265_0002
Step 2: l-(4'-{4-[2-(Acetyl-benzyl-amino)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[0826] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[2- (acetyl-benzyl-amino)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 143: Synthesis of l-(4'-{4-[2-(Benzyl-methanesulfonyl-amino)-ethyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-143)
Figure imgf000266_0001
Step 1 : l-(4'-{4-[2-(Benzyl-methanesulfonyl-amino)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid ethyl ester
[0827] Prepared according to the procedure described in Example 3, Step 7, using l-{4'-[4-(2- benzylamino-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and methane sulfonyl chloride.
Figure imgf000266_0002
Step 2: l-(4'-{4-[2-(Benzyl-methanesulfonyl-amino)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid
[0828] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[2- (benzyl-methanesulfonyl-amino)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 144: Synthesis of (cis)-2-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-144)
Figure imgf000267_0001
Step 1: (cis)-2-{4'-[4-((E)-l-Hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester
[0829] Prepared according to the procedure described in Example 3, Step 5, using (E)-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-but-3-en-l-ol and (cis)-2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000267_0002
Step 2: (cis)-2-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0830] Prepared according to the procedure described in Example 32, Step 1, using (cis)-2-{4'-[4- ((E)-l-Hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester.
Figure imgf000268_0001
Step 3: (cis)-2-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0831] Prepared according to the procedure described in Example 3, Step 8, using (cis)-2-{4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 145: Synthesis of 2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl- 4-yl]-3-phenyl-propionic acid (Compound 1-145)
Figure imgf000268_0002
Step 1: 2-(4-Bromo-phenyl)-3-phenyl-propionic acid ethyl ester
[0832] Ethyl 4-bromophenylacetate (3.0 g, 12.3 mmol) and potassium tert-butoxide (1.38 g, 12.3 mmol) were combined in DMF (35 mL). Benzyl bromide (2.1 g, 12.3 mmol) was added and the reaction was stirred at room temperature for 1 hour. Aqueous workup provided the title compound.
Figure imgf000268_0003
Step 2: 3-Phenyl-2-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid ethyl ester
[0833] Prepared according to the procedure described in Example 3, Step 4, using 2-(4-bromo- phenyl)-3 -phenyl-propionic acid ethyl ester and bis(pinacolato)diboron.
Figure imgf000269_0001
Step 3: 2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-3-phenyl- propionic acid ethyl ester
[0834] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-3-methyl-4-phenethylsulfanylmethyl-isoxazole and 3-phenyl-2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid ethyl ester.
Figure imgf000269_0002
Step 4: 2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-3-phenyl- propionic acid
[0835] Prepared according to the procedure described in Example 3, Step 8, using 2-[4'-(3-methyl-4- phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-3-phenyl-propionic acid ethyl ester.
Example 146: Synthesis of l-{4'-[4-(2-Benzylamino-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-146)
Figure imgf000270_0001
Step 1: l-[4'-(4-Formyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0836] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000270_0002
Step 2: l-[4'-(3-Methyl-4-oxiranyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[0837] n-Butyllithium (1.6 M in hexanes, 2.3 mL, 3.69 mmol) was dissolved in DMSO (8 mL). Trimethylsulfoxonium iodide (0.963 g, 4.29 mmol) was added, followed by l-[4'-(4-formyl-3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.46 g, 1.23 mmol) in DMSO (8 mL). The reaction was stirred at room temperature for 40 minutes and then poured over ice. The mixture was extracted three times with EtOAc, and the combined organic layers were washed three times with H20, dried, and concentrated. The crude material was purified by silica gel chromatography (0-40% EtOAc in hexanes) to give the title compound.
Figure imgf000271_0001
Step 3: l-{4'-[4-(2-Benzylamino-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0838] l-[4'-(3-Methyl-4-oxiranyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.100 g, 0.26 mmol) and benzylamine (0.034 mL, 0.31 mmol) were combined in NMP (5 mL) and the reaction was stirred overnight at 85 °C. Additional benzylamine (0.05 mL, 0.46 mmol) was added and the reaction was stirred for two days at 85 °C. Aqueous workup provided the title compound.
Figure imgf000271_0002
Step 4: l-{4'-[4-(2-Benzylamino-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0839] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(2- benzylamino- 1 -hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 147: Synthesis of l-{4'-[4-(l-Ethoxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid (Compound 1-147)
Figure imgf000272_0001
Step 1 : l-{4'-[4-(l-Ethoxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0840] l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (0.209 g, 0.44 mmol) was dissolved in EtOH (5 niL) then thionyl chloride (0.066 niL, 0.87 mmol) was added and the reaction stirred at room temperature. After 15 minutes, an additional portion of thionyl chloride (0.070 mL) was added. After stirring at room temperature for 12 minutes the reaction was heated to 70 °C for 30 minutes, then cooled. The reaction was then submitted to standard aqueous workup and purified via silica gel chromatography (0-40% EtOAc in hexanes) to afford a separable mixture of products, of which the major product was the title compound.
Figure imgf000272_0002
Step 2: l-{4'-[4-(l-Ethoxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0841] l-{4'-[4-(l-Ethoxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (0.070 g, 0.133 mmol) was dissolved in THF (3 mL) and MeOH (0.3 mL) then NaOH (3 N aq., 0.150 mL) was added. The reaction was heated to 70 °C overnight then an additional portion of NaOH (3 N aq., 0.150 mL) was added and the reaction was heated overnight again. After cooling the reaction was submitted to standard aqueous workup then purified by preparatory HPLC to afford a separable mixture of products, of which the major product was the title compound. Example 148: Synthesis of l-{4'-[4-(l-Methoxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-148)
Figure imgf000273_0001
Step 1 : l-{4'-[4-(l-Methoxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0842] Prepared according to the procedure described in Example 147, Step 2, where the minor product was the title compound.
Example 149: Synthesis of (cis)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-149)
Figure imgf000273_0002
Step 1 : (cis)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester (Enantiomer A)
[0843] Prepared according to the procedure described in Example 3, Step 5, using 5-(4-bromo- phenyl)-3-methyl-4-phenethylsulfanylmethyl-isoxazole and (cis)-2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester. After the reaction the material was purified using chiral preparatory HPLC (Chiralcel AS column, 5% EtOH in hexanes, 42 minute run). The first enantiomer to come off of the column is Enantiomer A.
Figure imgf000274_0001
Step 2: (cis)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Enantiomer A)
[0844] Prepared according to the procedure described in Example 3, Step 8, using (cis)-2-[4'-(3- methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (Enantiomer A).
Example 150: Synthesis of (cis)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-150)
Figure imgf000274_0002
Step 1 : (cis)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester (Enantiomer B)
[0845] Prepared according to the procedure described in Example 149, Step 1, where the second enantiomer to come off of the column is Enantiomer B.
Figure imgf000275_0001
Step 2: (cis)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Enantiomer B)
[0846] Prepared according to the procedure described in Example 3, Step 8, using (cis)-2-[4'-(3- methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (Enantiomer B).
Example 151: Synthesis of l-{4'-[4-(3,3-Dimethyl-butylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-151)
Figure imgf000275_0002
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(3,3-dimethyl-butyl)-amine
[0847] Prepared according to the procedure described in Example 20, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine an -dimethyl-butyraldehyde.
Figure imgf000275_0003
Step 2: l-{4'-[4-(3,3-Dimethyl-butylamino)-3-methyl-isoxazol-5-yl]-biphi
cyclopropanecarboxylic acid ethyl ester [0848] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(3,3-dimethyl-butyl)-amine and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000276_0001
Step 3: l-{4'-[4-(3,3-Dimethyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0849] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(3,3- dimethyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 152: Synthesis of l-[4'-(4-Hydroxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Compound 1-152)
Figure imgf000276_0002
Step 1: Cyclopentyl-carbamic acid 5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl ester
[0850] [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-methanol (0.120 g, 0.45 mmol) was mixed with cyclopentyl isocyanate (0.075 g, 0.68 mmol) in toluene and the reaction was heated to 120 °C overnight. After cooling, the crude material was submitted directly to silica gel purification to afford the title compound.
Figure imgf000277_0001
Step 2: l-[4'-(4-Cyclopentylcarbamoyloxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid ethyl ester
[0851] Prepared according to the procedure described in Example 1, Step 7, using cyclopentyl- carbamic acid 5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl ester and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000277_0002
Step 3: l-[4'-(4-Hydroxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid
[0852] Prepared according to the procedure described in Example 3, Step 8, using l-[4'-(4- cyclopentylcarbamoyloxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester.
Example 153: Synthesis of l-(4'-{4-[3-(3-Fluoro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-153)
Figure imgf000278_0001
Step 1: l-(4'-{4-[3-(3-Fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl 4-yl)-cyclopropanecarboxylic acid ethyl ester
[0853] Prepared according to the procedure described in Example 24, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 4-(3-fluoro- phenyl)-butan-2-one.
Figure imgf000278_0002
Step 2: l-(4'-{4-[3-(3-Fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl 4-yl)-cyclopropanecarboxylic acid
[0854] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[3-(3- fluoro-phenyl)- 1 -methyl-propylamino] -3 -methyl-isoxazol-5-yl } -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 154: Synthesis of l-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)- propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-154)
Figure imgf000279_0001
Step 1 : l-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0855] Prepared according to the procedure described in Example 24, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 4-(3- trifluoromethyl-phenyl)-butan-2-one.
Figure imgf000279_0002
Step 2: l-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0856] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{3-methyl-4- [l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 155: Synthesis of l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-155)
Figure imgf000279_0003
Step 1: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-ol (Enantiomer A) [0857] Prepared according to the procedure described in Example 114, Step 3, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and 3-(phenyl)propylmagnesium bromide. After the reaction the material was submitted to chiral preparatory HPLC (Chiralcel AS Column, 2% EtOH in hexanes, 60 minute run). The first enantiomer off of the column is Enantiomer A.
Figure imgf000280_0001
Step 2: l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (Enantiomer A)
[0858] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-ol (Enantiomer A) and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000280_0002
Step 3: l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Enantiomer A)
[0859] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester (Enantiomer A).
Example 156: Synthesis of l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-156)
Figure imgf000281_0001
Step 1: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-ol (Enantiomer B)
[0860] Prepared according to the procedure described in Example 155, Step 1, where the second enantiomer to come off of the column is Enantiomer B.
Figure imgf000281_0002
Step 2: l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (Enantiomer B)
[0861] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-ol (Enantiomer B) and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000281_0003
Step 3: l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Enantiomer B)
[0862] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester (Enantiomer B).
Example 157: Synthesis of l-{4'-[3-Methyl-4-(3-phenyl-propionyl)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-157)
Figure imgf000282_0001
Step 1: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-prop-2-en-l-ol
[0863] Prepared according to the procedure described in Example 114, Step 3, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and vinylmagnesium bromide.
Figure imgf000282_0002
Step 2: l-{4'-[4-(l-Hydroxy-allyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0864] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-prop-2-en-l-ol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2- yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000282_0003
Step 3: l-{4'-[3-Methyl-4-(3-phenyl-propionyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0865] Prepared according to the procedure described in Example 124, Step 1, using l-{4'-[4-(l- hydroxy-allyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and iodobenzene. The crude material was purified on silica gel (0-60% EtOAc in hexanes) to give a separable mixture of two compounds, one of which was the title compound.
Figure imgf000283_0001
Step 4: l-{4'-[3-Methyl-4-(3-phenyl-propionyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0866] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[3-methyl- 4-(3-phenyl-propionyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester. Example 158: Synthesis of l-{4'-[4-((E)-l-Hydroxy-3-phenyl-allyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-158)
Figure imgf000283_0002
Step 1 : l-{4'-[4-((E)-l-Hydroxy-3-phenyl-allyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0867] Prepared according to the procedure described in Example 157, Step 3, where the title compound was the other of the two separable compounds isolated.
Figure imgf000284_0001
Step 2: l-{4'-[4-((E)-l-Hydroxy-3-phenyl-allyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0868] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-((E)-l- hydroxy-3-phenyl-allyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 159: Synthesis of l-{4'-[4-(l-Hydroxy-3-phenyl-propyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-159)
Figure imgf000284_0002
Step 1: l-{4'-[4-(l-Hydroxy-3-phenyl-propyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0869] Prepared according to the procedure described in Example 89, Step 1, using l-{4'-[3-methyl- 4-(3-phenyl-propionyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid.
Example 160: Synthesis of l-(4'-{3-Methyl-4-[3-(3-trifluoromethyl-phenyl)-propionyl]-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-160)
Figure imgf000285_0001
Step 1 : l-(4'-{3-Methyl-4-[3-(3-trifluoromethyl-phenyl)-propionyl]-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid ethyl ester
[0870] Prepared according to the procedure described in Example 124, Step 1, using l-{4'-[4-(l- hydroxy-allyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and l-iodo-3-trifluoromethyl-benzene. The crude material was purified on silica gel (0-60% EtOAc in hexanes) to give a separable mixture of two compounds, one of which was the title compound.
Figure imgf000285_0002
Step 2: l-(4'-{3-Methyl-4-[3-(3-trifluoromethyl-phenyl)-propionyl]-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid
[0871] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{3-methyl- 4-[3-(3-trifluoromethyl-phenyl)-propionyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 161: Synthesis of l-(4'-{4-[(E)-l-Hydroxy-3-(3-trifluoromethyl-phenyl)-allyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-161)
Figure imgf000286_0001
Step 1 : l-(4'-{4-[(E)-l-Hydroxy-3-(3-trifluoromethyl-phenyl)-allyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0872] Prepared according to the procedure described in Example 160, Step 1, where the title compound was the other of the two separable compounds isolated.
Figure imgf000286_0002
Step 2: l-(4'-{4-[(E)-l-Hydroxy-3-(3-trifluoromethyl-phenyl)-allyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0873] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[(E)-l- hydroxy-3-(3-trifluoromethyl-phenyl)-allyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 162: Synthesis of l-(4'-{4-[l-Hydroxy-3-(3-trifluoromethyl-phenyl)-propyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-162)
Figure imgf000287_0001
Step 1 : l-(4'-{4-[l-Hydroxy-3-(3-trifluoromethyl-phenyl)-propyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0874] Prepared according to the procedure described in Example 32, Step 1, using l-(4'-{4-[(E)-l- hydroxy-3-(3-trifluoromethyl-phenyl)-allyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid.
Example 163: Synthesis of l-(4'-{4-[l-Hydroxy-4-(3-trifluoromethyl-phenyl)-butyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-163)
Figure imgf000287_0002
Step 1: l-{4'-[4-(l-Hydroxy-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0875] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-but-3-en-l-ol and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2- yl)-phenyl] -cyclopropanecarboxylic acid ethyl ester.
Figure imgf000288_0001
Step 2: l-(4'-{4-[(E)-l-Hydroxy-4-(3-trifluoromethyl-phenyl)-but-3-enyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0876] Prepared according to the procedure described in Example 124, Step 1, using l-{4'-[4-(l- hydroxy-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 1 -iodo-3-trifluoromethyl -benzene.
Figure imgf000288_0002
Step 3: l-(4'-{4-[l-Hydroxy-4-(3-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0877] Prepared according to the procedure described in Example 32, Step 1, using l-(4'-{4-[(E)-l- hydroxy-4-(3-trifluoromethyl-phenyl)-but-3-enyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Figure imgf000288_0003
Step 4: l-(4'-{4-[l-Hydroxy-4-(3-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0878] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[l- hydroxy-4-(3-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 164: Synthesis of l-{4'-[4-(l-Hydroxy-4-i«-tolyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-164)
Figure imgf000289_0001
Step 1 : l-{4'-[4-((E)-l-Hydroxy-4-iM-tolyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0879] Prepared according to the procedure described in Example 124, Step 1, using l-{4'-[4-(l- hydroxy-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 3-iodotoluene.
Figure imgf000289_0002
Step 2: l-{4'-[4-(l-Hydroxy-4-i«-tolyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0880] Prepared according to the procedure described in Example 32, Step 1, using l-{4'-[4-((E)-l- hydroxy-4-m-tolyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Figure imgf000290_0001
Step 3: l-{4'-[4-(l-Hydroxy-4-i«-tolyl-butyl)-3-niethyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0881] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(l- hydroxy-4-m-tolyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 165: Synthesis of (4'-{4-[3-(3-Fluoro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 1-165)
Figure imgf000290_0002
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[3-(3-fluoro-phenyl)-l-methyl-propyl]- amine
[0882] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine an-2-one.
Figure imgf000290_0003
Step 2: (4'-{4-[3-(3-Fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphi yl)-acetic acid ethyl ester [0883] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(3-fluoro-phenyl)-l-methyl-propyl]-amine and [4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester.
Figure imgf000291_0001
Step 3: (4'-{4-[3-(3-Fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-acetic acid
[0884] Prepared according to the procedure described in Example 3, Step 8, using (4'-{4-[3-(3- fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid ethyl ester.
Example 166: Synthesis of l-{4'-[4-(l-Hydroxy-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-166)
Figure imgf000291_0002
Step 1 : l-{4'-[4-(l-Hydroxy-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0885] Prepared according to the procedure described in Example 32, Step 1, using l-{4'-[4-(l- hydroxy-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000292_0001
Step 2: l-{4'-[4-(l-Hydroxy-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0886] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(l- hydroxy-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester. Example 167: Synthesis of l-{4'-[4-(2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-167)
Figure imgf000292_0002
Step 1 : l-{4'-[4-(2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0887] l-[4'-(3-Methyl-4-oxiranyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.100 g, 0.26 mmol) and potassium carbonate (0.054 g, 0.39 mmol) were stirred in DMF (5 mL) and then benzyl mercaptan (0.040 mL, 0.31 mmol) was added. After stirring 4 hours at room temperature an additional portion of benzyl mercaptan (0.010 mL) was added. After 1 hour the reaction was submitted to standard aqueous workup and purified on silica gel (0-40% EtOAc in hexanes) to afford the title compound.
Figure imgf000293_0001
Step 2: l-{4'-[4-(2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0888] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(2- benzylsulfanyl- 1 -hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 168: Synthesis of l-(4'-{4-[l-Hydroxy-4-(4-trifluoromethyl-phenyl)-butyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-168)
Figure imgf000293_0002
Step 1 : l-(4'-{4-[(E)-l-Hydroxy-4-(4-trifluoromethyl-phenyl)-but-3-enyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0889] l-{4'-[4-(l-Hydroxy-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (0.2518 g, 0.603 mmol), 1 -iodo-4-trifluoromethyl -benzene (0.089 mL, 0.603 mmol), and cesium carbonate (0.207 g, 11.38 mmol) were dissolved in ACN (2.6 mL) and the solution was purged with bubbling N2 (g). Palladium(II) acetate (0.008 g, 0.0302 mmol) was added, the reaction vessel was sealed, and the reaction was heated to 85 °C overnight. After cooling, the reaction was submitted to standard aqueous workup to afford the title compound.
Figure imgf000294_0001
Step 2: l-(4'-{4-[l-Hydroxy-4-(4-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0890] Prepared according to the procedure described in Example 32, Step 1, using l-(4'-{4-[(E)-l- hydroxy-4-(4 rifluoromethyl-phenyl)-but-3-enyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Figure imgf000294_0002
Step 3: l-(4'-{4-[l-Hydroxy-4-(4-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0891] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[l- hydroxy-4-(4-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 169: Synthesis of l-(4'-{4-[l-Hydroxy-4-(2-trifluoromethyl-phenyl)-butyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-169)
Figure imgf000295_0001
Step 1 : l-(4'-{4-[(E)-l-Hydroxy-4-(2-trifluoromethyl-phenyl)-but-3-enyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0892] Prepared according to the procedure described in Example 168, Step 1, using l-{4'-[4-(l- hydroxy-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 1 -iodo-2-trifluoromethyl -benzene
Figure imgf000295_0002
Step 2: l-(4'-{4-[l-Hydroxy-4-(2-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[0893] Prepared according to the procedure described in Example 32, Step 1, using l-(4'-{4-[(E)-l- hydroxy-4-(2-trifluoromethyl-phenyl)-but-3-enyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester. After the reaction a mixture of two products was recovered, the major of which was the title compound.
Figure imgf000296_0001
Step 3: l-(4'-{4-[l-Hydroxy-4-(2-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[0894] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[l- hydroxy-4-(2-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 170: Synthesis of {4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-acetic acid (Compou -170)
Figure imgf000296_0002
Step 1: {4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid ethyl ester
[0895] Prepared according to the procedure described in Example 110, Step 3, using 5-(4-bromo- phenyl)-4-(2,2-difluoro-4-phenyl-butyl)-3-methyl-isoxazole and [4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester.
Figure imgf000297_0001
Step 2: {4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid
[0896] Prepared according to the procedure described in Example 31 , Step 3, using {4'-[4-(2,2- difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -acetic acid ethyl ester.
Example 171: Synthesis of 2-(4'-{4-[l-Hydroxy-4-(2-trifluoromethyl-phenyl)-butyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-butyric acid (Compound 1-171)
Figure imgf000297_0002
Step 1 : 2-(4'-{4-[l-Hydroxy-4-(2-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-butyric acid ethyl ester
[0897] Prepared according to the procedure described in Example 169, Step 2, and the minor was the title compound.
Figure imgf000297_0003
Step 2: 2-(4'-{4-[l-Hydroxy-4-(2-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-butyric acid
[0898] Prepared according to the procedure described in Example 31, Step 3, using 2-(4'-{4-[l- hydroxy-4-(2-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-butyric acid ethyl ester.
Example 172: Synthesis of l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-172)
Figure imgf000298_0001
Step 1: l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid ethyl ester
[0899] Prepared according to the procedure described in Example 24, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 4-(3-chloro- phenyl)-butan-2-one.
Figure imgf000298_0002
Step 2: l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid
[0900] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[3-(3- chloro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 173: Synthesis of l-{4'-[4-(2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-173)
Figure imgf000299_0001
Step 1 : l-{4'-[4-(2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0901] Prepared according to the procedure described in Example 34, Step 4, using l-[4'-(3 -methyl - 4-oxiranyl-isoxazol-5-yl)-biphenyl-4- -cyclopropanecarboxylic acid ethyl ester and benzyl alcohol.
Figure imgf000299_0002
Step 2: l-{4'-[4-(2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0902] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(2- benzyloxy- 1 -hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 174: Synthesis of {4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl- 4-yl}-acetic acid (Enantiomer A) (Compound 1-174)
Figure imgf000299_0003
Step 1: {4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid ethyl ester (Enantiomer A)
[0903] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-ol (Enantiomer A) and [4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester.
Figure imgf000300_0001
Step 2: {4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid (Enantiomer A)
[0904] Prepared according to the procedure described in Example 31, Step 3, using {4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -acetic acid ethyl ester (Enantiomer A).
Example 175: Synthesis of (l-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic a
Figure imgf000300_0002
Step 1: (l-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester
[0905] Prepared according to the procedure described in Example 110, Step 3, using 5-(4-bromo- phenyl)-4-(2,2-difluoro-4-phenyl-butyl)-3-methyl-isoxazole and { 1 -[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000301_0001
Step 2: (l-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid
[0906] Prepared according to the procedure described in Example 31, Step 3, using (l-{4'-[4-(2,2- difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropyl)-acetic acid ethyl ester. Example 176: Synthesis of (l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic a mpound 1-176)
Figure imgf000301_0002
Step 1 : (l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester (Enantiomer A)
[0907] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-ol (Enantiomer A) and {l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000301_0003
Step 2: (l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid (Enantiomer A)
[0908] Prepared according to the procedure described in Example 31 , Step 3 , using (l-{4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropyl)-acetic acid ethyl ester (Enantiomer A).
Example 177: Synthesis of (l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic mpound 1-177)
Figure imgf000302_0001
Step 1 : (l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester (Enantiomer B)
[0909] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-ol (Enantiomer B) and {l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000302_0002
Step 2: (l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid (Enantiomer B)
[0910] Prepared according to the procedure described in Example 31, Step 3, using (l-{4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropyl)-acetic acid ethyl ester (Enantiomer B).
Example 178: Synthesis of l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-178)
Step 1: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2,2-difluoro-but-3-en-l-ol
[0911] 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde (0.511 g, 1.92 mmol), 3-bromo-3,3- difluoro-propene (0.4977 g, 3.07 mmol), indium (0.357 g, 3.07 mmol) and sodium iodide (0.0142 g, 0.096 mmol) were combined in DMF (5 mL) and stirred at room temperature overnight. The reaction mixture was submitted to standard aqueous workup to afford the title compound, which was taken to the next step without further puri
Figure imgf000303_0002
Step 2: l-{4'-[4-(2,2-Difluoro-l-hydroxy-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0912] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2,2-difluoro-but-3-en-l-ol and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000303_0003
Step 3: l-{4'-[4-((E)-2,2-Difluoro-l-hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester [0913] Prepared according to the procedure described in Example 168, Step 1, using l-{4'-[4-(2,2- difluoro- 1 -hydroxy -but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and iodobenzene.
Figure imgf000304_0001
Step 4: l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester
[0914] Prepared according to the procedure described in Example 32, Step 1, using l-{4'-[4-((E)- 2,2-difluoro- 1 -hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid ethyl est
Figure imgf000304_0002
Step 5: l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid
[0915] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(2,2- difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 179: Synthesis of l-{4'-[4-(l-Hydroxy-2-methyl-4-phenyl-butyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-179)
Figure imgf000305_0001
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-methyl-but-3-en-l-ol
[0916] Prepared according to the procedure described in Example 178, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehy - 1 -ene.
Figure imgf000305_0002
Step 2: l-{4'-[4-(l-Hydroxy-2-methyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0917] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-methyl-but-3-en-l-ol and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000305_0003
Step 3: l-{4'-[4-((E)-l-Hydroxy-2-methyl-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester
[0918] Prepared according to the procedure described in Example 168, Step 1, using l-{4'-[4-(l- hydroxy -2-methyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester and iodobenzene.
Figure imgf000306_0001
Step 4: l-{4'-[4-(l-Hydroxy-2-methyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0919] Prepared according to the procedure described in Example 32, Step 1, using l-{4'-[4-((E)-l- hydroxy-2-methyl-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl est
Figure imgf000306_0002
Step 5: l-{4'-[4-(l-Hydroxy-2-methyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0920] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(l- hydroxy-2-methyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 180: Synthesis of l-{4'-[4-(l-Hydroxy-2,2-dimethyl-4-phenyl-butyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-180)
Figure imgf000306_0003
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2,2-dimethyl-but-3-en-l-ol [0921] Prepared according to the procedure described in Example 178, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and 3-bromo-3-methyl-but- 1 -ene.
Figure imgf000307_0001
Step 2: l-{4'-[4-(l-Hydroxy-2,2-dimethyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0922] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2,2-dimethyl-but-3-en-l-ol and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000307_0002
Step 3: l-{4'-[4-((E)-l-Hydroxy-2,2-dimethyl-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester
[0923] Prepared according to the procedure described in Example 168, Step 1, using l-{4'-[4-(l- hydroxy-2,2-dimethyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and iodobenzene.
Figure imgf000308_0001
Step 4: l-{4'-[4-(l-Hydroxy-2,2-dimethyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester
[0924] Prepared according to the procedure described in Example 32, Step 1, using l-{4'-[4-((E)-l- hydroxy-2,2-dimethyl-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl est
Figure imgf000308_0002
Step 5: l-{4'-[4-(l-Hydroxy-2,2-dimethyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid
[0925] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(l- hydroxy-2,2-dimethyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester.
Example 181: Synthesis of (4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)- propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 1-181)
Figure imgf000309_0001
Step 1: [4'-(4-Amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-acetic acid ethyl ester
[0926] Prepared according to the procedure described in Example 1, Step 7, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and [4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- acetic acid ethyl ester.
Figure imgf000309_0002
Step 2: (4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-acetic acid ethyl ester
[0927] Prepared according to the procedure described in Example 24, Step 1, using [4'-(4-amino-3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-acetic acid ethyl ester and 4-(3-trifluoromethyl-phenyl)-butan- 2-one.
Figure imgf000309_0003
Step 3: (4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-acetic acid
[0928] Prepared according to the procedure described in Example 3, Step 8, using (4'-{3-methyl-4- [l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid ethyl ester.
Example 182: Synthesis of (4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 1-182)
Figure imgf000310_0001
Step 1 : (4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-acetic acid ethyl ester
[0929] Prepared according to the procedure described in Example 24, Step 1, using [4'-(4-amino-3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-acetic acid ethyl ester and 4-(3-chloro-phenyl)-butan-2-one.
Figure imgf000310_0002
Step 2: (4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-acetic acid
[0930] Prepared according to the procedure described in Example 3, Step 8, using (4'-{4-[3-(3- chloro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-acetic acid ethyl ester.
Example 183: Synthesis of [l-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)- propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-183)
Figure imgf000311_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-methyl-3-(3-trifluoromethyl-phenyl)- propyl] -amine
[0931] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylami henyl)-butan-2-one.
Figure imgf000311_0002
Step 2: [l-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl} biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester
[0932] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[l-methyl-3-(3-trifluoromethyl-phenyl)-propyl]-amine and {l-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxabor pyl}-acetic acid ethyl ester.
Figure imgf000311_0003
Step 3: [l-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl} biphenyl-4-yl)-cyclopropyl] -acetic acid [0933] Prepared according to the procedure described in Example 3, Step 8, using [l-(4'-{3-methyl- 4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-cycloprop acetic acid ethyl ester.
Example 184: Synthesis of [l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-184)
Figure imgf000312_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[3-(3-chloro-phenyl)-l-methyl-propyl]- amine
[0934] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine utan-2-one.
Figure imgf000312_0002
Step 2: [l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester
[0935] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(3-chloro-phenyl)-l-methyl-propyl]-amine and {l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000312_0003
Step 3: [l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl] -acetic acid
[0936] Prepared according to the procedure described in Example 3, Step 8, using [l-(4'-{4-[3-(3- chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester.
Example 185: Synthesis of [l-(4'-{4-[3-(3-Fluoro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-185)
Figure imgf000313_0001
Step 1: [l-(4'-{4-[3-(3-Fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cy clop ropyl] -acetic acid ethyl ester
[0937] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(3-fluoro-phenyl)-l-methyl-propyl]-amine and {l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000313_0002
Step 2: [l-(4'-{4-[3-(3-Fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cy clop ropyl] -acetic acid
[0938] Prepared according to the procedure described in Example 3, Step 8, using [l-(4'-{4-[3-(3- fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester.
Example 186: Synthesis of l-{4'-[4-(l,l-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-186)
Figure imgf000314_0001
Step 1 : 5-(4-Bromo-phenyl)-4-(l,l-difluoro-4-phenyl-butyl)-3-methyl-isoxazole
[0939] Prepared according to the procedure described in Example 135, Step 1, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan- 1 -one.
Figure imgf000314_0002
Step 2: l-{4'-[4-(l,l-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0940] Prepared according to the procedure described in Example 110, Step 3, using 5-(4-bromo- phenyl)-4-(l,l-difluoro-4-phenyl-butyl)-3-methyl-isoxazole and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000314_0003
Step 3: l-{4'-[4-(l,l-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0941] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(l,l- difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester. Example 187: Synthesis of l-(4'-{4-[l-Hydroxy-2-((S)-indan-l-ylamino)-ethyl]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-187)
Step 1: 5-(4-Bromo-phenyl)-3-methyl-4-oxiranyl-isoxazole
[0942] Prepared according to the procedure described in Example 146, Step 2, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde.
Figure imgf000315_0002
Step 2: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-((S)-indan-l-ylamino)-ethanol
[0943] 5-(4-Bromo-phenyl)-3-methyl-4-oxiranyl-isoxazole (0.180 g, 0.64 mmol) and (S)-indan-l- ylamine (0.171 g, 1.29 mmol) were mixed in N-methylpyrrolidone (4.0 mL) and then heated to 85 °C over 2 nights while monitoring with analytical LCMS. The reaction was submitted to standard aqueous workup then purified via pre e title compound.
Figure imgf000315_0003
Step 3: l-(4'-{4-[l-Hydroxy-2-((S)-indan-l-ylamino)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid ethyl ester
[0944] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-((S)-indan- 1 -ylamino)-ethanol and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000316_0001
Step 4: l-(4'-{4-[l-Hydroxy-2-((S)-indan-l-ylamino)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid
[0945] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[l- hydroxy-2-((S)-indan- 1 -ylamino)-ethyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 188: Synthesis of 2-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-3-phenyl-propionic acid (Compound 1-188)
Figure imgf000316_0002
Step 1 : 2-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-3-phenyl- propionic acid ethyl ester
[0946] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan- 1 -ol and 3-phenyl-2-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid ethyl ester.
Figure imgf000316_0003
Step 2: 2-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-3-phenyl- propionic acid
[0947] Prepared according to the procedure described in Example 31, Step 3, using 2-{4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -3 -phenyl -propionic acid ethyl ester.
Example 189: Synthesis of l-{4'-[4-(l-Benzylamino-2-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-189)
Figure imgf000317_0001
Step 1 : 2-Benzylamino-2-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol
[0948] Prepared according to the procedure described in Example 187, Step 2, using 5-(4-bromo- phenyl)-3-methyl-4-oxiranyl-isoxazole and benzyl amine.
Figure imgf000317_0002
Step 2: l-{4'-[4-(l-Benzylamino-2-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0949] Prepared according to the procedure described in Example 110, Step 3, using 2-benzylamino- 2-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000318_0001
Step 3: l-{4'-[4-(l-Benzylamino-2-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0950] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(l- benzylamino-2-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 190: Synthesis of l-{4'-[4-(2-Amino-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-190)
Figure imgf000318_0002
Step 1: l-{4'-[4-(2-Benzylamino-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0951] Prepared according to the procedure described in Example 187, Step 2, using l-[4'-(3- methyl-4-oxiranyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and benzyl amine.
Figure imgf000318_0003
Step 2: l-{4'-[4-(2-Amino-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0952] Prepared according to the procedure described in Example 31, Step 3, using l- {4'-[4-(2- benzylamino- 1 -hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. After the reaction the crude material was purified via preparatory HPLC to afford a separable mixture of products, of which the minor product was the title compound.
Example 191: Synthesis of 3-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl- 4-yl] -propionic acid (Compound 1-
Figure imgf000319_0001
Step 1: 3-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-propionic acid ethyl ester
[0953] Prepared according to the procedure described in Example 1, Step 7, using 5-(4-bromo- phenyl)-3-methyl-4-phenethylsulfanylmethyl-isoxazole and [4-(2- ethoxycarbonylethyl)phenyl]boronic acid.
Figure imgf000319_0002
Step 2: 3-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-propionic acid
[0954] Prepared according to the procedure described in Example 3, Step 8, using 3-[4'-(3-methyl-4- phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-propionic acid ethyl ester.
Example 192: Synthesis of 3-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)- propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Compound 1-192)
Figure imgf000320_0001
Step 1 : 3-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-propionic acid ethyl ester
[0955] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[l-methyl-3-(3-trifluoromethyl-phenyl)-propyl]-amine and [4-(2- ethoxycarbonylethyl)phenyl]boronic acid.
Figure imgf000320_0002
Step 2: 3-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-propionic acid
[0956] Prepared according to the procedure described in Example 3, Step 8, using 3-(4'-{3-methyl-4- [l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid ethyl ester.
Example 193: Synthesis of 3-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Compound 1-193)
Figure imgf000321_0001
Step 1: 3-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biph( 4-yl)-propionic acid ethyl ester
[0957] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(3-chloro-phenyl)-l-methyl-propyl]-amine and [4-(2- ethoxycarbonylethyl)phenyl]boronic acid.
Figure imgf000321_0002
Step 2: 3-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-propionic acid
[0958] Prepared according to the procedure described in Example 3, Step 8, using 3-(4'-{4-[3-(3- chloro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-propionic acid ethyl ester.
Example 194: Synthesis of l-{4'-[3-Methyl-4-(4-methyl-pyrazol-l-ylmethyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-194)
Figure imgf000322_0001
Step 1 : l-{4'-[3-Methyl-4-(4-methyl-pyrazol-l-ylmethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0959] Prepared according to the procedure described in Example 34, Step 4, using l-[4'-(4- bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 4- methyl- lH-pyrazole.
Example 195: Synthesis of l-(4'-{3-Methyl-4-[(6-methyl-benzothiazol-2-ylamino)-methyl]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-195)
Figure imgf000322_0002
Step 1 : l-(4'-{3-Methyl-4-[(6-methyl-benzothiazol-2-ylamino)-methyl]-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid
[0960] Prepared according to the procedure described in Example 34, Step 4, using l-[4'-(4- bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 6- methyl-benzothiazol-2-ylamine.
Example 196: Synthesis of l-{4'-[4-(4-Bromo-pyrazol-l-ylmethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-196)
Figure imgf000323_0001
Step 1 : l-{4'-[4-(4-Bromo-pyrazol-l-ylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0961] Prepared according to the procedure described in Example 34, Step 4, using l-[4'-(4- bromomethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 4- bromo-lH-pyrazole.
Figure imgf000323_0002
Step 2: l-{4'-[4-(4-Bromo-pyrazol-l-ylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0962] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(4- bromo-pyrazol- 1 -ylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 197: Synthesis of 3-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-propionic acid (Compound 1-197)
Figure imgf000324_0001
Step 1 : 3-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-propionic acid ethyl ester
[0963] Prepared according to the procedure described in Example 1 10, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-ol and [4-(2-ethoxycarbonylethyl)phenyl]boronic acid.
Figure imgf000324_0002
Step 2: 3-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-propionic acid
[0964] Prepared according to the procedure described in Example 31 , Step 3, using 3- {4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -propionic acid ethyl ester.
Example 198: Synthesis of l-{4'-[4-(2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-198)
Figure imgf000324_0003
Step 1: 2-Benzyloxy-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol (Enantiomer A) [0965] Prepared according to the procedure described in Example 34, Step 4, using 5-(4-Bromo- phenyl)-3-methyl-4-oxiranyl-isoxazole and benzyl alcohol. After the reaction the material was submitted to chiral preparatory HPLC (Chiralcel AS Column, 2% EtOH in hexanes, 65 minute run). The first enantiomer off of the column is Enantiomer A.
Figure imgf000325_0001
Step 2: l-{4'-[4-(2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (Enantiomer A)
[0966] Prepared according to the procedure described in Example 110, Step 3, using 2 -benzyloxy- 1 - [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol (Enantiomer A) and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000325_0002
Step 3: l-{4'-[4-(2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Enantiomer A)
[0967] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(2- benzyloxy- 1 -hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester (Enantiomer A).
Example 199: Synthesis of l-{4'-[4-(2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-199)
Step 1: 2-Benzyloxy-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol (Enantiomer B)
[0968] Prepared according to the procedure described in Example 198, Step 1, where the second product off of the column is Enantiom
Figure imgf000326_0002
Step 2: l-{4'-[4-(2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (Enantiomer B)
[0969] Prepared according to the procedure described in Example 110, Step 3, using 2 -benzyloxy- 1 - [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol (Enantiomer B) and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000326_0003
Step 3: l-{4'-[4-(2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Enantiomer B)
[0970] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(2- benzyloxy- 1 -hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester (Enantiomer B). Example 200: Synthesis of 3-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-3-yl}-propionic acid (Compound 1-200)
Figure imgf000327_0001
Step 1: 3-(3-Bromo-phenyl)-propionic acid methyl ester
[0971] Prepared according to the procedure described in Example 34, Step 1, using 3-(3-bromo- phenyl)-propionic acid and methanol.
Figure imgf000327_0002
Step 2: 3-[3-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid methyl ester
[0972] Prepared according to the procedure described in Example 3, Step 4, using 3-(3-bromo- phenyl)-propionic acid methyl ester and bis(pinacolato)diboron.
Figure imgf000327_0003
Step 3: 3-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-3-yl}-propionic acid methyl ester
[0973] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-ol and 3-[3-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid methyl ester.
Figure imgf000327_0004
Step 4: 3-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-3-yl}-propionic acid
[0974] Prepared according to the procedure described in Example 31, Step 3, using 3-{4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-3-yl} -propionic acid methyl ester.
Example 201: Synthesis of 3-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-2-yl}-propionic acid (Compo
Figure imgf000328_0001
Step 1: 3-(2-Bromo-phenyl)-propionic acid methyl ester
[0975] Prepared according to the procedure described in Example 34, Step 1, using 3-(2-bromo- phenyl)-propionic acid and methanol.
Figure imgf000328_0002
Step 2: 3-[2-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid methyl ester
[0976] Prepared according to the procedure described in Example 3, Step 4, using 3-(2-bromo- phenyl)-propionic acid methyl ester and bis(pinacolato)diboron.
Figure imgf000328_0003
Step 3: 3-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-2-yl}-propionic acid methyl ester
[0977] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-ol and 3-[2-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-propionic acid methyl ester.
Figure imgf000329_0001
Step 4: 3-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-2-yl}-propionic acid
[0978] Prepared according to the procedure described in Example 31, Step 3, using 3-{4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-2-yl} -propionic acid methyl ester. Example 202: Synthesis of l-{4'-[3-Methyl-4-(2-phenylmethanesulfinyl-acetyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-202)
Figure imgf000329_0002
Step 1 : 2-Benzylsulfanyl-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol
[0979] Prepared according to the procedure described in Example 167, Step 1, using 5-(4-bromo- phenyl)-3-methyl-4-oxiranyl-isoxazole and benzyl mercaptan.
Figure imgf000329_0003
Step 2: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-phenylmethanesulfinyl-ethanone
[0980] Prepared according to the procedure described in Example 26, Step 1, using 2- benzylsulfanyl-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol.
Figure imgf000330_0001
Step 3: l-{4'-[3-Methyl-4-(2-phenylmethanesulfinyl-acetyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0981] Prepared according to the procedure described in Example 110, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-phenylmethanesulfinyl-ethanone and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000330_0002
Step 4: l-{4'-[3-Methyl-4-(2-phenylmethanesulfinyl-acetyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0982] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[3-methyl- 4-(2-phenylmethanesulfinyl-acetyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 203: Synthesis of l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-2-yl}-cyclopropanecarboxylic acid (Compound 1-203)
Figure imgf000330_0003
Step 1: l-(2-Bromo-phenyl)-cyclopropanecarbonitrile
[0983] Prepared according to the procedure described in Example 3, Step 1, using (2-bromo- phenyl)-acetonitrile.
Figure imgf000331_0001
Step 2: l-(2-Bromo-phenyl)-cyclopropanecarboxylic acid
[0984] Prepared according to the procedure described in Example 3, Step 2, using l-(2-bromo- phenyl)-cyclopropanecarbonitrile.
Figure imgf000331_0002
Step 3: l-(2-Bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester
[0985] Prepared according to the procedure described in Example 3, Step 3, using l-(2-bromo- phenyl)-cyclopropanecarboxylic acid.
Figure imgf000331_0003
Step 4: l-(2-Bromo-phenyl)-cyclopropanecarboxylic acid ethyl ester
[0986] Prepared according to the procedure described in Example 3, Step 4, using l-(2-bromo- phenyl)-cyclopropanecarboxylic acid ethyl ester and bis(pinacolato)diboron.
Figure imgf000331_0004
Step 5: l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-2-yl}- cyclopropanecarboxylic acid ethyl ester
[0987] Prepared according to the procedure described in Example 110, Step 3, using l-[5 phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-ol and l-[2-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000332_0001
Step 6: l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-2-yl}- cyclopropanecarboxylic acid
[0988] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-2-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 204: Synthesis of (l-{4'-[4-(l,5-Dimethyl-hex-4-enylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-204)
Figure imgf000332_0002
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(l,5-dimethyl-hex-4-enyl)-amine
[0989] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine -one.
Figure imgf000332_0003
Step 2: (l-{4'-[4-(l,5-Dimethyl-hex-4-enylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester
[0990] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l,5-dimethyl-hex-4-enyl)-amine and {l-[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000333_0001
Step 3: (l-{4'-[4-(l,5-Dimethyl-hex-4-enylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid
[0991] Prepared according to the procedure described in Example 3, Step 8, using (l-{4'-[4-(l,5- dimethyl-hex-4-enylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropyl)-acetic acid ethyl ester.
Example 205: Synthesis of l-{4'-[4-(l,5-Dimethyl-hex-4-enylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-205)
Figure imgf000333_0002
Step 1: l-{4'-[4-(l,5-Dimethyl-hex-4-enylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[0992] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l,5-dimethyl-hex-4-enyl)-amine and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000334_0001
Step 2: l-{4'-[4-(l,5-Dimethyl-hex-4-enylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[0993] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(l,5- dimethyl-hex-4-enylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 206: Synthesis of (l-{4'-[3-Methyl-4-(l-naphthalen-2-yl-ethylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-206)
Figure imgf000334_0002
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(l-naphthalen-2-yl-ethyl)-amine
[0994] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine anone.
Figure imgf000334_0003
Step 2: (l-{4'-[3-Methyl-4-(l-naphthalen-2-yl-ethylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester [0995] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l-naphthalen-2-yl-ethyl)-amine and {l-[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000335_0001
Step 3: (l-{4'-[3-Methyl-4-(l-naphthalen-2-yl-ethylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid
[0996] Prepared according to the procedure described in Example 3, Step 8, using (l-{4'-[3-methyl- 4-(l-naphthalen-2-yl-ethylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid ethyl ester. Example 207: Synthesis of (l-{4'-[4-(l-Hydroxy-5-phenyl-pentyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-207)
Figure imgf000335_0002
Step 1: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-pent-4-en-l-ol
[0997] Prepared according to the procedure described in Example 114, Step 3, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and 3-butenylmagnesium bromide.
Figure imgf000335_0003
Step 2: (E)-l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-5-phenyl-pent-4-en-l-ol
[0998] Prepared according to the procedure described in Example 168, Step 1, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-pent-4-en-l-ol and iodobenzene.
Figure imgf000336_0001
Step 3: (l-{4'-[4-((E)-l-Hydroxy-5-phenyl-pent-4-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester
[0999] Prepared according to the procedure described in Example 110, Step 3, using (E)-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-5-phenyl-pent-4-en-l-ol and {l-[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000336_0002
Step 4: (l-{4'-[4-(l-Hydroxy-5-phenyl-pentyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester
[01000] Prepared according to the procedure described in Example 32, Step 1, using (l-{4'-[4-((E)-l- hydroxy-5-phenyl-pent-4-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid ethyl ester.
Figure imgf000336_0003
Step 5: (l-{4'-[4-(l-Hydroxy-5-phenyl-pentyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid
[01001] Prepared according to the procedure described in Example 31, Step 3, using (l-{4'-[4-(l- hydroxy-5-phenyl-pentyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid ethyl ester.
Example 208: Synthesis of [l-(4'-{4-[5-(3,4-Dichloro-phenyl)-l-hydroxy-pentyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-208)
Figure imgf000337_0001
Step 1 : (E)-l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-5-(3,4-dichloro-phenyl)-pent-4-en-l ol
[01002] Prepared according to the procedure described in Example 168, Step 1, using l-[5-(4-bromo phenyl)-3-methyl-isoxazol-4-yl]-p -iodo-benzene.
Figure imgf000337_0002
Step 2: [l-(4'-{4-[(E)-5-(3,4-Dichloro-phenyl)-l-hydroxy-pent-4-enyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester
[01003] Prepared according to the procedure described in Example 110, Step 3, using (E)-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-5-(3,4-dichloro-phenyl)-pent-4-en-l-ol and {l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000338_0001
Step 3: [l-(4'-{4-[5-(3,4-Dichloro-phenyl)-l-hydroxy-pentyl]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cy clop ropyl] -acetic acid ethyl ester
[01004] Prepared according to the procedure described in Example 32, Step 1, using [l-(4'-{4-[(E)-5- (3,4-dichloro-phenyl)-l-hydroxy-pent-4-enyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]- acetic acid ethyl ester.
Figure imgf000338_0002
Step 4: [l-(4'-{4-[5-(3,4-Dichloro-phenyl)-l-hydroxy-pentyl]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cy clop ropyl] -acetic acid
[01005] Prepared according to the procedure described in Example 31, Step 3, using [l-(4'-{4-[5-(3,4- dichloro-phenyl)- 1 -hydroxy-pentyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester.
Example 209: Synthesis of l-(4'-{4-[(S)-l-Hydroxy-2-((R)-l-phenyl-ethoxy)-ethyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-209)
Figure imgf000338_0003
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-((R)-l-phenyl-ethoxy)-ethanol
[01006] Prepared according to the procedure described in Example 34, Step 4, using 5-(4-bromo- phenyl)-3-methyl-4-oxiranyl-isoxazole and (R)-l-phenyl-ethanol.
Figure imgf000339_0001
Step 2: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-((R)-l-phenyl-ethoxy)-ethanone
[01007] Prepared according to the procedure described in Example 26, Step 1, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-((R)-l-phenyl-ethoxy)-ethanol.
Figure imgf000339_0002
Step 3: (S)-l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-((R)-l-phenyl-ethoxy)-ethanol
[01008] The (S)-Corey-Bakshi-Shibata catalyst (0.012 g, 0.04 mmol) was dissolved in THF (2 mL) and cooled to 0 °C. Borane dimethyl sulfide complex (2.0 M in THF, 0.387 mL, 0.77 mmol) was slowly added, followed by l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-((R)-l-phenyl-ethoxy)- ethanone (0.172 g, 0.43 mmol) in THF (3.3 mL) over 15 minutes. After stirring for 55 minutes the reaction was submitted to standard aqueous workup to afford the title compound.
Figure imgf000339_0003
Step 4: l-(4'-{4-[(S)-l-Hydroxy-2-((R)-l-phenyl-ethoxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[01009] Prepared according to the procedure described in Example 110, Step 3, using (S)-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-((R)-l-phenyl-ethoxy)-ethanol and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000340_0001
Step 5: l-(4'-{4-[(S)-l-Hydroxy-2-((R)-l-phenyl-ethoxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[01010] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[(S)-l- hydroxy-2-((R)- 1 -phenyl-ethoxy)-ethyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 210: Synthesis of l-(4'-{4-[3-(4-Methoxy-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-210)
Figure imgf000340_0002
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[3-(4-methoxy-phenyl)-l-methyl-propyl]- amine
[01011] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and 4-(4-methoxy-phenyl)-butan-2-one.
Figure imgf000340_0003
Step 2: l-(4'-{4-[3-(4-Methoxy-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester [01012] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(4-methoxy-phenyl)-l-methyl-propyl]-amine and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000341_0001
Step 3: l-(4'-{4-[3-(4-Methoxy-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[01013] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[3-(4- methoxy-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 211: Synthesis of [l-(4'-{4-[3-(4-Methoxy-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-211)
Figure imgf000341_0002
Step 1: [l-(4'-{4-[3-(4-Methoxy-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester
[01014] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(4-methoxy-phenyl)-l-methyl-propyl]-amine and {l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000342_0001
Step 2: [l-(4'-{4-[3-(4-Methoxy-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl] -acetic acid
[01015] Prepared according to the procedure described in Example 3, Step 8, using [l-(4'-{4-[3-(4- methoxy-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropyl]- acetic acid ethyl ester.
Example 212: Synthesis of l-{4'-[3-Methyl-4-(5-methyl-thieno[2,3-d]pyrimidin-4-ylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-212)
Figure imgf000342_0002
Step 1: l-{4'-[3-Methyl-4-(5-methyl-thieno[2,3-d]pyrimidin-4-ylamino)-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid
[01016] l-[4'-(4-Amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.0583 g, 0.161 mmol) and 4-chloro-5-methyl-thieno[2,3-JJpyrimidine (0.0297 g, 0.161 mmol) were mixed in isopropyl alcohol (1 mL) and 1 drop of cone. HC1 was added. The reaction was heated to 75 °C overnight, then THF (5 mL) was added, followed by NaOH (3N aq., 0.30 mL) and the reaction continued heating and stirring for 50 minutes. An additional portion of NaOH (3N aq., 0.10 mL) was added and the reaction was heated for 1 hour, then cooled. The reaction mixture was submitted to standard aqueous workup then purified on silica gel (30-100% EtOAc in hexanes) to yield the title compound.
Example 213: Synthesis of (l-{4'-[4-(l,3-Diphenyl-propylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-213)
Figure imgf000343_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(l,3-diphenyl-propyl)-amine
[01017] Prepared according to the procedure described in Example 24, Step 1, using 5-(4 phenyl)-3-methyl-isoxazol-4-ylamine 1 -one.
Figure imgf000343_0002
Step 2: (l-{4'-[4-(l,3-Diphenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester
[01018] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l,3-diphenyl-propyl)-amine and {l-[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000343_0003
Step 3: (l-{4'-[4-(l,3-Diphenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphi
cyclopropyl)-acetic acid [01019] Prepared according to the procedure described in Example 3, Step 8, using (l-{4'-[4-(l,3- diphenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropyl)-acetic acid ethyl ester. Example 214: Synthesis of l-{4'-[4-(l,3-Diphenyl-propylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-214)
Figure imgf000344_0001
Step 1 : l-{4'-[4-(l,3-Diphenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01020] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l,3-diphenyl-propyl)-amine and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000344_0002
Step 2: l-{4'-[4-(l,3-Diphenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01021] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(l,3- diphenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 215: Synthesis of (cis)-2-{4'-[4-((R)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-215)
Figure imgf000345_0001
Step 1 : 2-Benzyloxy-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone
[01022] Prepared according to the procedure described in Example 26, Step 1, using 2-benzyloxy- 1 -
[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol.
Figure imgf000345_0002
Step 2: 2-Benzyloxy-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol
[01023] Prepared according to the procedure described in Example 209, Step 3, using 2-benzyloxy- 1 -
[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone. The crude material was purified on silica gel (0-40% EtOAc in hexanes) to afford a mixture of enantiomers that was used directly in the next step.
Figure imgf000345_0003
Step 3: (cis)-2-{4'-[4-((R)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01024] Prepared according to the procedure described in Example 110, Step 3, using 2-benzyloxy- 1 - [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol and (cis)-2-[4-(4,4,5,5-tetramethyl-
[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester. After the reaction the crude material was dissolved in EtOH (3 mL) and purified via preparatory chiral HPLC (Chiralcel- AD column, 8% EtOH in hexanes, 70 minutes) to afford three separate compounds. The first compound off of the column, containing a mixture of cis-cyclopropyl diastereomers, was the title compound.
Figure imgf000346_0001
Step 4: (cis)-2-{4'-[4-((R)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01025] Prepared according to the procedure described in Example 31, Step 3, using (cis)-2-{4'-[4- ((R)-2-benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 216: Synthesis of (cis)-2-{4'-[4-((S)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-216)
Figure imgf000346_0002
Step 1 : (cis)-2-{4'-[4-((S)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (Enantiomer A)
[01026] Prepared according to the procedure described in Example 215, Step 3, where the second compound off the column was the title compound.
Figure imgf000346_0003
Step 2: (cis)-2-{4'-[4-((S)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Enantiomer A)
[01027] Prepared according to the procedure described in Example 31, Step 3, using (cis)-2-{4'-[4- ((S)-2-benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester (Enantiomer A).
Example 217: Synthesis of (cis)-2-{4'-[4-((S)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-217)
Figure imgf000347_0001
Step 1 : (cis)-2-{4'-[4-((S)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- cyclopropanecarboxylic acid ethyl ester (Enantiomer B)
[01028] Prepared according to the procedure described in Example 215, Step 3, where the third compound off the column was the title compound.
Figure imgf000347_0002
Step 2: (cis)-2-{4'-[4-((S)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Enantiomer B)
[01029] Prepared according to the procedure described in Example 31, Step 3, using (cis)-2-{4'-[4- ((S)-2-benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester (Enantiomer B).
Example 218: Synthesis of [l-(4'-{4-[3-(4-Chloro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-218)
Figure imgf000348_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[3-(4-chloro-phenyl)-l-methyl-propyl]- amine
[01030] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylami an-2-one.
Figure imgf000348_0002
Step 2: [l-(4'-{4-[3-(4-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester
[01031] Prepared according to the procedure described in Example 108, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(4-chloro-phenyl)-l-methyl-propyl]-amine and {l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-y -phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000348_0003
Step 3: [l-(4'-{4-[3-(4-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl] -acetic acid [01032] Prepared according to the procedure described in Example 31, Step 3, using [l-(4'-{4-[3-(4- chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester.
Example 219: Synthesis of [l-(4'-{4-[3-(2-Chloro-6-fluoro-phenyl)-l-methyl-propylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-219)
Figure imgf000349_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[3-(2-chloro-6-fluoro-phenyl)-l-methyl- propyl] -amine
[01033] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine nyl)-butan-2-one.
Figure imgf000349_0002
Step 2: [l-(4'-{4-[3-(2-Chloro-6-fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester
[01034] Prepared according to the procedure described in Example 108, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(2-chloro-6-fluoro-phenyl)-l-methyl-propyl]-amine and {l-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000350_0001
Step 3: [l-(4'-{4-[3-(2-Chloro-6-fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl] -acetic acid
[01035] Prepared according to the procedure described in Example 31, Step 3, using [l-(4'-{4-[3-(2- chloro-6-fluoro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropyl] -acetic acid ethyl ester.
Example 220: Synthesis of l-{4'-[3-Methyl-4-(l-methyl-3-phenyl-propylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-220)
Figure imgf000350_0002
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-3-phenyl-propyl)-amine (Enantiomer A)
[01036] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and 4-phenyl-butan-2-one. After the reaction the crude material was purified via preparatory chiral HPLC (Chiralcel-AD column, 2% EtOH in hexanes, 25 minutes) to afford two separate enantiomers. The first enantiomer eluted from the column is the title compound.
Figure imgf000351_0001
Step 2: l-{4'-[3-Methyl-4-(l-methyl-3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (Enantiomer A)
[01037] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-3 -phenyl -propyl)-amine (Enantiomer A) and l-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000351_0002
Step 3: l-{4'-[3-Methyl-4-(l-methyl-3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Enantiomer A)
[01038] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (1 -methyl-3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester (Enantiomer A).
Example 221: Synthesis of l-{4'-[3-Methyl-4-(l-methyl-3-phenyl-propylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-221)
Figure imgf000351_0003
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-3-phenyl-propyl)-amine (Enantiomer B)
[01039] Prepared according to the procedure described in Example 220, Step 1, where the second enantiomer to elute from the column is the title compound.
Figure imgf000352_0001
Step 2: l-{4'-[3-Methyl-4-(l-methyl-3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester (Enantiomer B)
[01040] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-3-phenyl-propyl)-amine (Enantiomer B) and l-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000352_0002
Step 3: l-{4'-[3-Methyl-4-(l-methyl-3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Enantiomer B)
[01041] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (1 -methyl-3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester (Enantiomer B).
Example 222: Synthesis of [l-(4'-{4-[3-(2-Chloro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-222)
Figure imgf000353_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[3-(2-chloro-phenyl)-l-methyl-propyl]- amine
[01042] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine an-2-one.
Figure imgf000353_0002
Step 2: [l-(4'-{4-[3-(2-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester
[01043] Prepared according to the procedure described in Example 110, Step 3, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(2-chloro-phenyl)-l-methyl-propyl]-amine and {l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000353_0003
Step 3: [l-(4'-{4-[3-(2-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl] -acetic acid [01044] Prepared according to the procedure described in Example 31, Step 3, using [l-(4'-{4-[3-(2- chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester.
Example 223: Synthesis of l-(4'-{4-[3-(2-Chloro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-223)
Figure imgf000354_0001
Step 1: l-(4'-{4-[3-(2-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid ethyl ester
[01045] Prepared according to the procedure described in Example 108, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(2-chloro-phenyl)-l-methyl-propyl]-amine and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000354_0002
Step 2: l-(4'-{4-[3-(2-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid
[01046] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[3-(2- chloro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 224: Synthesis of l-(4'-{4-[3-(4-Chloro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-224)
Figure imgf000355_0001
Step 1: l-(4'-{4-[3-(4-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid ethyl ester
[01047] Prepared according to the procedure described in Example 108, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(4-chloro-phenyl)-l-methyl-propyl]-amine and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000355_0002
Step 2: l-(4'-{4-[3-(4-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid
[01048] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[3-(4- chloro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 225: Synthesis of l-(4'-{4-[3-(2-Chloro-6-fluoro-phenyl)-l-methyl-propylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-225)
Figure imgf000356_0001
Step 1: l-(4'-{4-[3-(2-Chloro-6-fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl} biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[01049] Prepared according to the procedure described in Example 108, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(2-chloro-6-fluoro-phenyl)-l-methyl-propyl]-amine and l-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000356_0002
Step 2: l-(4'-{4-[3-(2-Chloro-6-fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl} biphenyl-4-yl)-cyclopropanecarboxylic acid
[01050] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[3-(2- chloro-6-fluoro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 226: Synthesis of (l-{4'-[3-Methyl-4-(l-methyl-pent-4-enylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-226)
Figure imgf000356_0003
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-pent-4-enyl)-amine [01051] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and hex-5-en-2-one.
Figure imgf000357_0001
Step 2: (l-{4'-[3-Methyl-4-(l-methyl-pent-4-enylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester
[01052] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-pent-4-enyl)-amine and {l-[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000357_0002
Step 3: (l-{4'-[3-Methyl-4-(l-methyl-pent-4-enylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid
[01053] Prepared according to the procedure described in Example 3, Step 8, using (l-{4'-[3-methyl- 4-(l-methyl-pent-4-enylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid ethyl ester. Example 227: Synthesis of l-{4'-[3-Methyl-4-(l-methyl-pent-4-enylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-227)
Figure imgf000358_0001
Step 1 : l-{4'-[3-Methyl-4-(l-methyl-pent-4-enylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01054] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-pent-4-enyl)-amine and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000358_0002
Step 2: l-{4'-[3-Methyl-4-(l-methyl-pent-4-enylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01055] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (1 -methyl-pent-4-enylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. Example 228: Synthesis of {4'-[3-Methyl-4-(l-methyl-pent-4-enylamino)-isoxazol-5-yl]- biphenyl-2-yl}-acetic acid (Compoun -228)
Figure imgf000358_0003
Step 1: {4'-[3-Methyl-4-(l-methyl-pent-4-enylamino)-isoxazol-5-yl]-biphenyl-2-yl}-acetic acid ethyl ester
[01056] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-pent-4-enyl)-amine and [2-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester.
Figure imgf000359_0001
Step 2: {4'-[3-Methyl-4-(l-methyl-pent-4-enylamino)-isoxazol-5-yl]-biphenyl-2-yl}-acetic acid
[01057] Prepared according to the procedure described in Example 3, Step 8, using {4'-[3-methyl-4- (l-methyl-pent-4-enylamino)-isoxazol-5-yl]-biphenyl-2-yl} -acetic acid ethyl ester.
Example 229: Synthesis of (l-{4'-[4-(4-Hydroxy-l-methyl-butylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-229)
Figure imgf000359_0002
Step 1 : 4- [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylamino] -pentan-l-ol
[01058] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine one.
Figure imgf000359_0003
Step 2: (l-{4'-[4-(4-Hydroxy-l-methyl-butylamino)-3-methyl-isoxazol-5-yl]-biphi
cyclopropyl)-acetic acid ethyl ester [01059] Prepared according to the procedure described in Example 1, Step 7, using 4-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamino]-pentan- 1 -ol and { 1 -[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000360_0001
Step 3: (l-{4'-[4-(4-Hydroxy-l-methyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid
[01060] Prepared according to the procedure described in Example 3, Step 8, using (l-{4'-[4-(4- hydroxy- 1 -methyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropyl)-acetic acid ethyl ester.
Example 230: Synthesis of l-{4'-[4-(4-Hydroxy-l-methyl-butylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-230)
Figure imgf000360_0002
Step 1 : l-{4'-[4-(4-Hydroxy-l-methyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01061] Prepared according to the procedure described in Example 1, Step 7, using 4-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamino]-pentan- 1 -ol and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000361_0001
Step 2: l-{4'-[4-(4-Hydroxy-l-methyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01062] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(4- hydroxy-l-methyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 231: Synthesis of {4'-[4-(4-Hydroxy-l-methyl-butylamino)-3-methyl-isoxazol-5-yl]- biphenyl-2-yl}-acetic acid (Compou -231)
Figure imgf000361_0002
Step 1 : {4'-[4-(4-Hydroxy-l-methyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-2-yl}-acetic acid ethyl ester
[01063] Prepared according to the procedure described in Example 1, Step 7, using 4-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamino]-pentan-l-ol and [2-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan- 2-yl)-phenyl] -acetic acid ethyl ester.
Figure imgf000361_0003
Step 2: {4'-[4-(4-Hydroxy-l-methyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-2-yl}-acetic acid [01064] Prepared according to the procedure described in Example 3, Step 8, using {4'-[4-(4- hydroxy-l-methyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-2-yl}-acetic acid ethyl ester.
Example 232: Synthesis of {4'-[4-(3-Benzo[l,3]dioxol-5-yl-l-methyl-propylamino)-3-methyl- isoxazol-5-yl]-biphenyl-2-yl}-acetic acid (Compound 1-232)
Figure imgf000362_0001
Step 1: (3-Benzo[l,3]dioxol-5-yl-l-methyl-propyl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]- amine
[01065] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and piperonyl acetone.
Figure imgf000362_0002
Step 2: {4'-[4-(3-Benzo[l,3]dioxol-5-yl-l-methyl-propylamino)-3-methyl-isoxazol-5-yl]- biphenyl-2-yl}-acetic acid ethyl ester
[01066] Prepared according to the procedure described in Example 108, Step 2, using (3- benzo [1,3] dioxol-5-yl- 1 -methyl-propyl)- [5-(4-bromo-phenyl)-3 -methyl-isoxazol-4-yl] -amine (4,4,5,5-tetramethyl-[l,3,2]dioxabo ethyl ester.
Figure imgf000362_0003
Step 3: {4'-[4-(3-Benzo[l,3]dioxol-5-yl-l-methyl-propylamino)-3-methyl-isoxazol-5-yl]- biphenyl-2-yl}-acetic acid [01067] Prepared according to the procedure described in Example 31, Step 3, using {4'-[4-(3- benzo[ 1 ,3]dioxol-5-yl- 1 -methyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-2-yl} -acetic acid ethyl ester.
Example 233: Synthesis of (l-{4'-[4-(3-Benzo[l,3]dioxol-5-yl-l-methyl-propylamino)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-233)
Figure imgf000363_0001
Step 1 : (l-{4'-[4-(3-Benzo[l,3]dioxol-5-yl-l-methyl-propylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic acid ethyl ester
[01068] Prepared according to the procedure described in Example 108, Step 2, using (3- benzo[l,3]dioxol-5-yl-l-methyl-propyl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-amine and {1- [4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000363_0002
Step 2: (l-{4'-[4-(3-Benzo[l,3]dioxol-5-yl-l-methyl-propylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic acid
[01069] Prepared according to the procedure described in Example 31, Step 3, using (l-{4'-[4-(3- benzo[ 1 ,3]dioxol-5-yl- 1 -methyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropyl)- acetic acid ethyl ester.
Example 234: Synthesis of 3-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)- propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Enantiomer A) (Compound 1-234)
Figure imgf000364_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-methyl-3-(3-trifluoromethyl-phenyl)- propyl] -amine (Enantiomer A)
[01070] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and 4-(3-trifluoromethyl-phenyl)-butan-2-one. After silica gel chromatography the crude material was purified via preparatory chiral HPLC (Chiralcel-AD column, 2% EtOH in hexanes, 35 minutes) to afford two separate enantiomers. The first enantiomer eluted from the column is the title compoun
Figure imgf000364_0002
Step 2: 3-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-propionic acid ethyl ester (Enantiomer A)
[01071] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[l-methyl-3-(3-trifluoromethyl-phenyl)-propyl]-amine (Enantiomer A) and [4-(2-ethoxycarbonylethyl)phenyl]boronic acid.
Figure imgf000364_0003
Step 3: 3-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-propionic acid (Enantiomer A)
[01072] Prepared according to the procedure described in Example 3, Step 8, using 3-(4'-{3-methyl-4- [l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid ethyl ester (Enantiomer A).
Example 235: Synthesis of 3-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)- propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Enantiomer B) (Compound 1-235)
Figure imgf000365_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[l-methyl-3-(3-trifluoromethyl-phenyl)- propyl] -amine (Enantiomer B)
[01073] Prepared according to the procedure described in Example 226, Step 1, where the second enantiomer eluted from the column is the title compound.
Figure imgf000365_0002
Step 2: 3-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-propionic acid ethyl ester (Enantiomer B)
[01074] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[l-methyl-3-(3-trifluoromethyl-phenyl)-propyl]-amine (Enantiomer B) and [4-(2-ethoxycarbonylethyl)phenyl]boronic acid.
Figure imgf000366_0001
Step 3: 3-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-propionic acid (Enantiomer B)
[01075] Prepared according to the procedure described in Example 3, Step 8, using 3-(4'-{3-methyl-4- [l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid ethyl ester (Enantiomer B).
Example 236: Synthesis of [l-(4'-{4-[2-(4-Methoxy-phenyl)-l-methyl-ethylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-236)
Figure imgf000366_0002
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[2-(4-methoxy-phenyl)-l-methyl-ethyl]- amine
[01076] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylami -propan-2-one.
Figure imgf000366_0003
Step 2: [l-(4'-{4-[2-(4-Methoxy-phenyl)-l-methyl-ethylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester
[01077] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[2-(4-methoxy-phenyl)-l-methyl-ethyl]-amine and { l-[4-(4 ,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl -phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000367_0001
Step 3: [l-(4'-{4-[2-(4-Methoxy-phenyl)-l-methyl-ethylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl] -acetic acid
[01078] Prepared according to the procedure described in Example 3, Step 8, using [l-(4'-{4-[2-(4- methoxy-phenyl)- 1 -methyl-ethylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester.
Example 237: Synthesis of [l-(4'-{4-[2-(4-Methoxy-phenyl)-l-methyl-ethylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-237)
Figure imgf000367_0002
Step 1 : l-(4'-{4-[2-(4-Methoxy-phenyl)-l-methyl-ethylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid ethyl ester
[01079] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[2-(4-methoxy-phenyl)- 1 -methyl-ethyl]-amine and 1 -[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000368_0001
Step 2: l-(4'-{4-[2-(4-Methoxy-phenyl)-l-methyl-ethylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid
[01080] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[2-(4- methoxy-phenyl)-l-methyl-ethylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 238: Synthesis of (4'-{4-[2-(4-Methoxy-phenyl)-l-methyl-ethylamino]-3-methyl- isoxazol-5-yl}-biphenyl-2-yl)-acetic
Figure imgf000368_0002
Step 1 : (4'-{4-[2-(4-Methoxy-phenyl)-l-methyl-ethylamino]-3-methyl-isoxazol-5-yl}-biphen; yl)-acetic acid ethyl ester
[01081] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[2-(4-methoxy-phenyl)- 1 -methyl-ethyl]-amine and [2-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester.
Figure imgf000369_0001
Step 2: (4'-{4-[2-(4-Methoxy-phenyl)-l-methyl-ethylamino]-3-methyl-isoxazol-5-yl}-biphenyl-2- yl)-acetic acid
[01082] Prepared according to the procedure described in Example 3, Step 8, using (4'-{4-[2-(4- methoxy-phenyl)-l-methyl-ethylamino]-3-methyl-isoxazol-5-yl}-biphenyl-2-yl)-acetic acid ethyl ester.
Example 239: Synthesis of l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-239)
Figure imgf000369_0002
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[3-(3-chloro-phenyl)-l-methyl-propyl]- amine (Enantiomer A)
[01083] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and 4-(3-chloro-phenyl)-butan-2-one. After silica gel chromatography the crude material was purified via preparatory chiral HPLC (Chiralcel-AD column, 1% EtOH in hexanes, 36 minutes) to afford two separate enantiomers. The first enantiomer eluted from the column is the title compoun
Figure imgf000369_0003
Step 2: l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid ethyl ester (Enantiomer A)
[01084] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(3-chloro-phenyl)-l-methyl-propyl]-amine (Enantiomer A) and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000370_0001
Step 3: l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid (Enantiomer A)
[01085] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[3-(3- chloro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester (Enantiomer A).
Example 240: Synthesis of l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-240)
Figure imgf000370_0002
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-[3-(3-chloro-phenyl)-l-methyl-propyl]- amine (Enantiomer B)
[01086] Prepared according to the procedure described in Example 231, Step 1, where the second enantiomer eluted from the column is the title compound.
Figure imgf000371_0001
Step 2: l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid ethyl ester (Enantiomer B)
[01087] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[3-(3-chloro-phenyl)-l-methyl-propyl]-amine (Enantiomer B) and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000371_0002
Step 3: l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid (Enantiomer B)
[01088] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[3-(3- chloro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester (Enantiomer B).
Example 241: Synthesis of (4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 1-241)
Figure imgf000371_0003
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-(3-trifluoromethyl-benzyloxy)-ethanol [01089] Prepared according to the procedure described in Example 34, Step 4, using 5-(4-bromo- phenyl)-3-methyl-4-oxiranyl-isoxazole and (3-trifluoromethyl-phenyl)-methanol.
Figure imgf000372_0001
Step 2: (4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-acetic acid ethyl ester
[01090] Prepared according to the procedure described in Example 1, Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-(3-trifluoromethyl-benzyloxy)-ethanol and [4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester.
Figure imgf000372_0002
Step 3: (4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-acetic acid
[01091] Prepared according to the procedure described in Example 3, Step 8, using (4'-{4-[l- hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid ethyl ester.
Example 242: Synthesis of 3-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Compound 1-242)
Figure imgf000373_0001
Step 1 : 3-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-propionic acid ethyl ester
[01092] Prepared according to the procedure described in Example 1, Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-(3-trifluoromethyl-benzyloxy)-ethanol and [4-(2- ethoxycarbonylethyl)phenyl]boronic acid.
Figure imgf000373_0002
Step 2: 3-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-propionic acid
[01093] Prepared according to the procedure described in Example 3, Step 8, using 3-(4'-{4-[l- hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid ethyl ester.
Example 243: Synthesis of l-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-243)
Figure imgf000374_0001
Step 1 : l-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[01094] Prepared according to the procedure described in Example 1, Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-(3-trifluoromethyl-benzyloxy)-ethanol and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000374_0002
Step 2: l-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[01095] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[l- hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 244: Synthesis of [l-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-244)
Figure imgf000375_0001
Step 1 : [l-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester
[01096] Prepared according to the procedure described in Example 1, Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-(3-trifluoromethyl-benzyloxy)-ethanol and {l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000375_0002
Step 2: [l-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl] -acetic acid
[01097] Prepared according to the procedure described in Example 3, Step 8, using [l-(4'-{4-[l- hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropyl] -acetic acid ethyl ester.
Example 245: Synthesis of 4-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-4-oxo-butyric acid (Compound 1-245)
Figure imgf000376_0001
Step 1: l-{3-Methyl-5-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-isoxazol-4-yl}- 4-phenyl-butan-l-ol
[01098] Prepared according to the procedure described in Example 3, Step 4, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl] -4-phenyl-butan- 1 -ol and bis(pinacolato)diboron.
Figure imgf000376_0002
Step 2: 4-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-4-oxo- butyric acid methyl ester
[01099] Prepared according to the procedure described in Example 1, Step 7, using l-{3-methyl-5-[4- (4,4,5,5-tetramethyl-[ 1 ,3,2]dioxaborolan-2-yl)-phenyl]-isoxazol-4-yl} -4-phenyl-butan- 1 -ol and 4-(4- bromo-phenyl)-4-oxo-butyric acid methyl ester.
Figure imgf000376_0003
Step 3: 4-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-4-oxo- butyric acid
[01100] Prepared according to the procedure described in Example 3, Step 8, using 4-{4'-[4-(l- hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-4-oxo-butyric acid methyl ester. Example 246: Synthesis of (l-{4'-[4-(l-Hydroxy-3-methyl-3-phenyl-butyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-246)
Figure imgf000377_0001
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-methyl-3-phenyl-butan-l-ol
[01101] Prepared according to the procedure described in Example 114, Step 3, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and 2-methyl-2-phenylpropylmagnesium chloride.
Figure imgf000377_0002
Step 2: (l-{4'-[4-(l-Hydroxy-3-methyl-3-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester
[01102] Prepared according to the procedure described in Example 108, Step 2, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-3-methyl-3-phenyl-butan- 1 -ol and { 1 -[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000378_0001
Step 3: (l-{4'-[4-(l-Hydroxy-3-methyl-3-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid
[01103] Prepared according to the procedure described in Example 31, Step 3, using (l-{4'-[4-(l- hydroxy-3-methyl-3-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid ethyl ester.
Example 247: Synthesis of [l-(4'-{4-[l-Hydroxy-3-(4-methoxy-phenyl)-propyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-247)
Figure imgf000378_0002
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-3-(4-methoxy-phenyl)-propan-l-ol
[01104] Prepared according to the procedure described in Example 114, Step 3, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carbaldehyde and 4-methoxyphenylmagnesium chloride.
Figure imgf000379_0001
Step 2: [l-(4'-{4-[l-Hydroxy-3-(4-methoxy-phenyl)-propyl]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropyl] -acetic acid ethyl ester
[01105] Prepared according to the procedure described in Example 108, Step 2, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-3-(4-methoxy-phenyl)-propan- 1 -ol and { 1 -[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000379_0002
Step 3: [l-(4'-{4-[l-Hydroxy-3-(4-methoxy-phenyl)-propyl]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropyl] -acetic acid
[01106] Prepared according to the procedure described in Example 31, Step 3, using [l-(4'-{4-[l- hydroxy-3-(4-methoxy-phenyl)-propyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester.
Example 248: Synthesis of l-{4'-[4-(l-Hydroxy-2-phenethyloxy-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-248)
Figure imgf000380_0001
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-phenethyloxy-ethanol
[01107] Prepared according to the procedure described in Example 34, Step 4, using 5-(4-bromo- phenyl)-3-methyl-4-oxiranyl-isoxazo
Figure imgf000380_0002
Step 2: l-{4'-[4-(l-Hydroxy-2-phenethyloxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01108] Prepared according to the procedure described in Example 1, Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-phenethyloxy-ethanol and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000380_0003
Step 3: l-{4'-[4-(l-Hydroxy-2-phenethyloxy-ethyl)-3-methyl-isoxazol-5-yl]-biphi
cyclopropanecarboxylic acid [01109] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(l- hydroxy-2-phenethyloxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 249: Synthesis of l-{4'-[4-(Hydroxy-phenethylcarbamoyl-methyl)-3-methyl-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-249)
Figure imgf000381_0001
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-hydroxy-acetic acid
[OHIO] 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde (1.160 g, 4.36 mmol), trimethylsilyl cyanide (0.700 mL, 2.62 mmol) and zinc iodide (0.015 g, 0.01 mmol) were combined in CH2CI2 (10 mL) and stirred at room temperature for 5 days. The reaction was then concentrated and cone. HC1 (2 mL) was added. The reaction was heated to reflux overnight then cooled, diluted with H20 (10 mL), extracted with 3 x CH2CI2 (30 mL), dried and concentrated to afford the title compound, which was used in the next step without further purification.
Figure imgf000381_0002
Step 2 : 2- [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl] -2-hydroxy-iV-phenethyl-acetamide
[01111] Prepared according to the procedure described in Example 33, Step 4, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-hydroxy-acetic acid and phenethylamine.
Figure imgf000381_0003
Step 3: l-{4'-[4-(Hydroxy-phenethylcarbamoyl-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01112] Prepared according to the procedure described in Example 108, Step 2, using 2-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-hydroxy-N-phenethyl-acetamide and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000382_0001
Step 4: l-{4'-[4-(Hydroxy-phenethylcarbamoyl-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01113] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4- (hydroxy-phenethylcarbamoyl-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester.
Example 250: Synthesis of l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-ylmethyl}-cyclopropanecarboxylic acid (Compound 1-250)
Figure imgf000382_0002
Step 1: l-(4-Bromo-benzyl)-cyclopropanecarbonitrile
[01114] Cyclopropanecarbonitrile (2.5 g, 37.3 mmol) was added to a solution of lithium
diisopropylamide (41 mmol) in THF (20 mL) at -78 °C and the reaction stirred for 1 hour. 1-Bromo- 4-bromomethyl-benzene (10.25 g, 41 mmol) in THF (50 mL) was slowly added and the reaction was allowed to warm to room temperature over 30 minutes. The reaction was submitted to standard aqueous workup to afford the title compound, which was used in the next step without further purification.
Figure imgf000383_0001
Step 2: l-(4-Bromo-benzyl)-cyclopropanecarboxylic acid
[01115] l-(4-Bromo-benzyl)-cyclopropanecarbonitrile (from the previous step) was dissolved in MeOH and NaOH (35% aq.) and the reaction was heated to reflux for 8 hours. After cooling the reaction was submitted to standard acid-base workup to afford the title compound.
Figure imgf000383_0002
Step 3: l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-ylmethyl}- cyclopropanecarboxylic acid
[01116] Prepared according to the procedure described in Example 1, Step 7, using l-{3-methyl-5-[4- (4,4,5,5-tetramethyl-[ 1 ,3,2]dioxaborolan-2-yl)-phenyl]-isoxazol-4-yl} -4-phenyl-butan- 1 -ol and 1 -(4- bromo-benzyl)-cyclopropanecarboxylic acid.
Example 251: Synthesis of l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-3-ylmethyl}-cyclopropanecarboxylic acid (Compound 1-251)
Figure imgf000383_0003
Step 1: l-(3-Bromo-benzyl)-cyclopropanecarbonitrile
[01117] Prepared according to the procedure described in Example 240, Step 1, using l-bromo-3- bromomethyl-benzene and cyclopropanecarbonitrile.
Figure imgf000384_0001
Step 2: l-(3-Bromo-benzyl)-cyclopropanecarboxylic acid
[01118] Prepared according to the procedure described in Example 240, Step 2, using l-(3-bromo- benzyl)-cyclopropanecarbonitrile.
Figure imgf000384_0002
Step 3: l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-3-ylmethyl}- cyclopropanecarboxylic acid
[01119] Prepared according to the procedure described in Example 1, Step 7, using l-(3-bromo- benzyl)-cyclopropanecarboxylic acid and l-{3-methyl-5-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan 2-yl)-phenyl]-isoxazol-4-yl} -4-phenyl-butan- 1 -ol.
Example 252: Synthesis of l-{4'-[4-(Benzylcarbamoyl-hydroxy-methyl)-3-methyl-isoxazol-5-yl] biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-252)
Figure imgf000384_0003
Step 1 : iV-Benzyl-2-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-hydroxy-acetamide
[01120] Prepared according to the procedure described in Example 33, Step 4, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-hydroxy-acetic acid and benzyl amine.
Figure imgf000385_0001
Step 2: l-{4'-[4-(Benzylcarbamoyl-hydroxy-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01121] Prepared according to the procedure described in Example 108, Step 2, using N-Benzyl-2-[5- (4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-hydroxy-acetamide and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000385_0002
Step 3: l-{4'-[4-(Benzylcarbamoyl-hydroxy-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01122] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4- (benzylcarbamoyl-hydroxy-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 253: Synthesis of l-(4'-{4-[Hydroxy-((R)-l-phenyl-ethylcarbamoyl)-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-253)
Figure imgf000385_0003
Step 1 : 2-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-hydroxy-AL((R)-l-phenyl-ethyl)- acetamide
[01123] Prepared according to the procedure described in Example 33, Step 4, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-hydroxy-acetic acid and (R)-l-phenyl-ethylamine.
Figure imgf000386_0001
Step 2: l-(4'-{4-[Hydroxy-((R)-l-phenyl-ethylcarbamoyl)-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[01124] Prepared according to the procedure described in Example 108, Step 2, using 2-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-hydroxy-N-((R)- 1 -phenyl-ethyl)-acetamide and 1 -[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000386_0002
Step 3: l-(4'-{4-[Hydroxy-((R)-l-phenyl-ethylcarbamoyl)-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[01125] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4- [hydroxy-((R)- 1 -phenyl-ethylcarbamoyl)-methyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 254: Synthesis of l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-254)
Figure imgf000387_0001
Step 1 : l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester (Enantiomer A)
[01126] Prepared according to the procedure described in Example 3, Step 3, using l-{4'-[4-(2,2- difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid. After the reaction, the crude material was purified via chiral preparatory HPLC (Chiralcel AD column, 8% EtOH in hexanes, 35 minutes) to afford two separate enantiomers. The first enantiomer to elute from the column was the title compound.
Figure imgf000387_0002
Step 2: l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Enantiomer A)
[01127] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(2,2- difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester (Enantiomer A).
Example 255: Synthesis of l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-255)
Figure imgf000388_0001
Step 1 : l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester (Enantiomer B)
[01128] Prepared according to the procedure described in Example 242, Step 1, where the second enantiomer to elute from the column was the title compound.
Figure imgf000388_0002
Step 2: l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Enantiomer B)
[01129] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-(2,2- difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester (Enantiomer B).
Example 256: Synthesis of (l-{4'-[4-(l-Acetylamino-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic a
Figure imgf000388_0003
Step 1 : (l-{4'-[4-(l-Acetylamino-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester
[01130] (l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)- acetic acid ethyl ester (0.20 g, 0.39 mmol) was dissolved in MeCN (5 mL) and cooled to 0 °C. Cone. H2S04 (0.3 mL) was added. The reaction was allowed to stir at room temperature overnight and was then submitted to standard aqueous workup. The residue was purified by silica gel chromatography (0-70% EtOAc in hexanes) to provide the title compound.
Figure imgf000389_0001
Step 2: (l-{4'-[4-(l-Acetylamino-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid
[01131] Prepared according to the procedure described in Example 3, Step 8, using (l-{4'-[4-(l- acetylamino-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid ethyl ester.
Example 257: Synthesis of l-{4'-[4-(l-Methanesulfonylamino-4-phenyl-butyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-257)
Figure imgf000389_0002
Step 1 : N- [1- [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl] -meth-(E)-ylidene] - methanesulfonamide
[01132] 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbaldehyde (2 g, 7.5 mmol), methane sulfonamide (0.714 g, 7.5 mmol) and -toluenesulfonic acid (0.010 g, 0.06 mmol) were combined in toluene. The reaction was heated to reflux for 24 hours with Dean-Stark apparatus in place. Upon cooling, the title compound precipitated from solution and was collected by filtration and used directly in the next step.
Figure imgf000390_0001
Step 2: iV-{l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butyl}-methanesulfonamide
[01133] Prepared according to the procedure described in Example 114, Step 3, using N-[l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-meth-(E)-ylidene]-methanesulfonamide and 3- (phenyl)propylmagnesium bromide.
Figure imgf000390_0002
Step 3: l-{4'-[4-(l-Methanesulfonylamino-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester
[01134] Prepared according to the procedure described in Example 108, Step 2, using N-{l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butyl}-methanesulfonamide and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000390_0003
Step 4: l-{4'-[4-(l-Methanesulfonylamino-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-bipheny yl}-cyclopropanecarboxylic acid
[01135] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(l- methanesulfonylamino-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester. Example 258: Synthesis of l-(4'-{4-[(Benzyl-methyl-carbamoyl)-hydroxy-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-258)
Figure imgf000391_0001
Step 1 : iV-Benzyl-2-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-hydroxy-ALmethyl- acetamide
[01136] Prepared according to the procedure described in Example 33, Step 4, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-hydroxy-acetic acid and N-methyl-benzylamine.
Figure imgf000391_0002
Step 2: l-(4'-{4-[(Benzyl-methyl-carbamoyl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[01137] Prepared according to the procedure described in Example 108, Step 2, using N-benzyl-2-[5- (4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-hydroxy-N-methyl-acetamide and 1 -[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000391_0003
Step 3: l-(4'-{4-[(Benzyl-methyl-carbamoyl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid [01138] Prepared according to the procedure described in Example 3, Step 8, using l-(4'- {4-[(benzyl- methyl-carbamoyl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 259: Synthesis of l-{4'-[3-Methyl-4-((E)-2-phenylmethanesulfonyl-vinyl)-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-259)
Figure imgf000392_0001
Step 1: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbonyl chloride
[01139] 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid (4.2 g, 14.89 mmol) was dissolved in CH2CI2 (42 mL) under N2 atmosphere. Oxalyl chloride (2.6 mL, 29.78 mmol) and DMF (5 drops) were added and the reaction stirred for 2.5 hours at room temperature. Then, additional oxalyl chloride (5 mL, 57.3 mmol) was added. After 30 minutes, the reaction mixture was concentrated and placed under high vacuum. The crude material was used directly in the next step.
Figure imgf000392_0002
Step 2 : 2-Bromo-l- [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl] -ethanone
[01140] 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carbonyl chloride (from the previous step) was dissolved in ACN (30 mL) then trimethylsilyl-diazomethane (2M in ΕΪ2Ο, 16.38 mL, 32.76 mmol) was slowly added and the reaction stirred at room temperature for 2 hours. Hydrobromic acid (30% aq., 7 mL) was carefully added and the reaction stirred for an additional 1 hour. The mixture was submitted to standard aqueous workup then purified on silica gel (0-20% EtOAc in hexanes) to afford the title compound.
Figure imgf000392_0003
Step 3: 2-Benzylsulfanyl-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone [01141] Prepared according to the procedure described in Example 120, Step 1, using 2-bromo-l-[5- (4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone and benzyl mercaptan.
Figure imgf000393_0001
Step 4: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-phenylmethanesulfinyl-ethanone
[01142] Prepared according to the procedure described in Example 52, Step 1, using 2- benzylsulfanyl-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone.
Figure imgf000393_0002
Step 5: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-phenylmethanesulfonyl-ethanone
[01143] Prepared according to the procedure described in Example 52, Step 1, using 2- benzylsulfanyl-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone.
Figure imgf000393_0003
Step 6: (S)-l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-phenylmethanesulfonyl-ethanol
[01144] Prepared according to the procedure described in Example 209, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-phenylmethanesulfonyl-ethanone.
Figure imgf000393_0004
Step 7: l-{4'-[4-((S)-l-Hydroxy-2-phenylmethanesulfonyl-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester
[01145] Prepared according to the procedure described in Example 110, Step 3, using (S)-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-phenylmethanesulfonyl-ethanol and 1 -[4-(4 ,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000394_0001
Step 8: l-{4'-[3-Methyl-4-((E)-2-phenylmethanesulfonyl-vinyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01146] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-((S)-l- hydroxy-2-phenylmethanesulfonyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid ethyl ester.
Example 260: Synthesis of l-{4'-[4-(l-Hydroxy-4-pyridin-3-yl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-260)
Figure imgf000394_0002
Step 1 : l-{4'-[4-((E)-l-Hydroxy-4-pyridin-3-yl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester
[01147] Prepared according to the procedure described in Example 124, Step 1, using l-{4'-[4-(l- hydroxy-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 3-bromopyridine.
Figure imgf000395_0001
Step 2: l-{4'-[4-(l-Hydroxy-4-pyridin-3-yl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01148] Prepared according to the procedure described in Example 32, Step 1, using l-{4'-[4-((E)-l- hydroxy-4-pyridin-3-yl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000395_0002
Step 3: l-{4'-[4-(l-Hydroxy-4-pyridin-3-yl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01149] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(l- hydroxy-4-pyridin-3-yl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 261: Synthesis of l-{4'-[4-(l-Hydroxy-4-pyridin-4-yl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-261)
Figure imgf000396_0001
Step 1: l-{4'-[4-((E)-l-Hydroxy-4-pyridin-4-yl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester
[01150] Prepared according to the procedure described in Example 124, Step 1, using l-{4'-[4-(l- hydroxy-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester and 4-bromopyridine.
Figure imgf000396_0002
Step 2: l-{4'-[4-(l-Hydroxy-4-pyridin-4-yl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01151] Prepared according to the procedure described in Example 32, Step 1, using l-{4'-[4-((E)-l- hydroxy-4-pyridin-4-yl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000396_0003
Step 3: l-{4'-[4-(l-Hydroxy-4-pyridin-4-yl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01152] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(l- hydroxy-4-pyridin-4-yl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 262: Synthesis of l-(4'-{3-Methyl-4-[(E)-2-(phenylmethanesulfinyl)-vinyl]-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-262)
Figure imgf000397_0001
Step 1 : (S)-l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-phenylmethanesulfinyl-ethanol
[01153] Prepared according to the procedure described in Example 209, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-phenylmethanesulfinyl-ethanone.
Figure imgf000397_0002
Step 2: l-{4'-[4-((S)-l-Hydroxy-2-phenylmethanesulfinyl-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester
[01154] Prepared according to the procedure described in Example 110, Step 3, using (S)-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-phenylmethanesulfinyl-ethanol and 1 -[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000398_0001
Step 3: l-(4'-{3-Methyl-4-[(E)-2-(phenylmethanesulfinyl)-vinyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Enantiomer A)
[01155] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-((S)-l- hydroxy-2-phenylmethanesulfinyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester. After the reaction the crude material was purified via preparatory HPLC to afford two separate enantiomers. The first enantiomer eluted from the column is the title compound.
Example 263: Synthesis of l-(4'-{3-Methyl-4-[(E)-2-(phenylmethanesulfinyl)-vinyl]-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-263)
Figure imgf000398_0002
Step 1 : l-(4'-{3-Methyl-4-[(E)-2-(phenylmethanesulfinyl)-vinyl]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Enantiomer B)
[01156] Prepared according to the procedure described in Example 245, Step 3,where the second enantiomer to elute from the column is Enantiomer B.
Example 264: Synthesis of l-(4'-{4-[2,2-Difluoro-4-(4-fluoro-phenyl)-l-hydroxy-butyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-264)
Figure imgf000399_0001
Step 1 : (E)-l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2,2-difluoro-4-(4-fluoro-phenyl)-but- 3-en-l-ol
[01157] Prepared according to the procedure described in Example 124, Step 1, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2,2 -fluoro-4-iodo-benzene.
Figure imgf000399_0002
Step 2: l-(4'-{4-[(E)-2,2-Difluoro-4-(4-fluoro-phenyl)-l-hydroxy-but-3-enyl]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[01158] Prepared according to the procedure described in Example 110, Step 3, using (E)-l-[5-(4- Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2,2-difluoro-4-(4-fluoro-phenyl)-but-3-en-l-ol and l-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxabor anecarboxylic acid ethyl ester.
Figure imgf000399_0003
Step 3: l-(4'-{4-[2,2-Difluoro-4-(4-fluoro-phenyl)-l-hydroxy-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[01159] Prepared according to the procedure described in Example 32, Step 1, using l-(4'-{4-[(E)- 2,2-difluoro-4-(4-fluoro-phenyl)-l-hydroxy-but-3-enyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Figure imgf000400_0001
Step 4: l-(4'-{4-[2,2-Difluoro-4-(4-fluoro-phenyl)-l-hydroxy-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[01160] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[2,2- difluoro-4-(4-fluoro-phenyl)- 1 -hydroxy -butyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 265: Synthesis of l-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-265)
Figure imgf000400_0002
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-(3-trifluoromethyl-benzylsulfanyl)- ethanol
[01161] Prepared according to the procedure described in Example 167, Step 1, using 5-(4-bromo- phenyl)-3-methyl-4-oxiranyl-isoxazole and (3-trifluoromethyl-phenyl)-methanethiol.
Figure imgf000400_0003
Step 2: l-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester [01162] Prepared according to the procedure described in Example 1, Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-(3-trifluoromethyl-benzylsulfanyl)-ethanol and 1 -[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000401_0001
Step 3: l-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
[01163] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[l- hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 266: Synthesis of (4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 1-266)
Figure imgf000401_0002
Step 1 : (4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-acetic acid ethyl ester
[01164] Prepared according to the procedure described in Example 1, Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-(3-trifluoromethyl-benzylsulfanyl)-ethanol and [4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester.
Figure imgf000402_0001
Step 2: (4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-acetic acid
[01165] Prepared according to the procedure described in Example 3, Step 8, using (4'-{4-[l- hydroxy -2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid ethyl ester.
Example 267: Synthesis of l-(4'-{3-Methyl-4-[methyl-(l-methyl-3-phenyl-propyl)-amino]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-267)
Figure imgf000402_0002
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-3-phenyl-propyl)-amine
[01166] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and 4-phenyl-butan-2-one.
Figure imgf000402_0003
Step 2: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-methyl-(l-methyl-3-phenyl-propyl)-amine
[01167] Prepared according to the procedure described in Example 123, Step 1, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-3-phenyl-propyl)-amine and iodomethane.
Figure imgf000403_0001
Step 3: l-(4'-{3-Methyl-4-[methyl-(l-methyl-3-phenyl-propyl)-amino]-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid ethyl ester
[01168] Prepared according to the procedure described in Example 3, Step 5, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-methyl-(l-methyl-3-phenyl-propyl)-amine and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Step 4: l-(4'-{3-Methyl-4-[methyl-(l-methyl-3-phenyl-propyl)-amino]-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid
[01169] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{3-methyl- 4-[methyl-(l-methyl-3-phenyl-propyl)-amino]-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 268: Synthesis of l-(4'-{4-[2,2-Difluoro-l-hydroxy-4-(4-trifluoromethyl-phenyl)- butyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-268)
Figure imgf000403_0003
Step 1 : (E)-l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2,2-difluoro-4-(4-fluoro-phenyl)-but- 3-en-l-ol
[01170] Prepared according to the procedure described in Example 124, Step 1, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2, -difluoro-but-3-en- 1 -ol and 1 -iodo-4-trifluoromethyl-benzene.
Figure imgf000404_0001
Step 2: l-(4'-{4-[(E)-2,2-Difluoro-l-hydroxy-4-(4-trifluoromethyl-phenyl)-but-3-enyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[01171] Prepared according to the procedure described in Example 110, Step 3, using (E)-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-2,2-difluoro-4-(4-fluoro-phenyl)-but-3-en-l-ol and l-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxabo ecarboxylic acid ethyl ester.
Figure imgf000404_0002
Step 3: l-(4'-{4-[2,2-Difluoro-l-hydroxy-4-(4-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[01172] Prepared according to the procedure described in Example 32, Step 1, using l-(4'-{4-[(E)- 2,2-difluoro- 1 -hydroxy-4-(4-trifluoromethyl-phenyl)-but-3-enyl]-3-methyl-isoxazol-5-yl} -biphenyl- 4-yl)-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000405_0001
Step 4: l-(4'-{4-[2,2-Difluoro-l-hydroxy-4-(4-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
[01173] Prepared according to the procedure described in Example 31, Step 3, using l-(4'-{4-[2,2- difluoro- 1 -hydroxy-4-(4-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 269: Synthesis of l-{4'-[4-((S)-2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-269)
Figure imgf000405_0002
Step 1 : (S)-2-Benzylsulfanyl-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol
[01174] Prepared according to the procedure described in Example 209, Step 3, using 2- benzylsulfanyl-l-[5-(4-bromo-phenyl -3-methyl-isoxazol-4-yl]-ethanone.
Figure imgf000405_0003
Step 2: l-{4'-[4-((S)-2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphi cyclopropanecarboxylic acid ethyl ester [01175] Prepared according to the procedure described in Example 1, Step 7, using (S)-2- benzylsulfanyl-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000406_0001
Step 3: l-{4'-[4-((S)-2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01176] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-((S)-2- benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 270: Synthesis of l-{4'-[3-Methyl-4-(l,2,3,4-tetrahydro-naphthalen-2-ylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-270)
Figure imgf000406_0002
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(l,2,3,4-tetrahydro-naphthalen-2-yl)- amine
[01177] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and 3,4-dihydro-lH-naphthalen-2-one.
Figure imgf000407_0001
Step 2: l-{4'-[3-Methyl-4-(l,2,3,4-tetrahydro-naphthalen-2-ylamino)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester
[01178] Prepared according to the procedure described in Example 108, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l,2,3,4-tetrahydro-naphthalen-2-yl)-amine and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000407_0002
Step 3: l-{4'-[3-Methyl-4-(l,2,3,4-tetrahydro-naphthalen-2-ylamino)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid
[01179] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (l,2,3,4-tetrahydro-naphthalen-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 271: Synthesis of l-{4'-[4-(Indan-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-271)
Figure imgf000407_0003
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-indan-2-yl-amine [01180] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and 2-indanone.
Figure imgf000408_0001
Step 2: l-{4'-[4-(Indan-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01181] Prepared according to the procedure described in Example 108, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-indan-2-yl-amine and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000408_0002
Step 3: l-{4'-[4-(Indan-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01182] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(indan-2- ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 272: Synthesis of {4'-[4-((S)-2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-acetic acid (Compound 1-272)
Figure imgf000409_0001
Step 1 : {4'-[4-((S)-2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- acetic acid ethyl ester
[01183] Prepared according to the procedure described in Example 1, Step 7, using (S)-2- benzylsulfanyl- 1 -[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol and [4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester.
Figure imgf000409_0002
Step 2: {4'-[4-((S)-2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- acetic acid
[01184] Prepared according to the procedure described in Example 3, Step 8, using {4'-[4-((S)-2- benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -acetic acid ethyl ester. Example 273: Synthesis of 3-{4'-[4-((S)-2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-propionic acid (Compound 1-273)
Figure imgf000410_0001
Step 1 : 3-{4'-[4-((S)-2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphi propionic acid ethyl ester
[01185] Prepared according to the procedure described in Example 1, Step 7, using (S)-2- benzylsulfanyl- 1 -[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol and [4-(2- ethoxycarbonylethyl)phenyl]boronic acid.
Figure imgf000410_0002
Step 2: 3-{4'-[4-((S)-2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- propionic acid
[01186] Prepared according to the procedure described in Example 3, Step 8, using 3-{4'-[4-((S)-2- benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-propionic acid ethyl ester. Example 274: Synthesis of 3-(4'-{4-[(S)-l-Hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]- 3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Compound 1-274)
Figure imgf000410_0003
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-(3-trifluoromethyl-benzylsulfanyl)- ethanone [01187] Prepared according to the procedure described in Example 3, Step 7, using 2-bromo-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4- -ethanone and (3-trifluoromethyl-phenyl)-methanethiol.
Figure imgf000411_0001
Step 2: (S)-l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-(3-trifluoromethyl-benzylsulfanyl)- ethanol
[01188] Prepared according to the procedure described in Example 209, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-(3-trifluoromethyl-benzylsulfanyl)-ethanone.
Figure imgf000411_0002
Step 3: 3-(4'-{4-[(S)-l-Hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-propionic acid ethyl ester
[01189] Prepared according to the procedure described in Example 1, Step 7, using (S)-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-(3-trifluoromethyl-benzylsulfanyl)-ethanol and [4-(2- ethoxycarbonylethyl)phenyl]boronic acid.
Figure imgf000411_0003
Step 4: 3-(4'-{4-[(S)-l-Hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-propionic acid [01190] Prepared according to the procedure described in Example 3, Step 8, using 3-(4'- {4-[(S)-l- hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- propionic acid ethyl ester.
Example 275: Synthesis of l-{4'-[4-(2-teri-Butylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-275)
Figure imgf000412_0001
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-teri-butylsulfanyl-ethanone
[01191] Prepared according to the procedure described in Example 3, Step 7, using 2-bromo-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone and 2-methyl-propane-2-thiol.
Figure imgf000412_0002
Step 2: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-teri-butylsulfanyl-ethanol
[01192] l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-iert-butylsulfanyl-ethanone (1 eq.) was dissolved in THF and cooled to 0 °C. Borane-dimethylsulfide (2 eq.) was added and the reaction was allowed to slowly warm to room temperature. After stirring for 2 hours the reaction mixture was concentrated then purified on silica gel to afford the title compound.
Figure imgf000412_0003
Step 3: l-{4'-[4-(2-teri-Butylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester [01193] Prepared according to the procedure described in Example 1, Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-iert-butylsulfanyl-ethanol and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000413_0001
Step 4: l-{4'-[4-(2-teri-Butylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01194] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(2-£ert- butylsulfanyl- 1 -hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 276: Synthesis of l-(4'-{4-[l-Hydroxy-2-(2,2,2-trifluoro-ethylsulfanyl)-ethyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-276)
Figure imgf000413_0002
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-(2,2,2-trifluoro-ethylsulfanyl)- ethanone
[01195] Prepared according to the procedure described in Example 3, Step 7, using 2-bromo-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone and 2,2,2-trifluoro-ethanethiol.
Figure imgf000413_0003
Step 2: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-(2,2,2-trifluoro-ethylsulfanyl)-ethanol
[01196] Prepared according to the procedure described in Example 275, Step 2, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-(2,2,2-trifluoro-ethylsulfanyl)-ethanone.
Figure imgf000414_0001
Step 3: l-(4'-{4-[l-Hydroxy-2-(2,2,2-trifluoro-ethylsulfanyl)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester
[01197] Prepared according to the procedure described in Example 1, Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-(2,2,2-trifluoro-ethylsulfanyl)-ethanol and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000414_0002
Step 4: l-(4'-{4-[l-Hydroxy-2-(2,2,2-trifluoro-ethylsulfanyl)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[01198] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[l- hydroxy-2-(2,2,2-trifluoro-ethylsulfanyl)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 277: Synthesis of l-{4'-[4-(l-Hydroxy-2-phenylsulfanyl-ethyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-277)
Figure imgf000414_0003
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-phenylsulfanyl-ethanone [01199] Prepared according to the procedure described in Example 3, Step 7, using 2-bromo-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone and benzenthiol.
Figure imgf000415_0001
Step 2: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-phenylsulfanyl-ethanol
[01200] Prepared according to the procedure described in Example 275, Step 2, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-phenylsulfanyl-ethanone.
Figure imgf000415_0002
Step 3: l-{4'-[4-(l-Hydroxy-2-phenylsulfanyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01201] Prepared according to the procedure described in Example 1, Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-phenylsulfanyl-ethanol and 1 -[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000415_0003
Step 4: l-{4'-[4-(l-Hydroxy-2-phenylsulfanyl-ethyl)-3-methyl-isoxazol-5-yl]-biphi
cyclopropanecarboxylic acid [01202] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(l- hydroxy-2-phenylsulfanyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 278: Synthesis of l-{4'-[3-Methyl-4-(l-methyl-2-phenylsulfanyl-ethylamino)-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-278)
Figure imgf000416_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-2-phenylsulfanyl-ethyl)-amine
[01203] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and 1 -phenylsulfanyl-propan-2-one.
Figure imgf000416_0002
Step 2: l-{4'-[3-Methyl-4-(l-methyl-2-phenylsulfanyl-ethylamino)-isoxazol-5-yl]-biphenyl-4 cyclopropanecarboxylic acid ethyl ester
[01204] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-2-phenylsulfanyl-ethyl)-amine and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000416_0003
Step 3: l-{4'-[3-Methyl-4-(l-methyl-2-phenylsulfanyl-ethylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01205] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (l-methyl-2-phenylsulfanyl-ethylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 279: Synthesis of l-{4'-[3-Methyl-4-(l-methyl-2-phenoxy-ethylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-279)
Figure imgf000417_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-2-phenoxy-ethyl)-amine
[01206] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and l-phenoxy-propan-2-one.
Figure imgf000417_0002
Step 2: l-{4'-[3-Methyl-4-(l-methyl-2-phenoxy-ethylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01207] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l-methyl-2-phenoxy-ethyl)-amine and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000418_0001
Step 3: l-{4'-[3-Methyl-4-(l-methyl-2-phenoxy-ethylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01208] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (1 -methyl-2-phenoxy-ethylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 280: Synthesis of l-{4'-[3-Methyl-4-(quinolin-2-ylamino)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-280)
Figure imgf000418_0002
Step 1: l-{4'-[3-Methyl-4-(quinolin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01209] l-[4'-(4-Amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.181 g, 0.5 mmol) was dissolved in DMF and then sodium hydride (60% in mineral oil, 0.028 g, 0.7 mmmol) was added. After 20 minutes 2-chloroquinoline (0.1145 g, 0.7 mmol) was added and the reaction was heated to 60 °C for 3 hours. No product was observed by analytical LCMS so the reaction was heated to 100 °C overnight. After cooling the reaction was submitted to standard aqueous workup to give the title compound.
Figure imgf000419_0001
Step 2: l-{4'-[3-Methyl-4-(quinolin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01210] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (quinolin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 281: Synthesis of l-{4'-[4-(l-Ethyl-3-phenyl-propylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-281)
Figure imgf000419_0002
Step 1 : l-{4'-[4-(l-Ethyl-3-phenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01211] Prepared according to the procedure described in Example 24, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 1-phenyl- pentan-3-one.
Figure imgf000420_0001
Step 2: l-{4'-[4-(l-Ethyl-3-phenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01212] Prepared according to the procedure described in Example 3, Step 8, using 1 -{4'-[4-(l -ethyl - 3-phenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 282: Synthesis of l-{4'-[4-(2-Hydroxy-l-methyl-3-phenyl-propylamino)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Diastereomer A) (Compound 1-282)
Figure imgf000420_0002
Step 1: Acetic acid l-benzyl-2-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylamino]-propyl ester
[01213] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine -oxo-propyl ester.
Figure imgf000420_0003
Step 2: l-{4'-[4-(2-Acetoxy-l-methyl-3-phenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid ethyl ester [01214] Prepared according to the procedure described in Example 1, Step 7, using acetic acid 1- benzyl-2-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylamino]-propyl ester and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000421_0001
Step 3: l-{4'-[4-(2-Hydroxy-l-methyl-3-phenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid (Diastereomer A)
[01215] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(2- acetoxy- 1 -methyl-3-phenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid ethyl ester. After the reaction, the crude material was purified on silica gel (0-5% MeOH in CH2CI2) to afford a separable mixture of diastereomers. The first diastereomer to elute from the column is Diastereomer A.
Example 283: Synthesis of l-{4'-[4-(2-Hydroxy-l-methyl-3-phenyl-propylamino)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Diastereomer B) (Compound 1-283)
Figure imgf000421_0002
Step 1 : l-{4'-[4-(2-Hydroxy-l-methyl-3-phenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid (Diastereomer B)
[01216] Prepared according to the procedure described in Example 258, Step 3, where the second compound to elute from the column was Diastereomer B.
Example 284: Synthesis of l-{4'-[4-(l-Benzo[6]thiophen-2-yl-ethylamino)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-284)
Figure imgf000422_0001
Step 1: (l-Benzo[6]thiophen-2-yl-ethyl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-amine
[01217] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and 1 -benzo[ ?]thiophen-2-yl-ethanone.
Figure imgf000422_0002
Step 2: l-{4'-[4-(l-Benzo[6]thiophen-2-yl-ethylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01218] Prepared according to the procedure described in Example 1, Step 7, using (1- benzo[ ?]thiophen-2-yl-ethyl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-amine and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000422_0003
Step 3: l-{4'-[4-(l-Benzo[6]thiophen-2-yl-ethylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01219] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(l- benzo[ ?]thiophen-2-yl-ethylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester. Example 285: Synthesis of l-{4'-[4-(l,3-Dimethyl-3-phenyl-butylamino)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-285)
Figure imgf000423_0001
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(l,3-dimethyl-3-phenyl-butyl)-amine
[01220] Prepared according to the procedure described in Example 24, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and 4-methyl-4-phenyl-pentan-2-one.
Figure imgf000423_0002
Step 2: l-{4'-[4-(l,3-Dimethyl-3-phenyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01221] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l,3-dimethyl-3-phenyl-butyl)-amine and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000423_0003
Step 3: l-{4'-[4-(l,3-Dimethyl-3-phenyl-butylamino)-3-methyl-isoxazol-5-yl]-biphi
cyclopropanecarboxylic acid [01222] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(l,3- dimethyl-3-phenyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 286: Synthesis of (l-{4'-[4-(l-Benzo[6]thiophen-2-yl-ethylamino)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-286)
Figure imgf000424_0001
Step 1: (l-{4'-[4-(l-Benzo[6]thiophen-2-yl-ethylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester
[01223] Prepared according to the procedure described in Example 1, Step 7, using (1- benzo[ ?]thiophen-2-yl-ethyl)-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-amine and { 1 -[4- (4,4,5,5-tetramethyl-[l,3,2]dioxaborol -2-yl)-phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000424_0002
Step 2: (l-{4'-[4-(l-Benzo[6]thiophen-2-yl-ethylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid
[01224] Prepared according to the procedure described in Example 3, Step 8, using (l-{4'-[4-(l- benzo[ ?]thiophen-2-yl-ethylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid ethyl ester.
Example 287: Synthesis of (l-{4'-[4-(l,3-Dimethyl-3-phenyl-butylamino)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-287)
Figure imgf000425_0001
Step 1 : (l-{4'-[4-(l,3-Dimethyl-3-phenyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid ethyl ester
[01225] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(l,3-dimethyl-3-phenyl-butyl)-amine and {l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropyl}-acetic acid ethyl ester.
Figure imgf000425_0002
Step 2: (l-{4'-[4-(l,3-Dimethyl-3-phenyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid
[01226] Prepared according to the procedure described in Example 3, Step 8, using (l-{4'-[4-(l,3- dimethyl-3-phenyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid ethyl ester.
Example 288: Synthesis of l-{4'-[3-Methyl-4-((E)-l-methyl-3-phenyl-allylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-288)
Figure imgf000425_0003
Step 1 : [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-(3-methoxy-l-methyl-3-phenyl-propyl)- amine [01227] Prepared according to the procedure described in Example 67, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylamine and 4-hydroxy-4-phenyl-butan-2-one. The reaction yielded a number of separable products, one of which was the title compound.
Figure imgf000426_0001
Step 2: l-{4'-[4-(3-Methoxy-l-methyl-3-phenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid ethyl ester
[01228] Prepared according to the procedure described in Example 1, Step 7, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-(3-methoxy-l-methyl-3-phenyl-propyl)-amine and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000426_0002
Step 3: l-{4'-[3-Methyl-4-((E)-l-methyl-3-phenyl-allylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01229] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(3- methoxy- 1 -methyl-3-phenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid ethyl ester.
Example 289: Synthesis of l-{4'-[4-(l-Hydroxy-3,3-dimethyl-4-phenyl-butyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-289)
Figure imgf000427_0001
Step 1: 5-(4-Bromo-phenyl)-3-methyl-isoxazole
[01230] Acetone oxime (4.85 g, 66.4 mmol) was dissolved in THF (100 mL) and cooled to 0 °C. n- Butyllithium (1.6M in hexanes, 81 mL, 129.6 mmol) was added and the reaction was stirred at room temperature for 1 hour. 4-Bromo-benzoic acid methyl ester (9.4 g, 43.7 mmol) in THF (30 mL) and the reaction stirred for 24 hours. The mixture was submitted to standard aqueous workup then dried over MgS04 and evaporated. The residue was taken up in EtOH and HCl (4N in dioxane, 1 mL) was added. The reaction was heated to 60 °C and monitored by analytical TLC. When completed, the reaction mixture was concentrated to dryness to afford the title compound, which was used directly in the next step.
Figure imgf000427_0002
Step 2: l-[4'-(3-Methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[01231] Prepared according to the procedure described in Example 1, Step 7, using 5-(4-bromo- phenyl)-3-methyl-isoxazole and l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]- cyclopropanecarboxylic acid ethyl ester.
Figure imgf000427_0003
Step 3: l-[4'-(4-Bromo-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester
[01232] l-[4'-(3-Methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (1.00 g, 2.88 mmol) was dissolved in acetic acid (12 mL) and N-bromosuccinimide (0.563 g, 3.2 mmol) was added. After stirring at room temperature for 1 hour, the reaction mixture was submitted to standard aqueous workup to give the title compound, which was used in the next step without further purification.
Figure imgf000428_0001
Step 4: l-{4'-[4-(l-Hydroxy-3,3-dimethyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid ethyl ester
[01233] l-[4'-(4-Bromo-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.100 g, 0.243 mmol) was dissolved in THF (0.25M) and cooled to -78 °C. n-Butyllithium (2.5M in hexanes, 0.1068 mL, 0.267 mmol) was slowly added and the reaction stirred for 30 minutes. 3,3-Dimethyl-4-phenyl-butyraldehyde (0.047 g, 0.254 mmol) was added and the reaction was stirred at -78 °C for 30 minutes then warmed to room temperature and continued stirring for 1 hour. The reaction mixture was submitted to standard aqueous workup to afford the title compound, which was used in the next step without further purification.
Figure imgf000428_0002
Step 5: l-{4'-[4-(l-Hydroxy-3,3-dimethyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphi yl}-cyclopropanecarboxylic acid [01234] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(l- hydroxy-3,3-dimethyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester.
Example 290: Synthesis of l-{4'-[3-Methyl-4-(pyridin-3-ylamino)-isoxazol-5-yl]-biphenyl-4 cyclopropanecarboxylic acid (Compound 1-290)
Figure imgf000429_0001
Step 1 : l-{4'-[3-Methyl-4-(pyridin-3-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01235] l-[4'-(4-Amino-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester (0.200 g, 0.552 mmol) and 3-bromo-pyridine (0.087 g, 0.552 mmol) were dissolved in toluene along with Pd(dba)2 (0.032 g, 0.055 mmol), BINAP (0.069 g, 0.11 mmol) and cesium carbonate (0.270 g, 0.828 mmol). The reaction was heated to 110 °C overnight then allowed to cool. The reaction mixture was filtered through Celite then purified via preparatory HPLC to afford the title compound.
Figure imgf000429_0002
Step 2: l-{4'-[3-Methyl-4-(pyridin-3-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01236] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (pyridin-3-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. Example 291: Synthesis of l-{4'-[4-(5-Methoxy-pyridin-3-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-291)
Figure imgf000430_0001
Step 1 : l-{4'-[4-(5-Methoxy-pyridin-3-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01237] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-bromo-5- methoxy-pyridine .
Figure imgf000430_0002
Step 2: l-{4'-[4-(5-Methoxy-pyridin-3-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01238] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(5- methoxy-pyridin-3-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 292: Synthesis of l-{4'-[4-(3-Bromo-benzoylamino)-3-methyl-isoxazol-5-yl]-biphenyl- 4-yl}-cyclopropanecarboxylic acid (Compound 1-292)
Figure imgf000431_0001
Step 1 : l-{4'-[4-(3-Bromo-benzoylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01239] Prepared according to the procedure described in Example 33, Step 4, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-bromo- benzoic acid.
Figure imgf000431_0002
Step 2: l-{4'-[4-(3-Bromo-benzoylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01240] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(3- bromo-benzoylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 293: Synthesis of l-{4'-[3-Methyl-4-(6-propoxy-pyridin-2-ylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-293)
Figure imgf000432_0001
Step 1 : l-{4'-[3-Methyl-4-(6-propoxy-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01241] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6- propoxy-pyridine.
Figure imgf000432_0002
Step 2: l-{4'-[3-Methyl-4-(6-propoxy-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01242] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- (6-propoxy-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Example 294: Synthesis of l-{4'-[4-(6-Ethoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-294)
Figure imgf000433_0001
Step 1 : l-{4'-[4-(6-Ethoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01243] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6- ethoxy-pyridine.
Figure imgf000433_0002
Step 2: l-{4'-[4-(6-Ethoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01244] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(6- ethoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 295: Synthesis of l-{4'-[4-(6-Butoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-295)
Figure imgf000434_0001
Step 1 : l-{4'-[4-(6-Butoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01245] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6- butoxy-pyridine.
Figure imgf000434_0002
Step 2: l-{4'-[4-(6-Butoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01246] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(6- butoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 296: Synthesis of l-{4'-[3-Methyl-4-(pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-296)
Figure imgf000435_0001
Step 1 : l-{4'-[4-(6-Bromo-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01247] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2,6-dibromo- pyridine.
Figure imgf000435_0002
Step 2: l-{4'-[4-(6-Bromo-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01248] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(6- bromo-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000436_0001
Step 3: l-{4'-[3-Methyl-4-(pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01249] Prepared according to the procedure described in Example 32, Step 1, using l-{4'-[4-(6- bromo-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. Additionally, hydrazine hydrate (10 eq.) was added to the reaction mixture.
Example 297: Synthesis of l-{4'-[4-(6-Isopropoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-297)
Figure imgf000436_0002
Step 1: l-{4'-[4-(6-Isopropoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01250] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6- isopropoxy-pyridine.
Figure imgf000437_0001
Step 2: l-{4'-[4-(6-Isopropoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01251] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(6- isopropoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 298: Synthesis of 6-{5-[4'-(l-Carboxy-cyclopropyl)-biphenyl-4-yl]-3-methyl-isoxazol- 4-ylamino}-pyridine-2-carboxylic aci
Figure imgf000437_0002
Step 1 : (6-Bromo-pyridin-2-yl)-(4-methyl-piperazin-l-yl)-methanone
[01252] Prepared according to the procedure described in Example 33, Step 4, using 6-bromo- pyridine-2-carboxylic acid and 1-methyl-piperazine.
Figure imgf000437_0003
Step 2: l-(4'-{3-Methyl-4-[6-(4-methyl-piperazine-l-carbonyl)-pyridin-2-ylamino]-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester [01253] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and (6-bromo- pyridin-2-yl)-(4-methyl-piperazin- 1 -yl)-methanone.
Figure imgf000438_0001
Step 3: 6-{5-[4'-(l-Carboxy-cyclopropyl)-biphenyl-4-yl]-3-methyl-isoxazol-4-ylamino}- pyridine-2-carboxylic acid
[01254] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{3-methyl-4- [6-(4-methyl-piperazine- 1 -carbonyl)-pyridin-2-ylamino]-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 299: Synthesis of l-(4'-{4-[6-(2-Dimethylamino-ethylcarbamoyl)-pyridin-2-ylamino]- 3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-299)
Figure imgf000438_0002
Step 1: 6-Bromo-pyridine-2-carboxylic acid (2-dimethylamino-ethyl)-amide
[01255] Prepared according to the procedure described in Example 33, Step 4, using 6-bromo- pyridine-2-carboxylic acid and NN-dimethylethylenediamine.
Figure imgf000438_0003
Step 2: l-(4'-{4-[6-(2-Dimethylamino-ethylcarbamoyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester [01256] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 6-bromo- pyridine-2-carboxylic acid (2-dimethylamino-ethyl)-amide.
Figure imgf000439_0001
Step 3: l-(4'-{4-[6-(2-Dimethylamino-ethylcarbamoyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
[01257] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[6-(2- dimethylamino-ethylcarbamoyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 300: Synthesis of l-(4'-{4-[6-(2,2-Dimethyl-propylcarbamoyl)-pyridin-2-ylamino]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-300)
Figure imgf000439_0002
Step 1: 6-Bromo-pyridine-2-carboxylic acid (2,2-dimethyl-propyl)-amide
[01258] Prepared according to the procedure described in Example 33, Step 4, using 6-bromo- pyridine-2-carboxylic acid and neopentylamine.
Figure imgf000439_0003
Step 2: l-(4'-{4-[6-(2,2-Dimethyl-propylcarbamoyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester [01259] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 6-bromo- pyridine-2-carboxylic acid (2,2-dimethyl-propyl)-amide.
Figure imgf000440_0001
Step 3: l-(4'-{4-[6-(2,2-Dimethyl-propylcarbamoyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
[01260] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[6-(2,2- dimethyl-propylcarbamoyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester.
Example 301: Synthesis of l-{4'-[4-(6-teri-Butoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-301)
Figure imgf000440_0002
Step 1 : l-{4'-[4-(6-teri-Butoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01261] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6-£ert- butoxy-pyridine.
Figure imgf000441_0001
Step 2: l-{4'-[4-(6-teri-Butoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01262] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(6-tert- butoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 302: Synthesis of l-{4'-[4-(6-Hydroxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-302)
Figure imgf000441_0002
Step 1: l-{4'-[4-(6-Hydroxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01263] Prepared according to the procedure described in Example 2, Step 2, using l-{4'-[4-(6-£ert- butoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid. Example 303: Synthesis of l-{4'-[4-(6-Dodecyloxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-303)
Figure imgf000441_0003
Step 1: 2-Bromo-6-dodecyloxy-pyridine [01264] Dodecanol (1.118 g, 6 mmol) was dissolved in toluene (2 mL) and sodium hydride (60% in mineral oil, 0.120 g, 3 mmol) was added. 2,6-Dibromopyridine (0.710 g, 3 mmol) was added and the reaction was heated to reflux for 16 hours. After cooling, the reaction mixture was filtered through Celite and purified on silica gel (0-5% EtOAc in hexanes) to afford the title compound.
Figure imgf000442_0001
Step 2: l-{4'-[4-(6-Dodecyloxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01265] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6- dodecyloxy-pyridine.
Figure imgf000442_0002
Step 3: l-{4'-[4-(6-Dodecyloxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01266] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(6- dodecyloxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 304: Synthesis of l-{4'-[4-(6-Methoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-304)
Figure imgf000443_0001
Step 1 : l-{4'-[4-(6-Methoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01267] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 2-bromo-6- methoxy-pyridine .
Figure imgf000443_0002
Step 2: l-{4'-[4-(6-Methoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01268] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(6- methoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 305: Synthesis of l-{4'-[4-(6-Methoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-305)
Figure imgf000444_0001
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-ylmethyl]-carbamic acid benzyl ester
[01269] Prepared according to the procedure described in Example 3, Step 7, using C-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-methylamine and benzyl chloro formate.
Figure imgf000444_0002
Step 2: 4'-[4-(Benzyloxycarbonylamino-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-3-carboxylic acid
[01270] Prepared according to the procedure described in Example 108, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-ylmethyl]-carbamic acid benzyl ester and 3-carboxyphenylboronic acid. Example 306: Synthesis of {l-[4'-(5-Methyl-4-phenethylsulfanylmethyl-isoxazol-3-yl)-biphenyl- 4-yl]-cyclopropyl} -acetic acid (Compound 1-306)
Figure imgf000444_0003
Step 1 : 3-(4-Bromo-phenyl)-5-methyl-4-phenethylsulfanylmethyl-isoxazole
[01271] Prepared according to the procedure described in Example 34, Step 4, using 4-bromomethyl-
3-(4-bromo-phenyl)-5-methyl-isoxazole and 2-phenyl-ethanethiol.
Figure imgf000445_0001
Step 2: {l-[4'-(5-Methyl-4-phenethylsulfanylmethyl-isoxazol-3-yl)-biphenyl-4-yl]-cyclopropyl}- acetic acid ethyl ester
[01272] Prepared according to the procedure described in Example 110, Step 3, using 3-(4-bromo- phenyl)-5-methyl-4-phenethylsulfanylmethyl-isoxazole and {l-[4-(4,4,5,5-tetramethyl- [1, 3, 2]dioxaborolan-2-yl)-phenyl]-cyclopropyl} -acetic acid ethyl ester.
Figure imgf000445_0002
Step 3: {l-[4'-(5-Methyl-4-phenethylsulfanylmethyl-isoxazol-3-yl)-biphenyl-4-yl]-cyclopropyl}- acetic acid
[01273] Prepared according to the procedure described in Example 31, Step 3, using {l-[4'-(5-methyl- 4-phenethylsulfanylmethyl-isoxazol-3-yl)-biphenyl-4-yl]-cyclopropyl} -acetic acid ethyl ester.
Example 307: Synthesis of (4'-{3-Methyl-4-[(S)-l-methyl-3-(3-trifluoromethyl-phenyl)- propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-propynoic acid (Compound 1-307)
Figure imgf000445_0003
Step 1: {3-Methyl-5-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-isoxazol-4-yl}-[l- methyl-3-(3-trifluoromethyl-phenyl)-propyl]-amine [01274] Prepared according to the procedure described in Example 3, Step 4, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-[l-methyl-3-(3-trifluoromethyl-phenyl)-propyl]-amine and bis(pinacolato)diboron.
Figure imgf000446_0001
Step 2: (4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-propynoic acid ethyl ester
[01275] Prepared according to the procedure described in Example 1, Step 7, using {3-methyl-5-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-isoxazol-4-yl}-[l-methyl-3-(3- trifluoromethyl-phenyl)-propyl] -amine and (4-bromo-phenyl)-propynoic acid ethyl ester.
Figure imgf000446_0002
Step 3: (4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-propynoic acid
[01276] Prepared according to the procedure described in Example 3, Step 8, using (4'-{3-methyl-4- [l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-propynoic acid ethyl ester.
Example 308: Synthesis of l-(4'-{4-[3-(3-Bromo-phenyl)-ureido]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-308)
Figure imgf000447_0001
Step 1 : l-(4'-{4-[3-(3-Bromo-phenyl)-ureido]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl ester
[01277] Prepared according to the procedure described in Example 7, Step 1, using l-[4'-(4-amino-3- methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-bromo-benzoic acid.
Figure imgf000447_0002
Step 2: l-(4'-{4-[3-(3-Bromo-phenyl)-ureido]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid
[01278] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[3-(3- bromo-phenyl)-ureido]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester.
Example 309: Synthesis of l-{4'-[4-(6-Isopropoxy-l-oxy-pyridin-2-ylamino)-3-methyl-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-309)
Figure imgf000448_0001
Step 1: l-{4'-[4-(6-Isopropoxy-l-oxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01279] Prepared according to the procedure described in Example 53, Step 1, using l-{4'-[4-(6- isopropoxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid.
Example 310: Synthesis of l-{4'-[4-(5-Isopropoxy-pyridin-3-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-310)
Figure imgf000448_0002
Step 1: 3-Bromo-5-isopropoxy-pyridine
[01280] Prepared according to the procedure described in Example 167, Step 1, using 5-bromo- pyridin-3-ol and 2-chloro-propane.
Figure imgf000448_0003
Step 2: l-{4'-[4-(5-Isopropoxy-pyridin-3-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01281] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 3-bromo-5- isopropoxy-pyridine.
Figure imgf000449_0001
Step 3: l-{4'-[4-(5-Isopropoxy-pyridin-3-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01282] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(5- isopropoxy-pyridin-3-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester.
Example 311: Synthesis of l-{4'-[4-(6-Acetyl-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-311)
Figure imgf000449_0002
Step 1: l-{4'-[4-(6-Acetyl-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01283] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and l-(6-bromo- pyridin-2-yl)-ethanone.
Figure imgf000450_0001
Step 2: l-{4'-[4-(6-Acetyl-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01284] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(6-acetyl- pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. Example 312: Synthesis of l-{4'-[4-(6-Carbamoyl-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-312)
Figure imgf000450_0002
Step 1 : l-{4'-[4-(6-Cyano-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01285] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and 6-bromo- pyridine-2-carbonitrile.
Figure imgf000451_0001
Step 2: l-{4'-[4-(6-Carbamoyl-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01286] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[4-(6-cyano- pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester. Example 313: Synthesis of l-{4'-[4-(6-Bromo-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-313)
Figure imgf000451_0002
Step 1: 2-Bromo-6-phenyl-pyridine
[01287] Prepared according to the procedure described in Example 3, Step 5, using 2,6-dibromo- pyridine and phenylboronic acid. After purification the product still contained some 2,6-dibromo- pyridine starting material. The mixture was used directly in the next step.
Figure imgf000451_0003
Step 2: l-{4'-[4-(6-Bromo-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01288] Prepared according to the procedure described in Example 290, Step 1, using l-[4'-(4-amino- 3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid ethyl ester and a mixture of (2- bromo-6-phenyl-pyridine and 2,6-dibromo-pyridine). The products were purified on silica but not separated from one another. The mixture was used in the next step.
Figure imgf000452_0001
Step 3: l-{4'-[4-(6-Bromo-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01289] Prepared according to the procedure described in Example 3, Step 8, using a mixture of 1- {4'-[4-(6-bromo-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl and l-{4'-[3-methyl-4-(6-phenyl-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester. After the reaction the products were separated preparatory HPLC to afford the title compound.
Example 314: Synthesis of iV-{l-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarbon -methanesulfonamide (Compound 2-1)
Figure imgf000452_0002
[01290] l-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (0.2 g, 0.43 mmol) was dissolved in dioxane along with
carbonyldiimidazole (0.2 g, 1.23 mmol), methanesulfonamide (0.14 g, 1.47 mmol) and Hiinig's base. The reaction was heated to reflux overnight then cooled and submitted to standard aqueous workup. The residue was purified via silica gel chromatography (0-60% EtOAc in hexanes) to give the title compound.
Example 315: Synthesis of iV-[l-(4'-{4-[(S)-l-Hydroxy-2-((R)-l-phenyl-ethoxy)-ethyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarbonyl]-methanesulfonamide (Compound 2-2)
Figure imgf000453_0001
[01291] 1 -(4'- {4-[(S)- 1 -Hydroxy-2-((R)- 1 -phenyl-ethoxy)-ethyl]-3-methyl-isoxazol-5-yl} -biphenyl- 4-yl)-cyclopropanecarboxylic acid (0.022 g, 0.044 mmol) was dissolved in THF (3 mL) and carbonyldiimidazole (0.022 g, 0.14 mmol) was added. After 1.5 hours an additional portion of carbonyldiimidazole (0.011 g) was added. The reaction stirred for 40 minutes then
carbonyldiimidazole (0.044 g) was added. The reaction stirred overnight then carbonyldiimidazole (0.044 g) was added and the reaction was heated to 50 °C. After heating for 3 hours, 1,8- diazabicyclo[5.4.0]undec-7-ene (0.100 mL, 0.67 mmol) and methanesulfonamide (0.050 g, 0.53 mmol) were added and the reaction was heated to 100 °C. The reaction was monitored by analytical LCMS and when it was complete it was cooled and purified on preparatory HPLC to afford the title compound.
Example 316: Synthesis of iV-(l-{4'-[4-((S)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide (Compound 2-3)
Figure imgf000453_0002
Step 1: (S)-2-Benzyloxy-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol
[01292] Prepared according to the procedure described in Example 209, Step 3, using 2-benzyloxy- 1 - [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone.
Figure imgf000454_0001
Step 2: l-{4'-[4-((S)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01293] Prepared according to the procedure described in Example 110, Step 3, using (S)-2- benzyloxy-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol and l-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000454_0002
Step 3: l-{4'-[4-((S)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01294] Prepared according to the procedure described in Example 31, Step 3, using l-{4'-[4-((S)-2- benzyloxy- 1 -hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Figure imgf000454_0003
Step 4: N-(l-{4'-[4-((S)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarbonyl)-methanesulfonamide
[01295] l-{4'-[4-((S)-2-benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (0.232 g, 0.49 mmol) was dissolved in THF (4.6 mL) along with 4- dimethylaminopyridine (0.0065 g, 0.05 mmol) and carbonyldiimidazole (0.200 g, 1.24 mmol). After stirring at room temperature for 3.5 hours, carbonyldiimidazole (0.040 g, 0.25 mmol) was added. The reaction stirred for 1 hour then methanesulfonamide (0.117 g, 1.23 mmol) and 1,8- diazabicyclo[5.4.0]undec-7-ene (0.242 mL, 1.62 mmol) were added and the reaction was heated to 100 °C. After 40 minutes the reaction was cooled and submitted to standard aqueous workup. The residue was purified on silica gel (0- 100% EtOAc in hexanes) to afford the a separable mixture of products, of which the minor product was the title compound.
Example 317: Synthesis of iV-Sulfonylmethyl carbamic acid (S)-2-benzyloxy-l-{5-[4'-(l- methanesulfonylaminocarbonyl-cyclopropyl)-biphenyl-4-yl]-3-methyl-isoxazol-4-yl}-ethyl ester (Compound 2-4)
Figure imgf000455_0001
[01296] Prepared according to the procedure described in Example 316, Step 4, where the major product isolated from the reaction was the title compound.
Example 318: Synthesis of 4-Methyl-iV-(l-{4'-[3-methyl-4-(3-p-tolunesulfonyl-ureido)-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-benzenesulfonamide (Compound 2-5)
Figure imgf000455_0002
Step 1: [5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-carbamic acid (S)-l-phenyl-ethyl ester
[01297] Prepared according to the procedure described in Example 7, Step 1, using 5-(4-bromo- phenyl)-3-methyl-isoxazole-4-carboxylic acid and (S)-l-phenyl-ethanol.
Figure imgf000456_0001
Step 2: l-{4'-[3-Methyl-4-((S)-l-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid ethyl ester
[01298] Prepared according to the procedure described in Example 108, Step 2, using [5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-carbamic acid (S)- 1 -phenyl-ethyl ester and l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000456_0002
Step 3: l-{4'-[3-Methyl-4-((S)-l-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid
[01299] Prepared according to the procedure described in Example 3, Step 8, using l-{4'-[3-methyl-4- ((S)- 1 -phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid ethyl ester.
Figure imgf000457_0001
Step 4: 4-Methyl-iV-(l-{4'-[3-methyl-4-(3-p-tolunesulfonyl-ureido)-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarbonyl)-benzenesulfonamide
[01300] Prepared according to the procedure described in Example 315 using l-{4'-[3-Methyl-4-((S)- l-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid and p- toluenesulfonamide.
Example 319: Synthesis of Cyclopropanesulfonic acid (l-{4'-[4-(3-cyclopropylsulfonyl-ureido)- 3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-amide (Compound 2-6)
Figure imgf000457_0002
Step 1: Cyclopropanesulfonic acid (l-{4'-[4-(3-cyclopropylsulfonyl-ureido)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-amide
[01301] Prepared according to the procedure described in Example 315 using l-{4'-[3-Methyl-4-((S)- l-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid and cyclopropanesulfonamide.
Example 320: Synthesis of iV-(l-{4'-[4-(l-Hydroxy-2-phenethyloxy-ethyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide (Compound 2-7)
Figure imgf000458_0001
Step 1: iV-[l-(4-Bromo-phenyl)-cyclopropanecarbonyl]-methanesulfonamide
[01302] l-(4-Bromo-phenyl)-cyclopropanecarboxylic acid (5.0 g, 20.7 mmol) was dissolved in toluene (30 mL) then thionyl chloride (17.7 mL, 243 mmol) was carefully added. The reaction was heated to reflux for 4 hours then concentrated and azeotroped with toluene (2 x 30 mL). The intermediate acid chloride was dissolved in toluene (50 mL) then methanesulfonamide (11.41 g, 120 mmol) and triethylamine (15 mL, 0.108 mmol) were added. The reaction was refluxed for 3 hours then cooled and submitted to standard aqueous workup. The crude material was purified on silica gel to give the title compound.
Figure imgf000458_0002
Step 2: iV-{l-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}- methanesulfonamide
[01303] Prepared according to the procedure described in Example 3, Step 4, using N-[l-(4-bromo- phenyl)-cyclopropanecarbonyl]- acolato)diboron.
Figure imgf000458_0003
Step 3: iV-(l-{4'-[4-(l-Hydroxy-2-phenethyloxy-ethyl)-3-methyl-isoxazol-5-yl]-biphi
cyclopropanecarbonyl)-methanesulfonamide [01304] Prepared according to the procedure described in Example 1 , Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-phenethyloxy-ethanol and N- { 1 -[4-(4,4,5,5-tetramethyl- [l ,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}-methanesulfonamide.
Example 321: Synthesis of iV-(l-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarbon -methanesulfonamide (Compound 2-8)
Figure imgf000459_0001
[01305] l- {4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (0.225 g, 0.441 mmol) was dissolved in CH2C12 (2.3 mL) and thionyl chloride (0.07 mL, 0.971 mmol) was added. After 30 minutes the reaction was concentrated.
Separately, methanesulfonamide (0.124 g, 1.30 mmol) was dissolved in THF (2 mL) and sodium hydride (60% in mineral oil, 0.044 g, 1.103 mmol) was added. The acid chloride from the first reaction was dissolved in THF and carefully added to the second mixture. The reaction was monitored by analytical LCMS and excess sodium hydride was added until the reaction went to completion. Standard aqueous workup and silica gel chromatography (0-100%) EtOAc in hexanes) afforded the title compound.
Example 322: Synthesis of iV-(l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide (Compound 2-9)
Figure imgf000459_0002
Step 1 : (E)-l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2,2-difluoro-4-phenyl-but-3-en-l-ol
[01306] Prepared according to the procedure described in Example 124, Step 1 , using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2,2-difluoro-but-3-en-l-ol and iodobenzene.
Figure imgf000460_0001
Step 2: iV-(l-{4'-[4-((E)-2,2-Difluoro-l-hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide
[01307] Prepared according to the procedure described in Example 110, Step 3, using (E)-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-2,2-difluoro-4-phenyl-but-3-en-l-ol and N-{l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}-methanesulfonamide.
Figure imgf000460_0002
Step 3: iV-(l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarbonyl)-methanesulfonamide
[01308] Prepared according to the procedure described in Example 32, Step 1, using N-(l-{4'-[4-((E)- 2,2-Difluoro-l-hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarbonyl)-methanesulfonamide.
Example 323: Synthesis of iV-(l-{4'-[4-((S)-2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide (Compound 2-10)
Figure imgf000461_0001
[01309] Prepared according to the procedure described in Example 1, Step 7, using (S)-2- benzylsulfanyl-l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanol and N-{l-[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}-methanesulfonamide.
Example 324: Synthesis of iV-(l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarbonyl)-4-methyl-benzenesulfonamide (Compound 2-11)
Figure imgf000461_0002
Step 1 : 5-(4-Bromo-phenyl)-4-[l-(teri-butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl- isoxazole
[01310] l-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-4-phenyl-butan-l-ol (4.2 g, 10.9 mmol) was dissolved in DMF (60 mL). iert-Butyldimethylsilyl chloride (4.92 g, 7.93 mmol) and imidazole (2.22 g, 32.6 mmol) were added and the reaction stirred at room temperature until completion. The reaction was submitted to aqueous workup to afford the title compound.
Figure imgf000461_0003
Step 2: l-(4'-{4-[l-(teri-Butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester [01311] Prepared according to the procedure described in Example 1, Step 7, using 5-(4-bromo- phenyl)-4-[ 1 -(iert-butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazole and 1 -[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarboxylic acid ethyl ester.
Figure imgf000462_0001
Step 3: l-(4'-{4-[l-(teri-Butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid
[01312] Prepared according to the procedure described in Example 3, Step 8, using l-(4'-{4-[l-(iert- butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid ethyl est
Figure imgf000462_0002
Step 4 : N- [1 -(4 ' - {4- [ 1 -(teri-butyl-dimethyl-silanyloxy)-4-phenyl-butyl] -3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarbonyl]-4-methyl-benzenesulfonamide
[01313] Prepared according to the procedure described in Example 315 using l-(4'-{4-[l-(iert-butyl- dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid and -toluenesulfonamide.
Figure imgf000463_0001
Step 5: iV-(l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarbonyl)-4-methyl-benzenesulfonamide
[01314] N-[ 1 -(4'- {4- [ 1 -(iert-butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarbonyl]-4-methyl-benzenesulfonamide (0.121 g, 0.165 mmol) was dissolved in THF (3 niL) then tetrabutylammonium fluoride (1.0 M in THF, 0.500 niL, 0.500 mmol) was added. The reaction was stirred at room temperature and monitored by analytical TLC until complete. The mixture was submitted to standard aqueous workup then purified on silica gel to afford the title compound.
Example 325: Synthesis of Cyclopropanesulfonic acid (l-{4'-[4-(l-hydroxy-4-phenyl-butyl)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-amide (Compound 2-12)
Figure imgf000463_0002
Step 1: Cyclopropanesulfonic acid [l-(4'-{4-[l-(½ri-butyl-dimethyl-silanyloxy)-4-phenyl-butyl]- 3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarbonyl]-amide
[01315] Prepared according to the procedure described in Example 315 using l-(4'-{4-[l-(iert-butyl- dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid and cyclopropanesulfonamide.
Figure imgf000464_0001
Step 2: Cyclopropanesulfonic acid (l-{4'-[4-(l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-amide
[01316] Prepared according to the procedure described in Example 324, Step 5, using
Cyclopropanesulfonic acid [ 1 -(4'- {4-[ 1 -(ieri-butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarbonyl]-amide.
Example 326: Synthesis of 7V-(l-{4'-[4-(l-Hydroxy-2-iM-tolylsulfanyl-ethyl)-3-niethyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide (Compound 2-13)
Figure imgf000464_0002
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-iM-tolylsulfanyl-ethanone
[01317] Prepared according to the procedure described in Example 3, Step 7, using 2-bromo-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone and m-thiocresol.
Step 2: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-i«-tolylsulfanyl-ethanol
[01318] Prepared according to the procedure described in Example 256, Step 3, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-m-tolylsulfanyl-ethanone.
Figure imgf000465_0001
Step 3: 7V-(l-{4'-[4-(l-Hydroxy-2-iM-tolylsulfanyl-ethyl)-3-niethyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarbonyl)-methanesulfonamide
[01319] Prepared according to the procedure described in Example 1, Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-m-tolylsulfanyl-ethanol and N- { 1 -[4-(4,4,5,5-tetramethyl-
[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}-methanesulfonamide.
Example 327: Synthesis of iV-[l-(4'-{4-[l-Hydroxy-2-(3-methoxy-phenylsulfanyl)-ethyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarbonyl]-methanesulfonamide (Compound
2-14)
Figure imgf000465_0002
Step 1 : l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-(3-methoxy-phenylsulfanyl)-ethanone
[01320] Prepared according to the procedure described in Example 3, Step 7, using 2-bromo-l-[5-(4- bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone and 3-methoxy-benzenethiol.
Figure imgf000465_0003
Step 2: l-[5-(4-Bromo-phenyl)-3-methyl-isoxazol-4-yl]-2-(3-methoxy-phenylsulfanyl)-ethanol
[01321] Prepared according to the procedure described in Example 275, Step 2, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-(3-methoxy-phenylsulfanyl)-ethanone.
Figure imgf000466_0001
Step 3: iV-[l-(4'-{4-[l-Hydroxy-2-(3-methoxy-phenylsulfanyl)-ethyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarbonyl]-methanesulfonamide
[01322] Prepared according to the procedure described in Example 1 , Step 7, using l-[5-(4-bromo- phenyl)-3-methyl-isoxazol-4-yl]-2-(3-methoxy-phenylsulfanyl)-ethanol and N- { 1 -[4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-cyclopropanecarbonyl}-methanesulfonamide.
Example 328: Synthesis of iV-Sulfonylmethyl carbamic acid l-(5-{4'-[l-(2- methanesulfonylamino-2-oxo-ethyl)-cyclopropyl]-biphenyl-4-yl}-3-methyl-isoxazol-4-yl)-4- phenyl-butyl ester (Compound 2-15
Figure imgf000466_0002
[01323] Prepared according to the procedure described in Example 315 using (l- {4'-[4-(l-hydroxy-4- phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropyl)-acetic acid and
methanesulfonamide .
Example 329: Synthesis of iV-[2-(l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetyl]-methanesulfonamide (Compound 2-16)
Figure imgf000467_0001
Step 1 : [l-(4'-{4-[l-(teri-butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl]-acetic acid ethyl ester
[01324] Prepared according to the procedure described in Example 1, Step 7, using 5-(4-bromo- phenyl)-4-[l-(iert-butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazole and { l-[4- (4,4,5,5-tetramethyl-[l,3,2]dioxaboro pyl}-acetic acid ethyl ester.
Figure imgf000467_0002
Step 2: [l-(4'-{4-[l-(teri-Butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropyl] -acetic acid
[01325] Prepared according to the procedure described in Example 3, Step 8, using [l-(4'-{4-[l-(iert- butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]- acetic acid ethyl ester.
Figure imgf000467_0003
Step 3: iV-{2-[l-(4'-{4-[l-(teri -Butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropyl]-acetyl}-methanesulfonamide
[01326] Prepared according to the procedure described in Example 315 using [l-(4'-{4-[l-(tert-butyl- dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid and methanesulfonamide.
Figure imgf000468_0001
Step 4: iV-[2-(l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetyl]-methanesulfonamide
[01327] Prepared according to the procedure described in Example 324, Step 5, using N-{2-[l-(4'-{4- [l-(iert-butyl-dimethyl-silanyloxy)-4-phenyl-butyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropyl]-acetyl} -methanesulfonamide.
[01328] In some embodiments, mass spectrometric data (mass spec, data) is obtained with a
Shimadzu LCMS 201 OA.
Example 330. Establishment of a CHO Cell Line Stably Expressing Human LPAx
[01329] A 1.1 kb cDNA encoding the human LPAi receptor was cloned from human lung. Human lung RNA (Clontech Laboratories, Inc. USA) was reverse transcribed using the RETROscript kit (Ambion, Inc.) and the full-length cDNA for human LPAi was obtained by PCR of the reverse transcription reaction. The nucleotide sequence of the cloned human LPAx was determined by sequencing and confirmed to be identical to the published human LPAi sequence (An et al. Biochem. Biophys. Res. Commun. 231 :619 (1997). The cDNA was cloned into the pCDNA5/FRT expression plasmid and trans fected in CHO cells using lipofectamine 2000 (Invitrogen Corp., USA). Clones stably expressing human LPAi were selected using hygromycin and identified as cells that show Ca- influx in response to LPA.
Example 331. Generation of Cells Transiently Expressing Human LPA2
[01330] A vector containing the human LPA2 receptor cDNA was obtained from the Missouri S&T cDNA Resource Center (www.cdna.org). The full-length cDNA fragment for human LPA2 was obtained by PCR from the vector. The nucleotide sequence of the cloned human LPA2 was determined by sequencing and confirmed to be identical to the published human LPA2 sequence (NCBI accession number NM_004720). The cDNA was cloned into the pCDNA3.1 expression plasmid and transfected into B103 cells (Invitrogen Corp., USA) by seeding cells in a 96-well poly- D-lysine coated plate at 30,000-35,000 cells per well together with 0.2 μΐ lipofectamine 2000 and 0.2 μg of the LPA2 expression vector. Cells were cultured overnight in complete media before being assayed for LPA-induced Ca-influx.
Example 332. Establishment of a CHO Cell Line Stably Expressing Human LPA3
[01331] A vector containing the human LP A3 receptor cDNA was obtained from the Missouri S&T cDNA Resource Center (www.cdna.org). The full-length cDNA fragment for human LP A3 was obtained by PCR from the vector. The nucleotide sequence of the cloned human LPA3 was determined by sequencing and confirmed to be identical to the published human LPA3 sequence (NCBI accession number NM_012152). The cDNA was cloned into the pCDNA5/FRT expression plasmid and transfected in CHO cells using lipofectamine 2000 (Invitrogen Corp., USA). Clones stably expressing human LPA3 were selected using hygromycin and identified as cells that show Ca- influx in response to LPA.
Example 333. LPA1 and LPA3 Calcium Flux Assays.
[01332] Human LPAi or LPA3 expressing CHO cells are seeded at 20,000-45,000 cells per well in a 96-well poly-D-lysine coated plate one or two days before the assay. Prior to the assay, the cells are washed once with PBS and then cultured in serum- free media overnight. On the day of the assay, a calcium indicator dye (Calcium 4, Molecular Devices) in assay buffer (HBSS with Ca2+ and Mg2+ and containing 20 mM Hepes and 0.3% fatty-acid free human serum albumin) is added to each well and incubation continued for 1 hour at 37°C. 10 μΐ of test compounds in 2.5% DMSO are added to the cells and incubation continued at room temperature for 30 minutes. Cells are the stimulated by the addition of 10 nM LPA and intracellular Ca2+ measured using the Flexstation 3 (Molecular Devices). IC50S are determined using Graphpad prism analysis of drug titration curves.
Example 334. LPA2 Calcium Flux Assay.
[01333] Following an overnight culture with lipofectamine 2000 and the LPA2 expression vector, the B103 cells are washed once with PBS then serum starved for 4 hours. A calcium indicator dye (Calcium 4, Molecular Devices) in assay buffer (HBSS with Ca2+ and Mg2+ and containing 20 mM Hepes and 0.3% fatty-acid free human serum albumin) is added to each well and incubation continued for 1 hour at 37°C. 10 μΐ of test compounds in 2.5% DMSO are added to the cells and incubation continued at room temperature for 30 minutes. Cells are the stimulated by the addition of 10 nM LPA and intracellular Ca2+ measured using the Flexstation 3 (Molecular Devices). IC50S are determined using Graphpad prism analysis of drug titration curves.
Example 335. GTPyS Binding Assay
[01334] The ability of a compound to inhibit binding of GTP to LPAi is assessed via a membrane
GTPyS assay. CHO cells stably expressing the recombinant human LPAi receptor are resuspended in 10 mM Hepes, 7.4 containing 1 mM DTT, lysed and centrifuged at 75,000 xg to pellet the membranes. The membranes are resuspended in 10 mM Hepes, 7.4 containing 1 mM DTT and 10% glycerol. Membranes (~25 μg per well) are incubated in 96-well plates with 0.1 nM [35S]-GTPyS, 900 nM LPA, 5 μΜ GDP, and test compound in Assay Buffer (50 mM Hepes, pH 7.4, 100 mM NaCl, 10 mM MgC . , 50 μg/ml saponin and 0.2% fatty-acid free human serum albumin) for 30 minutes at 30°C. The reactions are terminated by rapid filtration through Whatman GF/B glass fibre filter plates. The filter plates are washed 3 times with 1 ml cold Wash Buffer (50 mM Hepes, 7.5, 100 mM NaCl and 10 mM MgCl2) and dried. Scintillant is then added to the plates and the radioactivity retained on the filters is determined on a Packard TopCount (Perkin Elmer). Specific binding is determined as total radioactive binding minus non-specific binding in the absence of the ligand (900 nM LPA). IC50S were determined using Graphpad prism analysis of drug titration curves.
[01335] Illustrative in vitro biological data for representative compounds of Formula (I), (II), (III), (IV), (V), (VI), and (VII) is presented in the Table below.
Cmpd # HLPA1 Ca Flux IC50
1-1 C
1-2 c
1-3 c
1-4 c
1-5 c
1-6 A
1-7 A
1-8 c
1-9 c
1-10 A
1-11 A
1-12 A
1-13 D
1-14 B
1-15 C
1-16 B
1-17 C
1-18 C
1-19 A
1-20 A
1-21 A
1-22 C
1-23 A
1-24 B
1-25 A
1-26 B
1-27 C
1-28 D Cmpd # HLPAl Ca Flux IC50
1-29 C
1-30 A
1-31 A
1-32 A
1-33 A
1-34 A
1-35 A
1-36 C
1-37 C
1-38 c
1-39 c
1-40 c
1-41 c
1-42 c
1-43 D
1-44 A
1-45 C
1-46 C
1-47 c
1-48 A
1-49 A
1-50 C
1-51 A
1-52 D
1-53 C
1-54 A
1-55 A
1-56 A
1-57 A
1-58 A
1-59 C
1-60 C
1-61 c
1-62 c
1-63 c
1-64 A
1-65 D
1-66 D
1-67 A
1-68 C
1-69 A
1-70 A
1-71 B
1-72 A Cmpd# HLPAl Ca Flux IC50
1-73 C
1-74 c
1-75 c
1-76 c
1-77 D
1-78 A
1-79 A
1-80 A
1-81 A
1-82 A
1-83 A
1-84 C
1-85 D
1-86 C
1-87 A
1-88 A
1-89 A
1-90 A
1-91 A
1-92 C
1-93 A
1-94 A
1-95 B
1-96 A
1-97 C
1-98 A
1-99 A
1-100 B
1-101 A
1-102 B
1-103 A
1-104 A
1-105 A
1-106 C
1-107 D
1-108 A
1-109 C
1-110 A
1-111 C
1-112 A
1-113 C
1-114 B
1-115 A
1-116 A Cmpd # HLPAl Ca Flux IC50
1-1 17 C
1-1 18 c
1-1 19 B
1-120 C
1-121 A
1-122 A
1-123 A
1-124 C
1-125 A
1-126 A
1-127 C
1-128 C
1-129 A
1-130 B
1-131 A
1-132 C
1-133 A
1-134 A
1-135 A
1-136 A
1-137 A
1-138 C
1-139 A
1-140 A
1-141 B
1-142 C
1-143 C
1-144 A
1-145 A
1-146 A
1-147 B
1-148 A
1-149 A
1-150 C
1-151 B
1-152 C
1-153 A
1-154 A
1-155 A
1-156 A
1-157 C
1-158 A
1-159 A
1-160 C Cmpd # HLPAl Ca Flux IC50
1-161 A
1-162 A
1-163 A
1-164 A
1-165 A
1-166 C
1-167 A
1-168 A
1-169 A
1-170 A
1-171 B
1-172 A
1-173 A
1-174 A
1-175 A
1-176 A
1-177 A
1-178 A
1-179 A
1-180 A
1-181 B
1-182 A
1-183 A
1-184 A
1-185 A
1-186 C
1-187 A
1-188 A
1-189 A
1-190 A
1-191 A
1-192 A
1-193 A
1-194 C
1-195 C
1-196 c
1-197 A
1-198 A
1-199 A
1-200 A
1-201 C
1-202 c
1-203 c
1-204 A Cmpd # HLPAl Ca Flux IC50
1-205 A
1-206 A
1-207 A
1-208 A
1-209 A
1-210 A
1-21 1 B
1-212 C
1-213 B
1-214 B
1-215 A
1-216 A
1-217 A
1-218 A
1-219 A
1-220 A
1-221 A
1-222 A
1-223 A
1-224 A
1-225 A
1-226 B
1-227 A
1-228 C
1-229 D
1-230 C
1-231 C
1-232 D
1-233 A
1-234 D
1-235 A
1-236 C
1-237 C
1-238 c
1-239 A
1-240 A
1-241 C
1-242 B
1-243 A
1-244 A
1-245 C
1-246 C
1-247 c
1-248 A Cmpd # HLPAl Ca Flux IC50
1-249 A
1-250 A
1-251 B
1-252 A
1-253 A
1-254 B
1-255 A
1-256 C
1-257 C
1-258 A
1-259 C
1-260 A
1-261 A
1-262 A
1-263 C
1-264 A
1-265 A
1-266 A
1-267 A
1-268 A
1-269 A
1-270 A
1-271 B
1-272 A
1-273 A
1-274 A
1-275 A
1-276 A
1-277 A
1-278 A
1-279 A
1-280 A
1-281 A
1-282 A
1-283 A
1-284 A
1-285 A
1-286 A
1-287 A
1-288 A
1-289 A
1-290 C
1-291 A
1-292 B Cmpd # HLPA1 Ca Flux IC50
1-293 A
1-294 A
1-295 A
1-296 D
1-297 A
1-298 C
1-299 C
1-300 A
1-301 A
1-302 C
1-303 C
1-304 A
1-305 C
1-306 A
1-307 B
1-308 A
1-309 C
1-310 A
1-311 A
1-312 A
1-313 A
2-1 A
2-2 A
2-3 A
2-4 A
2-5 D
2-6 C
2-7 A
2-8 A
2-9 A
2-10 A
2-11 A
2-12 A
2-13 A
2-14 B
2-15 B
2-16 A
A = less than 0.3 μΜ; B = greater than 0.3 μΜ and less than 1 μΜ;
C= greater than 1 μΜ and less than 50 μΜ; D= greater than 50 μΜ.
Example 336. LPA1 Chemotaxis Assay.
[01336] Chemotaxis of the A2058 human melanoma cells was measured using the Neuroprobe
ChemoTx® System plates (8 μηι pore size, 5.7 mm diameter sites). The filter sites were coated with
0.001% fibronectin (Sigma) in 20 mM Hepes, pH 7.4 and allowed to dry. A2058 cells were serum- starved for 24 hours , then harvested with Cell Stripper and resuspended in DMEM containing 0.1% fatty-acid- free bovine serum albumin (BSA) to a concentration of 1 x 106/ml. Cells were mixed with an equal volume of test compound (2X) in DMEM containing 0.1% fatty-acid- free BSA and incubated at 37°C for 15 minutes. LP A (100 nM in DMEM containing 0.1% fatty-acid-free BSA) or vehicle was added to each well of the lower chamber and 50 μΐ of the cell suspension/test compound mix was applied to the upper portion of the ChemoTx plate. Plates were incubated at 37°C for three hours and then the cells removed from the upper portion by rinsing with PBS and scraping. The filter was dried then stained with HEMA 3 Staining System (Fisher Scientific). The absorbance of the filter was read at 590 nM and IC50s were determined using Symyx Assay Explorer.
[01337] In this experiment, compounds 1-25, 1-93, 1-116, 1-153, 1-155, 1-156, 1-167, 1-172, 1-173, 1-178, 1-198, 1-209, 1-220, 1-221, 1-224, 1-240, 1-255, 1-269, 2-2, 2-3, 2-9, 2-10 inhibited LPA- driven chemotaxis (IC50 less than 100 nM) of human A2058 melanoma cells.
Example 337: Bleomycin-induced Lung fibrosis model in mice
[01338] Female CD-I mice (Harlan, 25-30g) are housed 4 per cage, given free access to food and water and allowed to acclimate for at least 7 days prior to test initiation. After the habituation phase, mice are lightly anesthetized with isoflurane (5% in 100% O2) and administered with bleomycin sulfate (0.01-5 U/kg, Henry Schein) via intratracheal instillation (Cuzzocrea S et al. Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1095-104. Epub 2007 Jan 12.). Mice are returned to their cages and monitored daily for the duration of the experiment. Test compound or vehicle is delivered po, ip or sc daily. The route and frequency of dosing is based on previously determined
pharmacokinetic properties. All animals are sacrificed using inhaled isoflurane 3, 7, 14, 21 or 28 days after bleomycin instillation. Following sacrifice, mice are intubated with a 20 gauge angiocatheter attached to a 1 ml syringe. Lungs are lavaged with saline to obtain bronchoalveolar lavage fluid (BALF) and then removed and fixed in 10% neutral buffered formalin for subsequent histopathological analysis. BALF is centrifuged for 10 min at 800 x g to pellet the cells and the cell supernatant removed and frozen at -80 °C for subsequent protein analysis using the DC protein assay kit (Biorad, Hercules, CA.) and soluble collagen analysis using Sircol (Biocolor Ltd, UK). BALF is analyzed for concentrations of inflammatory, pro-fibrotic and tissue injury biomarkers including transforming growth factor βΐ, hyaluronic acid, tissue inhibitor of metalloproteinase- 1 , matrix matelloproteinase-7, connective tissue growth factor and lactate dehydrogenase activity, using commercially available ELISA. The cell pellet is re-suspended in PBS. Total cell counts are then obtained using a Hemavet hematology system (Drew Scientific, Wayne, PA.) and differential cells counts are determined using Shandon cytospin (Thermo Scientific, Waltham, MA.). Lung tissue is stained using hematoxylin and eosin (H&E) and trichrome and lung fibrosis. is determined by semiquantitative histopathological scoring (Ashcroft T. et al. J. Clin. Path. 1988;41;4, 467-470.) using light microscopy (lOx magnification) and quantitative, computer-assisted densitometry of collagen in lung tissue sections using light microscopy. The data are plotted using Graphpad prism and statistical differences between groups determined.
Example 338: Mouse carbon tetrachloride (CCl4)-induced liver fibrosis model
[01339] Female C57BL/6 mice (Harlan, 20-25g) housed 4/cage are given free access to food and water and allowed to acclimate for at least 7 days prior to test initiation. After the habituation phase, mice receive CC14 (0.5-1.0 ml/kg body weight) diluted in corn oil vehicle (100 volume) via i.p. injection twice a week for 4-6 weeks. (Higazi, A. A. et ah, Clin Exp Immunol . 2008 Apr;152(l): 163- 73. Epub 2008 Feb 14.). Control mice receive an equivalent volume of corn oil vehicle only. Test compound or vehicle is delivered po, ip or sc daily. At the end of the study (4-6 weeks after first i.p. injection of CC14), mice are sacrificed using inhaled isoflurane and blood is drawn via cardiac puncture for subsequent analysis of ALT/AST levels. The liver is harvested, and one half of the liver is frozen at -80°C and the other half is fixed in 10% neutral buffered formalin for histological assessment of liver fibrosis using light microscopy (lOx magnification). Liver tissue homogenates are analyzed for collagen levels using Sircol (Biocolor Ltd, UK). Fixed Liver tissue is stained using hematoxylin and eosin (H&E) and tri chrome and liver fibrosis is determined by quantitative, computer-assisted densitometry of collagen in liver tissue sections using light microscopy. Plasma and liver tissue lysates are also analyzed for concentrations of inflammatory, pro-fibrotic and tissue injury biomarkers including transforming growth factor βΐ, hyaluronic acid, tissue inhibitor of metalloproteinase- 1 , matrix matelloproteinase-7, connective tissue growth factor and lactate dehydrogenase activity, using commercially available ELISA. The resulting data are plotted using Graphpad prism and statistical differences between groups determined.
Example 339: Mouse intravenous LPA-induced histamine release
[01340] A mouse intravenous LPA-induced histamine release model is utilized to determine the in vivo potency of LPA receptor antagonists. Female CD-I mice (weighing 25 - 35 grams) are administered compound (i.p., s.c. or p.o.) in a volume of lOml/kg 30 minutes to 24 hours prior to intravenous LPA challenge (300μg/mouse in 0.1% FAF BSA). Immediately following LPA challenge mice are placed into an enclosed Plexiglas chamber and exposed to an isoflurane for a period of 2 minutes. They are removed, decapitated and trunk blood collected into tubes containing EDTA. Blood is then centrifuged at 10,000 X g for 10 minutes at 4°C. Histamine concentrations in the plasma are determined by EIA. Drug concentrations in plasma are determined by mass spectrometry. The dose to achieve 50% inhibition of blood histamine release is calculated by nonlinear regression (Graphpad Prism) and plotted as the ED50. The plasma concentration associated with this dose is plotted as the EC50.
Example 340: Mouse unilateral ureteral obstruction kidney fibrosis model
[01341] Female C57BL/6 mice (Harlan, 20-25g) housed 4/cage will be given free access to food and water and allowed to acclimate for at least 7 days prior to test initiation. After the habituation phase,. mice undergo unilateral ureteral obstruction (UUO) surgery or sham to left kidney. Briefly, a longitudinal, upper left incision is performed to expose the left kidney. The renal artery is located and 6/0 silk thread is passed between the artery and the ureter. The thread is looped around the ureter and knotted 3 times insuring full ligation of ureter. The kidney is returned to abdomen, the abdominal muscle is sutured and the skin is stapled closed. Mice are returned to their cages and monitored daily for the duration of the experiment. Test compound or vehicle is delivered po, ip or sc daily. The route and frequency of dosing is based on previously determined pharmacokinetic properties. All animals are sacrificed using inhaled isoflurane 4, 8 or 14 days after UUO surgery. Following sacrifice blood is drawn via cardiac puncture, the kidneys are harvested and one half of the kidney is frozen at -80°C and the other half is fixed in 10% neutral buffered formalin for histological assessment of kidney fibrosis using light microscopy (lOx magnification). Kidney tissue homogenates are analyzed for collagen levels using Sircol (Biocolor Ltd, UK). Fixed kidney tissue is also stained using hematoxylin and eosin (H&E) and trichrome and kidney fibrosis is determined by quantitative, computer-assisted densitometry of collagen in liver tissue sections using light microscopy. Plasma and kidney tissue lysates are also analyzed for concentrations of inflammatory, pro-fibrotic and tissue injury biomarkers including transforming growth factor β 1 , hyaluronic acid, tissue inhibitor of metalloproteinase- 1 , matrix matelloproteinase-7, connective tissue growth factor and lactate dehydrogenase activity, using commercially available ELISA. The resulting data are plotted using Graphpad prism and statistical differences between groups determined.
Example 341: Clinical Trial in Humans with Idiopathic Pulmonary Fibrosis (IPF)
Purpose
[01342] The purposes of this study is to assess the efficacy of treatment with a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) compared with placebo in patients with idiopathic pulmonary fibrosis (IPF) and to assess the safety of treatment with a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) compared with placebo in patients with IPF.
[01343] The primary outcome variable is the absolute change in percent predicted forced vital capacity (FVC) from baseline to Week 72.
[01344] Secondary outcome measures include: composite outcomes of important IPF-related events; progression- free survival; categorical assessment of absolute change in percent predicted FVC from baseline to Week 72; change in Shortness-of-Breath from baseline to Week 72; change in percent predicted hemoglobin (Hb)-corrected carbon monoxide diffusing capacity (DLco) of the lungs from baseline to Week 72; change in oxygen saturation during the 6 minute walk test (6MWT) from baseline to Week 72; change in high-resolution computed tomography (HRCT) assessment from baseline to Week 72; change in distance walked in the 6MWT from baseline to Week 72.
Criteria [01345] Patients eligible for this study include those patients that satisfy the following inclusion criteria: diagnosis of IPF; 40 to 80 years of age; FVC > 50% predicted value; DLco > 35% predicted value; either FVC or DLco < 90% predicted value; no improvement in past year; able to walk 150 meters in 6 minutes and maintain saturation > 83%) while on no more than 6 L/min supplemental oxygen.
[01346] Patients are excluded from this study if they satisfy any of the following criteria: unable to undergo pulmonary function testing; evidence of significant obstructive lung disease or airway hyper-responsiveness; in the clinical opinion of the investigator, the patient is expected to need and be eligible for a lung transplant within 72 weeks of randomization; active infection; liver disease; cancer or other medical condition likely to result in death within 2 years; diabetes; pregnancy or lactation; substance abuse; personal or family history of long QT syndrome; other IPF treatment; unable to take study medication; withdrawal from other IPF trials.
[01347] Patients are orally dosed with either placebo or an amount of compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) (1 mg/day - 1000 mg/day). The primary outcome variable will be the absolute change in percent predicted FVC from Baseline to Week 72. Patients will receive blinded study treatment from the time of randomization until the last patient randomized has been treated for 72 weeks. A Data Monitoring Committee (DMC) will periodically review safety and efficacy data to ensure patient safety.
[01348] After week 72, patients who meet the Progression of Disease (POD) definition, which is a > 10%) absolute decrease in percent predicted FVC or a > 15%o absolute decrease in percent predicted DLco, will be eligible to receive permitted IPF therapies in addition to their blinded study drug. Permitted IPF therapies include corticosteroids, azathioprine, cyclophosphamide and N-acetyl- cysteine.
Example 342: Parenteral Composition
[01349] To prepare a parenteral pharmaceutical composition suitable for administration by injection (subcutaneous, intravenous, and the like), 100 mg of a water-soluble salt of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is dissolved in water and then mixed with 10 mL of 0.9% sterile saline. The mixture is incorporated into a dosage unit form suitable for administration by injection
[01350] In another embodiment, the following ingredients are mixed to form an injectable formulation: 1.2 g of a compound of Formulas (I), (II), (III), (IV), (V), (VI), or (VII), 2.0 mL of sodium acetate buffer solution (0.4 M), HC1 (1 N) or NaOH (1 M) (q.s. to suitable pH), water (distilled, sterile) (q.s.to 20 mL). All of the above ingredients, except water, are combined and stirred and if necessary, with slight heating if necessary. A sufficient quantity of water is then added. Example 343: Oral Composition
[01351] To prepare a pharmaceutical composition for oral delivery, 100 mg of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is mixed with 750 mg of starch. The mixture is incorporated into an oral dosage unit for, such as a hard gelatin capsule, which is suitable for oral administration.
Example 344: Sublingual (Hard Lozenge) Composition
[01352] To prepare a pharmaceutical composition for buccal delivery, such as a hard lozenge, mix 100 mg of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with 420 mg of powdered sugar mixed, with 1.6 mL of light corn syrup, 2.4 mL distilled water, and 0.42 mL mint extract. The mixture is gently blended and poured into a mold to form a lozenge suitable for buccal
administration.
Example 345: Fast-Disintegrating Sublingual Tablet
[01353] A fast-disintegrating sublingual tablet is prepared by mixing 48.5% by weigh of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII), 44.5% by weight of microcrystalline cellulose (KG-802), 5%) by weight of low-substituted hydroxypropyl cellulose (50 μηι), and 2% by weight of magnesium stearate. Tablets are prepared by direct compression (AAPS PharmSciTech.
2006;7(2):E41). The total weight of the compressed tablets is maintained at 150 mg. The formulation is prepared by mixing the amount of compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) with the total quantity of microcrystalline cellulose (MCC) and two-thirds of the quantity of low- substituted hydroxypropyl cellulose (L-HPC) by using a three dimensional manual mixer (lnversina ®, Bioengineering AG, Switzerland) for 4.5 minutes. All of the magnesium stearate (MS) and the remaining one-third of the quantity of L-HPC are added 30 seconds before the end of mixing.
Example 346: Inhalation Composition
[01354] To prepare a pharmaceutical composition for inhalation delivery, 20 mg of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.
Example 347: Rectal Gel Composition
[01355] To prepare a pharmaceutical composition for rectal delivery, 100 mg of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is mixed with 2.5 g of methylcelluose (1500 mPa),
100 mg of methylparapen, 5 g of glycerin and 100 mL of purified water. The resulting gel mixture is then incorporated into rectal delivery units, such as syringes, which are suitable for rectal administration.
Example 348: Topical Gel Composition
[01356] To prepare a pharmaceutical topical gel composition, 100 mg of a compound of Formula (I),
(II), (III), (IV), (V), (VI), or (VII) is mixed with 1.75 g of hydroxypropyl celluose, 10 mL of propylene glycol, 10 mL of isopropyl myristate and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into containers, such as tubes, which are suitable for topicl administration.
Example 349: Ophthalmic Solution Composition
[01357] To prepare a pharmaceutical opthalmic solution composition, 100 mg of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is mixed with 0.9 g of NaCl in 100 mL of purified water and filterd using a 0.2 micron filter. The resulting isotonic solution is then incorporated into ophthalmic delivery units, such as eye drop containers, which are suitable for ophthalmic administration.
Example 350: Nasal spray solution
[01358] To prepare a pharmaceutical nasal spray solution, 10 g of a compound of Formula (I), (II), (III), (IV), (V), (VI), or (VII) is mixed with 30 mL of a 0.05M phosphate buffer solution (pH 4.4). The solution is placed in a nasal administrator designed to deliver 100 μΐ of spray for each application.
[01359] The examples and embodiments described herein are for illustrative purposes only and various modifications or changes suggested to persons skilled in the art are to be included within the spirit and purview of this application and scope of the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A compound with a structure of Formula (I), or a pharmaceutically acceptable solvate, a pharmaceutically acceptable salt, a rodrug, or a metabolite thereof:
Figure imgf000484_0001
Formula (I)
wherein
and R5 is H, Ci-C4alkyl, or Ci-C4fluoroalkyl; or
Figure imgf000484_0002
and R3 is H, Ci-C4alkyl, or Ci-C4fluoroalkyl;
m is 0, 1 or 2; n is 0, 1 or 2;
L1 is absent, Ci-C4alkylene, Ci-C4fluoroalkylene, C3-C6Cycloalkylene, -C3-C6Cycloalkylene- C C4alkylene-, or -[C(Rla)(Rlb)]q-; q is 1 , 2 or 3;
Rla and Rlb are each independently selected from H, Ci-C4alkyl and substituted or unsubstituted benzyl;
R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, -C(=0)NH-OH, -C(=0)NH-CN, -CN, P(=0)(OH)2, P(=0)(ORD)2, -OP03H2, -S02NHC(=0)RE, tetrazolyl, -C(=NH)NH2, - C(=NH)NHC(=0)RE, or carboxylic acid bioisostere; RD is H or Ci-C6alkyl; RE is C C6alkyl or a substituted or unsubstituted phenyl;
L3 is a substituted or unsubstituted Ci-C6alkylene, substituted or unsubstituted Ci-
C6fluoroalkylene, or substituted or unsubstituted Ci-Ceheteroalkylene, where if L3 is substituted then L3 is substituted with 1 , 2 or 3 R13; each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy, Ci-C4fluoroalkoxy and a substituted or unsubstituted phenyl; or
L3 is -ΙΛΧ1-!.5-;
L4 is absent or a substituted or unsubstituted Ci-C4alkylene, where if L4 is substituted then L4 is substituted with 1 , 2, or 3 R14; each R14 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy;
X1 is a absent, -0-, -S-, -S(O)-, -S(0)2-, -NR7-, -C(0)NR8-, -NR8C(=0)-, -
NR8C(=0)CH20-, -NR8C(=0)-CH(CH3)0-, -NR8C(=0)-C(CH3)20-, -N(R8)S(=0)2- -S(=0)2N(R8)-, -C(=0)-, -OC(=0)-, -C(=0)0-, -OC(=0)0-, -OC(=0)N(R8)-, - NR8C(=0)0-, or -NR8C(=0)N(R8)-; provided that when L4 is absent then X1 is not - NR8C(=0)0-;
R7 is H, -S(=0)2R10, -S(=0)2N(R9)2, -C(=0)R10, -C02R9, -C(=0)N(R9)2, d-C4alkyl, Ci-C4fluoroalkyl, or Ci-C4heteroalkyl;
R8 is H, C C4alkyl, or d-Qfluoroalkyl;
L5 is absent or a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1, 2, or 3 R15; each R15 is independently selected from F,
Ci-C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy and Ci-C4fluoroalkoxy;
R6 is Ci-C6alkyl, Ci-C6fluoroalkyl, substituted or unsubstituted C3-Ciocycloalkyl, a
substituted or unsubstituted C3-Cioheterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted monocyclic heteroaryl, or a substituted or unsubstituted bicyclic heteroaryl, wherein if R6 is substituted then R6 is substituted with 1 , 2 or 3 Rc;
each of RA, RB, and Rc are independently selected from halogen, -CN, -N02, -OH, -OR , - SR9, -S(=0)R10, -S(=0)2R10, -N(R9)S(=0)2R10, -S(=0)2N(R9)2, -C(=0)R10, -OC(=0)R10, -C02R9, -OC02R10, -N(R9)2, -C(=0)N(R9)2, -OC(=0)N(R9)2, -NR9C(=0)N(R9)2, - NR9C(=0)R10, -NR9C(=0)OR10, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, C C4alkoxy, and Ci-C4heteroalkyl;
each R9 is independently selected from H, Ci-Ci2alkyl, Ci-C6heteroalkyl, Ci-C6fiuoroaikyl, a substituted or unsubstituted C3-C6cycloalkyl, a substituted or unsubstituted C2- Ceheterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted monocyclic heteroaryl, -Ci-C4alkylene-(substituted or unsubstituted C3-C6cycloalkyl), - Ci-C4alkylene-(substituted or unsubstituted C2-C6heterocycloalkyl), -Ci-C4alkylene- (substituted or unsubstituted phenyl), or -Ci-C4alkylene-(substituted or unsubstituted heteroaryl); or
two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted heterocycle;
R10 is selected from Ci-C6alkyl, Ci-C6heteroalkyl, Ci-C6fluoroalkyl, a substituted or
unsubstituted C3-C6cycloalkyl, a substituted or unsubstituted C2-C6heterocycloalkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted naphthyl, a substituted or unsubstituted monocyclic heteroaryl, -Ci-C4alkylene-(substituted or unsubstituted C3-
C6cycloalkyl), -Ci-C4alkylene-(substituted or unsubstituted C2-C6heterocycloalkyl), -Ci-
C4alkylene-(substituted or unsubstituted phenyl), and -Ci-C4alkylene-(substituted or unsubstituted heteroaryl).
The compound of claim 1, wherein the compound has the structure of Formula (II):
Figure imgf000486_0001
wherein,
R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, -CN, or tetrazolyl;
RD is H or Ci-C6alkyl;
REis Ci-C6alkyl or a substituted or unsubstituted phenyl;
L1 is absent, Ci-C4alkylene, Ci-C4iluoroalkylene, C3-C6cycloalkylene, -C3-C6cycloalkylene-
Ci-C4alkylene-, -Ci-C4alkylene-C3-C6cycloalkylene-, or -C(Rla)(Rlb)-;
Rla and Rlb are each independently selected from H, Ci-C4alkyl and benzyl;
each RA is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci
C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
each RB is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci
C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
R5 is H or C C4alkyl;
m is 0 or 1 ;
n is 0 or 1.
The compound of claim 1, wherein the com ound has the structure of Formula (III):
Figure imgf000486_0002
RD is H or Ci-C6alkyl;
RE is Ci-C6alkyl or a substituted or unsubstituted phenyl;
L1 is absent, Ci-C4alkylene, C3-C6cycloalkylene, -C3-C6cycloalkylene-Ci-C4alkylene-, -Cr C4alkylene-C3-C6cycloalkylene-, or -C(Rla)(Rlb)-;
Rla and Rlb are each independently selected from H, Ci-C4alkyl and benzyl;
each RA is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci
C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
each RB is independently selected from halogen, -CN, -OH, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci
C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl;
R3 is H or Ci-C4alkyl;
m is 0 or 1 ;
n is 0 or 1.
The compound of any one of claims 1 -3, wherein:
R1 is -C02RD or -C(=0)NHS02RE;
L1 is absent, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH2CH2-, cyclopropyl-l ,l-diyl, cyclopropyl-l,2-diyl, cyclobutyl-l ,l-diyl, cyclopentyl-l ,l-diyl, cyclohexyl-l ,l-diyl, - C(CH2CH2)CH2- or -CH2C(CH2CH2)-;
R6 is C3-C6cycloalkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic heteroaryl, wherein if R6 is substituted then R6 is substituted with 1 , 2 or 3 Rc; each Rc is independently selected from halogen, -CN, -OH, -OR9, -S(=0)2R10, - C(=0)R10, -C02R9, -N(R9)2, -C(=0)N(R9)2, -NR9C(=0)R10, Ci-C4alkyl, C
C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-C4heteroalkyl
The compound of claim 4, wherein:
L1 is -CH2-, cyclopropyl-l ,l-diyl, or -C(CH2CH2)CH2-;
L3 is a substituted or unsubstituted C3-C6alkylene, substituted or unsubstituted C3-
C6fluoroalkylene, or substituted or unsubstituted C3-C6heteroalkylene, where if L3 is substituted then L3 is substituted with 1 , 2 or 3 R13; each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, hydroxyl, Ci-C4alkoxy, Ci-C4fluoroalkoxy and phenyl.
The compound of claim 5, wherein:
L3 is a substituted or unsubstituted C3-C4alkylene, substituted or unsubstituted C3-
C4fluoroalkylene, -(substituted or unsubstituted C3-C4alkylene)-0-, -(substituted or unsubstituted Ci-C3alkylene)-0-(substituted or unsubstituted Ci-C3alkylene)-, -O-
(substituted or unsubstituted C3-C4alkylene)-, -(substituted or unsubstituted C3-
C4alkylene)-S-, -(substituted or unsubstituted Ci-C3alkylene)-S-(substituted or unsubstituted Ci-C3alkylene)-, -S-(substituted or unsubstituted C3-C4alkylene)-, - (substituted or unsubstituted C3-C4alkylene)-NH-, -(substituted or unsubstituted Ci- C3alkylene)-NH-(substituted or unsubstituted Ci-C3alkylene)-, -NH-(substituted or unsubstituted C3-C4alkylene)-; where if L3 is substituted then L3 is substituted with 1 or 2 R13.
7. The compound of claim 6, wherein:
L3 is a substituted or unsubstituted C3-C4alkylene, substituted Λ or unsubstituted Λ C r 3
C4fluoroalkylene, -(substituted or unsubstituted Ci-C3alkylene)-0-(substituted or unsubstituted Ci-C3alkylene)-, -(substituted or unsubstituted Ci-C3alkylene)-S- (substituted or unsubstituted Ci-C3alkylene)-, -NH-(substituted or unsubstituted C3- C4alkylene)-; where if L3 is substituted then L3 is substituted with 1 or 2 R13.
8. The compound of any one of claims 1-3, wherein:
R1 is -C02RD or -C(=0)NHS02RE;
L1 is -CH2-, cyclopropyl-l,l-diyl, or -C(CH2CH2)CH2-;
L3 is -ΐΛΧ1-!.5-;
L4 is a substituted or unsubstituted Ci-C4alkylene, where if L4 is substituted then L4 is substituted with 1 or 2 R14; each R14 is independently selected from F, -CH3, -
CH2CH3, -CF3, hydroxyl, -OCH3, -OCH2CH3, and -OCF3;
X1 is -0-, -S-, -S(O)-, -S(0)2-, -NR7-, -C(0)NR8-, -NR8C(=0)-, -NR8C(=0)CH20-, -
NR8C(=0)-CH(CH3)0-, -NR8C(=0)-C(CH3)20-, -C(=0)-, -OC(=0)-, -C(=0)0-, - OC(=0)0-, -OC(=0)N(R8)-, -NR8C(=0)0-, or -NR8C(=0)N(R8)-;
R7 is H, -C(=0)R10, or Ci-C4alkyl;
R8 is H, or Ci-C4alkyl;
L5 is absent or a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1 or 2 R15; each R15 is independently selected from F, - CH3, -CH2CH3, -CF3, hydroxyl, -OCH3, -OCH2CH3, and -OCF3.
9. The compound of claim 8, wherein:
L5 is a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is
substituted with 1 or 2 R15; each R15 is independently selected from F, -CH3, -CH2CH3, CF3, hydroxyl, -OCH3, -OCH2CH3, and -OCF3.
10. The compound of claim 8 or claim 9, wherein:
X1 is -0-, -S-, or -NR7-.
11. The compound of any one of claims 1 -3, wherein:
R1 is -C02RD or -C(=0)NHS02RE;
L1 is -CH2-, cyclopropyl-l,l-diyl, or -C(CH2CH2)CH2-;
L3 is -L4-Xx-L5-;
L4 is absent; X1 is -NR7-;
R7 is H or Ci-C4alkyl;
L5 is absent or a substituted or unsubstituted Ci-C4alkylene, where if L5 is substituted then L5 is substituted with 1 or 2 R15; each R15 is independently selected from F, - CH3, -CH2CH3, -CF3, hydroxyl, -OCH3, -OCH2CH3, and -OCF3.
12. The compound of claim 1, wherein the compound has a structure of Formula (VI), or a
pharmaceutically acceptable salt thereof:
Figure imgf000489_0001
wherein,
R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, or tetrazolyl;
RD is H or C C6alkyl;
REis Ci-C6alkyl, C3-C6cycloalkyl, or substituted or unsubstituted phenyl;
L3 is a substituted or unsubstituted C3-C6alkylene, a substituted or unsubstituted C3-
C6fluoroalkylene, or a substituted or unsubstituted C3-C6heteroalkylene, where if L3 is substituted then L3 is substituted with 1, 2 or 3 R13; each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, and -OH;
each of RA, RB, and Rc are independently selected from H, halogen, -CN, -N02, -OH, -OR9, -
N(R9)2, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-
C4heteroalkyl;
R5 is H or C C4alkyl;
each R9 is independently selected from H, Ci-C6alkyl, Ci-C6fiuoroalkyl, a substituted or unsubstituted phenyl, or -CH2-(substituted or unsubstituted phenyl); or
two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted Ci-Csheterocycle;
m is 0 or 1 ;
n is 0 or 1 ;
p is 0, 1, or 2.
3. The compound of claim 1, wherein the compound has a structure of Formula (VII), or a pharmaceutically acceptable salt thereof:
Figure imgf000490_0001
wherein,
R1 is -C02RD, -C(=0)NHS02RE, -C(=0)N(RD)2, or tetrazolyl;
RD is H or Ci-C6alkyl;
REis Ci-C6alkyl, C3-C6Cycloalkyl, or substituted or unsubstituted phenyl;
L3 is a substituted or unsubstituted C3-C6alkylene, a substituted or unsubstituted C3-
C6fluoroalkylene, or a substituted or unsubstituted C3-C6heteroalkylene, where if L3 is substituted then L3 is substituted with 1, 2 or 3 R13; each R13 is independently selected from F, Ci-C4alkyl, Ci-C4fluoroalkyl, and -OH;
each of RA, RB, and Rc are independently selected from H, halogen, -CN, -N02, -OH, -OR9, -
N(R9)2, Ci-C4alkyl, Ci-C4fluoroalkyl, Ci-C4fluoroalkoxy, Ci-C4alkoxy, and Ci-
C4heteroalkyl;
R3 is H or Ci-C4alkyl;
each R9 is independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, a substituted or unsubstituted phenyl, or -CH2-(substituted or unsubstituted phenyl); or
two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted Ci-Csheterocycle;
m is 0 or 1 ;
n is 0 or 1 ;
p is 0, 1, or 2.
The compound of claim 12 or claim 13, wherein:
R1 is -C02RD, or -C(=0)NHS02RE;
RD is H or Ci-C4alkyl;
REis Ci-C4alkyl.
L3 is a substituted or unsubstituted C3-C4alkylene, a substituted or unsubstituted C3-
C4fluoroalkylene, or a substituted or unsubstituted C3-C6heteroalkylene; where if L3 is substituted then L3 is substituted with 1 , 2 or 3 R13; each R13 is independently selected from F, -CH3, -CH2CH3, -CF3, and -OH;
m is 0;
n is 0.
15. The compound of claim 14, wherein:
L3 is a substituted or unsubstituted butylene, a substituted or unsubstituted fluorobutylene, or a substituted or unsubstituted difluorobutylene; where if L3 is substituted then L3 is substituted with 1 or 2 R13.
16. The compound of claim 14, wherein:
L3 is a substituted or unsubstituted C3-C6heteroalkylene; where if L3 is substituted then L3 is substituted with 1 or 2 R13.
17. The compound of claim 16, wherein:
L3 is -(substituted or unsubstituted C3-C4alkylene)-0-, -(substituted or unsubstituted Ci- C3alkylene)-0-(substituted or unsubstituted Ci-C3alkylene)-, -0-(substituted or unsubstituted C3-C4alkylene)-, -(substituted or unsubstituted C3-C4alkylene)-S-, - (substituted or unsubstituted Ci-C3alkylene)-S-(substituted or unsubstituted Ci- C3alkylene)-, -S-(substituted or unsubstituted C3-C4alkylene)-, -(substituted or unsubstituted C3-C4alkylene)-NH-, -(substituted or unsubstituted Ci-C3alkylene)-NH- (substituted or unsubstituted Ci-C3alkylene)-, or -NH-(substituted or unsubstituted C3- C4alkylene)-.
18. The compound of claim 17, wherein:
L3 is -NH-(substituted or unsubstituted C3-C4alkylene); where if L3 is substituted then L3 is substituted with R13.
19. The compound of claim 17, wherein:
L3 is -(substituted or unsubstituted Ci-C3alkylene)-0-(substituted or unsubstituted Ci- C3alkylene)-, or -(substituted or unsubstituted Ci-C3alkylene)-S-(substituted or unsubstituted Ci-C3alkylene)-; where if L3 is substituted then L3 is substituted with R13.
20. The compound of claim 19, wherein:
L3 is -(substituted or unsubstituted ethylene)-0-(substituted or unsubstituted methylene)-, or - (substituted or unsubstituted ethylene)-S-(substituted or unsubstituted methylene)-; where if L3 is substituted then L3 is substituted with R13.
21. The compound of any one of claims 12-20, wherein:
Figure imgf000491_0001
A compound selected from: 4'-[3-Methyl-4-(3-phenyl-propionylamino)-isoxazol-5-yl]-biphenyl-3-carboxylic acid (Compound 1 - 1); 4'-[4-(3-Benzyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-3-carboxylic acid (Compound 1-2); 1- {4'-[3-Methyl-4-(3-methyl-butyrylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-3); l-{4'-[3-Methyl-4-(3-phenyl-propionylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-4); l-{4'-[3-Methyl-4-(2-phenoxy-acetylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-5); l-{4'-[4-(3-Benzyl- ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-6); 1- {4'-[4-(3-iert-Butyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-7); l-{4'-[4-(3-Isopropyl-3-methyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-8); l-(4'-{3-Methyl-4-[3-methyl-3-((R)-l-phenyl-ethyl)- ureido]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-9); l-{4'-[3- Methyl-4-(3-phenyl-butylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1 - 10); 1 -(4'- (3-Methyl-4-[3-((R)- 1 -phenyl-ethyl)-ureido]-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-11); l-(4'-{4-[3-(2-Fluoro-benzyl)-ureido]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-12); l-(4'-{3-Methyl-4-[3- (2,2,2-trifluoro-ethyl)-ureido]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
(Compound 1-13); 1 - {4'-[4-(2-Chloro-phenylmethanesulfonylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-14); l-(4'-{4-[3-(2-Fluoro-5- trifluoromethyl-benzyl)-ureido]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-15); l-(4'-{4-[3-(2,6-Difluoro-benzyl)-ureido]-3-methyl-isoxazol-5-yl}-biphenyl-4- yl)-cyclopropanecarboxylic acid (Compound 1-16); l-{4'-[3-Methyl-4-(2-phenoxy-propionylamino)- isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-17); l-{4'-[4-(3- Benzenesulfonyl-ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-18); 1 - (4'-[3-Methyl-4-((R)- 1 -phenyl-ethylcarbamoyloxymethyl)-isoxazol-5-yl]- biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-19); l-{4'- [3 -Methyl-4-(3 -phenyl - propylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-20); l-[4'- (4-Benzylcarbamoyloxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-21); 1 - (4'-[3-Methyl-4-((S)- 1 -phenyl-ethylcarbamoyloxymethyl)-isoxazol-5-yl]- biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-22); l-[4'-(4- Cyclopentylcarbamoyloxymethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-23); l-(4'-{4-[3-(4-Isopropyl-phenyl)-2-methyl-propylamino]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-24); l-{4'-[3-Methyl-4-(l-methyl- 3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1- 25); 1 - {4'-[3-Methyl-4-(phenethylamino-methyl)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 1-26); l-(4'-{4-[(Cyclopropylmethyl-amino)-methyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-27); l-(4'-{4- [(Cyclohexylmethyl-amino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-28); l-{4'-[4-(Benzylamino-methyl)-3-methyl-isoxazol- 5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-29); l-(4'-{4-[(Acetyl-phenethyl- amino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1- 30); l-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-31); l-{4'-[3-Methyl-4-(4-phenyl-butyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-32); l-(4'-{3-Methyl-4-[(l-phenyl-ethylcarbamoyl)- methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-33); l-{4'-[4-(2- Benzyloxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-34); l-{4'-[4-(2-Cyclopropylmethoxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-35); l-{4'-[4-(2-Benzoylamino-ethyl)-3-methyl-isoxazol- 5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-36); l-{4'-[4-(2-Dibenzylamino- ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-37); l-[4'- (3-Methyl-4-phenethylcarbamoyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-38); l-{4'-[4-(2-Cyclopropylcarbamoyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl} -cyclopropanecarboxylic acid (Compound 1-39); l-(4'-{4-[2-(Cyclopropylmethyl-carbamoyl)- ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-40); l-{4'- [3-Methyl-4-(3-oxo-3-pyrrolidin-l-yl-propyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-41); 1 - {4'-[4-(2-Benzylcarbamoyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 1-42); l-{4'-[3-Methyl-4-(2-phenylcarbamoyl-ethyl)- isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-43); l-[4'-(4-{2-[(2- Fluoro-benzyl)-methyl-carbamoyl]-ethyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Compound 1-44); l-[4'-(4-Benzyloxymethyl-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-45); l-{4'-[4-(2-Chloro- benzyloxymethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-46); l-{4'-[3-Methyl-4-(l-phenyl-ethoxymethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-47); l-[4'-(3-Methyl-4-phenethyloxymethyl-isoxazol-5- yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-48); l-{4'-[3-Methyl-4-(l-methyl-2- phenyl-ethoxymethyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1 -49); l-[4'-(4-Benzylsulfanylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1 -50); 1 -[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Compound 1-51); l-[4'-(3-Methyl-4-phenylmethanesulfinylmethyl- isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-52); l-[4'-(3-Methyl-4- phenylmethanesulfonylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid
(Compound 1 -53); 1 - {4'-[3-Methyl-4-(2-phenyl-ethanesulfinylmethyl)-isoxazol-5-yl]-biphenyl-4- yl} -cyclopropanecarboxylic acid (Compound 1-54); l-{4'-[3-Methyl-4-(2-phenyl- ethanesulfonylmethyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1- 55); l-{4'-[3-Methyl-4-(2-phenyl-propoxymethyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-56); l-{4'-[4-(Benzyloxycarbonylamino-methyl)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-57); l-{4'-[3- Methyl-4-(phenylacetylamino-methyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-58); l-{4'-[4-(3-Benzyl-ureidomethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-59); l-(4'-{3-Methyl-4-[(3-phenyl-propionylamino)- methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-60); l-(4'-{4-[(2- Chloro-phenylmethanesulfonylamino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-61); l-{4'-[3-Methyl-4-((Z)-4-phenyl-but-l-enyl)- isoxazol-5-yl]-biphenyl-2-yl} -cyclopropanecarboxylic acid (Compound 1-62); l-{4'-[3-Methyl-4- ((E)-4-phenyl-but- 1 -enyl)-isoxazol-5-yl]-biphenyl-2-yl} -cyclopropanecarboxylic acid (Compound 1 - 63); l-[4'-(3-Methyl-4-{[(l-phenyl-cyclopropanecarbonyl)-amino]-methyl}-isoxazol-5-yl)-biphenyl- 4-yl] -cyclopropanecarboxylic acid (Compound 1-64); l-{4'-[4-(Indan-l-ylcarbamoylmethyl)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-65); l-(4'-{4-[2- (l,3-Dihydro-isoindol-2-yl)-2-oxo-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-66); l-(4'-{3-Methyl-4-[(methyl-phenethyl-amino)- methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-67); l-(4'-{4-[(2- Hydroxy-2-phenyl-ethylamino)-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-68); l-(4'-{3-Methyl-4-[(2-phenyl-propylamino)- methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-69); l-[4'-(4- {[Acetyl-(2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Compound 1-70); l-(4'-{3-Methyl-4-[(methyl-phenylacetyl-amino)- methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-71); l-[4'-(3- Methyl-4-{[methyl-(2-phenoxy-propionyl)-amino]-methyl}-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Compound 1-72); l-[4'-(4-{[Cyclopropanecarbonyl-(2 -phenyl -propyl)- amino]-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1- 73); l-[4'-(4-{[Benzoyl-(2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Compound 1-74); l-(4'-{3-Methyl-4-[2-(pyridin-2-ylmethoxy)-ethyl]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-75); l-(4'-{3-Methyl-4-[2- (pyridin-3-ylmethoxy)-ethyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
(Compound 1 -76); 1 -(4'- {3-Methyl-4-[2-(pyridin-4-ylmethoxy)-ethyl]-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-77); l-(4'-{3-Methyl-4-[2-(l-phenyl-ethoxy)-ethyl]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-78); l-(4'-{4-[2-(2-Chloro- benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-79); l-(4'-{4-[2-(3-Chloro-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-80); l-(4'-{4-[2-(4-Chloro-benzyloxy)-ethyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-81); l-(4'-{3-Methyl-4-[2- (methyl-phenyl-carbamoyl)-ethyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-82); l-{4'-[4-(2-Benzylsulfanyl-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-83); l-{4'-[3-Methyl-4-(2-phenylmethanesulfinyl-ethyl)- isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-84); l-{4'-[3-Methyl-4-(2- phenylmethanesulfonyl-ethyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid
(Compound 1 -85); 1 - {4'-[4-(2-Hydroxy-2-phenyl-propoxymethyl)-3-methyl-isoxazol-5-yl]-biphenyl- 4-yl} -cyclopropanecarboxylic acid (Compound 1-86); l-[4'-(3-Methyl-4-{[methyl-(2 -phenyl - propyl)-amino]-methyl}-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1- 87); l-{4'-[3-Methyl-4-(2-oxo-4-phenyl-butyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-88); l-{4'-[4-(2-Hydroxy-4-phenyl-butyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-89); l-{4'-[4-(Indan-2- ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid
(Compound 1-90); l-[4'-(4-{[(2-Fluoro-benzyl)-methyl-carbamoyl]-methyl}-3-methyl-isoxazol-5- yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-91); l-(4'-{4-[((lS,2R)-2-Hydroxy- indan- 1 -ylcarbamoyl)-methyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-92); l-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-93); l-{4'-[3-Methyl-4-((Z)-4-phenyl-but-l-enyl)- isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-94); l-{4'-[3-Methyl-4-
((E)-4-phenyl-but- 1 -enyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1 - 95); l-[4'-(4-Isobutylsulfanylmethyl-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-96); l-(4'-{3-Methyl-4-[l-(l-phenyl-ethylcarbamoyl)-ethyl]-isoxazol-5-yl}- biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-97); l-(4'-{3-Methyl-4-[(2-methyl-2- phenyl-propionylamino)-methyl]-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid
(Compound 1 -98); 1 - {4'-[4-((S)-Indan- 1 -ylcarbamoylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl} -cyclopropanecarboxylic acid (Compound 1-99); l-(4'-{3-Methyl-4-[(2-phenoxy- propionylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1- 100); (l-{4'-[3-Methyl-4-((Z)-4-phenyl-but-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)- acetic acid (Compound 1-101); (l-{4'-[3-Methyl-4-((E)-4-phenyl-but-l-enyl)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-102); l-(4'-{3-Methyl-4-[((R)-2-phenyl- propylamino)-methyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1- 103); l-[4'-(4-{[Ethyl-((R)-2-phenyl-propyl)-amino]-methyl}-3-methyl-isoxazol-5-yl)-biphenyl-4- yl] -cyclopropanecarboxylic acid (Compound 1-104); l-[4'-(3-Methyl-4-{2-[(R)-methyl-(l-phenyl- ethyl)-carbamoyl]-ethyl}-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-
105); 1 -(4'- {3-Methyl-4-[2-(l -methyl- 1 -phenyl-ethylcarbamoyl)-ethyl]-isoxazol-5-yl} -biphenyl-4- yl)-cyclopropanecarboxylic acid (Compound 1-106); l-(4'-{4-[3-(l,3-Dihydro-isoindol-2-yl)-3-oxo- propyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-107);
[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-acetic acid (Compound 1- 108); {4'-[3-Methyl-4-(2-phenyl-ethanesulfonylmethyl)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid (Compound 1-109); l-{4'-[3-Methyl-4-(4-phenyl-pent-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-110); l-(4'- {4- [4-(4-Isopropyl-phenyl)-3 -methyl -but- 1- enyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-111); 1- {4'-[3-Methyl-4-((Z)-4-phenyl-pent-l-enyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-112); l-{4'-[3-Methyl-4-((E)-4-phenyl-pent-l-enyl)-isoxazol-5-yl]-biphenyl-4- yl} -cyclopropanecarboxylic acid (Compound 1-113); 1 - {4'-[4-(3-Hydroxy-4-phenyl-butyl)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-114); l-{4'-[4- ((E)-l-Hydroxy-4-phenyl-but-3-enyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-115); l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-116); l-(4'-{4-[2- (Cyclopropylmethyl-methyl-carbamoyl)-ethyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-117); l-[4'-(3-Methyl-4-{2-[methyl-(l-methyl-l-phenyl- ethyl)-carbamoyl]-ethyl} -isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1 - 118); l-(4'-{4-[2-(Cyclopropylmethyl-methyl-carbamoyl)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl- 4-yl)-cyclopropanecarboxylic acid (Compound 1-119); l-{4'-[3-Methyl-4-(2-oxo-2-phenyl- ethylsulfanylmethyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-120); l-{4'-[4-(2-Hydroxy-2-methyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-121); 2-[4'-(3-Methyl-4-phenethylsulfanylmethyl- isoxazol-5-yl)-biphenyl-4-yl]-butyric acid (Compound 1-122); 2-[4'-(3-Methyl-4- phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-propionic acid (Compound 1-123); l-{4'-[3- Methyl-4-(4-phenyl-butyryl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-124); {l-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropyl}- acetic acid (Compound 1-125); l-{4'-[4-(l-Hydroxy-l-methyl-4-phenyl-butyl)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-126); l-(4'-{4-[2-(Cyclopropyl- methyl-carbamoyl)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1 - 127); (trans)-2- {4'-[3-Methyl-4-(4-phenyl-but- 1 -enyl)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 1-128); (cis)-2-{4'-[3-Methyl-4-(4-phenyl-but-l-enyl)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-129); (trans)-2-[4'-(3- Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-130); (cis)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Compound 1-131); l-{4'-[4-(3-Benzylamino-2-hydroxy-propyl)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-132); 2-Methyl-2- [4'-(3-methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-propionic acid (Compound 1 - 133); l-[4'-(4-{2-[Hydroxyimino]-4-phenyl-butyl}-3-methyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Compound 1-134); (lR,2S)-2-{4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-135); 2-{4'-[4- (2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -propionic acid (Compound 1- 136); 3-Methyl-2-[4'-(3-methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-butyric acid (Compound 1-137); l-(4'-{4-[3-(Acetyl-benzyl-amino)-2-hydroxy-propyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-138); l-(4'-{4-[3-(Benzyl- methanesulfonyl-amino)-propenyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-139); (l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropyl)-acetic acid (Compound 1-140); l-{4'-[4-(2-Benzylamino-ethyl)-3-methyl-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-141); l-(4'-{4-[2-(Acetyl-benzyl- amino)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1- 142); l-(4'-{4-[2-(Benzyl-methanesulfonyl-amino)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-143); (cis)-2-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-144); 2-[4'-(3- Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-3-phenyl-propionic acid
(Compound 1 - 145); 1 - {4'-[4-(2-Benzylamino- 1 -hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl} -cyclopropanecarboxylic acid (Compound 1-146); l-{4'-[4-(l-Ethoxy-4-phenyl-butyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-147); l-{4'-[4-(l-
Methoxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-148); (cis)-2-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-149); (cis)-2-[4'-(3-Methyl-4- phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-150); l-{4'-[4-(3,3-Dimethyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-151); l-[4'-(4-Hydroxymethyl-3-methyl-isoxazol-5-yl)- biphenyl-4-yl]-cyclopropanecarboxylic acid (Compound 1-152); l-(4'-{4-[3-(3-Fluoro-phenyl)-l- methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
(Compound 1-153); 1 -(4'- {3-Methyl-4-[ 1 -methyl-3-(3-trifluoromethyl-phenyl)-propylamino]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-154); l-{4'-[4-(l-
Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-155); l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-156); l-{4'-[3-Methyl-4- (3-phenyl-propionyl)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1- 157); l-{4'-[4-((E)-l-Hydroxy-3-phenyl-allyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-158); 1 -{4'-[4-(l-Hy droxy-3 -phenyl -propy l)-3 -methyl - isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-159); l-(4'-{3-Methyl-4- [3 -(3 -trifluoromethyl-phenyl)-propionyl] -isoxazol-5-yl } -biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-160); 1 -(4'- (4-[(E)- 1 -Hydroxy-3-(3-trifluoromethyl-phenyl)-allyl]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-161); l-(4'-{4-[l-Hydroxy-3-(3- trifluoromethyl-phenyl)-propyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-162); l-(4'-{4-[l-Hydroxy-4-(3-trifluoromethyl-phenyl)-butyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-163); l-{4'-[4-(l- Hydroxy-4-m-tolyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-164); (4'-{4-[3-(3-Fluoro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}- biphenyl-4-yl)-acetic acid (Compound 1-165); l-{4'-[4-(l-Hydroxy-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-166); l-{4'-[4-(2-Benzylsulfanyl-l- hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1- 167); 1 -(4'- {4-[ 1 -Hydroxy-4-(4-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl} -biphenyl-4- yl)-cyclopropanecarboxylic acid (Compound 1-168); l-(4'-{4-[l-Hydroxy-4-(2-trifluoromethyl- phenyl)-butyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1- 169); {4'-[4-(2,2-Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -acetic acid (Compound 1-170); 2-(4'- {4-[ 1 -Hydroxy-4-(2-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-butyric acid (Compound 1-171); l-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl- propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1- 172); 1 - {4'-[4-(2-Benzyloxy- 1 -hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 1-173); {4'-[4-(l-Hydroxy-4-phenyl-butyl)-3 -methyl - isoxazol-5-yl]-biphenyl-4-yl}-acetic acid (Enantiomer A) (Compound 1-174); (l-{4'-[4-(2,2- Difluoro-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid
(Compound 1 - 175); (1 - {4'-[4-(l -Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropyl)-acetic acid (Enantiomer A) (Compound 1-176); (l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)- 3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid (Enantiomer B) (Compound 1-177); l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-178); l-{4'-[4-(l-Hydroxy-2-methyl-4-phenyl-butyl)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-179); l-{4'-[4-(l- Hydroxy-2,2-dimethyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-180); (4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl- phenyl)-propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 1-181); (4'-{4-[3-(3- Chloro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-acetic acid
(Compound 1-182); [ 1 -(4'- {3-Methyl-4-[ 1 -methyl-3-(3-trifluoromethyl-phenyl)-propylamino]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-183); [l-(4'-{4-[3-(3-Chloro- phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-184); [ 1 -(4'- (4-[3-(3-Fluoro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-185); l-{4'-[4-(l,l-Difluoro-4-phenyl-butyl)- 3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-186); l-(4'-{4- [1 -Hydroxy -2-((S)-indan-l-ylamino)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-187); 2-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-3-phenyl-propionic acid (Compound 1-188); l-{4'-[4-(l-Benzylamino- 2-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-189); 1 - {4'-[4-(2-Amino- 1 -hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 1-190); 3-[4'-(3-Methyl-4-phenethylsulfanylmethyl- isoxazol-5-yl)-biphenyl-4-yl]-propionic acid (Compound 1-191); 3-(4'-{3-Methyl-4-[l-methyl-3-(3- trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Compound 1- 192); 3-(4'-{4-[3-(3-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- propionic acid (Compound 1-193); l-{4'-[3-Methyl-4-(4-methyl-pyrazol-l-ylmethyl)-isoxazol-5-yl]- biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-194); l-(4'-{3-Methyl-4-[(6-methyl- benzothiazol-2-ylamino)-methyl]-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropanecarboxylic acid
(Compound 1-195); 1 - {4'-[4-(4-Bromo-pyrazol- 1 -ylmethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 1-196); 3-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-propionic acid (Compound 1-197); l-{4'-[4-(2-Benzyloxy-l-hydroxy- ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Enantiomer A)
(Compound 1-198); l-{4'-[4-(2-Benzyloxy-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl} -cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-199); 3-{4'-[4-(l-Hydroxy-4-phenyl- butyl)-3-methyl-isoxazol-5-yl]-biphenyl-3-yl}-propionic acid (Compound 1-200); 3-{4'-[4-(l- Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-2-yl}-propionic acid (Compound 1-201); l-{4'-[3-Methyl-4-(2-phenylmethanesulfinyl-acetyl)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-202); l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl- isoxazol-5-yl]-biphenyl-2-yl}-cyclopropanecarboxylic acid (Compound 1-203); (l-{4'-[4-(l,5- Dimethyl-hex-4-enylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-204); l-{4'-[4-(l,5-Dimethyl-hex-4-enylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl} -cyclopropanecarboxylic acid (Compound 1-205); (l-{4'-[3-Methyl-4-(l-naphthalen-2-yl- ethylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-206); (l-{4'-[4-(l- Hydroxy-5-phenyl-pentyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid
(Compound 1 -207); [ 1 -(4'- {4- [5-(3 ,4-Dichloro-phenyl)- 1 -hydroxy-pentyl]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-208); l-(4'-{4-[(S)-l-Hydroxy-2-((R)-l- phenyl-ethoxy)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
(Compound 1-209); l-(4'-{4-[3-(4-Methoxy-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5- yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-210); [l-(4'-{4-[3-(4-Methoxy- phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-211); l-{4'-[3-Methyl-4-(5-methyl-thieno[2,3-d]pyrimidin-4-ylamino)-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-212); (l-{4'-[4-(l,3-Diphenyl- propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-213); l-{4'-[4-(l,3-Diphenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-214); (cis)-2-{4'-[4-((R)-2-Benzyloxy-l-hydroxy-ethyl)- 3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-215); (cis)-2-{4'- [4-((S)-2-Benzyloxy- 1 -hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-216); (cis)-2-{4'-[4-((S)-2-Benzyloxy-l- hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-217); [1 -(4'- (4-[3-(4-Chloro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-218); [l-(4'-{4-[3-(2-Chloro-6-fluoro-phenyl)- l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-219); 1 - {4'-[3-Methyl-4-(l -methyl-3-phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-220); l-{4'-[3-Methyl-4-(l-methyl-3- phenyl-propylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Enantiomer B) (Compound 1 -221); [ 1 -(4'- (4-[3-(2-Chloro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-222); l-(4'-{4-[3-(2-Chloro-phenyl)-l-methyl- propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1- 223); l-(4'-{4-[3-(4-Chloro-phenyl)-l-methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-224); l-(4'-{4-[3-(2-Chloro-6-fluoro-phenyl)-l -methyl - propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1- 225); (l-{4'-[3-Methyl-4-(l-methyl-pent-4-enylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)- acetic acid (Compound 1-226); l-{4'-[3-Methyl-4-(l-methyl-pent-4-enylamino)-isoxazol-5-yl]- biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-227); {4'-[3-Methyl-4-(l-methyl-pent-4- enylamino)-isoxazol-5-yl]-biphenyl-2-yl}-acetic acid (Compound 1-228); (l-{4'-[4-(4-Hydroxy-l- methyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropyl)-acetic acid (Compound 1 - 229); 1 - {4'-[4-(4-Hydroxy- 1 -methyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} - cyclopropanecarboxylic acid (Compound 1-230); {4'-[4-(4-Hydroxy-l-methyl-butylamino)-3- methyl-isoxazol-5-yl]-biphenyl-2-yl}-acetic acid (Compound 1-231); {4'-[4-(3-Benzo[l,3]dioxol-5- yl-l-methyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-2-yl} -acetic acid (Compound 1-232); (l-{4'-[4-(3-Benzo[l,3]dioxol-5-yl-l-methyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid (Compound 1-233); 3-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl- phenyl)-propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Enantiomer A) (Compound 1- 234); 3-(4'-{3-Methyl-4-[l-methyl-3-(3-trifluoromethyl-phenyl)-propylamino]-isoxazol-5-yl}- biphenyl-4-yl)-propionic acid (Enantiomer B) (Compound 1-235); [l-(4'-{4-[2-(4-Methoxy-phenyl)- l-methyl-ethylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-236); 1 -(4'- (4-[2-(4-Methoxy-phenyl)- 1 -methyl-ethylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4- yl)-cyclopropanecarboxylic acid (Compound 1-237); (4'- {4- [2-(4-Methoxy-phenyl)-l -methyl - ethylamino]-3-methyl-isoxazol-5-yl}-biphenyl-2-yl)-acetic acid (Compound 1-238); l-(4'-{4-[3-(3- Chloro-phenyl)- 1 -methyl-propylamino]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-239); 1 -(4'- {4- [3 -(3 -Chloro-phenyl)- 1- methyl-propylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
(Enantiomer B) (Compound 1-240); (4'-{4-[l-Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3- methyl-isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 1-241); 3-(4'-{4-[l-Hydroxy-2-(3- trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)-propionic acid
(Compound 1 -242); 1 -(4'- {4-[ 1 -Hydroxy-2-(3-trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol- 5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-243); [l-(4'-{4-[l-Hydroxy-2-(3- trifluoromethyl-benzyloxy)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1-244); 4-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-4- oxo-butyric acid (Compound 1-245); (l-{4'-[4-(l-Hydroxy-3-methyl-3-phenyl-butyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetic acid (Compound 1-246); [l-(4'-{4-[l-Hydroxy-3- (4-methoxy-phenyl)-propyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropyl]-acetic acid (Compound 1 -247); 1 - {4'-[4-(l -Hydroxy-2-phenethyloxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-248); l-{4'-[4-(Hydroxy-phenethylcarbamoyl- methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-249); 1- {4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-ylmethyl}- cyclopropanecarboxylic acid (Compound 1-250); l-{4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl- isoxazol-5-yl]-biphenyl-3-ylmethyl}-cyclopropanecarboxylic acid (Compound 1-251); l-{4'-[4- (Benzylcarbamoyl-hydroxy-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-252); l-(4'-{4-[Hydroxy-((R)-l-phenyl-ethylcarbamoyl)-methyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-253); l-{4'-[4-(2,2- Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer A) (Compound 1-254); l-{4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Enantiomer B) (Compound 1- 255); (l-{4'-[4-(l-Acetylamino-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropyl)-acetic acid (Compound 1-256); l-{4'-[4-(l-Methanesulfonylamino-4-phenyl-butyl)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-257); l-(4'-{4- [(Benzyl-methyl-carbamoyl)-hydroxy-methyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-258); l-{4'-[3-Methyl-4-((E)-2-phenylmethanesulfonyl- vinyl)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-259); l-{4'-[4-(l-
Hydroxy-4-pyridin-3-yl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-260); l-{4'-[4-(l-Hydroxy-4-pyridin-4-yl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl}-cyclopropanecarboxylic acid (Compound 1-261); l-(4'-{3-Methyl-4-[(E)-2- (phenylmethanesulfinyl)-vinyl]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
(Enantiomer A) (Compound 1-262); l-(4'-{3-Methyl-4-[(E)-2-(phenylmethanesulfinyl)-vinyl]- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Enantiomer B) (Compound 1-263); 1- (4'- {4-[2,2-Difluoro-4-(4-fluoro-phenyl)- 1 -hydroxy-butyl]-3-methyl-isoxazol-5-yl} -biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-264); l-(4'-{4-[l-Hydroxy-2-(3-trifluoromethyl- benzylsulfanyl)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid
(Compound 1 -265); (4'- {4-[ 1 -Hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-acetic acid (Compound 1-266); l-(4'-{3-Methyl-4-[methyl-(l-methyl-
3- phenyl-propyl)-amino]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1- 267); 1 -(4'- {4-[2,2-Difluoro- 1 -hydroxy -4-(4-trifluoromethyl-phenyl)-butyl]-3-methyl-isoxazol-5-yl} - biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-268); l-{4'-[4-((S)-2-Benzylsulfanyl-l- hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1- 269); l-{4'-[3-Methyl-4-(l,2,3,4-tetrahydro-naphthalen-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-270); l-{4'-[4-(Indan-2-ylamino)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-271); {4'-[4-((S)-2-Benzylsulfanyl-l- hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -acetic acid (Compound 1-272); 3-{4'-[4-((S)- 2-Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -propionic acid
(Compound 1 -273); 3-(4'- (4-[(S)- 1 -Hydroxy-2-(3-trifluoromethyl-benzylsulfanyl)-ethyl]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-propionic acid (Compound 1-274); l-{4'-[4-(2-tert-Butylsulfanyl-l- hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1- 275); 1 -(4'- {4-[ 1 -Hydroxy-2-(2,2,2-trifluoro-ethylsulfanyl)-ethyl]-3-methyl-isoxazol-5-yl} -biphenyl-
4- yl)-cyclopropanecarboxylic acid (Compound 1-276); l-{4'-[4-(l-Hydroxy-2-phenylsulfanyl-ethyl)- 3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-277); l-{4'-[3-
Methyl-4-(l-methyl-2-phenylsulfanyl-ethylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-278); l-{4'-[3-Methyl-4-(l-methyl-2-phenoxy- ethylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-279); l-{4'- [3-Methyl-4-(quinolin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-280); l-{4'-[4-(l-Ethyl-3-phenyl-propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl} -cyclopropanecarboxylic acid (Compound 1-281); l-{4'-[4-(2-Hydroxy-l-methyl-3-phenyl- propylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Diastereomer A) (Compound 1-282); l-{4'-[4-(2-Hydroxy-l-methyl-3-phenyl-propylamino)-3-methyl-isoxazol-5- yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Diastereomer B) (Compound 1-283); l-{4'-[4-(l- Benzo[b]thiophen-2-yl-ethylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-284); l-{4'-[4-(l,3-Dimethyl-3-phenyl-butylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-285); (l-{4'-[4-(l-Benzo[b]thiophen-2- yl-ethylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropyl)-acetic acid (Compound 1 -286); (l-{4'-[4-(l,3-Dimethyl-3-phenyl-butylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)- acetic acid (Compound 1-287); l-{4'-[3-Methyl-4-((E)-l-methyl-3-phenyl-allylamino)-isoxazol-5- yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-288); l-{4'-[4-(l-Hydroxy-3,3- dimethyl-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-289); l-{4'-[3-Methyl-4-(pyridin-3-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-290); l-{4'-[4-(5-Methoxy-pyridin-3-ylamino)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-291); l-{4'-[4-(3-Bromo- benzoylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1- 292); l-{4'-[3-Methyl-4-(6-propoxy-pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-293); l-{4'-[4-(6-Ethoxy-pyridin-2-ylamino)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-294); l-{4'-[4-(6-Butoxy- pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid
(Compound 1-295); l-{4'-[3-Methyl-4-(pyridin-2-ylamino)-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-296); l-{4'-[4-(6-Isopropoxy-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-297); 6-{5-[4'-(l- Carboxy-cyclopropyl)-biphenyl-4-yl]-3-methyl-isoxazol-4-ylamino}-pyridine-2-carboxylic acid (Compound 1-298); l-(4'-{4-[6-(2-Dimethylamino-ethylcarbamoyl)-pyridin-2-ylamino]-3-methyl- isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-299); l-(4'-{4-[6-(2,2- Dimethyl-propylcarbamoyl)-pyridin-2-ylamino]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)- cyclopropanecarboxylic acid (Compound 1-300); l-{4'-[4-(6-iert-Butoxy-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-301); l-{4'-[4-(6- Hydroxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-302); l-{4'-[4-(6-Dodecyloxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4- yl} -cyclopropanecarboxylic acid (Compound 1-303); l-{4'-[4-(6-Methoxy-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-304); 4'-[4- (Benzyloxycarbonylamino-methyl)-3-methyl-isoxazol-5-yl]-biphenyl-3-carboxylic acid (Compound 1-305); {l-[4'-(5-Methyl-4-phenethylsulfanylmethyl-isoxazol-3-yl)-biphenyl-4-yl]-cyclopropyl}- acetic acid (Compound 1-306); (4'-{3-Methyl-4-[(S)-l-methyl-3-(3-trifluoromethyl-phenyl)- propylamino]-isoxazol-5-yl}-biphenyl-4-yl)-propynoic acid (Compound 1-307); l-(4'-{4-[3-(3- Bromo-phenyl)-ureido]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid (Compound 1-308); l-{4'-[4-(6-Isopropoxy-l-oxy-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-309); l-{4'-[4-(5-Isopropoxy-pyridin-3- ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-310); l-{4'-[4-(6-Acetyl-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarboxylic acid (Compound 1-31 1); l- {4'-[4-(6-Carbamoyl-pyridin-2-ylamino)-3- methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1-312); l- {4'-[4-(6- Bromo-pyridin-2-ylamino)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarboxylic acid (Compound 1-313); N- { l-[4'-(3-Methyl-4-phenethylsulfanylmethyl-isoxazol-5-yl)-biphenyl-4-yl]- cyclopropanecarbonyl} -methanesulfonamide (Compound 2-1); N-[l-(4'- {4-[(S)-l-Hydroxy-2-((R)-l- phenyl-ethoxy)-ethyl]-3-methyl-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarbonyl]- methanesulfonamide (Compound 2-2); N-(l - {4'-[4-((S)-2-Benzyloxy-l-hydroxy-ethyl)-3-methyl- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide (Compound 2-3); N- Sulfonylmethyl carbamic acid (S)-2-benzyloxy-l- {5-[4'-(l-methanesulfonylaminocarbonyl- cyclopropyl)-biphenyl-4-yl]-3-methyl-isoxazol-4-yl}-ethyl ester (Compound 2-4); 4-Methyl-N-(l- {4'-[3-methyl-4-(3-p-tolunesulfonyl-ureido)-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarbonyl)- benzenesulfonamide (Compound 2-5); Cyclopropanesulfonic acid (l- {4'-[4-(3-cyclopropylsulfonyl- ureido)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-amide (Compound 2-6); N- (l- {4'-[4-(l-Hydroxy-2-phenethyloxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}- cyclopropanecarbonyl)-methanesulfonamide (Compound 2-7); N-(l- {4'-[4-(2,2-Difluoro-4-phenyl- butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide
(Compound 2-8); N-(l- {4'-[4-(2,2-Difluoro-l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]- biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide (Compound 2-9); N-(l- {4'-[4-((S)-2- Benzylsulfanyl-l-hydroxy-ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl} -cyclopropanecarbonyl)- methanesulfonamide (Compound 2-10); N-(l- {4'-[4-(l-Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol- 5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-4-methyl-benzenesulfonamide (Compound 2-1 1);
Cyclopropanesulfonic acid (l- {4'-[4-(l-hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-
4- yl}-cyclopropanecarbonyl)-amide (Compound 2-12); N-(l- {4'-[4-(l-Hydroxy-2-m-tolylsulfanyl- ethyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarbonyl)-methanesulfonamide
(Compound 2- 13); N-[ 1 -(4'- {4-[ 1 -Hydroxy-2-(3-methoxy-phenylsulfanyl)-ethyl]-3-methyl-isoxazol-
5- yl}-biphenyl-4-yl)-cyclopropanecarbonyl]-methanesulfonamide (Compound 2-14); N- Sulfonylmethyl carbamic acid l-(5- {4'-[l-(2-methanesulfonylamino-2-oxo-ethyl)-cyclopropyl]- biphenyl-4-yl}-3-methyl-isoxazol-4-yl)-4-phenyl-butyl ester (Compound 2-15); N-[2-(l- {4'-[4-(l- Hydroxy-4-phenyl-butyl)-3-methyl-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropyl)-acetyl]- methanesulfonamide (Compound 2-16);
or a pharmaceutically acceptable salt thereof.
23. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-22, or a pharmaceutically acceptable salt thereof.
24. The pharmaceutical composition of claim 23, wherein the pharmaceutical composition is formulated for intravenous injection, subcutaneous injection, oral administration, inhalation, nasal administration, topical administration, ophthalmic administration or otic administration.
25. The pharmaceutical composition of claim 23, wherein the pharmaceutical composition is a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop or an ear drop.
26. A method of inhibiting the physiological activity of LP A in a mammal comprising
administering a therapeutically effective amount of a compound according to any one of claims 1-22 or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
27. A method for treating or preventing a LPA-dependent or LPA-mediated disease or condition in a mammal comprising administering a therapuetically effective amount of a compound according to any one of claims 1-22 or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
28. The method of claim 27, wherein the LPA-dependent or LPA-mediated disease or condition is selected from lung fibrosis, asthma, chronic obstructive pulmonary disease (COPD), renal fibrosis, acute kidney injury, chronic kidney disease, liver fibrosis, skin fibrosis, fibrosis of the gut, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, glioblastoma, bone cancer, colon cancer, bowel cancer, head and neck cancer, melanoma, multiple myeloma, chronic lymphocytic leukemia, cancer pain, tumor metastasis, transplant organ rejection, scleroderma, ocular fibrosis, age related macular degeneration (AMD), diabetic retinopathy, collagen vascular disease, atherosclerosis, Raynaud's phenomenom, or neuropathic pain. 29. A method of controlling the activation of LPA receptors in a tissue in a mammal comprising administering a compound of any one of claims 1-22 to mammal.
30. The method of claim 29, wherein the activation of LPA receptors in a tissue in a mammal results in fibrosis.
31. A method for the treatment or prevention of fibrosis in a mammal comprising administering a therapeutically effective amount of a compound of any one of claims 1 -22 to the mammal in need thereof.
32. The method of claim 31 , wherein the fibrosis comprises lung fibrosis, renal fibrosis, hepatic fibrosis or cutaneous fibrosis.
33. A method of controlling an abnormal accumulation or activation of cells, fibronectin,
collagen or increased fibroblast recruitment in a tissue of a mammal comprising
administering a compound of any one of claims 1-22 to mammal.
34. The method of claim 33, wherein the abnormal accumulation or activation of cells,
fibronectin, collagen or increased fibroblast recruitment in the tissue results in fibrosis.
35. The method of any one of claims 26-34 further comprising administering to the mammal one or more additional therapeutically active agents selected from: corticosteroids,
immunosuppresant, analgesics, anti-cancer agent, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, monoacylglycerol kinase inhibitors, phosphohpase Ai inhibitors, phosphohpase A2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, decongestants, antihistamines, mucolytics, anticholinergics, antitussives, expectorants, and β- 2 agonists.
PCT/US2010/051150 2009-10-01 2010-10-01 Compounds as lysophosphatidic acid receptor antagonists WO2011041694A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US13/498,491 US9090573B2 (en) 2009-10-01 2010-10-01 Compounds as lysophosphatidic acid receptor antagonists
JP2012532357A JP2013506694A (en) 2009-10-01 2010-10-01 Compounds as lysophosphatidic acid receptor antagonists
CN2010800546595A CN102639515A (en) 2009-10-01 2010-10-01 Compounds as lysophosphatidic acid receptor antagonists
IN2735DEN2012 IN2012DN02735A (en) 2009-10-01 2010-10-01
EP10821345.5A EP2483252B1 (en) 2009-10-01 2010-10-01 Compounds as lysophosphatidic acid receptor antagonists
US14/755,383 US9624182B2 (en) 2009-10-01 2015-06-30 Compounds as lysophosphatidic acid receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24786109P 2009-10-01 2009-10-01
US61/247,861 2009-10-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/498,491 A-371-Of-International US9090573B2 (en) 2009-10-01 2010-10-01 Compounds as lysophosphatidic acid receptor antagonists
US14/755,383 Continuation US9624182B2 (en) 2009-10-01 2015-06-30 Compounds as lysophosphatidic acid receptor antagonists

Publications (2)

Publication Number Publication Date
WO2011041694A2 true WO2011041694A2 (en) 2011-04-07
WO2011041694A3 WO2011041694A3 (en) 2011-08-18

Family

ID=43128102

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2010/051199 WO2011041729A2 (en) 2009-10-01 2010-10-01 Compounds as lysophosphatidic acid receptor antagonists
PCT/US2010/051150 WO2011041694A2 (en) 2009-10-01 2010-10-01 Compounds as lysophosphatidic acid receptor antagonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2010/051199 WO2011041729A2 (en) 2009-10-01 2010-10-01 Compounds as lysophosphatidic acid receptor antagonists

Country Status (10)

Country Link
US (3) US8217066B2 (en)
EP (2) EP2483253A4 (en)
JP (2) JP2013506695A (en)
CN (2) CN102666504B (en)
AR (1) AR078497A1 (en)
GB (1) GB2474120B (en)
IN (2) IN2012DN02177A (en)
TW (1) TWI401082B (en)
UY (1) UY32926A (en)
WO (2) WO2011041729A2 (en)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048902B2 (en) 2008-12-15 2011-11-01 Amira Pharmaceuticals, Inc. Antagonists of lysophosphatidic acid receptors
US8058300B2 (en) 2009-06-03 2011-11-15 Amira Pharmaceuticals, Inc. Polycyclic antagonists of lysophosphatidic acid receptors
US8217066B2 (en) 2009-10-01 2012-07-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
WO2012078593A3 (en) * 2010-12-07 2012-08-02 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
EP2483269A2 (en) * 2009-10-01 2012-08-08 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2013078283A1 (en) 2011-11-22 2013-05-30 Intermune, Inc. Methods of diagnosing and treating idiopathic pulmonary fibrosis
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
US8541587B2 (en) 2011-04-05 2013-09-24 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists
US8592402B2 (en) 2009-08-04 2013-11-26 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
WO2014104372A1 (en) 2012-12-28 2014-07-03 宇部興産株式会社 Halogen-substituted heterocyclic compound
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2015082587A1 (en) 2013-12-05 2015-06-11 Bayer Cropscience Ag N-cycloalkyl-n-{[2-(1-substitutedcycloalkyl)phenyl]methylene}-(thio)carboxamide derivatives
WO2015082586A1 (en) 2013-12-05 2015-06-11 Bayer Cropscience Ag N-cycloalkyl-n-{[2-(1-substitutedcycloalkyl)phenyl]methylene}-(thio)carboxamide derivatives
WO2016197009A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
KR20170016988A (en) 2014-06-27 2017-02-14 우베 고산 가부시키가이샤 Salt of halogen-substituted heterocyclic compound
WO2017223016A1 (en) 2016-06-21 2017-12-28 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
WO2019034686A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2020035465A1 (en) * 2017-08-15 2020-02-20 Inflazome Limited Novel sulfoneurea compounds
US10662172B2 (en) 2017-12-19 2020-05-26 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
US11130731B2 (en) 2015-02-16 2021-09-28 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
US11261174B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
US11261180B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as LPA antagonists
US11267800B2 (en) 2017-12-19 2022-03-08 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as LPA antagonists
US11312706B2 (en) 2017-12-19 2022-04-26 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as LPA antagonists
US11319315B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as LPA antagonists
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
US11352345B2 (en) 2017-12-19 2022-06-07 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as LPA antagonists
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11384067B2 (en) 2017-12-19 2022-07-12 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
US11465992B2 (en) 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11548871B2 (en) 2019-11-15 2023-01-10 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
US11584738B2 (en) 2020-06-03 2023-02-21 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
RU2805922C2 (en) * 2019-07-30 2023-10-24 Таишо Фармасьютикал Ко., Лтд. Urea compound that is antagonist of lpa1 receptor
US11884627B2 (en) 2022-02-25 2024-01-30 Lhotse Bio, Inc. Compounds and compositions for treating conditions associated with LPA receptor activity
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11980609B2 (en) 2021-05-11 2024-05-14 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US12012392B2 (en) 2017-11-09 2024-06-18 Inflazome Limited Sulfonamide carboxamide compounds

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742029B1 (en) * 2011-08-08 2016-10-05 Merck Patent GmbH N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
WO2013070879A1 (en) * 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
EP2804605A4 (en) * 2012-01-20 2015-07-08 Acucela Inc Substituted heterocyclic compounds for disease treatment
WO2014159814A1 (en) * 2013-03-13 2014-10-02 Patricia Oliver Formulations and tablets for treatment or prevention of neurological disorders
WO2019246109A1 (en) * 2018-06-18 2019-12-26 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
EA038294B1 (en) * 2013-05-24 2021-08-05 Эпиджен Байосайенсиз, Инк. Heterocyclic compounds useful in the treatment of diseases
EP3116870A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015138909A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015196071A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
MA41253A (en) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
WO2016105468A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
CA2971855A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10392378B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2017019589A1 (en) 2015-07-24 2017-02-02 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
AU2016336437B2 (en) 2015-10-06 2020-06-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
NZ746793A (en) 2016-04-07 2022-10-28 Proteostasis Therapeutics Inc Silicone atoms containing ivacaftor analogues
US10899751B2 (en) 2016-06-21 2021-01-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
KR101798840B1 (en) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same
US10961242B2 (en) 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
DE102017118230B4 (en) * 2017-08-10 2021-04-22 Christoph Lucks Method for analyzing and / or monitoring bridges and the corresponding system and use
WO2019041340A1 (en) * 2017-09-04 2019-03-07 Eli Lilly And Company Lysophosphatidic acid receptor 1 (lpar1) inhibitor compounds
HU231223B1 (en) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. Bicyclic derivatives as gabaa a5 receptor modulators
CA3148244A1 (en) * 2019-07-30 2021-02-04 Taisho Pharmaceutical Co., Ltd. Urea compound for antagonizing lpa1 receptor
JPWO2021107125A1 (en) * 2019-11-29 2021-06-03
CN114907282B (en) * 2022-05-24 2023-08-22 华南理工大学 Method for synthesizing 4-phenyl alkenyl isoxazole derivative
CN117126044B (en) * 2023-04-12 2024-01-26 延边大学 Microwave-assisted synthesis method of methyl ketone compound

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
EP0791576A2 (en) 1995-11-23 1997-08-27 Bayer Ag Leukotriene antagonistic benzoic acid derivatives
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
US20030114505A1 (en) 2000-02-18 2003-06-19 Akihiro Ueno Novel isoxazole and thiazole compounds and use thereof as drugs
US7060697B2 (en) 2003-05-19 2006-06-13 Irm Llc Immunosuppressant compounds and compositions
US20060194850A1 (en) 2003-08-05 2006-08-31 Ajinomoto Co. Inc Novel azole compound
WO2007016784A1 (en) 2005-08-11 2007-02-15 Merck Frosst Canada Ltd. Novel substituted 1,2,3-tπazolylmethyl-benzothiophene or -indole and their use as leukotπene biosynthesis inhibitors
US20070105866A1 (en) 2005-11-04 2007-05-10 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070123522A1 (en) 2005-10-11 2007-05-31 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070149579A1 (en) 2005-03-23 2007-06-28 Marc Blouin Novel pharmaceutical compounds
US20070173508A1 (en) 2006-01-23 2007-07-26 Amira Pharmaceuticals, Inc. Tricyclic inhibitors of 5-lipoxygenase
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2633641B2 (en) 1988-08-26 1997-07-23 本田技研工業株式会社 Exhaust gas concentration detector
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
JPH096712A (en) 1995-06-23 1997-01-10 Canon Inc Data processor
ES2196396T3 (en) 1996-12-23 2003-12-16 Bristol Myers Squibb Pharma Co HETEROAROMATIC COMPOUNDS OF 5 MEMBERS CONTAINING OXYGEN OR SULFUR AS INHIBITORS OF THE XA FACTOR.
JP3237608B2 (en) 1997-04-21 2001-12-10 住友製薬株式会社 Isoxazole derivative
ATE241621T1 (en) 1999-04-02 2003-06-15 Bristol Myers Squibb Pharma Co ARYLSULFONYLS AS FACTOR XA INHIBITORS
DE10013485C1 (en) 2000-03-18 2001-07-12 Krupp Bilstein Gmbh Vehicle lifting jack has cog segment of pivoted carrier arm cooperating with cog section of control slider displaced parallel to support column
EP1277743A4 (en) 2000-03-28 2005-03-23 Nippon Soda Co Oxa(thia)zolidine derivative and anti-inflammatory drug
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
US7022725B2 (en) 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
ATE406915T1 (en) 2001-07-17 2008-09-15 Ono Pharmaceutical Co AGENT FOR REGULATING THE SECRETION OF PANCREATIC JUICE USING AN LPA RECEPTOR REGULATOR
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
EP1466602A4 (en) 2001-12-25 2006-03-01 Ajinomoto Kk Organ fibrosis inhibitors
JP2003261545A (en) 2001-12-28 2003-09-19 Takeda Chem Ind Ltd Neurotrophic factor production/secretion accelerator
WO2003062392A2 (en) 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor
US20050101518A1 (en) 2002-01-18 2005-05-12 David Solow-Cordero Methods of treating conditions associated with an EDG-2 receptor
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20050261298A1 (en) 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
WO2003074483A1 (en) 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US20040014662A1 (en) 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
JP2005529923A (en) 2002-05-13 2005-10-06 イーライ・リリー・アンド・カンパニー Polycyclic compounds for use as melanin-concentrating hormone antagonists in the treatment of obesity and diabetes
EP1533294A4 (en) 2002-05-28 2007-07-04 Ono Pharmaceutical Co Beta-alanine derivative and use thereof
WO2004002530A1 (en) 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. Remedy for chronic disease
JP4691988B2 (en) 2002-10-03 2011-06-01 小野薬品工業株式会社 LPA receptor antagonist
WO2004046332A2 (en) 2002-11-19 2004-06-03 Amgen Inc. Amplified genes involved in cancer
US20050065194A1 (en) 2003-01-16 2005-03-24 Geetha Shankar Methods of treating conditions associated with an Edg-2 receptor
US20040192739A1 (en) 2003-01-16 2004-09-30 David Solow-Cordero Methods of treating conditions associated with an Edg-2 receptor
US20040167132A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associted with an Edg-2 receptor
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
US20060089398A1 (en) * 2003-03-19 2006-04-27 Gang Liu Isoxazole carboxamide derivatives as ghrelin receptor modulators
US7115642B2 (en) 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
ATE528276T1 (en) 2003-12-19 2011-10-15 Ono Pharmaceutical Co LYSOPHOSPHATIDYL ACID RECEPTOR ANTAGONIST COMPOUNDS AND THEIR APPLICATIONS
DE10360369A1 (en) 2003-12-22 2005-07-14 Bayer Cropscience Ag amides
WO2005123671A1 (en) 2004-06-22 2005-12-29 Taisho Pharmaceutical Co., Ltd. Pyrrole derivative
US7405237B2 (en) * 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
JP2006096712A (en) 2004-09-30 2006-04-13 Senju Pharmaceut Co Ltd Corneal sensitivity improver containing lpa receptor antagonist
CA2610310A1 (en) 2005-06-08 2006-12-14 Novartis Ag Polycyclic oxadiazoles or isoxazoles and their use as s1p receptor ligands
WO2007007588A1 (en) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. Compound having cyclic group with planarity as core
BRPI0615133A2 (en) 2005-08-23 2011-05-03 Irm Llc immunosuppressive compounds, pharmaceutical compositions containing them as well as said use
WO2007096647A2 (en) 2006-02-27 2007-08-30 Sterix Limited Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
US20080051372A1 (en) 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
WO2008024979A2 (en) 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
WO2008112201A2 (en) 2007-03-12 2008-09-18 The General Hospital Corporation Lysophosphatidic acid receptor targeting for lung disease
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
ES2637805T3 (en) 2008-05-05 2017-10-17 Sanofi Fused cyclopentanecarboxylic acid derivatives substituted by acylamino and their use as pharmaceuticals
JP4933512B2 (en) 2008-10-09 2012-05-16 住友化学株式会社 Light guide plate
WO2010068775A2 (en) 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
TW201116540A (en) * 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
EP0791576A2 (en) 1995-11-23 1997-08-27 Bayer Ag Leukotriene antagonistic benzoic acid derivatives
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US20030114505A1 (en) 2000-02-18 2003-06-19 Akihiro Ueno Novel isoxazole and thiazole compounds and use thereof as drugs
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
US7060697B2 (en) 2003-05-19 2006-06-13 Irm Llc Immunosuppressant compounds and compositions
US20060194850A1 (en) 2003-08-05 2006-08-31 Ajinomoto Co. Inc Novel azole compound
US20070149579A1 (en) 2005-03-23 2007-06-28 Marc Blouin Novel pharmaceutical compounds
WO2007016784A1 (en) 2005-08-11 2007-02-15 Merck Frosst Canada Ltd. Novel substituted 1,2,3-tπazolylmethyl-benzothiophene or -indole and their use as leukotπene biosynthesis inhibitors
US20070123522A1 (en) 2005-10-11 2007-05-31 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070105866A1 (en) 2005-11-04 2007-05-10 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070173508A1 (en) 2006-01-23 2007-07-26 Amira Pharmaceuticals, Inc. Tricyclic inhibitors of 5-lipoxygenase

Non-Patent Citations (90)

* Cited by examiner, † Cited by third party
Title
"Metal-Catalyzed Cross-Coupling Reactions", 2004, JOHN WILEY & SONS
"Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT WILLIAMS & WILKINS
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
"Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING COMPANY
"REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY", 2005
"The USP Pharmacists' Pharmacopeia", 2005
A. KANTATCI ET AL., J PATHOL., vol. 210, 2006, pages 59 - 66
AAPS PHARMSCITECH., vol. 7, no. 2, 2006, pages E41
ACKERMANN ET AL., ORG. LETT., vol. 8, 2006, pages 3457 - 3460
AESOP CHO: "Recent Advances in Oral Prodrug Discovery", ANNUAL REPORTS IN MEDICINAL CHEMISTRY, vol. 41, 2006, pages 395 - 407, XP009184520
ANSEL, H. C. ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1995
ASHCROFT T., J. CLIN. PATH., vol. 41, no. 4, 1988, pages 467 - 470
BIOCHEM BIOPHYS RES COMMUN., vol. 193, no. 2, 15 December 1992 (1992-12-15), pages 497
BIOCHEM BIOPHYS RES COMMUN., vol. 363, no. 4, pages 1001 - 8,2007
BLAKEY ET AL., J AM. CHEM. SOC., vol. 125, 2003, pages 6046 - 6047
BOUCHARABA ET AL., J. CLIN. INVEST., vol. 114, no. 12, 2004, pages 1714 - 1725
BOUCHARABA ET AL., PROC. NATL. ACAD SCI., vol. 103, no. 25, 2006, pages 9643 - 9648
C. HAN; J. A. PORCO, JR, ORG. LETT., vol. 9, 2007, pages 1517 - 1520
C.N. INOUE ET AL., CLIN. SCI. (COLCH., vol. 96, 1999, pages 431 - 436
CAREY; SUNDBERG: "ADVANCED ORGANIC CHEMISTRY", vol. A, B, 2000, PLENUM
CHEN ET AL., FEBS LETT., vol. 580, no. 19, 21 August 2006 (2006-08-21), pages 4737 - 45
CHOI ET AL., BIOCHEMICA ET BIOPHYSICA ACTA, vol. 1781, 2008, pages 531 - 539
CUZZOCREA S ET AL., AM JP YSIOL LUNG CELL MOL PHYSIOL., vol. 292, no. 5, 12 January 2007 (2007-01-12), pages LI095 - 104
DAI ET AL., ORG. LETT., vol. 6, 2004, pages 221 - 224
EDIGER ET AL., EUR RESPIR J, vol. 21, 2003, pages 759 - 769
GARDELL ET AL., TRENDS IN MOLECULAR MEDICINE, vol. 12, no. 2, February 2006 (2006-02-01)
GARDELL, TRENDS IN MOLECULAR MEDICINE, vol. 12, no. 2, 2006, pages 65 - 75
GREEN; WUTS: "PROTECTIVE GROUPS IN ORGANIC SYNTHESIS", 1999, WILEY
GREENE; WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS
H. LEBEL; O. LEOGANE, ORG. LETT., vol. 8, 2006, pages 5717 - 5720
HASHIMOTO ET AL., J PHARMACOL SCI, vol. 100, 2006, pages 82 - 87
HIGAZI, A. A. ET AL., CLIN EXP IMMUNOL., vol. 152, no. 1, 14 February 2008 (2008-02-14), pages 163 - 73
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
ISHII, ANNU. REV. BIOCHEM, vol. 73, 2004, pages 321 - 354
ISHII, I. ET AL., ANNU. REV. BIOCHEM., vol. 73, 2004, pages 321 - 354
J. A. FRITZ ET AL., ORG. LETT., vol. 8, 2006, pages 2531 - 2534
J. IMUUNOL., vol. 162, 1999, pages 2049
J. NEUROCHEM., vol. 61, 1993, pages 340
J. NEUROCHEM., vol. 70, 1998, pages 66
J.J.A. CONTOS ET AL., MOL. PHARMACOL., vol. 58, 2000, pages 1188 - 1196
J.P. PRADERE ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, 2008
J.P. PRADERE ET AL.: "LPA receptor activation promotes renal interstitial fibrosis", AM. SOC. NEPHROL., vol. 18, 2007, pages 3110 - 3118, XP002682319, DOI: doi:10.1681/ASN.2007020196
J.S. KOH, J. CLIN. INVEST., vol. 102, 1998, pages 716 - 727
JEAN JACQUES; ANDRE COLLET; SAMUEL H. WILEN: "Enantiomers, Racemates and Resolutions", 1981, JOHN WILEY AND SONS, INC.
K. KURODA ET AL.: "Phospholipid concentration in lung lavage fluid as biomarker for pulmonary fibrosis", INHAL. TOXICOL., vol. 18, 2006, pages 389 - 393
K. YASUDA ET AL., LUNG, vol. 172, 1994, pages 91 - 102
KOCIENSKI: "Protective Groups", 1994, THIEME VERLAG
KOTANI, HUM. MOL. GENET., vol. 17, 2008, pages 1790 - 1797
L. MARINESCU ET AL., J. ORG. CHEM., vol. 68, 2003, pages 9453 - 9455
M. AMISHIMA ET AL., AM. J RESPIR. CRIT. CARE MED., vol. 157, 1998, pages 1907 - 1912
M. B. BERTRAND; J. P. WOLFE, TETRAHEDRON, vol. 61, 2005, pages 6447 - 6459
M. INOUE ET AL.: "Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling", NAT. MED., vol. 10, 2004, pages 712 - 718, XP002693859, DOI: doi:10.1038/nm1060
M. MCLAUGHLIN; M. PALUCKI; I. W. DAVIES, ORG. LETT., vol. 8, 2006, pages 3311 - 3314
MAGUIRE, J.J. ET AL., TRENDS PHARMACOL. SCI., vol. 26, 2005, pages 448 - 454
MARCH: "ADVANCED ORGANIC CHEMISTRY", 1992, WILEY
MILLS ET AL., NAT REV. CANCER, vol. 3, 2003, pages 582 - 591
MILLS ET AL., NAT. REV. CANCER, vol. 3, 2003, pages 582 - 591
MILLS, NAT. REV. CANCER., vol. 3, 2003, pages 582 - 591
MOL CANCER THER, vol. 7, no. 10, 2008, pages 3352 - 62
MOOLENAAR, CURR. OPIN. CELL BIOL., vol. 7, 1995, pages 203 - 10
MOTOTANI ET AL., HUM. MOL. GENETICS, vol. 17, no. 12, 2008
MUNGER ET AL., CELL, vol. 96, 1999, pages 319 - 328
MURATA ET AL., SYNTHESIS, 2001, pages 2231 - 2233
MURPH ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1781, 2008, pages 547 - 557
N. WATANABE ET AL.: "Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity", LIFE SCI., vol. 81, 2007, pages 1009 - 1015, XP022248228, DOI: doi:10.1016/j.lfs.2007.08.013
N. WIEDMAIER ET AL., INT J MED MICROBIOL, vol. 298, no. 3-4, 2008, pages 231 - 43
N.WATANABE ET AL., J CLIN. GASTROENTEROL., vol. 41, 2007, pages 616 - 623
NOGRADY: "Medicinal Chemistry A Biochemical Approach", 1985, OXFORD UNIVERSITY PRESS, pages: 388 - 392
OSBORNE, N.; STAINIER, D.Y., ANNU. REV. PHYSIOL., vol. 65, 2003, pages 23 - 43
OZDEMIR ET AL., TETRAHEDRON, vol. 61, 2005, pages 9791 - 9798
ROOSEBOOM ET AL., PHARMACOLOGICAL REVIEWS, vol. 56, 2004, pages 53 - 102
ROTHER, E. ET AL., CIRCULATION, vol. 108, 2003, pages 741 - 747
S.-H. LEE ET AL., TETRAHEDRON, vol. 60, 2004, pages 3439 - 3443
See also references of EP2483252A4
SIESS, W, BIOCHIM. BIOPHYS. ACTA, vol. 1582, 2002, pages 204 - 215
SILVERMAN: "The Organic Chemistry of Drug Design and Drug Action", 1992, ACADEMIC PRESS, INC., pages: 352 - 401
SIMON ET AL., J.BIOL. CHEM., vol. 280, no. 15, 2005, pages 14656
SINGH ET AL.: "Encyclopedia of Pharmaceutical Technology", 2002, pages: 754 - 757
SUTPHEN ET AL., CANCER EPI EMIOL. BIOMARKERS PREV., vol. 13, 2004, pages 1185 - 1191
T. HIGUCHI; V. STELLA: "Pro-drugs as Novel Delivery Systems", vol. 14, A.C.S. SYMPOSIUM SERIES
TAGER ET AL., NATURE MEDICINE, vol. 14, no. 1, 2008, pages 45 - 54
TANG ET AL., J ORG. CHEM., vol. 71, 2006, pages 2167 - 2169
THE JOURNAL OF UROLOGY, vol. 162, 1999, pages 1779 - 1784
THE JOURNAL OF UROLOGY, vol. 163, 2000, pages 1027 - 1032
TSUJI ET AL., ORG. BIOMOL. CHEM., vol. 1, 2003, pages 3139 - 3141
XU ET AL., AM. J. PATHOLOGY, vol. 174, no. 2, 2009, pages 1264 - 1279
YAMADA ET AL., BIOL. CHEM., vol. 279, 2004, pages 6595 - 6605
YAMADA, CANCER SCI., vol. 99, no. 8, 2008, pages 1603 - 1610
YOSHIKAI ET AL., J AM. CHEM. SOC., vol. 127, 2005, pages 17978 - 17979
ZHAO ET AL., MOL. PHARMACOL., vol. 73, no. 2, 2008, pages 587 - 600

Cited By (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
US8440707B2 (en) 2008-12-15 2013-05-14 Amira Pharmaceuticals, Inc. Antagonists of lysophosphatidic acid receptors
US8048902B2 (en) 2008-12-15 2011-11-01 Amira Pharmaceuticals, Inc. Antagonists of lysophosphatidic acid receptors
US8058300B2 (en) 2009-06-03 2011-11-15 Amira Pharmaceuticals, Inc. Polycyclic antagonists of lysophosphatidic acid receptors
US8273780B2 (en) 2009-06-03 2012-09-25 Amira Pharmaceuticals, Inc. Polycyclic antagonists of lysophosphatidic acid receptors
US8592402B2 (en) 2009-08-04 2013-11-26 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US8664220B2 (en) 2009-10-01 2014-03-04 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
US9090573B2 (en) 2009-10-01 2015-07-28 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US9624182B2 (en) 2009-10-01 2017-04-18 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
EP2483269A2 (en) * 2009-10-01 2012-08-08 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
US10000456B2 (en) 2009-10-01 2018-06-19 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
US8217066B2 (en) 2009-10-01 2012-07-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US8778983B2 (en) 2009-10-01 2014-07-15 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists
EP2483269A4 (en) * 2009-10-01 2013-05-01 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2012078593A3 (en) * 2010-12-07 2012-08-02 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
US9272990B2 (en) 2010-12-07 2016-03-01 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US8541587B2 (en) 2011-04-05 2013-09-24 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists
WO2013078283A1 (en) 2011-11-22 2013-05-30 Intermune, Inc. Methods of diagnosing and treating idiopathic pulmonary fibrosis
US10000463B2 (en) 2012-12-28 2018-06-19 Ube Industries, Ltd. Halogen-substituted heterocyclic compound
EP3360869A1 (en) 2012-12-28 2018-08-15 Ube Industries, Ltd. Halogen-substituted heterocyclic compound useful for the treatment of diseases caused by lpa
KR20150100756A (en) 2012-12-28 2015-09-02 우베 고산 가부시키가이샤 Halogen-substituted heterocyclic compound
WO2014104372A1 (en) 2012-12-28 2014-07-03 宇部興産株式会社 Halogen-substituted heterocyclic compound
US10597375B2 (en) 2012-12-28 2020-03-24 Ube Industries, Ltd. Halogen-substituted heterocyclic compound
US11427552B2 (en) 2013-03-15 2022-08-30 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
US10526298B2 (en) 2013-03-15 2020-01-07 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
US10570103B2 (en) 2013-03-15 2020-02-25 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
WO2015082586A1 (en) 2013-12-05 2015-06-11 Bayer Cropscience Ag N-cycloalkyl-n-{[2-(1-substitutedcycloalkyl)phenyl]methylene}-(thio)carboxamide derivatives
WO2015082587A1 (en) 2013-12-05 2015-06-11 Bayer Cropscience Ag N-cycloalkyl-n-{[2-(1-substitutedcycloalkyl)phenyl]methylene}-(thio)carboxamide derivatives
KR20170016988A (en) 2014-06-27 2017-02-14 우베 고산 가부시키가이샤 Salt of halogen-substituted heterocyclic compound
US10023554B2 (en) 2014-06-27 2018-07-17 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt
US11130731B2 (en) 2015-02-16 2021-09-28 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
WO2016197009A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
JP2022106974A (en) * 2016-06-21 2022-07-20 ブリストル－マイヤーズ スクイブ カンパニー Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
EP3666771A1 (en) 2016-06-21 2020-06-17 Bristol-Myers Squibb Company Lpa antagonists
CN109963843A (en) * 2016-06-21 2019-07-02 百时美施贵宝公司 Carbamyl oxygen methyl-triazole cyclohexyl acid as LPA antagonist
JP2019518766A (en) * 2016-06-21 2019-07-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Carbamoyloxymethyltriazole cyclohexyl acid as an LPA antagonist
CN109963843B (en) * 2016-06-21 2022-03-11 百时美施贵宝公司 Carbamoyloxymethyltriazolylcyclohexanes as LPA antagonists
JP7312295B2 (en) 2016-06-21 2023-07-20 ブリストル－マイヤーズ スクイブ カンパニー Carbamoyloxymethyltriazole cyclohexylates as LPA antagonists
US10071078B2 (en) 2016-06-21 2018-09-11 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
US10576062B2 (en) 2016-06-21 2020-03-03 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
JP7073281B2 (en) 2016-06-21 2022-05-23 ブリストル－マイヤーズ スクイブ カンパニー Carbamic acid as an LPA antagonist
AU2021209334B2 (en) * 2016-06-21 2023-06-01 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
KR20190020049A (en) * 2016-06-21 2019-02-27 브리스톨-마이어스 스큅 컴퍼니 Carbamoyloxymethyltriazole cyclohexylic acid as an LPA antagonist
KR102377340B1 (en) 2016-06-21 2022-03-21 브리스톨-마이어스 스큅 컴퍼니 Carbamoyloxymethyl triazole cyclohexyl acid as an LPA antagonist
EA037585B1 (en) * 2016-06-21 2021-04-19 Бристол-Майерс Сквибб Компани Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
TWI725200B (en) * 2016-06-21 2021-04-21 美商必治妥美雅史谷比公司 Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
USRE49352E1 (en) 2016-06-21 2023-01-03 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
TWI757128B (en) * 2016-06-21 2022-03-01 美商必治妥美雅史谷比公司 Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
US11007180B2 (en) 2016-06-21 2021-05-18 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
WO2017223016A1 (en) 2016-06-21 2017-12-28 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
US11465992B2 (en) 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11981667B2 (en) 2017-07-07 2024-05-14 Inflazome Limited Sulfonamide carboxamide compounds
US11613542B2 (en) 2017-08-15 2023-03-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
CN112789264A (en) * 2017-08-15 2021-05-11 英夫拉索姆有限公司 Novel sulfonylurea compound
WO2019034686A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited Novel sulfonamide carboxamide compounds
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
CN111132974B (en) * 2017-08-15 2023-11-21 英夫拉索姆有限公司 Sulfonamide carboxamide compounds
WO2020035465A1 (en) * 2017-08-15 2020-02-20 Inflazome Limited Novel sulfoneurea compounds
CN111132974A (en) * 2017-08-15 2020-05-08 英夫拉索姆有限公司 Novel sulfonamide carboxamide compounds
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US12012392B2 (en) 2017-11-09 2024-06-18 Inflazome Limited Sulfonamide carboxamide compounds
US11261174B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
US11352345B2 (en) 2017-12-19 2022-06-07 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as LPA antagonists
US11008300B2 (en) 2017-12-19 2021-05-18 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
US11312706B2 (en) 2017-12-19 2022-04-26 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as LPA antagonists
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
US10662172B2 (en) 2017-12-19 2020-05-26 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
US11384067B2 (en) 2017-12-19 2022-07-12 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists
US11697646B2 (en) 2017-12-19 2023-07-11 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
US11319315B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as LPA antagonists
US11261180B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as LPA antagonists
US11267800B2 (en) 2017-12-19 2022-03-08 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as LPA antagonists
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
RU2805922C2 (en) * 2019-07-30 2023-10-24 Таишо Фармасьютикал Ко., Лтд. Urea compound that is antagonist of lpa1 receptor
US11999717B2 (en) 2019-11-15 2024-06-04 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
US11548871B2 (en) 2019-11-15 2023-01-10 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
US11584738B2 (en) 2020-06-03 2023-02-21 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11912686B2 (en) 2020-06-03 2024-02-27 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11980609B2 (en) 2021-05-11 2024-05-14 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US11884627B2 (en) 2022-02-25 2024-01-30 Lhotse Bio, Inc. Compounds and compositions for treating conditions associated with LPA receptor activity

Also Published As

Publication number Publication date
TWI401082B (en) 2013-07-11
EP2483252B1 (en) 2017-03-08
US9090573B2 (en) 2015-07-28
CN102666504B (en) 2016-06-01
WO2011041729A2 (en) 2011-04-07
GB2474120B (en) 2011-12-21
US9624182B2 (en) 2017-04-18
WO2011041729A3 (en) 2011-08-04
IN2012DN02177A (en) 2015-08-21
EP2483252A2 (en) 2012-08-08
EP2483253A2 (en) 2012-08-08
AR078497A1 (en) 2011-11-09
TW201116278A (en) 2011-05-16
US8217066B2 (en) 2012-07-10
CN102666504A (en) 2012-09-12
CN102639515A (en) 2012-08-15
WO2011041694A3 (en) 2011-08-18
US20150329502A1 (en) 2015-11-19
IN2012DN02735A (en) 2015-09-11
JP2013506694A (en) 2013-02-28
US20120289522A1 (en) 2012-11-15
EP2483252A4 (en) 2013-04-03
GB201016314D0 (en) 2010-11-10
GB2474120A (en) 2011-04-06
US20110082181A1 (en) 2011-04-07
UY32926A (en) 2010-11-30
EP2483253A4 (en) 2013-04-03
JP2013506695A (en) 2013-02-28

Similar Documents

Publication Publication Date Title
US9624182B2 (en) Compounds as lysophosphatidic acid receptor antagonists
US8664220B2 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
EP2462128B1 (en) Compounds as lysophosphatidic acid receptor antagonists
EP2648714B1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
US8455499B2 (en) Alkyne antagonists of lysophosphatidic acid receptors
US20110301142A1 (en) Antagonists of lysophosphatidic acid receptors
US8541587B2 (en) Lysophosphatidic acid receptor antagonists
WO2010141768A2 (en) Polycyclic antagonists of lysophosphatidic acid receptors
EP2714680B1 (en) Heterocyclic autotaxin inhibitors and uses thereof
AU2011338417B2 (en) Polycyclic LPA1 antagonist and uses thereof
WO2011159550A2 (en) Lysophosphatidic acid receptor antagonist and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080054659.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10821345

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2735/DELNP/2012

Country of ref document: IN

REEP Request for entry into the european phase

Ref document number: 2010821345

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012532357

Country of ref document: JP

Ref document number: 2010821345

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13498491

Country of ref document: US